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ABSTRACT
In this thesis, the synthesis of novel analogues of the second messenger D-myo-inositol
1.4.5-trisphosphate is described. The first four sections of the thesis describe the biology 
and chemistry of the analogues of myo-inositol 1,4,5-trisphosphate.
DL-3,6-Di-0-benzoyl-l,2:4,5-di-0-isopropylidene-myo-inositol was treated with acid to 
give DL-l,4-di-0-benzoyl-myo-inositol. Phosphitylation of this compound with 
diethoxychlorophosphine followed by oxidation with f-butylhydroperoxide gave the fully 
protected, phosphoiylated compound. The eight ethyl groups were removed with 
bromotrimethylsilane and basic hydrolysis of the intermediate gave DL-myo-inositol
1.2.4.5-tetrakisphosphate.
Treatment of d l -  1,4-di-0-benzyl-5,6-di-0-p-methoxybenzyl-/nyo-inositol with S-(+)-0- 
acetylmandelic acid and dicyclohexylcarbodiimide acylated the 3-position selectively to 
give two diastereoisomers which were separated by flash chromatography. The acyl 
groups of the individual diastereoisomers were hydrolysed followed by acidic hydrolysis 
of the p-methoxybenzyl ethers to give d -  and L-3,6-di-0-benzyl-myo-inositol. 
Phosphitylation of the tetrols using bis(benzyloxy)diisopropylaminophosphine and 1H- 
tetrazole followed by oxidation with mCPBA gave the protected 1,2,4,5- 
tetrakisphosphate. Alternatively, sulphoxidation of the d -  enantiomer with sulphur in 
pyridine-DMF gave the protected 1,2,4,5-tetrakisphosphorothioate. Deprotection of the 
individual compounds with sodium in liquid ammonia gave d -  and L-myo-inositol 1,2,4,5- 
tetrakisphosphate and D-wyo-inositol 1,2,4,5-tetrakisphosphorothioate.
d l -  1,4-Di-0-ally l-myo-inositol was p-methoxybenzylated selectively to give DL-l,4-di-0- 
allyl-3,6-di-0-p-methoxybenzyl-myo-inositol. This intermediate was methylated at the 2- 
and 5-positions followed by deprotection of the allyl and p-methoxybenzyl groups to give
2.5-di-O-methyl-myo-inositol. 2,5-Di-O-benzyl-myo-inositol was synthesised in a similar 
way. Each of these tetrols were phosphitylated and the 2,5-di-O-methyl-myo-inositol 
derivative was oxidised or sulphoxidised followed by deprotection of the phosphate 
triester whereas the 2,5-di-O-benzyl-myo-inositol derivative was sulphoxidised and 
deprotected to give wyo-inositol 1,3,4,6-tetrakisphosphorothioate.
DL-l,2,5-Tri-0-benzyl-my<9-inositol was prepared in several steps from DL-3,6-di-0-allyl- 
l,2:4,5-di-0-isopropylidene-myo-inositol. This triol was phosphitylated and oxidised or 
sulphoxidised followed by deprotection with sodium in liquid ammonia to give d l - 1,4,6- 
myo-inositol trisphosphate and DL-myo-inositol 1,4,6-trisphosphorothioate respectively.
Di^l,4-Di-0-allyl-5-0-benzyl-6-0-p-methoxybenzyl-myo-inositol was selectively acylated 
at the 3-position using S-(+)-0-acetylmandelic acid and dicyclohexylcarbodiimide to give 
two diastereoisomers which were separated by flash chromatography. Basic hydrolysis of 
the ester group followed by several protection and deprotection steps gave d -  and l -2,3,5- 
tri-0-benzy l-myo-inositol. Phosphitylation and oxidation followed by deprotection of 
both isomers gave the chiral 1,4,6-trisphosphates. Sulphoxidation and deprotection of the 
d -  isomer gave D-myo-inositol 1,4,6-trisphosphorothioate.
Phosphitylation of benzene-1,2,4-triol with diethoxychlorophosphine followed by ethyl 
group deprotection using bromotrimethylsilane gave benzene-1,2,4-trisphosphate.
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CHAPTER ONE 
A Brief History Of Second Messengers
1.1 General Introduction to Communication Between cells
The cell receives a plethora of external information from its surrounding environment, 
which must somehow be translated into the cell to produce an appropriate response. 
When cells become organised to form an organism, the individual cells need to assess 
both the general status of the organism in relation to its environment, and the specific 
functional status of other cells. The individual cells of a multicellular organism need to 
communicate with each other so that the basic processes of life may occur, for example, 
growth, movement and metabolic activity. This communication may occur in several 
ways. First, via cytoplasmic bridges or gap junctions, which form a pore between two 
cells whose plasma membranes are in direct contact, and which facilitate the direct 
exchange of cytoplasmic contents (for example, some metabolites and certain ions). This 
type of direct exchange suffers from a slow flow-rate of information between cells, I1*2!
Second, by secreting chemical messengers: these chemical messengers, or first 
messengers, may be classified into three functional types: (a) hormones, (b) 
neurotransmitters and (c) local mediators. First, hormones are secreted by endocrine 
glands, and transported long distances to their respective target organs by the 
bloodstream. Major endocrine organs include the hypothalamus and pituitary in the 
brain; thyroid and parathyroid in the neck region, the liver, pancreas, ovaries and testis. 
There are over two hundred steroid hormones, both natural and synthetic. These are based 
on the four ring sterane nucleus which is synthesised from cholesterol by cleavage of the 
aliphatic side chain.
A second class of messenger are the neurotransmitters, which are released by nerve cells 
called neurones. Sensory neurones for example, take input from the sense organs back to
r
the central nervous system: intemeurones, which connect other neurones and perform the 
complex summation of information which result in the final output, and motor neurones, 
which take the output from the central nervous system in order to control voluntary 
muscles. The sympathetic nerve network controls the involuntary contraction of smooth 
muscle and secretion by endocrine and exocrine glands. The communication between 
neurones occurs at synapses via neurotransmitters. Some neurotransmitters are 
synthesised in vivo e.g. acetylcholine is derived from acetyl co-enzyme A and choline. 
Some amino acids, for example glycine and glutamate are used as neurotransmitters 
without modification.
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Finally, local mediators form a diverse group of first messengers. Nerve growth factor 
(NGF) seems to direct the growth of the axon of a sympathetic nerve to its target cell. 
Platelet-derived growth factor (PDGF) stimulates proliferation of fibroblasts at the site of 
injury which is involved in the initiation of wound repair. Local mediators such as the 
eicosanoids, including prostaglandins, are ubiquitous in mammals, with many functions. 
Purines, for example adenosine, have physiological effects on the same cells which 
release them. Retinoic acid is a special type of local mediator, gradients of which control 
the development of digits of the wing in birds.
First messengers, such as those described above, work by binding to a protein receptor on 
the ectoplasmic surface of the cell, (with the exceptions of steroid and thyroid hormones 
and retinoic acid), which is then transmitted into a chemical change on the cytoplasmic 
surface of the membrane. Signal transduction at the receptor protein in the cell works by 
one of three mechanisms. The first of these is by a receptor, which contains or is closely 
linked to an ion channel which spans the membrane. For example, the nicotinic 
acetylcholine receptor has an excitatory cation channel, however, the cell also has two 
receptor proteins for inhibiting transmitters [y-aminobutyrate (GABA) and glycine] that 
are anion channels and related to the nicotinic receptor. The ion channel receptor of 
nicotinic acetylcholine has five closely related subunits that associate in a 
pseudosymmetrical manner and line a central ion channel.
Second, signal transduction may be carried out by second messenger systems. The 
classical cyclic-3',5'-adenosine monophosphate (cyclic AMP) produces a response to p- 
adrenergic agonists and many other first messenger agonists. The second messenger is 
produced catalytically in response to an agonist or first messenger and the signal is 
amplified, because it is not produced stoichiometrically. The first messenger in this type 
of system increases the concentration of the second messenger on the cytoplasmic side of 
the cell membrane and also mimics the effect of the first messenger.
Adenylate cyclase, the enzyme responsible for producing cyclic AMP, is coupled 
indirectly to the receptor via GTP-binding proteins (G-proteins). The receptors are 
members of the "seven-pass" family containing seven transmembrane domains. The 
system outlined above shows analogies to the system involved in light absorbtion by 
rhodopsin with the activation of cyclic guanosine monophosphate phosphodiesterase in 
the eye. Several receptors inhibit adenylate cyclase via inhibitory G-proteins, which may 
also be involved in coupling to ion channels.
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Many agonists that act as first messengers cause an increase in calcium concentration in 
the cytosol, by releasing the divalent cation from the endoplasmic reticulum. The second 
messenger in this case is D-rayoinositol 1,4,5-trisphosphate [Ins(l,4,5)P3], which is 
released from the phospholipid, phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2], by 
the action of phospholipase C (PLC). This enzyme exists in several isoforms, some are 
coupled to receptors via G-proteins. Diacylglycerol (DAG) is another second messenger 
that is released as a consequence of PtdIns(4,5)P2 hydrolysis, which activates another 
enzyme, protein kinase C (PKC).
Finally, receptors that contain an integral enzyme activity include the insulin and growth 
factor class, which exhibit ligand activated protein (tyrosine) kinase activity, and the 
resact and atrial natriuretic peptide receptors, which directly produce the second 
messenger, cyclic GMP. I1*2!
The Discovery of cyclic AMP, cyclic GMP, Ins(l,4,5)P3 and Diacylglycerol
1.2 Cyclic AMP
In the 1950s Sutherland and his colleagues [3»4] discovered cyclic AMP. It was known 
that adrenaline and glucagon caused the breakdown of glycogen by the increased activity 
of glycogen phosphorylase in the liver. Cori and Cori (1945) ^  had previously isolated 
two types of glycogen phosphorylase named a and b from skeletal muscle. Glycogen 
phosphorylase b required AMP as an activator. I51 Sutherland, Rail and coworkers (1956) 
M showed that ATP (1) and Mg2+ were necessary for the conversion of inactive glycogen 
phosphorylase b into the active type a. Rail and coworkers ( 1 9 5 7 ) developed a cell- 
free system where an increase in phosphorylase activity occurred after the addition of 
adrenaline or glucagon to liver homogenate, in the presence of ATP and Mg2+ ions. The 
compound that resulted from this research was a heat stable substance that was shown to 
activate glycogen phosphorylase in dog liver homogenates in the absence of glucagon or 
adrenaline. Lipkin and coworkers (1959) M were investigating the degradation of ATP 
by aqueous barium hydroxide. One of the degradation products was found to be similar 
in biological properties to the heat-stable substance responsible for activating 
phosphorylase. The two groups collaborated and identified the structure as 3',5'-cyclic 
adenosine monophosphate (Figure 1). At about the same time Sutherland and Rail [4] 
discovered adenylate cyclase, then another group followed by discovering cyclic AMP
3
phosphodiesterase; cyclic AMP-dependent protein kinase l10l was discovered in later 
years. Following the discovery of cyclic AMP, the possibility that it may play a role for 
the activation of different hormones in other cells was investigated.
The groundwork had been established and the next step was to determine how cyclic 
AMP was involved in response to a first messenger. Two criteria were put forward: first, 
the first messenger on binding to its receptor, increases the concentration of cyclic AMP 
inside the cell: second, increasing the second messenger concentration inside the cell 
should mimic the effect of the first messenger. (Some of the major roles of cyclic AMP 
are shown in Table 1).
In unstimulated cell types cyclic AMP is present in low concentration (106 mol l*1), so 
testing the first criteria needed a sensitive assay. Another problem was that cyclic AMP 
was not cell permeable. Less polar analogues have been synthesised by modification of 
the N6 and O2 of cyclic AMP to produce dibutyryl cyclic AMP (3) that moves across the 
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the detection of cyclic GMP and cyclic GMP-dependent protein kinase, may have 
suggested that this nucleotide may perform a role similar to that of cyclic AMP. The first 
description of a function for cyclic GMP was provided by Miki and coworkers W  and 
Chader and coworkers t13J who discovered that light activated the cyclic nucleotide 
phosphodiesterase in photoreceptor cells. It was in 1984 when definitive evidence for an 
intracellular messenger function for cyclic GMP other than the photoreceptor response 
was reported. [14] The initial clues came from observations that certain drugs that were 
used to lower blood pressure (for example nitroprusside) activated the soluble guanylate 
cyclase in atrial muscle which caused relaxation of the muscle. Recently, it has been 
found that atrial natriuretic peptides, released by the atria of the heart in response to high 
blood pressure activate particulate guanylate cyclase in artrial smooth muscle, causing 
relaxation of the blood vessel wall. The particulate guanylate cyclase that was activated 
is an integral component of the atrial natriuretic peptide receptor. [14] A closely related 
system is involved in the response of sea urchin spermatozoa to the chemotactic peptide, 
resact, released by eggs. It is likely that cyclic GMP has a more widespread role as an 
intracellular messenger than present knowledge indicates. Experimental difficulties may 
have prevented the elucidation of roles for cyclic GMP in many cell types (Table 2).
Table 2 Some o f the roles o f cyclic GMP as an intracellular messenger.
Agonist
Light
Atrial natriuretic peptide 
Atrial natriuretic peptide 
5-Hydroxytryptamine 
Speract and other sperm- 
activating peptides secreted 
by egg cells 
Endothelial-derived 
relaxing factor (EDRF)
1.4 Ins(l,4,5)P3 and Diacylglycerol
The discovery of the inositol lipid signalling pathway represented a long period of basic 
research. This was undertaken in two quite unrelated areas which culminated in an
Cell










Excretion of Na+ and water 
Muscle relaxation 
Increased Ca2+ inflow 




understanding, albeit not complete, of a novel mechanism that regulates many cell 
functions. In 1953 Hokin and Hokin l15l showed that acetylcholine stimulated the 
incorporation of [32P]HP04~ into phospholipids from pancreatic acinar cells. This result 
was interpreted as the first messenger (acetylcholine) stimulating the synthesis of 
phospholipid. Further experiments showed that the major phospholipid involved was 
phosphatidylinositol (Ptdlns).
The implications of the experiments performed by Hokin and Hokin [15] were not fully 
realised until many years later. The reason, in part, was due to many scientists thinking 
that cyclic AMP and cyclic GMP were the only second messengers in cells. These second 
messengers were discovered around the same period as Hokin and Hokin initially 
observed acetylcholine induced-Ptdlns turnover. In the period from 1970 to 1975 it was 
realised that for some agonists, cyclic AMP was not the second messenger which conveys 
information from the plasma membrane to intracellular sites. Also found, was some 
indirect evidence which indicated that changes in intracellular calcium concentration 
were essential for the actions of many agonists. Within the same time period three 
separate groups (Durell, l16J DeRobertis, [171 and Michell [18]) performed a series of 
experiments which led to the proposition that agonist-stimulated Ptdlns hydrolysis caused 
an increase in intracellular calcium concentration. tl6’19J The key link between 
phosphoinositides and calcium movement remained undetected for several more years. It 
was also shown that certain agonists, not only caused an increase in plasma-membrane 
calcium influx, but also induce the release of calcium from intracellular stores.
The next piece of evidence to suggest a role for phosphoinositides in intracellular signal 
transduction came from experiments carried out in 1979 by Fain and Berridge. f201 They 
showed that 5-hydroxytryptamine stimulated calcium movement across the plasma 
membrane of blowfly salivary glands, which was dramatically decreased by prior removal 
of the inositol content from the glands. [20] The calcium response was restored by the 
addition of exogenous myo-inositol. The implication of this observation was that inositol 
metabolites played a crucial role in the action of 5-hydroxytryptamine.
In 1977 Abdel-Latif f21l and his coworkers and Michell and Kirk[22] in 1981 working with 
iris smooth muscle and liver, respectively, showed that agonists which use calcium as an 
intracellular messenger induce the rapid hydrolysis of PtdIns(4,5)P2 and 
phosphatidylinositol 4-phosphate (Ptdlns 4P) as well as Ptdlns.
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The observation that certain agonists stimulate PtdIns(4,5)P2 hydrolysis focused attention 
on the unique chemistry of the PtdIns(4,5)P2 polar head group. In 1983 Berridge t23l 
observed that in blowfly salivary gland, 5-hydroxytryptamine increased the concentration 
of D-myo-inositol trisphosphates as well as bis- and monophosphates. In the same year, 
the critical paper presented in Nature by Streb, Berridge, Irvine and Schultz W  
demonstrated the crucial link, in pancreatic acinar cells, between D-rayo-Inositol 1,4,5- 






Ins(l,4,5)P3 (7) Figure 3
and the release of calcium from intracellular stores. This observation has been repeated 
in many other cells. (For examples see Table 3).
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Meanwhile, Nishizuka l25l and his coworkers discovered a protein kinase that requires 
calcium and phospholipid for activity, this was named protein kinase C. Nishizuka's 
group I26*27! observed that diacylglycerols and tumour-promoting phorbol esters are potent 
activators of protein kinase C. Nishizuka's group proposed that diacylglycerols are 
formed by the hydrolysis of PtdIns(4,5)P2 and the hydrophobic diacylglycerol (8 in Figure
8
4) activates protein kinase C. [261 Some of the roles of diacylglycerol as an intracellular 
second messenger are given in Table 4
s n ~l  i—  OC- 




Some intracellular processes which require the action o f diacylglycerol as anTable 4
intracellular messenger.
Intracellular Process
Activation of protein-tyrosine kinase 
receptors
Activation of receptors linked to GTP-
binding proteins
Release of calcium
Release of cyclic GMP
Muscle contraction and movement of the
cytoskeleton
Metabolic pathways
Target Proteins for Diacylglycerol- 
Activated Protein Kinase C
Receptors for EGF, insulin
P-adrenergic receptors
Voltage operated calcium channels
Guanylate cyclase
Myosin light chains (kinase)
Cytoskeletal proteins
Regulatory enzymes of glycogenolysis and 
glycolysis. Glucose transport. Tyrosine 
hydroxylase (neurotransmitter release).
9
Figure 5 shows the complex interactions between the signalling systems as depicted by 

















A Review Of Second Messenger Pharmacology
2.1 Introduction
This chapter will provide a detailed account of the events known to date which link the 
first messenger (agonist) binding to its receptor, together with the events that follow and 
the formation and degradation of Ins(l,4,5)P3 and Ca2+ release from intracellular stores, 
and a description of the macromolecules involved in these events. The Ins(l,4,5)P3/DAG 
pathway operates throughout the life of a cell, starting with gametogenesis, fertilisation, 
cell proliferation and early development thereafter, continuing through differentiation in 
order to perform very precise control functions in many plant and animal cells. The 
overall picture is shown briefly in Figure 6.
2.2 G-Protein-linked Receptors
The membrane-spanning transducing unit that is controlled by G-protein-linked receptors 
has three main parts. First, the receptor that receives the primary messenger; second, the 
G-proteins, which transduce and amplify the initial signal and third, the enzyme 
phospholipase C-p, which hydrolyses PtdIns(4,5)P2 to give the hydrophobic DAG and 
hydrophilic Ins(l,4,5)P3. Tyrosine kinase receptors also generate Ins(l,4,5)P3 and DAG, 
by interacting with PLC-y. (See Figure 6).
The primary structure of several plasma-membrane receptors which couple with effector 
enzymes or ion channels are known in detail, and there are a number of different 
receptors known to be coupled to phosphoinositide turnover and are given in Table 5 .1281 
The amino acid sequences of the PtdIns(4,5)P2-linked muscarinic acetylcholine receptor, 
I29l the adenylate cyclase-linked p-adrenergic receptor f30’31] and the cyclic GMP 
phosphodiesterase-linked photoreceptor, rhodopsin, I32J were the first to be elucidated. 
The G-protein-linked receptors discovered so far are composed of a single polypeptide 
chain having seven membrane-spanning domains connected by extracellular and 
intracellular loops. These transmembrane domains interact with one another to provide a 
pocket or pore for the agonist to bind, so inducing the conformation and thus activating 
the G-protein, which in turn is responsible for activating PLC. The second and third 
cytoplasmic loops of the receptor have an essential role in activating a member of the G- 

























The stereospecific binding site for the first messenger is a sequence of amino acids in the 
extracellular domain of a G-protein-coupled receptor. For example, by the use of a 
radioactively labelled agonist which covalently binds to the receptor the precise location 
of the catecholamine binding site on the P-adrenergic receptor has been found. This 
methodology has shown that the catacholamine binding site is formed by the 
juxtaposition of membrane-spanning sequences 3,4, 5 and 7.
Site-directed mutagenesis in the third loop of the adrenergic-IB receptor resulted in 
activation of PLC, probably by mimicking the active conformation which is usually
12
induced by the first messenger. I36l Substituting alanine at position 293 (present in loop 3, 
close to the transmembrane domain 6) with any one of 19 amino acids, resulted in an
Table 5 Receptors known to be coupled to phosphoinositide turnover. Compiled from  




Bombesin BB, and BB2 
Bradykinin B2 
a-Chemokine IL8AIL8B 
P-Chemokine M IPla, MCP1 
Cholecystokinin (CCKA, CCKB), gastrin
Endothefin ETA and ETB 
Glutamate mGluR, and mGluR5 
Histamine H,
5-HT2A.2c
Leukotriene LTB4 and LTD4 
Muscarine M, and M3 
Neurotensin
Platelet activating factor (PAF) 
Prostanoid EP, and EP3 
FP 
TP





Noradrenaline and adrenaline 
Angiotensin II
Gastrin releasing peptide, neuromedin B 
Bradykinin, kallidin and T-kinin 
Interleukin 8 (IL8), GROa and (NAP-2) 
MIPa, RANTES and MCP-1 
Cholecystokinin (CCK4, CCK8, CCK33,) 
and gastrin






Neurotensin and neuromedin N
PAF and C-PAF
PGE2
p g f 2«
t x a 2
ATP, ADP, AMP and (UTP P2U only) 
Substance P, neurokinins A + B and 
neuropeptide K and y 
Vasopressin 
Oxytocin
Key: M IPa = Human macrophage inflammatory protein-la.
RANTES = Human reduced upon activation normal T-expressed and secreted. 
MCP-1 = Human monocyte chemoattractant protein-1.
LT = Leukotriene, TX = Thromboxane.
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increase in PLC activity. It may be concluded that the native receptor has evolved a loop 
structure that provides the lowest basal activity. Transfection of cells with mutant 
receptors showing the highest constitutive activity results in transformation and
tumorgenesis.[37]
Site-directed mutagenesis in the third loop of the adrenergic-IB receptor resulted in
activation of PLC, probably by mimicking the active conformation which is usually
induced by the first messenger. t36J Substituting alanine at position 293 (present in loop 3, 
close to the transmembrane domain 6) with any one of 19 amino acids, resulted in an 
increase in PLC activity. It may be concluded that the native receptor has evolved a loop 
structure that provides the lowest basal activity. Transfection of cells with mutant 
receptors showing the highest constitutive activity results in transformation and
tumorgenesis. ^
2.3 G-Proteins
G-proteins are a family of heterotrimeric guanine nucleotide-binding proteins that serve a 
critical role in transducing and amplifying signals across the plasma membrane to 
stimulate PLC. The G-proteins are part of a larger superfamily of GTPases that include 
factors involved in protein synthesis, for example elongation factor Tu (EF-Tu) and a 
larger number of monomeric 20-25kDa proteins such as ras p21.
2.3.1 Structure and properties
G-proteins consist of three subunits: a  (molecular mass = 39-46kDa), P (35-37kDa) and y 
(8kDa). The a-subunit possesses the binding site for GTP and the catalytic activity 
responsible for the hydrolysis of the nucleotide. The a-subunit also contains sites which 
interact with the Py complex, with the receptor, and with the effector enzyme or ion 
channel.
Each of the subunits ( a , p and y) of a G-protein is attached to the cytoplasmic side of the 
plasma membrane. None of the subunits contain a membrane-spanning sequence. The a  
-subunit is attached to the membrane through an acylated cysteine residue near the 
carboxyl terminus of the polypeptide chain. A possible function of the P- and y- subunits,
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which have both hydrophilic and hydrophobic sequences, may be to assist the anchoring 
of a-subunits to the plasma membrane.
The functional domains of the a-subunit have been identified and characterised by 
biochemical, immunochemical and molecular biological approaches. It has been shown 
that a region of l-2kDa at the amino-terminal is involved in binding to the py-subunit. At 
the other end of the molecule, the carboxyl terminus is critical for receptor interactions. 
There is evidence for the latter; for example, a mutation from arginine to proline at the 
sixth residue from the carboxyl terminus uncouples the G-protein from its receptor. t38] 
Pertussis toxin ADP-ribosylates those a-subunits which possess a specific cysteine 
residue near the carboxyl terminus, thereby uncoupling the G-protein from its receptor. 
Antibodies to the carboxyl terminal decapeptide also uncouple the G-protein from its 
receptor. I39] Cholera toxin also catalyses the transfer of the ADP-ribose moiety of NAD 
to a specific arginine residue in certain a-subunits. This modification reduces intrinsic 
GTPase activity and leads to constitutive activation of the a-subunits. Mutations of this 
specific arginine residue within the guanine nucleotide-binding region (compare to ras 
position 61) act in the same way to reduce GTPase activity. I38’4°l
The a-subunit is in an inactive conformation when GDP is bound. By analogy with the 
X-ray crystallographic studies of ras p21, t41l when GTP binds to the a-subunit, a 
conformational change is observed which is associated with activation. l38l Several 
studies have suggested that an aluminium fluoride complex, A1F4“ activates the a-subunit 
by mimicking the y-phosphate of GTP. I42*43! A mutation of a glycine residue comparable 
to ras position 60 prevents the activation of a-subunits by GTP or A1F4", presumably by 
preventing the specific conformational change engendered by the y-phosphate of GTP.
The P-subunits show a repetitive segmented structure made up of contiguous homologous 
domains, approximately 43 amino acids long and delineated by a tryptophan-aspartic acid 
motif. t44l Together with the y-subunit, the py-heterodimer serves an essential role in G- 
protein-receptor coupling. I45] The role of this complex in effector regulation is 
controversial. The Py-complex activates an undefined form of PLC in HL-60 
granulocytes. [46J The Py-complex appears to have effects on K+ channel activity, 
although it is not known if these effects are mediated directly or indirectly.[47] The py- 
complex also plays an obligatory role in agonist-induced receptor phosphorylation and 
desensitisation. [48l
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G-Proteins can be divided into four major subfamilies according to amino acid sequence 
relationships; these include Gs, Gi? Gq, and G12. Recent findings (49'531 have identified the 
Gq family as regulators of the activation of PLC~pi, which in turn hydrolyses 
PtdIns(4,5)P2. The Gq family of G-proteins includes G aq, G an , G a14, G a,5 and G a16. 
A mixture of Gaq and G a ,, has been purified from bovine brain ^  and rat liver; I50! a 
related protein has also been isolated from turkey erythrocytes. I51l Reconstitution of the 
proteins with purified PLC-pl [52»53l or turkey PLC t51* results in specific and marked 
stimulation of the enzyme.
2.3.2 GTPase Cycle
The inactive G-protein (Figure 7) exists as a heterotrimer with GDP tightly bound to the 
a-subunit; under these conditions the agonist receptor (R) is empty and the effector is 
inactive (for example PLC-pl). When the agonist binds to the receptor (R), the receptor 
interacts with the heterotrimer complex to induce a conformational change with the 
dissociation of GDP from the guanine nucleotide-binding site. Under normal conditions 
GTP fills the site immediately. The GTP binds to the a-subunit to induce a 








agonist-receptor complex, reducing the affinity of the agonist for the receptor and thus 
freeing the receptor for an encounter with a neighbouring inactive G-protein. The binding
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of GTP to the heterotrimer also leads to reduced affinity of a  for Py, and subunit 
dissociation occurs. The a-GTP complex is now free and is allowed to fulfil its primary 
role as a regulator of effectors. In some systems, the free py-subunit may interact directly 
with an effector and modulate the activity of the active complex, or it may act 
independently at a distinct effector. The a-subunits possess an intrinsic GTPase activity 
and determine the lifetime of the species and the associated physiological response. The 
a-catalysed hydrolysis of GTP provides GDP in the binding site and causes dissociation 
and deactivation of the complex. The GTPase activity of the a-subunit is essentially an 
internal clock acting as an on/off switch. The a-GDP complex has a high affinity for the 
Py-dimer, and subsequent reassociation of a-GTP with the Py-complex returns the system 
to a basal state.
2.4 Phospholipid-specific Phospholipase C
The enzyme responsible for hydrolysing the phospholipid, PtdIns(4,5)P2 is a 
phosphodiesterase, of the family of phospholipase C. The function of PLC is to 
hydrolyse the bond between the bridging oxygen and the phosphate. The products are the 
hydrophobic diacylglycerol and the water-soluble Ins(l,4,5)P3. The generation of these 
two second messengers set in motion many events that culminates in a particular cellular 
response, for example growth, movement and metabolism. A large number of receptors 
have been discovered which use this signalling pathway. The enzymes of the PLC family 
are regulated by receptors via two distinct pathways: these have been unambiguously 
identified as G-protein-mediated and tyrosine kinase-mediated regulation of the different 
PLC isoforms. Direct protein isolation and molecular cloning studies have revealed the 
presence of many PLC isoforms in mammalian tissue. The PLC isoforms are activated by 
different receptors and different mechanisms and their inhibition is mediated by several 
mechanisms, for example cyclic AMP-dependent protein kinase (PKA) and protein 
kinase C (PKC).
2.4.1 Phospholipase C Isoforms
Classification of PLCs for this review will be based upon sequence homology which 
includes only those enzymes with known amino acid sequences deduced from their 
respective complementary DNA (cDNA). Three families of phospholipase C have been 
established, p, y and 8. Each family has several subtypes which are designated by adding 
an arabic numeral after the Greek letter, for example PLC-pi, PLC-yl.[54]
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Although the amino acid sequence homology between different families of PLC is low, 
there is significant sequence homology shared by the three families, arbitrarily designated 
X and Y of ~ 170 amino acids and ~ 260 amino acids, respectively. t55J All the PLCs 
contain an amino-terminal of ~ 300 amino acids that precede the X region. Both PLC-P 
and PLC-5 contain sequences of 50-70 amino acids which separate the X and Y regions, 
whereas PLC-y is characterised by a longer sequence of ~ 400 amino acids, which contain 
the src homology (SH2 and SH3) domains; these were identified as noncatalytic regions 
common to a variety of src family tyrosine kinases. t56l In PLC-P the carboxyl terminal 
sequence which follows the Y region is ~ 450 amino acids long, but is nonexistent in 
PLC-5.
2.4.2 Properties of PLC's
All three families of PLC are dependent on calcium. I57-59] The Y sector of the PLC has 
tentitively been suggested as the binding site for Ca2+ on the evidence that this region is 
homologous to the Ca2+-binding domains of PKC and cytosolic phospholipase A2. 1561 
PLC-p, PLC-y and PLC-5 hydrolyse all three common myoinositol-containing 
phospholipids: phosphatidylinositol (Ptdlns), phosphatidylinositol 4-phosphate (Ptdlns 
4P), phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2]. The selectivity for 
PtdIns(4,5)P2 over Ptdlns, decreases in the order PLC-P 1 > PLC-yl > PLC-5. The 
hydrolysis of the three types of myo-inositol phospholipid may yield cyclic and noncyclic 
myoinositol phosphates. [61] It has been demonstrated that cells containing lower than 
normal concentrations of cyclic myoinositol phosphates grow to a lower density at 
confluence than cells with normal concentrations. 1621 A stereochemical analysis at the 
chiral phosphorus of the myoinositol phosphate, in the presence of H2lsO has shown that 
PLC initially generates cyclic myoinositol phosphate which is then released or converted 
into the noncyclic myoinositol phosphate, [63]
2.4.3 Activation of the PLC-P family
The nature of the PLC-p remained unknown until recently when the G-protein subfamily 
Gq, was identified and characterised by several laboratories (see section 2.3.1). A number 
of cDNAs have been sequenced and characterised which correspond to the a-subunits of 
the Gq subfamily. There are at least five distinct members of this family which have been 
named (see section 2.3.1). There is considerable homology in amino acid sequence
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between Gocq and G an with 88% of the amino acids being identical. However, G a14 and 
G a 16 possess only 55-60% homology with G aq, and none of the members of the Gq 
family possesses a site for pertussis toxin modification.
A mixture of G aq and G an has been purified I53] which activates PLC from bovine liver 
membranes that have been incubated with GTPyS. (GDP exchanges very slowly with 
GTPyS). When G aq and G an were reconstituted in the presence of GTPyS, only PLC-p 
1 was activated and not PLC-yl or PLC-51. l53l The affinity of the G-protein mixture for 
GTPyS was low, being 4pM for half-maximal activation. [641 A1F4" also activated PLC-p 
1 in the presence of G aq and G au . The two G-proteins were resolved and both were 
shown to stimulate the activity of PLC-pl.
The receptors which activate PLC-p via the Gq family are given in Table 5. It has been 
established that the second and third intracellular loops within the Mj muscarinic 
acetylcholine receptor interact with the PLC-activating G-protein. t65l When the agonist 
occupies the receptor, the heterotrimeric GDP-bound G aq dissociates to give the GTP- 
bound G aq complex which remains in the membrane. PLC-P 1 then binds the GTP- 
bound G aq via the carboxyl-terminal region of G aq and G an , which results in the 
activation of PLC-P 1.
The interaction between the Ga-subunits and PLC-P 1 have been analysed further by 
introducing the corresponding cDNA into COS-7 cells and measuring the corresponding 
formation of myoinositol phosphates, formed after stimulation with aluminium fluoride 
A1F4‘. [661 Cotransfection of G aq (or G an ) cDNA and PLC-P 1 cDNA resulted in even 
higher levels of myoinositol phosphate formation. A mutation of Gln-209 to Leu which 
constitutively activates G aq and G an resulted in persistent activation of PLC and higher 
levels of myoinositol phosphates. However, transfection with cDNAs of other G- 
proteins did not increase myoinositol phosphate formation. Thus, only G aq and G an 
activates PLC-P 1 responsible for myoinositol phosphate formation.
Purified G aq only stimulated PLC-pl and not PLC-p2. [67] All the G-proteins of the Gq 
family stimulate PLC-pl, with G aq and G an being most effective. G-Protein G a16 was 
found to activate PLC-P2 most effectively, thus there appears to be specificity for the 
interaction of certain Gq-proteins with different members of PLC-p enzymes. This 
specificity is probably important in generating receptor-specific responses in vivo.
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The G-protein signalling transduction pathway has been established for the peptide 
cytokine interleukin-8 (IL-8).[68J Interleukin-8 is one of the most potent chemoattractants 
for neutrophils. I69] Interleukin-8 also induces angionesis, mediates cytokine-induced 
transendothelial neutrophil migration, l70l and triggers many other effects associated with 
the inflammatory response. t69i The complementary DNA (cDNAs) which encodes two 
distinct types of IL-8 receptors a  and p, has been cloned and sequenced. 171-73] These IL-8 
receptors couple to G-proteins and activate PLC in neutrophils. t69l In order to determine 
whether the two IL-8 receptors, IL-8Ra and EL-8Rp, transduce signals via the known Gq 
family, it was necessary to cotransfect COS-7 cells with cDNA's encoding IL-8Ra or IL- 
8RP either alone or together with G aq, G an , G a14, G a15, or G a16. However, 
reconstitution was not observed with cells that overexpressed G aq, or G an . The IL-8 
receptors were able to interact with endogenous pertussis toxin-sensitive G-proteins or 
with the recombinant Gj-protein, which released free Py-subunits and activated PLC-p2. 
Thus it was found that the cytokine IL-8 acted through G-proteins via PLC-P2 with an 
increase in myoinositol phosphates. The enzyme PLC-P2 may therefore be a potential 
target for the selective action of anti-inflammatory drug design. t68l
2.4.4 Regulation of PLC-p Mediated by Protein Kinase C
There is evidence [74] to support the claim that protein kinase C and protein kinase A (in 
other systems) attenuate receptor-coupled PLC activity in different cell types, which 
provides a negative feedback loop so as to control precisely the receptor signalling. PLC- 
Pl can be phosphorylated by protein kinase C, but is not a substrate for protein kinase A. 
Phorbol myristate acetate (PMA) stimulated the phosphorylation of a serine residues (Ser- 
887) of PLC-pl, but not of PLC-51, and only a small increase for PLC-yl in cell lines 
PC 12, C6BuI and NIH 3T3 was observed. I74l Protein kinase C can also phosphorylate 
stoichiometrically Ser-887 of PLC-pl in vivo. It has been proposed that the 
phosphorylation of PLC-P 1 by protein kinase C may alter its interaction with Gq. [741
2.5 Types of my o-Inositol Phospholipids
There are several types of myo-inositol containing phospholipids: these include 
phosphatidylinositol (Ptdlns) (9), phosphatidylinositol 4-phosphate [PtdIns(4)P] (10), and 
phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2] (11) (Figure 8) which together 
constitute 2-8% of the total phospholipid. Ptdlns accounts for over 80% of the total myo-
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inositol phospholipid [75’76] and is mainly found in the endoplasmic reticulum: the 
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Recent developments have indicated the presence of several other minor myoinositol 
phospholipids. Phosphatidylinositol 3-phosphate [PtdIns(3)P] (12) has been discovered 
in intact polyoma middle T-antigen transformed fibroblasts. [77] Later, this phospholipid 
was also found in non-transformed fibroblasts, I78l astrocytoma cells [79J and in NG 115- 
401L-C3 neuroblastoma cells. t8°J Phosphatidylinositol 3,4-bisphosphate [PtdIns(3,4)P2]
(13) has been detected in smooth muscle cells. [81’82] Phosphatidylinositol 3,4,5- 
trisphosphate [PtdIns(3,4,5)P3] (14) has also been found in stimulated neutrophils, l83*84! 
smooth muscle cells, macrophage cell lines and rat cerebrum. [81.85,86] The identification 
of the myoinositol phospholipids was based upon deacylation and degradation of these 
lipids, followed by ion exchange high performance liquid chromatography of the 
remaining myoinositol phosphate moiety. The level of PtdIns(3)P, PtdIns(3,4)P2 and 
PtdIns(3,4,5)P3, in macrophage cell lines, is 0.2-3.2% of the levels of PtdIns(4)P. 
Furthermore, these myoinositol phospholipids are present in trace amounts and they are 
not substrates for phospholipase C. I78l The 3-phosphoinositides may possibly undergo 
further metabolism, for example dephosphorylation.[87]
21
2.5.1 Phosphoinositide Kinases
Recently, distinct forms of phosphoinositide kinase have been isolated and characterised. 
Phosphoinositide 3-kinase was purified from fibroblasts t88l and later, to near 
homogeneity from bovine brain cytosol. [89] Phosphoinositide 3-kinase specifically 
phosphorylates Ptdlns at the 3-position, has a high affinity for ATP and is strongly 
inhibited by detergents. Phosphoinositide 3-kinase will also phosphorylate PtdIns(4)P 
and PtdIns(4,5)P2 to give the respective products PtdIns(3,4)P2 and PtdIns(3,4,5)P3. *891 
Another phosphoinositide kinase with a lower molecular mass than phosphoinositide 3- 
kinase, may be distinguished from the latter enzyme in that it is an integral membrane 
protein that only phosphorylates the 4-position of Ptdlns, and is activated by detergents 
and inhibited by adenosine. A third type of phosphoinositide kinase present in brain also 
phosphorylates the 4-position, but has a larger molecular mass and a lower affinity for 
ATP than the second type of phosphoinositide kinase. Phosphoinositide 5-kinases exist 
in both soluble and particulate forms. The 5-kinase enzyme phosphorylates PtdIns(4)P 
but not Ptdlns. It was suggested that PtdIns(4)P 5-kinase in brain membranes may be 
activated by GTP and its nonhydrolysable analogues, an effect apparently not mediated 
via an inhibition of phosphomonoesterase or PLC activities. I90*91! Another way of 
regulating PtdIns(4)P 5-kinase may be via a brain-specific protein B50 which upon 
phosphorylation by protein kinase C inhibits PtdIns(4)P 5-kinase.[92]
2.5.2 Phosphatidylinositol 3-Kinase
The enzyme is a heterodimer whose subunit molecular weights are 85kDa and llOkDa. 
Two complementary DNA clones for the 85kDa subunit p85a and p85P have been 
isolated. [93»94] The two polypeptides do not possess intrinsic phosphoinositide 3-kinase 
activity, however, p85a exists in a tightly bound complex with the llOkDa protein, 
thought to be the catalytic subunit. t95l The p85a and p85p polypeptides possess an 
amino-terminal SH3 domain and two SH2 domains. The SH2 domains of p85a and p85P 
allow interaction with phosphotyrosine-containing sequences in activated growth factor 
receptors and possibly with tyrosine phosphorylated substrates of receptor tyrosine 
kinases. t96'99] The p85 proteins may serve as adaptors that bring the catalytic domains of 
the 3-kinase llOkDa subunit into apposition with the activated tyrosine kinases. This 
association may activate the 3-kinase by translocating it to the inner surface of the plasma 
membrane where PtdIns(4,5)P2 is located. The translocation of phosphoinositide 3- 
kinase may be carried out by the SH3 domain of p85 l10°] because SH3 domains of other
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proteins mediate interactions with the cytoskeleton. The larger subunit (pllOkDa) also 
shows sequence homology with VPS34, which has an undefined role in sorting proteins 
destined for the yeast vacuole, an intracellular hydrolytic compartment. I1013 The yeast 
mutants defficient in VSP34 exhibit decreased phosphoinositide 3-kinase activity. I101l
The evidence that phosphoinositide 3-kinase activation is crucial to mitogenic signalling 
by growth factor receptor kinases has been gathered from experiments involving the 
deletion of "kinase insert" regions from the intracellular domains of the platelet-derived 
growth factor (PDGF) receptor. Deletion of the kinase insert region abolishes the effects 
of stimulation of the receptors and selectively destroys the ability of the receptor to 
activate phosphoinositide 3-kinase, [102J Several recent reviews have covered the 
structure and function of this enzyme. £103,104]
2.5.3 Properties and Signalling Role of PtdIns(3,4,5)P3
The occurrence of PtdIns(3,4,5)P3 is well established, however the physiological 
significance of PtdIns(3,4,5)P3 is not known at present, although it is commonly accepted 
to be a signalling molecule. PtdIns(3,4,5)P3 is probably not involved in the synthesis of 
Ins(l,3,4,5)P4 because it is not a substrate for PLC.
Many agonists such as as formylated Met-Leu-Phe (fMLP), platelet-activating factor
(PAF), ATP and several nonhydrolysable guanine nucleotides stimulated the
accumulation of PtdIns(3,4,5)P3 in intact neutrophils. [105] This accumulation of 
PtdIns(3,4,5)P3 is rapid and apparently not driven by activation of other known signalling 
pathways. I106l These factors have led to the suggestion that PtdIns(3,4,5)P3 was a new 
"second messenger". This proposal is supported by two pieces of evidence. First, the 
agonists which cause the rapid accumulation of PtdIns(3,4,5)P3 also provide the signal for 
phosphoinositide 3-kinase activity, which can synthesise PtdIns(3,4,5)P3 in vitro. [107] 
Second, in whole cells PtdIns(3,4,5)P3 may be synthesised by phosphorylation of 
PtdIns(4,5)P2 at the 3-hydroxyl position.[1081 This observation implies that PtdIns(4,5)P2 
is being phosphorylated by phosphoinositide 3-kinase. PtdIns(3,4,5)P3 may also be 
synthesised from PtdIns(3,4,)P2 via a phosphoinositide 5-kinase, [1091 however, rapid 
degradation of PtdIns(3,4,5)P3 raises the possibility that an agonist-sensitive lipid 
phosphatase may drive the accumulation of PtdIns(3,4,5)P3. [108]
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The accumulation of PtdIns(3,4,5)P3 is elicited by a collection of receptors found on 
neutrophils, thought to generate their effects via G-proteins. I110! These receptors are 
unusual, since the majority of them are known to utilise either receptor or src-type protein 
tyrosine kinase activities to transduce their signals. [1071 Many protein tyrosine kinase 
receptors have been shown to cause translocation of phosphoinositide 3-kinase into 
signalling complexes in a manner that is dependent on both protein tyrosine kinase 
activity and the ability of the associating phosphoinositide 3-kinase to specifically 
recognise tyrosine phosphatase targets in the receptor-activated complex. t1071 Thus, a 
direct pathway by which receptors regulating protein tyrosine kinase activities might 
control a phosphoinositide 3-kinase has been established. No other form of receptor- 
controlled regulatory mechanism has been shown to interact with phosphoinositide 3- 
kinase activity. These factors have led to the expectation that the apparently anomalous 
situation presented by the capacity of G-protein-linked receptors to regulate 
PtdIns(3,4,5)P3 accumulation can be explained by a G-protein dependent regulation of a 
protein tyrosine kinase activity. Thus, a number of G-protein-linked receptors have been 
shown to activate tyrosine phosphorylation of proteins, f1111 and cause an increase in 
phosphoinositide 3-kinase activity in antiphosphotyrosine and/or anti src-type protein 
tyrosine kinase antibody-directed immunoprecipitates. I1121 However, in neutrophils these 
pathways may drive only a small proportion of the rapid accumulation of PtdIns(3,4,5)P3 
which may be elicited via G-protein-linked receptors and the majority (> 90%) is a result 
of a pathway which regulates a PtdIns(4,5)P2-directed phosphoinositide 3-kinase activity 
by a currently undefined mechanism. [112,113] T h is  major pathway for the synthesis of 
PtdIns(3,4,5)P3 is staurosporine-resistant which accumulates during the first 10-20s in the 
presence of a maximal effective dose of the agonist fMLP. 0121 Thus the predominant 
staurosporine-resistant pathways for the activation of phosphoinositide 3-kinase in 
neutrophils are unlikely to contain multiple steps between their G-proteins and the 
responsive phosphoinositide 3-kinase and could be direct.
It has been found that PtdIns(3,4,5)P3 is a potent activator of protein kinase C in the 
presence of phosphatidylserine and calcium ions. PtdIns(3,4,5)P3 may also play a role as 
an intracellular signal molecule which can aid the cross talk between two or more signals, 
for example the interaction between serine/threonine kinase and threonine/tyrosine 
kinase. 11141 The high negative charge density of PtdIns(3,4,5)P3 also indicates that the 
lipid may partake in a pH maintenance system, such as the Na+/H+ antiport mechanism.
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2.5.4 Other Functions of Phosphoinositides
myoinositol lipids play a crucial role in the maintenance of the cytoskeleton which is 
based upon the ability of PtdIns(4,5)P2 to bind to actin-binding proteins, for example 
gelsolin. The bound PtdIns(4,5)P2 aids the release of gelsolin from the actin filiament, 
thus regulating new filiament formation. t115l PtdIns(4,5)P2 also binds to profilin (KD < 
0.1 p.M) which inhibits actin polymerisation. I116l Thus PtdIns(4,5)P2 may guide actin 
polymerisation by regulation of the gelsolin-actin and the profilin-actin complexes. It has 
also been suggested that there is a direct role for phosphoinositides in exocytosis from 
chromaffin cells. [1171 It is the cytoskeletal element involved in exocytosis that is 
regulated by the phosphoinositides.
Preparations of a-actinin from striated muscle contain bound PtdIns(4,5)P2. However, a - 
actinin from smooth and striated muscle bind exogenous PtdIns(4,5)P2 with fairly high 
affinity. a-Actinin in vitro binds to F-actin and crosslinks actin filiaments, thereby 
increasing the viscosity of F-actin solutions. By adding PtdIns(4,5)P2 to a-actinin/G- 
actin solutions from either muscle preparation increased the viscosity markedly.[118] The 
results indicate that PtdIns(4,5)P2 is necessary for a-actinin to obtain maximum gelating 
activity.
Human brain contains an inositol lipid linked to glucosamine, mannose and 
ethanolamine. I119J Ptdlns glycans serve to anchor proteins to the outer cell membrane, 
thus increasing lateral mobility. The ethanolamine residue forms an amide by linking to 
the terminal carboxyl group of the protein; there is a mannose-containing glycan and a 
monoacetylated glucosamine residue linked to the 6-position of rayo-inositol via a 
glycosidic linkage. (For reviews see references [122,123]) jn brain, cell surface 
glycoproteins, for example Thy-1, are anchored to the membrane via glycosyl Ptdlns 
linkages, [124,125] the expression of the glycoproteins may be regulated during 
development. Fouchier and coworkers [1261 have demonstrated two types of PLC which 
are specific for glycosylated forms of Ptdlns. The bulk of the hydrophobic sn-1,2 
diacylglycerol moiety contains two long fatty acids linked to the sn-l and sn-2 hydroxyl 
groups of glycerol. First, stearic acid, a C18 saturated fatty acid linked to the sn-1 of 
glycerol. Second, arachidonic acid, a C20 unsaturated fatty acid consisting of four cis 
double bonds linked to the sn-2 position of glycerol. (Figure 8). This is not the case in 
Ptdlns anchors, where these fatty acid residues are replaced by myristate, octadecanol (as 
a 1-alkyl substituent), or docosanoate depending on the tissue source. The addition of
25
nerve growth factor to PC 12 phaeochromocytoma cells stimulated the production of 
[3H]myristate-labelled species of diacylglycerol (but not for [3H]arachidonic- 
diacylglycerol) and a myo-inositol phosphate glycan. I82l The latter may serve as an 
intracellular second messenger, which has been proposed for insulin action. l127l
2.6 Inositol Phosphate Receptors
Activation of PLC via G-proteins results in the formation of DAG and Ins(l,4,5)P3 by the 
hydrolysis of PtdIns(4,5)P2. Ins(l,4,5)P3 elicits an increase in Ca2+, released from non- 
mitochondrial stores. The release of calcium is specific for the D-isomer, is unaffected by 
known Ca2+-channel blockers, requires the presence of K+ and may occur even at low 
temperatures. (Ins(l,4,5)P3 receptors are reviewed in t128-130!). The effects of Ins(l,4,5)P3 
on Ca2+-release are mediated through intracellular receptors which were observed some 
time ago. The first demonstration of these sites was made in tissues such as liver and 
neutrophils. i131l The low levels of receptors present in these tissues precluded their direct 
characterisation. Higher levels of Ins(l,4,5)P3 receptors were then found in the central 
nervous system (CNS) where they are present in high density in the Purkinje cells of the 
cerebellum. U32,i33]
2.6.1 Purification and Characterisation of the Ins(l,4,5)P3 Receptor
The Ins(l,4,5)P3 receptor possesses intrinsic properties which reflect its biological 
function. For example, physiological levels of Ca2+ inhibit the binding of Ins(l,4,5)P3 to 
its receptor with an IC50 of 300nM [13*435] which implies that the Ca2+ released via the 
action of Ins(l,4,5)P3 feeds back to inhibit further Ca2+-release by Ins(l,4,5)P3. Raising 
the intracellular pH from 7.8 to 8.5 causes a 3-fold increase in the binding of Ins(l,4,5)P3 
to its receptor.
The high concentration of the Ins(l,4,5)P3 receptor in the endoplasmic reticulum (ER) of 
cerebellar Purkinje cells allowed Supattapone and coworkers to purify the receptor to 
homogeneity. [136] The potent inhibition of Ca2+-release by heparin binding to the 
Ins(l,4,5)P3 receptor Ii34,i37-i40] allowed the Ins(l,4,5)P3 receptor to be purified on 
heparin-agarose affinity columns. A second purification step utilised concanavalin-A 
Sepharose chromatography, taking advantage of the glycosylation of the Ins(l,4,5)P3 
receptor. The combination of both steps allowed an overall 1000-fold purification of the 
receptor. The same purification was also achieved using an Ins(l,4,5)P3 affinity column.
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U4i] when the protein was analysed by polyacrylamide gel electrophoresis (PAGE) it 
moved as a single 260kDa band. The native receptor is about lOOOkDa which indicated a 
homotetramer l136l and has been confirmed by cross-linking studies. l142l Ins(l,4,5)P3 
induced Ca2+-release may be positively cooperative, [143,144] indicating that the four 
subunits communicate with each other such that activation of one subunit increases the 
probability that another subunit will be activated. However, tritium-labelled Ins(l,4,5)P3 
binding to the purified receptor showed no evidence of cooperativity with a Hill 
coefficient of one. t136i
2.6.2 Regulation of Receptor Function and Calcium Release
Three different enzymes, cyclic AMP-dependent protein kinase (PKA), [i4s,i46] protein 
kinase C t146l (PKC) and Ca2+/calmodulin-dependent protein kinase (CAM-K-II) I146l may 
stoichiometrically phosphorylate a serine residue of the Ins(l,4,5)P3 receptor, albeit at 
different sites of the polypeptide chain, (Figure 9). The peptide chain was phosphorylated 









PKA, Ser-1755 was phosphorylated, but higher concentrations of this enzyme were 
required to phosphorylate the serine residue at position 1589. Following this work, Ferris 
and coworkers t148l also found that the Ins(l,4,5)P3 receptor could autophosphorylate. 
Positive evidence has come from renaturation experiments in which autophosphorylation 
has been seen on nitrocellulose membranes following SDS-PAGE. l148l The Ins(l,4,5)P3 
receptor can also phosphorylate a synthetic peptide, indicating that the Ins(l,4,5)P3 
receptor has intrinsic protein kinase activity. This phosphoiylation regulates the function 
of the Ins(l,4,5)P3 receptor. Receptor phosphorylation by PKA in cerebellar cell 
membranes decreases the potency of Ins(l,4,5)P3 to release Ca2+. I145l Since the 
phosphorylation of the Ins(l,4,5)P3 receptor by PKA stimulates the Ca2+ pump, the 
endoplasmic reticulum Ca2+ levels are increased so that the absolute amount of Ca2+ 
released by Ins(l,4,5)P3 is enhanced. l145l Cyclic AMP-dependent hormones increase 
Ins(l,4,5)P3-induced Ca2+-release in liver cells. [149] Phosphorylation of the Ins(l,4,5)P3 
receptor by CAM-K-II and PKC may provide some feedback regulation of the Ptdlns 
cycle, following the production of DAG which stimulates the action of PKC, and release 
of Ca2+ by Ins(l,4,5)P3, which activates PKC and CAM-K-II. A cerebellar-specific form 
of CAM-K-II present in high concentrations in Purkinje cells [iso-is2] js found in a similar 
location to the Ins(l,4,5)P3 receptor.
The Ins(l,4,5)P3 binding protein also contains a calcium channel. Evidence for this has 
come from experiments using lipid vesicles containing the Ins(l,4,5)P3 receptor in the 
reconstituted membrane. Experiments using lipid vesicles allowed 45Ca2+-release by 
Ins(l,4,5)P3 to be measured. F53] Ca2+-release by Ins(l,4,5)P3 reflects the affinity of 
Ins(l,4,5)P3 at its binding sites. Heparin, an antagonist of Ins(l,4,5)P3 binding and Ca2+- 
release, demonstrated the Ins(l,4,5)P3 receptor contained the Ins(l,4,5)P3 recognition site 
and a Ca2+-channel.[153]
ATP has been shown to regulate the Ins(l,4,5)P3 receptor in an allosteric manner. [154] 
Between 1 and 10|iM, ATP cooperatively enhances the ability of Ins(l,4,5)P3 to release 
Ca2+. This effect is biphasic, since increasing the concentration of ATP to physiological 
levels of O.l-l.OmM diminishes the effect of Ins(l,4,5)P3 on Ca2+-release. At 
physiological concentrations of ATP (about ImM), one would expect no obvious 
influence of this adenine nucleotide on the action of Ins(l,4,5)P3. Once Ins(l,4,5)P3 has 
released Ca2+, the Ca2+-dependent ATPase would be activated in order to replenish the 
Ca2+ stores, which deplete ATP near the Ins(l,4,5)P3 receptor. The ATP bound with low
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affinity will then dissociate and the release of Ca2+ would be increased in a feed forward 
manner. When ATP concentrations are further depleted then the ATP bound with high 
affinity would dissociate and the release of Ca2+ by Ins(l,4,5)P3 would fall, possibly 
protecting the cell from harmful fluctuations of Ca2+ levels. This model may also 
contribute to the spike-like changes in intracellular Ca2+ concentrations associated with 
Ca2+ oscillations uss-issj ancj help account for the marked cooperativity of Ins(l,4,5)P3- 
induced Ca2+-release. t159460]
Ca2+ release by Ins(l,4,5)P3 in permeablised pancreatic acinar cells is a noncontinuous 
process, such that submaximal Ins(l,4,5)P3 concentrations release submaximal amounts 
of Ins(l,4,5)P3-sensitive Ca2+ stores I161J even under conditions where the Ins(l,4,5)P3 is 
not degraded. This activity may be described as "quantal" since subfractions of 
Ins(l,4,5)P3-sensitive Ca2+ stores are activated by Ins(l,4,5)P3. The quantal release of 
Ca2+ in purified reconstituted Ins(l,4,5)P3 receptor indicate that the phenomenon is a 
property of the Ins(l,4,5)P3 receptor. I162l Ca2+ channels are not activated by submaximal 
Ins(l,4,5)P3 concentrations in the reconstituted system. l162l The successive addition of 
Ins(l,4,5)P3 provide an arithmetic increase in Ca2+-release over a range of 10-200nM 
Ins(l,4,5)P3. P62l Ca2+ signalhng is complex involving oscillations and waves, I156,i58] so 
the sequential release properties of the Ins(l,4,5)P3 receptor are critical for the regulation 
of Ca2+ concentrations in all cells.
A recent study l163l has demonstrated a Ca2+-induced degradation of the neuronal 
Ins(l,4,5)P3 receptor which generated two fragments of 130 and 95kDa. The fragments 
retained immunoreactivity towards a C-terminal-specific antibody, so presumably they 
are derived from the part of the receptor where the Ca2+-channel domain is located. The 
results may indicate that activation of the Ins(l,4,5)P3 receptor, by causing an increase in 
intracellular Ca2+ concentration may result in degradation of the N-terminal, Ins(l,4,5)P3 
binding receptor site. The Ins(l,4,5)P3 receptor was shown to be an excellent substrate 
for a purified Ca2+-activated enzyme from the calpain family which are nonlysosomal 
proteolytic enzymes, are active at physiological pH and require millimolar or micromolar 
calcium ions for activation. Calpains may be autolytically cleaved by Ca2+ ions, thereby 
increasing the sensitivities of these enzymes so they become responsive to fluctuations of 
physiological Ca2+ ion concentration. Thus, it is possible that the increase in Ca2+ ion 
concentration could induce degradation of the Ins(l,4,5)P3 Ca2+-channel.
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2.6.3 Cloned Ins(l,4,5)P3 Receptors
The Ins(l,4,5)P3 receptor was originally identified as a 400kDa cerebellar membrane 
glycoprotein designated P400 localised to Purkinje cells t164l of normal mice, but was 
reduced in Purkinje cell-deficient mutants. P400 is a glycoprotein with a molecular mass 
of 250kDa on SDS-PAGE and highly enriched in the cerebellum. The Ins(l,4,5)P3 
receptor gene was cloned and its amino acid sequence determined. t165l On the basis of its 
cDNA sequence, P400 comprised 2749 amino acids with a molecular mass of 313kDa, a 
value greater than that obtained by SDS-PAGE. This difference in molecular mass may 
be due to either an aberrant electrophoretic migration of the protein or posttranslational 
proteolytic processing. Purified P400 bound [3H]Ins(l,4,5)P3 in a saturable and specific 
manner analogous to that observed for the purified Ins(l,4,5)P3 receptor. t166l Definitive 
proof that P400 and the Ins( 1,4,5)P3 receptor are identical was obtained from experiments 
in which transfection of P400 cDNA into NG108-15 cells resulted in the expression of 
Ins(l,4,5)P3-binding sites. t165J The Ins(l,4,5)P3 receptor is highly conserved among 
mammals, because the sequences in rodents and humans differ by less than 10% and only 















A model for the Ins(l,4,5)P3 receptor is shown in Figure 10. A subunit consists of six or 
eight transmembrane domains.[165] In the eight subunit domain, the first four are flanked 
by net positive charges and the last four by net negative charges. The last four domains 
show closest homology with the ryanodine receptor, the Ca2+-stimulated Ca2+-release 
channel of muscle, so they are likely to comprise the Ca2+-permeable pore.
Mutagenesis studies have shown that the Ins(l,4,5)P3 binding site lies in the amino- 
terminal 400 amino acid residue since when this domain is deleted Ins(l,4,5)P3 does not 
bind to the receptor, l165^ Moreover, the receptor retaining only the N-terminal quarter of 
the molecule provides soluble peptides which are monomeric but retain the ability to 
bind. 1165,166] xhe N-terminal peptide binds Ins(l,4,5)P3 with substantially less affinity 
than does the full receptor protein, therefore the overall conformation of the intact protein 
may be important for physiological Ins(l,4,5)P3 binding. If the Ins(l,4,5)P3 binding site 
is present at the N-terminal end of the protein and the Ca2+ channel is regarded as being at 
the extreme C-terminal, then Ins(l,4,5)P3 binding must elicit a conformational change 
over a span of 1400 amino acids. Both sites for serine phosphorylation by PKA, t147i as 
well as the ATP binding sites [1671 are located in the "coupling region" between domains 
for Ins(l,4,5)P3 binding and the Ca2+ channel, where these regulatory sites may affect the 
ability of Ins(l,4,5)P3 to open the Ca2+ channel.
Other receptors of the same family, derived from different genes have been identified. 
The complete sequences of three members of this family, designated type-1 [165] type-2 
[168] type-3 f169^ have been reported as well as partial cDNA's for two other subtypes. 
[168,170] xhe original Ins(l,4,5)P3 receptor is designated the type-1 receptor. The type-2 
receptor has significant homology with type-1 receptor especially in Ins(l,4,5)P3 binding 
and transmembrane domains.[168] The type-2 receptor has a significant higher affinity for 
Ins(l,4,5)P3 than type-1 receptor. A specific tissue may also contain more than one 
different receptor-type, which raises the possibility that intracellular Ca2+ signalling may 
involve multiple pathways having different regulatory properties on different receptor- 
type transduction pathways.
Receptor type-3 is 2670 amino acids in size and has 62% and 64% identity with type-1 
and type-2 receptor respectively. The expression of recombinant rat type-3 receptor in 
COS-7 cells demonstrated its ability to bind Ins(l,4,5)P3, Ins(l,3,4,5)P4 and 
Ins(l,2,3,4,5,6)P6. Other studies have shown the type-3 receptor to be wicely distributed 
in the endoplasmic reticulum. t169l The type-3 receptor is predominantly expressed in
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pancreatic islets over type-1 and type-2 indicating that type-3 may be responsible for 
initiating the effects of Ins(l,4,5)P3 on insulin secretion. Finally, the type-3 receptor does 
not appear, at present, to be a substrate for the kinases that are responsible for 
phosphorylation of type-1 receptor.
A relative of the Ins(l,4,5)P3 receptor is the ryanodine receptor. U 65,171,172] Ryanodine is 
an alkaloid that binds to a protein responsible for CICR from the sarcoplasmic reticulum 
of striated muscle as a key component of excitation-contraction coupling. [173,174] Both 
Ins(l,4,5)P3 and ryanodine receptors possess Ca2+ channels to promote Ca2+-release. 
Both types of receptor are large homotetrameric proteins and the tetramer of the receptor 
binds three to four molecules of Ins(l,4,5)P3. t159l ATP induces Ca2+-release in the 
ryanodine receptor, but in the Ins(l,4,5)P3 receptor, ATP enhances the stimulation of 
Ca2+-release by Ins(l,4,5)P3. Ryanodine receptors are concentrated in skeletal and 
cardiac muscle, whereas Ins(l,4,5)P3 receptors are at their highest levels in smooth 
muscle and brain.
2.7 The Role of Ca2+ in the Cell
When life started, the oceans were more alkaline than at present, with micromolar 
concentrations of Ca2+. I175i A phosphate-based metabolism would have been difficult if 
Ca2+ concentrations were higher. In eukaryotes, the Ca2+ concentration is several orders 
of magnitude higher in the extracellular space than in the cytoplasm. This situation of 
Ca2+ concentration arose through evolution, in order to protect phosphate-based 
metabolism in cells, because high concentrations of calcium would cause calcium 
phosphate solubility products to be exceeded. During evolution has seen how 
concentration gradients of calcium have been exploited to provide a rapid intracellular 
signalling mechanism.
Ringer, in 1883 [1761 was the first to publish an effect of calcium on cell function. He 
observed that cardiac muscle could not continue to beat in vitro without a minimum 
concentration of extracellular calcium. Much later other groups [177478] discovered new 
roles for Ca2+ in a variety of cell types. The signalling function of this cation is brought 
about by the interaction of specific Ca2+-binding proteins with low calcium 
concentrations, resulting in phosphorylation, or enzyme activation, depending on the 
target for Ca2+-binding protein. [179,180] other aspects of Ca2+ in cell function include 
fertilization of oocytes, control of cell growth, beating of the heart, transmission of nerve
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impulses, contraction of skeletal and vascular muscle, the clotting of blood, and the 
secretion of hormones and digestive enzymes.
2.7.1 Regulation of Intracellular Ca2+ An Overview
Cells maintain a basal cytosolic free Ca2+ concentration [Ca2+]j in the order of 50-200nM, 
whereas the extracellular concentration of Ca2+ is normally in the millimolar range. This 
occurs by active extrusion of Ca2+ across the plasma membrane and sequestration of Ca2+ 
within the cell by pumping Ca2+ into intracellular compartments or by binding of Ca2+ to 
structures such as cytosolic proteins. There are two mechanisms for removing Ca2+ from 
the cell, both of them involve the plasma membrane. First, ATP fuels a Ca2+-ATPase and 
pumps Ca2+ out of the cell. fl81’184l Second, at the expense of a Na+ ion gradient, 
intracellular Ca2+ is removed by the cell in a Na+/Ca2+ exchanger. t185l These mechanisms 
offset the continued passive influx of Ca2+ into the cytoplasm from the extracellular 
space. The leakage of Ca2+ occurs through specialised channels, present in the plasma 
membrane. Also present are intracellular compartments which sequester Ca2+ via Ca2+- 
pumping mechanisms. These compartments include the endoplasmic reticulum and 
mitochondria. P86l Specialised Ca2+-sequestering organelles exist which are cell specific; 
these include the sarcoplasmic reticulum of muscle fibres [187] and the dense tubular 
system of platelets. A Ca2+ channel is located in the membranes of the intracellular 
organelles which in some instances may be controlled by certain small molecules such as 
Ins(l,4,5)P3, releasing Ca2+ into the cytoplasm.
2.7.2 Ca2+ Regulation via Ins(l,4,5)P3
The mobilisation of Ca2+ ions via the phosphoinositide signalling pathway involves two 
phases. First, Ca2+-release from an intracellular store and second, a longer phase of 
extracellular Ca2+ entry, [i®*489] in the absence of extracellular Ca2+, agonist stimulation 
via the phosphoinositide signalling pathway results in a transient increase in [Ca2+]i5 
originating from the release of a finite intracellular Ca2+ pool. When physiological (mM) 
extracellular Ca2+ is present, the elevation in [Ca2+]j is sustained due to the additional 
component of extracellular Ca2+ influx. Extracellular Ca2+ influx is also the source for 
refilling of the intracellular Ca2+ pool upon termination of receptor activation.
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2.7.3 Ca2+-Release
The early studies of Ca2+ release by Ins(l,4,5)P3 identified the Ca2+-release pool as the 
endoplasmic reticulum (ER) because Ca2+-release occurred in the presence of toxins 
which inactivate the mitochondrial. Subsequently, the Ca2+-release pool was thought to 
reside in a highly specialised component of the ER, or a unique Ca2+-releasing organelle 
termed the "calciosome". [190] The evidence for supporting either the ER or the 
calciosome or both comes from two experimental approaches: first, analysis of the 
functional organisation of the Ins(l,4,5)P3-sensitive Ca2+ pool: second, the identification 
of its location within the cell and its relation to other cellular compartments.
Only a fraction of the total Ca2+ is released by Ins(l,4,5)P3 in permeabilised cells. This 
may indicate segragation of some of the Ins(l,4,5)P3-regulated Ca2+-release sites from the 
entirety of the Ca2+ uptake and storage capacity available within the cell. It may be 
possible that some of the nonmitochondrial Ins(l,4,5)P3-insensitive Ca2+ pools (for 
example CICR) are also involved in Ca2+ signalling. This segregation may in part be an 
artifact of the permeabilisation process. I191-193] When cells are permeabilised the 
apparent communication mechanism between Ins(l,4,5)P3-sensitive and Ins(l,4,5)P3- 
insensitive Ca2+ pools is disrupted. GTP can cause a link between the Ins(l,4,5)P3- 
sensitive and insensitive Ca2+ pools in several permeabilised systems. A segregation of 
Ca2+-release and uptake sites has also been observed in rat parotid cells under 
circumstances [194] where Ca2+-release was induced by the 5-phosphatase resistant 
analogue of Ins(l,4,5)P3, myo-inositol-l,4,5-trisphosphorothioate, Ins(l,4,5)PS3 was 
rapidly resequested into the Ins(l,4,5)P3-sensitive pool. The compartment involved in 
Ca2+-release was structurally different from the compartment within the pool for the 
reuptake of Ca2+. In the presence of Ins(l,4,5)P3 there was no substantial reuptake into 
the Ins(l,4,5)P3-sensitive pool. Thus, it may be concluded that a kinetic delay in 
translocation of Ca2+ from uptake to release sites was caused or exaggerated by cell 
permeabilisation. This may result from distinction of the translocation of Ca2+ between 
the uptake and release sites. It should be noted that GTP has no effect on the kinetics of 
translocation of Ca2+ between the uptake and release sites in the parotid cells, [1941 
indicating that different mechanisms are involved in this system. These two lines of 
experimental evidence suggest there is at least some separation of Ins(l,4,5)P3-sensitive 
Ca2+-release and uptake sites. This separation is reminiscent of that attributed to skeletal 
muscle sarcoplasmic reticulum (SR) l195l and, based on the observed effects of GTP in
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various permeabilised cells, it is likely to be a general phenomenon in nonmuscle cells as 
well.
2.7.4 Capacitive Ca2+ Entry
Ins(l,4,5)P3 binds to its receptor to release Ca2+, followed by a subsequent entry of Ca2+ 
from the extracellular space. However, Ins(l,4,5)P3 may not directly activate the entry of 
Ca2+ since application of Ins(l,4,5)P3 to plasma membranes has no effect on Ca2+ 
permeability. U96-198] Thus, it appears that Ca2+ entry is activated by the emptying of the 
Ins(l,4,5)P3-sensitive pool, t1"! When phosphoinositide turnover takes place, the Ca2+ 
pool is emptied and the pathway for Ca2+ entiy from the extracellular space is open. This 
mechanism has been termed "capacitative Ca2+ entry" [1" l  and is supported by several 
pieces of experimental evidence.
2.7.5 Ca2+ as a Signal for Ca2+ Entry
It has been demonstrated that that Ca2+ flows directly into the pool during refilling using 
the Ca2+ indicator fura-2. This has been used to monitor changes in cytosolic Ca2+ in 
acinar and parotid cell types. [200*2021 A piece of evidence to support the capacitative 
model was shown in parotid cells, which were stimulated with the muscarinic agonist 
methacholine, in a Ca2+-free medium, followed by treatment with the receptor antagonist 
atropine and extracellular Ca2+ to produce an elevation of [Ca2+]j. The elevation of 
[Ca2+]i produced under these conditions was larger than that produced by the addition of 
Ca2+ to unstimulated cells in a Ca2+-free medium. The elevation of [Ca2+]j on the 
addition of Ca2+ was seen 20min after the addition of atropine, although it is not seen if 
the intracellular stores were first allowed to refill. It was also discovered that thapsigagin 
[203] (the nonphorbol ester tumour promotor) releases intracellular Ca2+ by a mechanism 
which eliminates the need for phosphoinositide turnover. t202l Thapsigargin is a toxin 
which depletes intracellular Ca2+ stores by a specific action on the Ca2+-ATPase on 
intracellular membranes; it does not, however, inhibit active Ca2+ transport by the plasma 
membrane of cells. l203l In the presence of extracellular Ca2+ this agent induces a 
sustained increase in [Ca2+]j, which in turn depends on extracellular Ca2+; in other words, 
it results from Ca2+ entry. However, when the muscarinic agonist methacholine, is added 
to cells during Ca2+ entry induced by thapsigargin, only a small transient increase in 
[Ca2+]j was achieved, which then returned to the level produced by thapsigargin alone. 
This indicated that the Ca2+ entry induced by the toxin is not additive with that induced
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by the agonist. Methacholine and thapsigargin thus appear to activate the same 
mechanism for Ca2+ entry.
Another study i204l has examined divalent cation entry into single human umbilical vein 
endothelial cells. Earlier it was demonstrated that histamine and thrombin stimulate Ca2+ 
entry into these cells, t205*206! in such studies, manganese ions (Mn2+) were used which 
bind to fura-2 with high affinity and quench its fluorescence, so that the rate of quench of 
fluorescence of intracellular fura-2 when Mn2+ is present extracellularly is taken as a 
measure of surface membrane divalent cation permeability. In many cell types Mn2+ 
enters through the same channels as Ca2+. [2071 When Mn2+ is added during histamine 
receptor stimulation, Mn2+ entry coincides with intracellular Ca2+-release. When 
histamine stimulation occurs to deplete intracellular stores and Mn2+ is added, then Mn2+ 
entry also occurs. However, if external Ca2+ is added (allowing the stores to refill) before 
the addition of Mn2+ then there is no Mn2+ entry, indicating that Mn2+ only enters the cell 
if the Ca2+ stores are depleted. It was found that the rate of Mn2+ entry varies inversely 
with the Ca2+ content of the intracellular stores. These results do not reveal a mechanism 
for this phenomenon. The emptying of the intracellular stores may influence the 
permeability of the plasma membrane at some distance in which case it may be 
considered that this communication could be accomplished through some kind of 
intracellular signalling.
2.7.6 Metabolites of Cytochrome P-450
There is recent evidence indicating that the binding of Ins(l,4,5)P3 followed by Ca2+ 
release is not a sufficient stimulus for initiating Ca2+ influx. One such finding suggests 
that a product of the oxidative cytochrome P-450 enzyme system somehow produces a 
messenger for Ca2+ entry. I208*209! Several compounds that inhibited cytochrome P-450 
were also found to inhibit Ca2+ entry and therefore provided a correlation between the two 
inhibitory activities appears to exist. 1210-212] However, these compounds also inhibit 
Ca2+-activated K+ channels.[213] Ca2+ entry and Ca2+-activated K+ channels are regulated 
by different mechanisms, therefore the compounds may block the Ca2+ entry channels 
themselves, rather than the formation of the unknown messenger which activates the 
channel.
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2.7.7 The Possible Role of Ins(l,3,4,5)P4 and Ins(l,3,4,6)P4 in Ca2+ Influx
Two myoinositol tetrakisphosphates, namely Ins(l,3,4,5)P4 and Ins(l,3,4,6)P4 have 
longer half-lives in cells than Ins(l,4,5)P3 and may have a direct role in Ca2+ regulation 
because both compounds are capable of Ca2+ release from the Ins(l,4,5)P3 sensitive 
stores. I214*218] The efficacy of both compounds however, is much lower than that of 
Ins(l,4,5)P3, which may indicate that the major role for these two compounds is not as a 
mobiliser of Ca2+ ions. However, there is evidence that Ins(l,3,4,5)P4 may somehow act 
in concert with Ins(l,4,5)P3.1219*22*)] This hypothesis is the subject of intense discussion. 
One piece of evidence has refuted it, l221l but the converse suggestion has been made that 
in cells which overexpress the 3-kinase enzyme, the accumulation of Ins(l,3,4,5)P4 may 
be a negative regulator of the Ca2+-phosphoinositide signal transduction pathway. [222J
Several pieces of experimental evidence have contributed towards explaining the 
confusion. First, in Xenopus oocytes, there appears to be a marked degree of synergism 
between Ins(l,4,5)P3 and Ins(l,3,4,5)P4 in controlling Ca2+ entry. I223l Second, several 
reports have indicated that emptying the Ins(l,4,5)P3-sensitive Ca2+-stores is not a 
sufficient stimulus for initiating Ca2+ influx. l224-226] Third, in the absence of Ins(l,4,5)P3 
it has been demonstrated that Ins(l,3,4,5)P4 alone can activate a low conductance (2.5 
picosiemens) divalent cation channel in inside-out patches prepared from endothelial cell 
plasma membranes.
It has also been demonstrated that high concentrations of Ins(l,4,5)P3 (>100pM) and the 
non-phosphorylatable Ins(2,4,5)P3, caused mobilisation and influx of Ca2+ ions in the 
absence of Ins(l,3,4,5)P4. I221l A report demonstrated a Ca2+-induced Cl" current l224i 
whose regulation mirrored the behaviour described previously. I221l Another group f225l 
has shown that Ins(l,4,5)P3 and Ins(l,3,4,5)P4 can independently activate Ca2+-release 
from crude microsomal preparations of lymphoid cell lines, indicating the presence of 
sub-populations of Ins(l,4,5)P3- and Ins(l,3,4,5)P4-sensitive vesicles. Ca2+ was released 
from enriched plasma membranes from U937 cells by low concentrations of 
Ins(l,3,4,5)P4, but only by much higher concentrations of Ins(l,4,5)P3. This effect of 
Ins(l,3,4,5)P4 was lost in the presence of detergents which was interpreted as showing 
that Ins(l,3,4,5)P4 induced a Ca2+ influx across the plasma membrane in the absence of 
Ins(l,4,5)P3, perhaps by a specific Ins(l,3,4,5)P4-activated ion channel. This work has 
been reviewed in two references. I227*228!
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2.7.8 Calcium Influx Factor (CIF)
The concentration of Ca2+ outside the cell is some 10,000 times higher than inside the 
cell. When Ins(l,4,5)P3 binds to its receptor Ca2+ is released from intracellular stores, 
however, what is not known is how the empty Ca2+ stores signal to the plasma membrane 
allowing the intracellular stores to be refilled.
Two pieces of evidence, the first by Randriamampita and Tsien [2291 indicated that a novel 
molecule gated this entry mechanism, at least in certain cell types. This group partially 
characterised an anionic compound with a molecular mass less than 500, which had 
hydroxyl, and/or amino groups, on adjacent carbons, together with at least one phosphate 
group. This molecule has been named calcium influx factor (CIF). Calcium influx factor 
is produced (in an unknown manner) by cells whose Ca2+ stores have been depleted. It 
appears that CIF moves from organelles to cytoplasm and across the cell membrane into 
the supernatant where it may stimulate adjacent cells. A group of cross-desensitisation 
experiments has demonstrated that CIF is not a known second messenger.
A second piece of evidence by Parekh, Terlau and Stiihmer [23°l independently supports 
the main aspects of CIF. They used Xenopus oocytes which express exogenous serotonin 
receptors (5-HTlc) and it was demonstrated that an /cRAc-like current is enhanced by 
okadaic acid. Okadaic acid is a phosphatase inhibitor: thus the removal of a covalently 
bound phosphate by an okadaic acid-sensitive phosphatase may inactivate the messenger 
or protein that that has become phosphorylated as a result of the action of the messenger. 
This result agrees with the previous finding of Randriamampita and Tsien, [2291 in so 
much as the CIF contains at least one phosphate group and the activity of this messenger 



















CIF is released from an intracellular organelle when the stores of Ca2+ are depleted. The 
CIF opens influx pathways, presumably ion channels that allow Ca2+ back into the 
cytoplasm where Ca2+-ATPase transporters pump it back into the cell's stores, (Figure 
11). The cell also uses other proteins to refill Ca2+ stores such as voltage-activated Ca2+- 
channels and exchangers. In the last few years the ion channel responsible for a certain 
current named the calcium release-activated current / crac [231>232l has been identified. The 
current has a very low single-channel conductance (about 20 femtosiemens), has a high 
selectivity for Ca2+ ions over other divalent cations, and little or no voltage dependence 
for channel opening. The equilibrum potential for Ca2+ is +150 millivolts, so the more 
hyperpolarised the cell the greater the influx of Ca2+ through the Ca2+ channel.
Two papers which followed on from the discovery of CIF, presented evidence I231*232! for 
at least one GTP-dependent step for Ca2+ influx. Two GTP analogues, GTPpS and GTPy 
S both inhibit Ca2+ influx, l233*234! and this process somehow involves a GTP-binding 
protein and the hydrolysis of GTP rather than simple binding of GTP, which occurs with
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heterotrimeric G-proteins, and small G-proteins, such as ras. It is known that the small 
protein rab requires the hydrolysis of GTP: £2331 so a protein such as this may be the signal 
suggested by the work of Parekh and coworkers. I23°l However, if this messenger is a 
diffusable signal then its release or its action at the plasma membrane could involve the 
hydrolysis of GTP.
2.7.9 Tyrosine Kinases and Calcium Influx
Several reports have suggested a link between phosphorylation of tyrosine residues and 
Ca2+ influx. [235-237] Tyrosine phosphorylation of platelet proteins occurred on stimulation 
with thrombin and thapsigargin and this appeared to result from depletion of intracellular 
Ca2+ stores, rather than a rise in cytoplasmic Ca2+. [2351 Ca2+ influx was inhibited in 
platelets using two different inhibitors of tyrosine kinases. f236l Again in fibroblasts, three 
different tyrosine kinase inhibitors blocked tyrosine phosphorylation and Ca2+ influx to 
the PLC-linked hormone bradykinin and also blocked Ca2+ influx due to the Ca2+-ATPase 
inhibitor, thapsigargin. Future work will hopefully clarify the position concerning 
tyrosine phosphorylation and Ca2+ influx.
2.8 Calcium Oscillations and Waves
Oscillations of [Ca2+]j have been observed in many cell types in response to agonists. 
The nature of the oscillations varies among different cell types and for a given type of 
cell, the shapes of Ca2+ transients may depend on which agonist induces the oscillations.
[238,239]
There are two types of Ca2+ oscillations: first, a sinusoidal fluctuation in [Ca2*^ that 
occurs on top of a sustained elevation in [Ca2+]j. It was observed that this type of 
oscillation occurs following muscarinic receptor stimulation. These oscillations occur at 
low agonist concentrations and an increase of agonist causes an increase in amplitude of 
oscillation with little change in frequency. These oscillations usually diminish in 
magnitude with time suggesting a lack of feed forward mechanism to sustain them. The 
second type of oscillation is characterised by discrete spikes in [Ca2+]j. t239*240! The spikes 
occur with a variety of PLC-linked agonists. The [Ca2+]j in the intervening periods 
between the Ca2+ transients remain at or close to basal level. Spiking occurs at low 
agonist concentration, however the effect of the agonist is to increase the frequency of 
oscillation, not the amplitude. These oscillations may be sustained for long periods,
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indicating a feed forward mechanism that serves to regenerate each spike. Above a 
certain threshold of stimulation only a single spike occurs, which may not be followed by 
a sustained nonoscillating elevation of [Ca2+]j.
The mechanisms of [Ca2+]j oscillation in cells is still speculative. Oscillations in the 
production of Ins(l,4,5)P3 may produce the periodic release of Ca2+. The periodic 
formation of Ins(l,4,5)P3 may occur based on a negative feedback loop operating through 
protein kinase C l241l which reversibly phosphorylates a G-protein and inhibits the 
transduction of receptor binding to PLC activation. An alternative may be the reciprocal 
coupling between Ca2+ and Ins(l,4,5)P3 [2421 resulting in spiking. In this model the 
production of Ins(l,4,5)P3 leads to a rapid increase of Ca2+ that positively feeds back to 
increase PLC activity and provide the cell with a burst of Ins(l,4,5)P3. The [Ca2+]j is 
lowered by reuptake of the Ca2+ into the Ins(l,4,5)P3-sensitive store which removes this 
positive feedback on PLC, thus Ins(l,4,5)P3 levels fall.
Other mechanisms have been proposed in order to explain Ca2+ oscillations in 
photoreceptors [243] and Xenopus oocytes, [2441 Another model l238l necessitates the 
existence of a Ca2+-releasable Ca2+ pool. Ca2+ released from an Ins(l,4,5)P3-sensitive 
pool would be taken into a second Ca2+ pool which is Ins(l,4,5)P3 insensitive when Ca2+ 
reaches a threshold level, a release channel opens and Ca2+ is released back into the 
cytosol. In the presence of Ins(l,4,5)P3 the process continues cyclically as long as the 
Ca2+ concentration in the second pool manages to reach the threshold required for release.
2.9 The Metabolism of Inositol Phosphates
More than twenty of the possible sixty three myoinositol phosphate isomers have been 
identified in tissues. Now that it has been established that Ins(l,4,5)P3 acts as a second 
messenger in the mobilisation of Ca2+, the routes of enzymatic metabolism and the 
regulation of the products together with the specific kinases and phosphatases are of 
considerable importance. Therefore, as well as the synthesis of Ins(l,4,5)P3 in the cell, its 
degradation is also important to provide homeostasis within the cell. Ins(l,4,5)P3 may be 
deactivated in one of two ways, (Figure 12). First, a 5-phosphatase removes the 5- 
phosphate group from Ins(l,4,5)P3 to give myo-inositol 1,4-bisphosphate, Ins(l,4)P2 
which is inactive in stimulating Ca2+-release. It has been demonstrated that Ins(l,4)P2 is 
an allosteric activator of 6-phosphofructo-l-kinase I245! and has been reported to activate 
DNA polymerase-a. [246] Ins(l,4,5)P3 can also be phosphorylated by a 3-kinase to give
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Ins(l,3 ,4 ,5)P4, and both products can be regarded as "off’ signals. The Ins(l,4)P2 
resulting from 5-phosphatase action on Ins(l,4,5)P3 is further dephosphorylated to myo­
inositol 4-phosphate, Ins(4)P via the action of a Mg2+-dependent myo-inositol 
polyphosphate 1-phosphatase. [247-249] T h is  enzyme has been purified from brain cytosol, 
has a molecular mass of 40-44,OOODa and is inhibited by Ca2+ and uncompetitively by 
Li+. There is also some evidence that less than 5% of Ins(l,4)P2 undergoes 
dephosphorylation to myo-inositol 1-phosphate, Ins(l)P, which suggests that a 4- 
phosphatase can slowly hydrolyse Ins(l,4)P2. The activity of this enzyme is only 
observed in homogenates with very high concentrations (100-700|iM) of Ins(l,4)P2 even 
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Figure 12
The major route of Ins(l,3,4,5)P4 metabolism is the dephosphorylation by the 5- 
phosphatase to provide the cell with Ins(l,3,4)P3. However, a Li+ insensitive 3- 
phosphatase is present in the brain cytosol, which results in the reformation of 
Ins(l,4,5)P3. [252’2531 Ins(l,3,4)P3 is further metabolised by myo-inositol polyphosphate 1- 
phosphatase [247-249] t0 produce Ins(3,4)P2. Ins(l,3,4)P3 may be dephosphorylated by the
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Li+ insensitive 4-phosphatase to give Ins(l,3)P2. These two compounds, Ins(3,4)P2 and 
Ins(l,3)P2 are then further dephosphorylated by the 4- and 3-phosphatases respectively to 
give Ins(3)P and Ins(l)P. The enzyme, myoinositol monophosphatase has similar 
affinities for the dephosphorylation of Ins(l)P and Ins(4)P and can dephosphorylate at the 
3- and 5-positions for monophosphates. The enzyme has been purified to homogeneity. 
[254,255] x h e  protein is a dimer, is inhibited by Li+ in an uncompetitive manner, (K{ <lnM) 
and the cDNA indicated it has 277 amino acids and is unrelated to any other known 
protein. t256l
2.9.1 Higher Inositol Phosphates
A interesting aspect of the metabolism of myo-inositol phosphates is the 3-kinase 
pathway which phosphorylates Ins(l,4,5)P3 to give Ins(l,3,4,5)P4. The majority of the 
Ins(l,3,4,5)P4 is dephosphorylated to Ins(l,3,4)P3 which may be then further 
phosphorylated by a 6-kinase to provide Ins(l,3,4,6)P4. [2571 The 6-kinase enzyme is 
widely distributed and has a Km of 29jiM for Ins(l,3,4)P3. The activity is unaffected by 
Ca2+ or by Li+ [258] but is inhibited by 10|iM Ins(l,3,4,5)P4. [259J The symmetrical 
tetrakisphosphate, Ins(l,3,4,6)P4 is metabolised slowly in comparison to Ins(l,4,5)P3, 
arguing against a role in Ca2+-release although it can mobilise Ca2+ in Xenopus oocytes 
[irn and neuroblastoma cells. l216J It may be possible that Ins(l,3,4,6)P4 is the major 
precursor to the higher myo-inositol phosphates Ins(l,3,4,5,6)P5 and phytic acid, 
Ins(l,2,3,4,5,6)P6. I26°l It appears that the phosphorylation of Ins(l,3,4,6)P4 is rate- 
limiting and proceeds at maximum rates even when the PLC-linked receptors are not 
stimulated and thus are not regulated by PLC-linked agonists.
Another myoinositol phosphate, Ins(3,4,5,6)P4 is derived from Ins(l,3,4,5,6)P5 and its 
formation is dramatically increased by PLC-linked agonists. f260] Agents such as 
thapsigargin and phorbol myristate acetate that by-pass PLC activation do not mimic 
agonist activation by increasing levels of Ins(3,4,5,6)P4. Thus the reaction is regulated by 
a mechanism other than a Protein Kinase C/Ca2+-signalling pathway. The levels of 
Ins(l,3,4,5,6)P5 are not reduced by agonists and are high in most cells, indicating that 
Ins(3,4,5,6)P4 may provide some function which as yet is unknown.
Within the last few years further discoveries in the myoinositol polyphosphate field have 
provided myoinositol polyphosphates more polar than Ins(l,2,3,4,5,6)P6. I261*263! These 
compounds are pyrophosphorylated derivatives of Ins(l,3,4,5,6)P5 and phytic acid and are
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present in AR4-2J pancreatoma cells [2621 and in the slime mould Dictyostelium. I263l 
These pyrophosphate compounds are synthesised in an ATP-dependent manner from the 
respective myo-inositol polyphosphates. Enzymes are also present to dephosphorylate 
them back to the precursors and the standard free energy of hydrolysis of the 
pyrophosphate bond is in the region of 6.5-6.6kcal mol-1, which is a similar value to the 
hydrolysis of pyrophosphate bonds of ATP. The function of these compounds is yet to be 
established. There is no evidence at present to show that these pyrophosphorylated 
derivatives are under the control of hormones or neurotransmitters.
2.9.2 Functions of Ins(l,3,4,5,6)Ps and Ins(l,2,3,4,5,6)P6
The two myoinositol polyphosphates Ins(l,3,4,5,6)P5 and Ins(l,2,3,4,5,6)P6 are found in 
most cells in a micromolar to millimolar concentration range. Phytic acid can act as an 
enzyme inhibitor [264] and an antioxidant.[265] Phytic acid can increase the oxygen affinity 
for haemoglobin in a similar fashion to 2,3-diphosphoglycerate. t266*267! Ins(l,3,4,5,6)P5 
and Ins(l,2,3,4,5,6)P6 but no other myoinositol phosphates can lower blood pressure and 
decrease the heart rate in rat. 068,269] ins(l,2,3,4,5,6)P6 has also been reported to elicit 
Ca2+ entry into neurones [27°l anterior pituitary cells I271.! and adrenal chromaffin cells I272! 
and also stimulate the secretion of [3H]D-aspartate, prolactin and catecholamines from the 
respective cell types. Certain experiments require caution however, because phytic acid 
is an extremely potent Ca2+ chelator.
There are several phytic acid binding proteins in the nervous system. One of these 
proteins has the same amino-acid sequence as the 50kDa a-subunit of the assembly 
protein (AP)-2. AP-2 is associated with clathrin-coated vesicles at the plasma membrane 
but not at the trans-face of the Golgi complex and is involved in the regulation of 
receptor-mediated endocytosis and exocytosis rather than in secretion of newly 
synthesised proteins. 073-275l
2.9.3 my0 -Inositol Polyphosphate 5-Phosphatase
The myo-inositol polyphosphate 5-phosphatase is present in most tissues and found 
between membranes and cytosol. [58] The 5-phosphatase enzyme removes the 5- 
phosphate group from several metabolic intermediates including Ins(l,4,5)P3, 
Ins(l,3,4,5)P4 and myo-inositol-1,2-cyclic-4,5-trisphosphate, [Ins(l:2-c,4,5)P3]. The
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latter compound is hydrolysed by the 5-phosphatase some 100-200 fold more slower than 
Ins(l,4,5)P3, which may explain the accumulation of cyclic phosphates in cells. I276J
Most tissue 5-phosphatase activity is associated with the particulate fraction [277] however, 
cells such as platelets may contain large amounts of the soluble form. t259l In brain there 
are two types of 5-phosphatase, type I and type n, £78,279] defined on the basis of the order 
of elution from DEAE (diethylaminoethyl) resin. Type I 5-phosphatase has an apparent 
molecular mass of 45kDa in human platelets. [280] The enzyme requires Mg2+ and is 
inhibited by high concentrations of Ca2+. Type I and the particulate 5-phosphatase have 
similar Km values for Ins(l,4,5)P3 of about 3|iM and 18jiM respectively £79l and they 
share an antigenic determinants. I281l This may suggest that in brain, most 5-phosphatase 
activity is type I. This enzyme has a higher Km value for Ins(l,3,4,5)P4 than for 
Ins(l,4,5)P3 (with a lower vmax) suggesting that the 5-phosphatase is rapidly saturated 
with Ins(l,3,4,5)P4, particularly in brain which synthesises more Ins(l,3,4,5)P4 than any 
other tissue. Consistent with what is already known, lpM  of Ins(l,3,4,5)P4 inhibits the 
breakdown of either Ins(l,4,5)P3 or Ins(l:2-c,4,5)P3 which may prolong the half-lives of 
these molecules in vivo.
Type II soluble 5-phosphatase has a much higher specificity for Ins(l,4,5)P3 (Km = 24pM) 
and may be an additional regulatory enzyme. It hydrolyses the same substrates as type I 
from platelets, although the kinetic constants are different, especially for Ins(l,3,4,5)P4 
(Km = 7.5jiM), l282l for type I (range 0.8-1.0|iM) t277l and has a molecular mass of 
160kDa.
Type I 5-phosphatase from human platelets is activated by PKC phosphorylation. t283l 
The platelet type II 5-phosphatase is however, not phosphorylated by PKC. [282] The 
outcome of this difference is a complex regulation of intracellular myo-inositol 
phosphates. One awaits how the enzymes interact in vivo, and how myo-inositol 
phosphates are regulated by the complex interelationships between 5-phosphatase and 3- 
kinase.
2.9.4 myo-Inositol Polyphosphate 3-Kinase
Ins(l,4,5)P3 may be converted to Ins(l,3,4,5)P4 by a specific 3-kinase, in the presence of 
ATP and Mg2+. £84J The enzyme does not phosphorylate Ins(l:2-c,4,5)P3 [285] and has a 
high affinity for Ins(l,4,5)P3 (Km 0.2-1.5pM). [2861 The 3-kinase competes effectively
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with the 5-phosphatase for Ins(l,4,5)P3 since the Km value for the 5-phosphatases is in the 
range 17-25p.M. t280*282! The 3-kinase has been purified from brain I287*288! and its cDNA 
has been cloned and sequenced, t289*2"] The predicted molecular mass (50kDa) is in close 
agreement to that found by SDS-PAGE. Ca2+ increases Ins(l,4,5)P3 3-kinase activity, an 
effect which is mediated by calmodulin. t288l The control by intracellular Ca2+ levels is 
also shared by other regulatory enzymes, such as glycogen synthase and cyclic nucleotide 
phosphodiesterase and represents a mechanism where the ratio of phosphatase to kinase 
may be modulated. Quantitative analysis has indicated that Ca2+/calmodulin binds to the 
enzyme with a Ka value of 8.23nM (one of the highest affinities for a calmodulin 
activated enzyme). [291] A rise in [Ca2+]j thus has an effect of increasing the concentration 
of Ins( 1,3,4,5)P4 first by the action of 3-kinase on Ins(l,4,5)P3 and second by inhibition of 
Ins(l,4,5)P3 dephosphorylation. The 3-kinase has been shown to be enriched in 
sequences that contain five amino acids (aspartate, glutamate, proline, serine and 
threonine) which render the 3-kinase susceptible to hydrolysis by the protease calpain. 
[286] Regulation of the 3-kinase is also by phosphorylation of the enzyme. It has also 
been demonstrated that PKA- and PKC-induced phosphorylation of serine residues on 
brain Ins(l,4,5)P3 3-kinase increase and decrease, respectively, the vmax of enzyme 
activity.
2.10 The Calcium Mobiliser Cyclic ADP Ribose
It is well documented that Ins(l,4,5)P3 releases Ca2+ from intracellular Ca2+ stores as 
described in earlier sections. Certain agonists may in addition to producing Ins(l,4,5)P3 
also activate a ryanodine sensitive Ca2+ channel, t292*293] In pancreatic acinar cells, normal 
Ca2+ mobilisation patterns cannot be mimicked by the action of Ins(l,4,5)P3 alone. 
However, co-treatment with caffeine gives a similar response as the agonist. l293l Even 
though caffeine is not the physiological ligand, it has been suggested that a caffeine-like 
substance activates the ryanodine sensitive Ca2+ channel. One such physiological 
molecule which may be a Ca2+ mobilising agent is a metabolite of NAD+ (Nicotinamide 
Adenide Dinucleotide), namely cyclic ADP-ribose [294] (Figure 13). Cyclic ADP-ribose 
(16) is a Ca2+-mobilising agent with a half maximum response of 18nM in purified sea 
urchin egg microsomes. t295] The cyclic metabolite has a molecular mass of 541Da and is 
formed by condensing the adenine group of NAD+ with the terminal ribosyl unit and 
displacing the nicotinamide moiety. I296l The enzyme which forms cyclic ADP-ribose has 
been found in many tissues including rabbit liver, brain, heart, spleen and kidney [297] and 
also in pituitary cells, t2981 The enzyme, called ADP-ribosyl cyclase has several isoforms
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and has been purified from various sources. [299,300] The release of Ca2+ activated by cyclic 
ADP-ribose is separate from that of Ins(l,4,5)P3 because it is insensitive to the 
Ins(l,4,5)P3 receptor antagonist, heparin. t294l Ins(l,4,5)P3 is also less effective than 








Ryanodine opens Ca2+ channels at nanomolar concentrations, but closes the channels at 
higher, micromolar concentrations. The ryanodine receptors contribute to Ca2+ signalling 
in many cells including skeletal muscle, cardiac muscle, neurones, chromaffin cells, 
smooth muscle, pituitary cells and sea urchin eggs. The mechanism of Ca2+-release by 
cyclic ADP-ribose is similar to another mechanism named CICR. Both ryanodine and 
caffeine are activators of the CICR mechanism in muscle t302*303! and the two compounds 
abrogate the response to cyclic ADP-ribose while leaving the Ca2+-release mechanism 
intact. t304] The reverse is also true because egg homogenates become insensitive to 
caffeine and iyanodine after prior treatment with large concentrations of cyclic ADP- 
ribose. I304l More recent has been the evidence that in cardiac ryanodine receptors 
(present in planar lipid bilayers) the frequency of channel opening is increased by cyclic
48
ADP-ribose. I305] Cyclic ADP-ribose has no effect on type-1 ryanodine receptor of 
skeletal muscle but is effective in type-2, cardiac receptors [305l and perhaps type-3 
receptor. This evidence appears to directly support cyclic ADP-ribose as a second 
messenger. However, a little caution must be taken because it appears to have no effect 
in certain cell types. Maybe the cyclic ADP-ribose is more restricted than Ins(l,4,5)P3 in 
Ca2+-release and cell function?
The crucial prerequisite to ascertain that cyclic ADP-ribose is a second messenger, is to 
show that levels of cyclic ADP-ribose change in response to specific stimuli. This has 
been observed, albeit controversially, in the levels of cyclic ADP-ribose which change in 
pancreatic p-cells in response to stimulation with glucose. I306! It has also been shown 
that cyclic GMP enhanced the formation of cyclic ADP-ribose. I307] There may also be a 
link with nitric oxide (NO), a local hormone, and it may be fruitful to demonstrate that 
levels of cyclic ADP-ribose change in response to other types of agonist such as 
neurotransmitters. The link between cyclic GMP and cyclic ADP-ribose is a crucial step 
to substantiate that cyclic ADP-ribose is a messenger which regulates some of the 
ryanodine receptors.
2.10.1 Cyclic ADP-Ribose Antagonists
Many cells contain both Ins(l,4,5)P3 receptors and ryanodine receptors and it is known 
that both compounds contribute to the fertilisation Ca2+ wave in sea urchin eggs. [308,309] 
If one pathway is inhibited, for example the Ins(l,4,5)P3 sensitive Ca2+ channel with 
heparin then the fertilisation response is still intact because the Ca2+ wave comes from the 
back-up mechanism by cyclic ADP-ribose. The cyclic ADP-ribose pathway is inhibited 
by ruthenium red and, more importantly, by modification of the 8-position of the adenine 
ring. t308] Substitution of the hydrogen by an amino group at the 8-position of the adenine 
ring of cyclic ADP-ribose provided an antagonist at 150nM, blocking Ca2+-release from 
sea urchin egg homogenates. The 8-position modified inhibition was reversible and 
could be overcome by high concentrations of cyclic ADP-ribose. 8-Amino cyclic ADP- 
ribose was as efficient as cyclic ADP-ribose in binding to its receptor. Finally 8-bromo 
cyclic ADP-ribose and 8-azido cyclic ADP-ribose were also found to be reversible 
antagonists, eliminating the Ca2+-release but not altering the ability of the molecule to 
bind to its receptor. [31°J In summary, the new Ca2+-mobilising molecule, cyclic ADP- 
ribose, in conjunction with Ins(l,4,5)P3 may generate complex Ca2+ signals which may be 
the key to unlocking the fundamental processes of life.
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2.11 Adenophostin, the Most Potent Reported Mobiliser of Ca2+ at the Ins(l,4,5)P3 
Receptor
Previous sections have discussed how an agonist stimulates the production of Ins(l,4,5)P3 
via enzymatic cleavage of PtdIns(4,5)P2, which then binds to its receptor and releases 
Ca2+ from intracellular stores. Until recently, there were no other naturally occurring 
small ligands binding to the Ins(l,4,5)P3 receptor and releasing Ca2+, or inhibiting the 
release of Ca2+. However, Takahashi and coworkers, i311l have recently described two 
unique antibiotics, adenophostin A (18) and adenophostin B (19), which were isolated 
from the cultured broth of Penicillium brevicompactum SANK 11991 and SANK 12177, 
respectively (Figure 14). Both adenophostins are potent Ins(l,4,5)P3 receptor agonists 
and release Ca2+ from Ins(l,4,5)P3 sensitive stores. The structures of the adenophostins 
are unique and have been characterised by UV and NMR experiments, chemical and 
enzymatic degradation experiments together with elemental analysis and high resolution 
mass spectra. I312l These techniques have assigned the structure of the adenophostins to a 
glucose unit possessing phosphate groups on the C-3" and C-4" positions, with a glucosyl 
linkage at the C-31 position on the ribose sugar of adenosine. There is also a phosphate 
group on the C-2' ribose unit, t311*312! The only structural difference between 
adenophostin A and B is that adenophostin B has an acetate group present on the C-6" 
hydroxyl group of the glucose unit. The chemical structures of adenophostins A and B 
are distinct from Ins(l,4,5)P3 except for the presence of three phosphate groups. The 
structures of adenophostin A and Ins(l,4,5)P3 have been modelled using the Alchemy II 
program. It was found that the three phosphate groups of adenophostin A could not be 
superimposed on the Ins(l,4,5)P3 structure. [313] However, the 3"- and 4"-diequatorial 
bisphosphate on the glucose ring could be superimposed on the 4,5-bisphosphate of 
Ins(l,4,5)P3. It is the 4,5-bisphosphate on Ins(l,4,5)P3 that is important for the release of 
Ca2+, the 1-phosphate being less important. However, the 2-phosphate on the ribose ring 
of the adenophostins must be more effective at binding to the receptor than the 1- 
phosphate of Ins(l,4,5)P3. Removal of the 2-phosphate on the ribose sugar reduced the 
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The adenophostins represent the first microbial (fungal) metabolites isolated which are 
receptor agonists, and are some 100-fold more potent than Ins(l,4,5)P3 itself. For 
example, in a competition assay, the binding of adenophostins to rat cerebellar 
Ins(l,4,5)P3 receptor was found to inhibit [3H]Ins(l,4,5)P3 binding more potently than 
Ins(l,4,5)P3 itself: the IC50 values for adenophostin A, B and Ins(l,4,5)P3 were 1.3, 1.3 
and 23nM respectively. The Kx values for adenophostin A and B were both 0.18nM while 
that of Ins(l,4,5)P3 was 15nM. The adenophostins did not inhibit the binding of 
[3H]Ins(l,3,4,5)P4 to purified Ins(l,3,4,5)P4 binding protein, demonstrating the high 
selectivity of these new compounds for the Ins(l,4,5)P3 receptor. Adenophostin A may 
produce Ca2+ release at a concentration as low as InM, indeed, after lmin the amount of 
Ca2+ released by lOnM of adenophostin A was equivalent to that released by lpM  of 
Ins(l,4,5)P3. In addition, whereas Ins(l,4,5)P3 is quickly metabolised, the adenophostins 
demonstrate sustained Ca2+ release. The EC50 (the concentration required for half 
maximum Ca2+-release) for adenophostin A, B and Ins(l,4,5)P3 were 1.4, 1.5 and 170|iM 
respectively in cerebellar microsomes. When Ins(l,4,5)P3 was added after sufficient 
Ca2+-release by adenophostin A, no additional Ca2+-release was observed indicating that 
Ca2+ is released from Ins(l,4,5)P3 stores. Furthermore, incubation of the microsomes 
with heparin resulted in the complete disappearance of Ca2+-release by adenophostin A, 
showing that the adenophostins are Ins(l,4,5)P3 receptor agonists. The prolonged 
activities of the adenophostins to the Ins(l,4,5)P3 metabolising enzymes, 3-kinase and 5- 
phosphatase have also been investigated. It was found that the binding affinities did not 
decrease even after a 30min exposure to the enzymes.[3131
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In summary, new highly potent Ca2+-mobilising compounds called adenophostins, 
extracted from microbial sources have been discovered. These antibiotics release Ca2+ 
from Ins(l,4,5)P3-sensitive stores and are resistant to the Ins(l,4,5)P3-metabolising 
enzymes, 3-kinase and 5-phosphatase. The adenophostins induce Ca2+-release through 
the Ins(l,4,5)P3 receptor and has higher activity and specificity than Ins(l,4,5)P3 itself. 
Adenophostins and structurally modified analogues (to be synthesised) will hopefully be 
useful tools to further our understanding of the Ins(l,4,5)P3 receptor.
2.12 Some Recent Developments in Signal Transduction
New phospholipases C from the p-family have been identified by several groups together 
with interesting revelations concerning PLC-81. First, a new PLC-P was cloned, 
sequenced and characterised as PLC-p4. [314] PLC-p4 is the most selective PLC for 
PtdIns(4,5)P2 over Ptdlns (at present), and has a molecular mass of 134kDa. PLC-P4 was 
activated by all the a-subunits t315i of the Gq class including G aq, Gaj j ,  G a ^ , G a ^  and 
Goci6> but none of the G-Py subunits tested. PLC-p4 shares the highest homology with 
Norp A protein that mediates the visual process in Drosophila t316i suggesting a role for 
PLC-P4 in the mammalian visual system.
Two other PLC-p types have been identified and characterised from lower eukaryotic 
sources. First, PLC-XP was cloned from Xenopus oocytes and found to have substantial 
homology (33-64%) with mammalian p i, p2, P3 and P4 and was nearest to PLC-P3 with 
80% similarity and 64% identity. PLC-Xp appears to be involved in the pertussis toxin- 
sensitive receptor stimulation of the Ca2+-activated Cl" current in Xenopus oocytes, which 
only respond to the Ga-subunits.
A second novel form of PLC-P has been found in embryos of the brine shrimp Artemia. 
[317] Artemia is of interest from an evolutionary point of view because it branched off 
considerably earlier than Drosophila in the evolutionary tree, with the nearest relative 
dating back some 550 million years. Therefore the analysis of the PLC sequence between 
Artemia and higher organisms may shed some light on the fundamental structural 
requirements for PLC function. This PLC type was named PLC~PX and interestingly was 
activated by concentrations of lithium ions used to treat manic depression.
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Another family of phospholipases, named PLC-8 is smaller than the PLC-P or the PLC-y 
family. Very little is known about the types of receptor coupled to PLC-8 except that 
PLC-81 is associated with thrombin-triggered mitogenic response, in which PLC-81 
activation is regulated by G-proteins and calcium. l318l Furthermore, it has been shown 
that binding of PLC-81 to lipid bilayer membranes [composed of phosphatidylcholine and 
PtdIns(4,5)P2] was inhibited by D-Ins(l,4,5)P3 with an IC50 value of 5.4|iM. t319l 
However, L-Ins(l,4,5)P3 did not inhibit the binding process. D-Ins(2,4,5)P3 and l-(a- 
glycerophosphoryl)-D-myo-inositol 4,5-bisphosphate were nearly as effective. Other 
analogues such as D-Ins(l,4)P2 weakly inhibited the binding process, but D-Ins(4,5)P2 was 
nearly as potent as Ins(l,4,5)P3 and PtdIns(4,5)P2. Inorganic phosphate and ATP did not 
significantly affect binding. Another study [32°J has located the D-Ins(l,4,5)P3 binding 
region on PLC-81 to the amino terminal where a peptide relating to residues 30-43 
(containing 6 basic amino acids) of PLC-81 binds to D-Ins(l,4,5)P3 immobilised on a 
matrix. Thus, these results are consistent with feedback inhibition by the product of PLC 
hydrolysis, i.e. D-Ins(l,4,5)P3, at a step that preceeds catalysis, namely interfacial 
stereospecific recognition.
The enzyme Ptdlns 3-kinase has received much attention over the last few years. Its 
structure has been described in section (2.5.2) and the inhibition of this enzyme will be 
discussed briefly. Ptdlns 3-kinase has been implicated in growth factor signal 
transduction by associating with the tyrosine kinases, including platelet-derived growth 
factor receptor. Specific inhibitors of Ptdlns 3-kinase will hopefully piece together some 
of the clues to form and function, which are held within the protein architecture of this 
enzyme. The bioflavinoid quercetin, has been shown to inhibit Ptdlns 3-kinase with an 
IC50 value of 3.8|iM, t321l but it can also inhibit other kinases such as Ptdlns 4-kinase and 
several tyrosine and serine/threonine kinases. The compound 2-(4-morpholinyl)-8- 
phenyl-4//-1 -benzopyran-4-one was found to be a selective inhibitor of Ptdlns 3-kinase 
with a potency 2.7-fold greater than quercetin with an IC50 value of 1.40pM. t322l The 
compound did not interact with other kinases tested including Ptdlns 4-kinase, EGF 
receptor tyrosine kinase, MAP kinase and S6-kinase. The fungal metabolite wortmannin 
has been shown to bind covalently to the ATP binding site of the p i 10 subunit of Ptdlns
3-kinase and inhibit the enzyme irreversibly when added at nanomolar concentrations in 
mammalian cells.[323] At this low concentration wortmannin does not affect other protein 
and lipid kinases. However, at micromolar concentrations wortmannin inhibits other 
enzymes such as phospholipase D P24-326] and myosin light chain kinase. t327] Another 
compound, demethoxyviridin l328l has also been used as a tool to investigate Ptdlns 3-
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kinase. The use of these small molecules and other inhibitors will give a greater insight 
into the functional activity of this enzyme.
In the last few months a paper presented in Nature has demonstrated that Ins(l,4,5)P3 
inactivates its own specific intracellular Ca2+ channel. t329J The inhibitory effect of 
Ins(l,4,5)P3 can be reversed by Ins(l,4,5)P3 washout or chelation of cysosolic Ca2+. 
Thus, both Ins(l,4,5)P3 and Ca2+ act as co-inhibitors of the Ins(l,4,5)P3-sensitive Ca2+ 
channel. The Ins(l,4,5)P3 inactivation may provide a mechanism for adaptation to 
partially elevated basal levels of Ins(l,4,5)P3. The inactivation should be most potent 
once the Ca2+ channel is open and the Ca2+ is released. The process of Ca2+ channel 
inactivation should serve to limit the duration of channel opening and may play an 
important role in the termination phase of [Ca2+]i spikes.
In the last few years, several disease states have been attributed to a defect of the myo­
inositol phospholipid signalling pathway. The first was Lowe's oculocerebrorenal 
syndrome t33°l and second was a defect seen in the phosphatidylinositol pathway in HIV- 
infected lymphocytes and lymphoblastoid cells. t331l The two disease states share a 
common cause in that they are both defective in a 5-phosphatase enzyme. Lowe's 
oculocerebrorenal syndrome has an open reading frame which encodes a protein with 
71% similarity and 53% identity to human myo-inositol polyphosphatase 5-phosphatase, 
and thus may be the first identified inborn error of myo-inositol phosphate metabolism. 
This inborn error is a rare X-linked disorder which is characterised by mental retardation 
and affects the lens opacity, brain, kidneys and muscle. Recently, characterisation of a 
cDNA encoding the 43kDa membrane-associated myo-inositol polyphosphatase 5- 
phosphatase has been presented. [332] This 43kDa 5-phosphatase was expressed in the 
heart, skeletal muscle and brain with no significant homology between the 5-phosphatase 
and other proteins of the phosphoinositide pathway. However, and significantly, a 73- 
amino acid sequence in the carboxyl terminus of the membrane associated 5-phosphatase 
enzyme showed a 30% sequence identity and 67% similarity to a region in the 75kDa 5- 
phosphatase and 34% identity and 70% similarity to a specific sequence in the protein 
that is encoded by the defective gene in Lowe's oculocerebrorenal syndrome.
Lymphocytes which are infected with HTV in vivo showed a defect at the level of the 
Ins(l,3,4,5)P4 5-phosphatase together with abnormal Ca2+ regulation. It is uncertain at 
present whether it is the same enzyme that also dephosphorylates Ins(l,4,5)P3 to 
Ins(l,4)P2. A requirement for tools to investigate the consequences of metabolic
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dysfunction along the phosphoinositide pathway is demonstrated by the above examples 
(albeit the mode of inhibition was different) and underpins the importance of 
pharmacological inhibitors so that we may gain a fruitful understanding of the signal 
transduction process.
The most outstanding review to date, which covers some of the biological aspects of 
signal transduction discussed in this review has been presented by M. J. Berridge. [3331
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CHAPTER THREE 
A Review Of Myo-Inositol Phosphate Synthesis
3.1 Structure of the Inositols
There are nine 1,2,3,4,5,6-hexahydroxycyclohexanes called the inositols. Figure 15 
shows all nine possible configurations and their trivial names. Only two of these are 
optically active: d -(27) and L-c/nVoinositol (28). The other seven isomers are 
optically inactive, meso-cyclitols, with a plane of symmetry through the cyclitol.
myoinositol was first isolated by Scherer in 1850 l334l and was given the name 
"inosit" and later the suffix ol in English, myoinositol is the most common inositol, 
occuring naturally and appearing in several forms in all living organisms. t335l myo­
inositol is extracted from corn-steep liquor in large quantities and sold by suppliers 
such as Aldrich as a high purity white crystalline solid, at a cost of £29.80, for 500g 
(Aldrich 1994-1995).
scy//oinositol (20) myoinositol (21) neoinositol (22)
epi-inositol (23) c/s-inositol (24) mwcoinositol (25)
a//oinositol (26) D-c/nroinositol (27) L-c/uroinositol (28)
Figure 15
myoinositol possesses a single axial hydroxyl group, and the carbon to which it is 
attached is designated position 2. The C-l position of myoinositol is designated to 
the carbon nearest position 2. Asymetric substitution of the myoinositol 
configuration is, by convention, l  when the numbering proceeds clockwise from 1—>6,
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and is d  when the numbering proceeds anticlockwise. The choice of prefix is 
normally determined by giving preference to that which results in the lowest 
numbering of substituents and the two configurations are shown in Figure 16 for d -(7) 
and L-myoinositol 1,4,5-trisphosphate (29). In a metabolic sequence however, for 
example in the dephosphorylation of D-Ins(l,3,4)P3 to give D-Ins(3,4)P2 the lowest 
nomenclature should be L-Ins(l,6)P2, but recent recommendations 0361 on the 
numbering of the atoms of myoinositol relax this rule and the D-prefix is used in order 
to avoid confusion.
D-Ins(l,4,5)P3 (7) L-Ins(l,4,5)P3 (29)
Figure 16
The rules for cyclitol nomenclature are often confusing and long. I337! However, two 
main points of note are: first, when numbering substituted carbons, the substituents 
must be placed in alphabetical order, for example, allyl before benzyl which comes 
before prop-l-enyl, regardless of the position of the substituent in the ring. Second, a 
small Roman capital letter should be used in print for d -  and l -  derivatives and sn is an 
abbreviation for stereospecific numbering.
3.2 The Biosynthesis of myoinositol
Most myo-inositol for cellular processes in humans comes from dietary intake 
especially from vegetation. A small proportion of myoinositol is biosynthesised. De 
novo biosynthesis occurs in man by isomerisation of D-glucose-6-phosphate (30) to 
give L-myoinositol-l-phosphate (31) in a NAD-dependent process requiring the 
enzyme L-myoinositol synthase. This enzyme is present in all animals and plants and 
is abundant in the mammalian testis, from which source it has been purified, 038,339] 
and also occurs in brain {vide infra).
The reaction mechanism includes a stereospecific intramolecular aldol condensation 
I340! via a keto intermediate, to give the aldol product, L-myo2-inosose-1 -phosphate. 
The ketone is then stereospecifically reduced by NADH to give L-myoinositol-1-
57
phosphate followed by dephosphorylation by myoinositol-1 -phosphatase to give myo­
inositol (Figure 17).
y U r U '
OH
glucose-6-phosphate (30
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3.3 Introduction to the Synthesis of myo-Inositol Phosphates
The following sections of this chapter will deal with the principals for the synthesis of 
inositol phosphates and analogues. The preparation of these compounds poses four 
distinct problems, all of which have been solved. First, using myo-inositol as starting 
material, suitable protecting groups must be introduced into the myoinositol ring so 
that phosphates (or other groups) may be incorporated into their respective positions. 
Second, myo-inositol is a meso compound and the natural configuration of 
Ins(l,4,5)P3 is the D-enantiomer. It is therefore necessary to resolve racemic myo­
inositol phosphate precursors. Third, an efficient phosphorylation methodology must 
be employed with a reagent possessing suitable phosphate-protecting groups in order 
to avoid the formation of cyclic phosphates and also to effect efficient 
phosphorylation of the vicinal diol so inositol polyphosphates may be successfully 
synthesised. Finally, once protected phosphates (or other similar functional groups) 
are on the ring, the protecting groups must be cleanly removed without causing 
migration or cyclisation of the phosphates.
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3.4 The Use of Protective Groups in the Synthesis of myu-Inositol Phosphate 
Precursors
3.4.1 Protection of Diols with Acetal Groups
myo-Inositol is a cheap readily available starting material. Three isomeric bisacetals 
are produced when cyclohexanone t341] or more appropriately a cyclohexanone 
precursor [342,343] ls reacted with myoinositol in the presence of an acid catalyst. The 
three isomeric bisacetals (Figure 18) were obtained in pure form by a combination of 
crystallisation and chromatography, d l -  1,2:4,5-Di-0-cyclohexylidene-myoinositol 
(32) was recovered from the mixture by crystallisation and the other two isomers, d l -  
l,2:3,4-(33) and d l -  1,2:5,6-di-0-cyclohexylidene-myoinositol (34) may be separated 
by chromatography, d l -  1,2-O-Cyclohexylidene-myoinositol (35) was obtained by 
mild acid hydrolysis of the less stable trans-acetal. The di-O-cyclohexylidene-myo 
inositol derivatives can be selectively alkylated or acylated and further manipulated to 
provide a series of phosphorylation precursors which will be described in due course.
The isopropylidene group f344! has also been used to protect cis- and trans- 1,2-diols. It 
was introduced into the myoinositol ring using 2,2-dimethoxypropane or 2- 
methoxypropene and an acid catalyst. Initially, derivatisation with benzoyl chloride 
was necessary in order to obtain DL-3,6-di-0-benzoyl-1,2:4,5-di-O-isopropylidene- 
myoinositol (36). Since the other benzoylated derivatives were soluble, DL-3,6-di-0- 
benzoyl-1,2:4,5-di-0-isopropylidene-myoinositol was isolated from the mixture by 
washing with pyridine, ether, water and acetone. The benzoyl esters were then 












Several years after the above procedure was published, further investigation improved 
the preparation of isopropylidene acetals of myoinositol. I345] When myoinositol was 
treated with 5 equivalents of 2-methoxypropene and toluene-p-sulphonic acid in 
dimethyl sulphoxide (DMSO) a mixture of d l - 1,2:4,5- d l - 1,2:5,6- and d l - 1,2:3,4-di- 
O-isopropylidene-myoinositol (in a ratio of 3.5:2:1) was obtained, together with 
1,2:3,4:5,6-tri-O-isopropylidene-myoinositol in a total yield of 90%. Column 
chromatography of the mixture gave the tri-O-isopropylidene-myoinositol derivative 
(11%), whereas the d l - 1,2:4,5- and d l - 1,2:5,6- derivatives were isolated by fractional 
crystallisation and characterised as the diacetates. Under slightly different conditions, 
using a shorter reaction time and a lower amount of reagent in the same solvent, a 
larger proportion of the d l -  1,2:4,5-di-CMsopropylidene-myoinositol derivative was 
produced and the tri-O-isopropylidene was not formed. However, changing the 
solvent from DMSO to DMF increased the formation of DL-l,2:5,6-di-0- 
isopropylidene-myoinositol and gave the compounds, d l - 1,2:4,5-, d l - 1,2:5,6- and d l -  
l,2:3,4-di-0-isopropylidene-myoinositol in the ratio of 2.5:2:1 in a total yield of 92%.
The cyclopentylidene acetal has also been used. [3461 The only advantage of this diol 
protecting group is that it is more easily removed by acid hydrolysis than 
cyclohexylidene or isopropylidene.
In a one pot reaction, the treatment of myoinositol and the dimethyl acetal of d -  
camphor in DMSO and a catalytic amount of acid gave a mixture of acetals which 
were subsequently hydrolysed to give four possible cw-monoacetals. Furthermore, 
toluene-p-sulphonic acid catalysed equilibration of the crude mixture and afforded just 
one monoacetal, the favoured D-2,3-0-camphor-myoinositol (38), (Figure 20) 
derivative, which precipitated from the mixture in 65% yield and high optical purity. 
t347! L-Camphor dimethylacetal gave the d -  1,2-O-camphor-myoinositol derivative. 
This one pot procedure has been used to protect the cis-1,2- and 2,3-diol using the l -  
and D-camphor derivatives respectively as well as resolving myoinositol with the 
chiral acetal. The camphor acetal has been further manipulated to provide optically 









The removal of these 1,2-diol protecting groups may be carried out easily and 
selectively depending on the acidic conditions. For example, keeping a solution of d l -
3,6-di-O-benzyl-1,2:4,5-di-0-isopropylidene-myoinositol in 80% acetic acid at reflux 
temperature hydrolysed both cis- and trans-diol protecting acetals I344! to give d l -1,4- 
di-O-benzy l-myo-inositol. The isopropylidene group was hydrolysed from DL-4,5-di- 
O-allyl-l,2-O-isopropylidene-5,6-di-O-/?-methoxybenzyl-my0-inositol using 1M HC1 
-methanol (9:1) at 50°C to expose the c/s-1,2-diol. I349! A prolonged reaction time 
hydrolysed the p-methoxybenzyl group. The trans cyclohexylidene acetal was 
removed from DL-5,6-di-0-benzyl-l,2:3,4-di-0-cyclohexylidene-myc-inositol using 
one equivalent of ethane 1,2-diol and a catalytic amount of toluene-p-sulphonic acid 
in chlorinated solvent at room temperature, to expose the trans-diol in a 60% yield.
[350]
3.4.2 The Synthesis and Manipulation of my o-Inositol Orthoformate
The reaction of myoinositol with triethylorthoformate at 100-140°C and an acid 
catalyst afforded a single orthoformate derivative l351l (Figure 21). The reaction was 
originally carried out using dry DMSO as a solvent in 76% yield. However, DMF 
replaced DMSO as the solvent of choice providing the orthoformate derivative in a 
higher yield (92%) and resulting in a cleaner product. I352l The orthoformate structure 
(39) is unique in myoinositol protection chemistry, because the 1-, 3- and 5-positions 
are protected in one step and the positions of the hydroxyl groups are reversed, so only 
the 2-hydroxyl is now equatorial and the others are axial. The 1,3-diaxial orientation 
of the hydroxyl groups in the 4- and 6-positions of the myo-inositol ring allowed the 
regioselective mono-alkylation at one of the axial positions. Selectivity is thought to 
be initiated by the internal co-ordination of the intermediate alkoxide ion (between the
4- and 6-positions). [3531 Monoalkylation occurred in DMF when one equivalent of 
alkylating reagent such as allyl bromide or benzyl bromide was used together with one 
equivalent of sodium hydride as base. I353l The yields for this selective reaction are
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consistent and within the range of 67-80%. For example, for p-methoxybenzyl 
chloride the yield is 67%, for benzyl bromide, 75% and for allyl bromide 80%. 
Furthermore, treatment of DL-4-O-benzyl-myo-inositol-orthoformate with sodium 
hydride (one equivalent) in DMF followed by the addition of benzyl bromide gave ca. 
5:1 mixture of 4,6- and DL-2,4-di-0-benzyl-myo-inositol-orthoformate derivatives 
together with 2,4,6-tri-O-benzyl-myo-inositol-orthoformate. Direct di-O-benzylation 
of myo-inositol-orthoformate in DMF with sodium hydride and benzyl bromide (two 
equivalents each) gave a mixture of 4,6- and DL-2,4-di-Obenzyl derivatives, albeit in 
a lower yield.
3.4.3 O ther Uses of the Orthoformate Structure
Finally, the orthoformate structure has been utilised to produce analogues of 
enterobactin, [354] a siderophore produced by enteric bacteria to trap ferric ions [355] 
under iron-deficient conditions. The monoorthoformate of scyllo-inositol (40) (Figure 
22) was prepared by the procedure described previously. I351! Kishi was particularly 
intrigued with the three axially disposed hydroxyl groups present at the 1-, 3- and 5- 
positions in the cyclohexane ring and this structural feature was utilised for the design 
of enterobactin analogues. Two types of analogues have been synthesised from this 
•scyZZo-orthoformate derivative. First, a chiral ligand has been attached to each of the 
three axial hydroxyl groups and the compound may form a complex with chirality at 
the metal centre. Second, the orthoformate group of the .scyZZo-derivative may be 
replaced by other longer chain alkyl groups, increasing the lipophilicity and thus 
tuning the polarity of the metal complexes. Thus, the treatment of the jcyZZo-inositol 
orthoformate with 3-bromo-2-phenyl-l-propene in the presence of sodium hydride, 
followed by ozonolysis, gave the triketone (41) (77% yield). Asymmetric reduction of 
the triketone with Corey's (S)-oxazaborolidine [(S)-CBS] reagent gave the (5)-triol, 
(42) with very high stereoselectivity. Mesylation of the triol followed by treatment 





Hydrogenation of the triazide and coupling with O-dibenzyl 2,3-dihydroxybenzoic 
acid followed by catalytic hydrogenation furnished the chiral enterobactin analogue
The orthoester derivative was replaced by a long alkyl chain, undecyl, Cn -derivative. 
Thus hydrolysis of l,3,5-tri-0-benzyl-jcy//o-inositol monoorthoformate gave 1,3,5-tri- 
0-benzyl-5cy//o-inositol (45). Reaction of the scy/Zo-derivative with trimethyl 
orthoundecanoate in the presence of a catalytic amount of toluene-p-sulphonic acid 
followed by catalytic hydrogenation gave the orthoundecanoate (46). This undecyl 
derivative was manipulated as for the orthoformate to give the more lipophilic 
analogue (47) (in Figure 23). Both analogues chelated ferric ions to give a deep red 
complex. However, the lipophilic analogue also showed excellent solubility in 
organic solvents and upon partitioning between water and ethyl acetate, the lipophilic 
analogue complex only appeared in the organic layer, whereas the monoorthoformate 
derivative appeared in the aqueous layer. Thus the monoorthoformate derivative may 


























3.5 Protection of Hydroxyl Groups with Allyl Ethers
A brief overview of the common hydroxyl protecting groups and their use in the 
synthesis of myoinositol phosphate precursors will follow. The allyl group is 
normally introduced into the myoinositol ring using allyl bromide in DMF with 
sodium hydride as base, at room temperature. I349! Allyl ethers are stable to many 
conditions used to remove other protective groups, for example, 1M HC1, reflux lOh, 
[35(1] which can remove isopropylidene and p-methoxybenzyl groups. The deprotection 
of the allyl group usually takes place in a two-step procedure consisting of 
rearrangement to a prop-l-enyl ether and may be carried out in several ways. First, 
isomerisation may be induced by using freshly sublimed potassium t-butoxide (five 
equivalents per allyl) in dry DMSO at 50°C for 3h to give the cw-prop-l-enyl ether in 
near quantitive yield. I357l Second, Wilkinson's catalyst,
tris(triphenylphosphine)rhodium (I) chloride [(PPh3)3RhCl] in the presence of 
DABCO (l,4-diazabicyclo[2.2.2]octane) with ethanol-toluene-water, (7:3:1, v/v/v) at 
reflux, gave a mixture of cis- and trans-prop-l-enyl ethers in a ratio of ca. (5:1) and 
82% yield. [358] Third, another organometallic reagent, 1,5-cyclooctadiene- 
&/s(methyldiphenylphosphine)iridium hexafluorophosphate, used in a catalytic 
amount, under an inert atmosphere of helium and activated by passing over a stream
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of hydrogen for 2min also isomerised an allyl group to give a trans-prop-l-enyl ether 
in near quantitative yield. I359J
The resulting prop-l-enyl ethers may be cleaved under several conditions, including 
1M HCl-methanol (1:5), reflux 30min in near quantitative yield (95%). I357l Stirring 
with mercury (II) chloride and mercury (II) oxide (one equivalent of each) in acetone- 
water (10:1) for 5min furnished the exposed hydroxyl group in 87% yield. I357l A final 
method for regenerating the hydroxyl group directly, in a two step one pot reaction, 
uses palladium on carbon with an ethanol-water mixture at reflux and a catalytic 
amount of toluene-p-sulphonic acid, 13601 Caution must be taken however, because 
prolonged reflux leads to loss of benzyl groups and careful monitoring of the reaction 
mixture is essential. Other methods for allyl ether deprotection may be found in a 
recent publication. t3611 Selective methods for introducing the allyl group into the 
myo-inositol ring will be discussed in section 3.9.1 and 3.9.2 for the first two synthesis 
of Ins(l,4,5)P3.
3.5.1 Benzyl and p-Methoxybenzyl Protective Groups
Unsubstituted benzyl ethers were originally prepared under harsh conditions, using the 
alcohol and neat benzyl chloride in the presence of excess potassium hydroxide for 
several hours at 130-140°C. [362] Nowadays, however, there are two main methods 
for introducing benzyl groups into the myoinositol ring. First, d l - 1,2:4,5-di-O 
isopropylidene-myoinositol was benzylated using benzyl bromide in the presence of 
sodium hydride as a base with DMF as solvent. The yield was high, 90-95%, after 
crystallisation from hot petroleum-ether, 60-80°C. The benzylation produced d l -3,6- 
di-O-benzyl-1,2:4,5-di-0-isopropylidene-myoinositol, an important intermediate in 
the synthesis of d l - 1,2,4-tri-O-benzyl-myo-inositol, I349! which was used to synthesise 
Ins(l,4,5)P3. A second method involves the mild acid-catalysed reaction of benzyl 
trichloroacetamidate with the hydroxyl group, under conditions which do not affect 
the acid sensitive acetal protective groups. Thus, DL-3-(9-benzoyl-1,2:4,5-di-O- 
cyclohexylidene-myo-inositol was benzylated at the 6-position in 85% yield with 
benzyl trichloroacetamidate in dichloromethane and a catalytic amount of 
trifluoromethane sulphonic acid. l363l The use of strong base such as sodium hydride 
was not satisfactory in the presence of the benzoyl group. However, sodium hydride 
and benzyl bromide were used to benzylate the 2-hydroxyl group of DL-2,3,6-tri-0- 
benzyl-4,5-di-0-butanoyl-l-D-p-methoxybenzyl-myo-inositol in 89% yield after 





There are two examples of regiospecific benzylation of d l - 1,2:4,5-di-0- 
cyclohexylidene-myo-inositol at the free 3-hydroxyl group, (Figure 24). First, sodium 
hydride and benzyl bromide (1.1 equivalents each) were added to a solution of the diol 
with toluene as solvent. The mixture was heated at reflux for 6h then stirred at room 
temperature overnight. The major product, DL-3-O-benzyl-1,2:4,5-di-0- 
cyclohexylidene-myo-inositol (48) could be separated from the DL-3,6-di-0-benzyl and 
d l - 6- 0-benzyl derivatives in 60% yield. [364] In a second example, the synthesis of d l -  
3-0-benzyl-1,2:4,5-di-0-cyclohexylidene-myo-inositol was carried out using 2 
equivalents of barium oxide and 0.125 equivalents of barium hydroxide octahydrate in 
DMF and 1.1 equivalents of benzyl bromide. I365l A final example of regioselective 
benzylation has appeared in the last few years. The diol, DL-3,6-di-0-allyl-1,2-0- 
cyclohexylidene-myo-inositol was regioselectively benzylated (49; Figure 25) under 
phase-transfer conditions (tetrabutylammonium hydrogen sulphate in 5% aqueous 
sodium hydroxide) to afford a 3:2 mixture [4-0-benzyl, (50) 53%, 5-0-benzyl (51) 
36%] of mono-0-benzyl derivatives at the 4- and 5- positions respectively together 
with a small portion of the di-0-benzyl derivative (52) (5%). [359J Other selective 





Figure 25 R| = Bn, R2 = H (50)
R, = H,R2 = Bn (51)
Rj = Bn, R2 = Bn (52)
The benzyl group is resistant to harsh acidic and basic conditions, therefore the 
majority of the phosphorylation precursors for the synthesis of myo-inositol tris- and 
tetrakis-phosphates in the literature contain di- or tri-0-benzyl-myo-inositol 
precursors. The main reason for using benzyl groups is that they can be removed
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under the same conditions as the benzyl phosphate protecting groups, without 
migration or cyclisation of the phosphates. The two main methods used for 
deblocking the protected phosphate are catalytic or chemical reduction. For example, 
catalytic reduction of D-2,5,6-tri-0-benzyl-l,3,4-tris(dibenzyloxyphospho)-myc>- 
inositol with 5% palladium on carbon using ethanol as solvent, under an atmosphere 
of hydrogen, at room temperature for 24h, gave Ins(l,3,4)P3. t35°i The second method 
used to expose the naked myoinositol phosphate is chemical reduction, where the 
cyanoethoxyphosphate/phosphorothioate protective groups were removed within 
15min using sodium in liquid ammonia. f358^ Other methods used for the deprotection 
of benzyl groups may be found in "Protective Groups in Organic Synthesis". [3661
The p-methoxybenzyl group is not as stable to the harsh acidic conditions as 
unsubstituted benzyl groups. It is introduced into the myoinositol ring using p- 
methoxybenzyl chloride with sodium hydride as base, in DMF. Its special place in the 
synthesis of myoinositol phosphate derivatives arises because it may be deprotected 
by several different methods. First, the p-methoxybenzyl group of DL-2,3,6-tri-0- 
benzyl-4,5-bis[di(2-cyanoethoxyphospho)]-l-0-p-methoxybenzyl-myoinositol, was 
removed using 1.5 equivalents of 2,3-dichloro-5,6-dicyano-l,4-benzoquinone, (DDQ) 
in dichloromethane-water (15:1) within lh  at room temperature. l358l The p- 
methoxybenzyl group has also been removed from another phosphorylated precursor 
using cerium (IV) ammonium nitrate. Thus, D-2,3,6-tri-0-benzyl-1,4- 
bis(dibenzyloxyphospho)-5-0-p-methoxybenzyl-myoinositol (53 in Figure 26) was 
stirred at 20°C and treated with a solution of cerium (IV) ammonium nitrate (CAN) in 
acetonotrile-water (9:1). The product was extracted and purified to give the 5- 
hydroxyl derivative in 72% yield. l36?l Two methods have been used to remove the p- 
methoxybenzyl group under acidic conditions. First, d l - 1,2:4,5-di-D-isopropylidene- 
3-0-p-methoxybenzyl-6-0-methyl-myoinositol was heated under reflux in 1M HC1- 
ethanol (1:2) for 3h to remove the isopropylidene acetals and the p-methoxybenzyl 
group to give DL-4-O-methy l-myoinositol. I349! Second, DL-2,3,6-tri-0-benzyl-l,4- 
bis(dibenzyloxyphospho)-5-0-p-methoxybenzyl-myoinositol (53) was treated with 
2.5% trifluoroacetic acid (TFA) in dichloromethane. The mixture was stirred for
1. (CAN)
(BnO)2PO
PM B O ^i
(BnO)2PO
H O ^OP(OBn)2 OP(OBn)2
Bn°  (53) O 2. (TFA) (54) O
Figure 26
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30min at 20°C and concentrated in vacuo, neutralised and chromatographed to expose 
the 5-hydroxyl group (54) in 82% yield. f359l
3.5.2 Ester Protective Groups
Esters are generally prepared with an acid chloride or anhydride in the presence of an 
alcohol using pyridine or triethylamine as a base. The benzoate group has previously 
been used for derivatising a mixture of di-O-isopropylidene-myo-inositols to give d l -
3 ,6 -di-O-benzoyl-l,2 :4 ,5 -di-O-isopropylidene-my0 -inositol. I344! Pivaloyl chloride has 
been used to derivatise selectively, D-2 ,3 -0 -camphor-my<9-inositol. Treatment of d -
2.3-O-camphor-myo-inositol with 1.1 equivalents of pivaloyl chloride in pyridine gave 
the D-2,3-0-camphor-l-0-pivaloyl-myo-inositol (55) derivative in 44% yield, t348! 
Furthermore, when the tetrol was treated with 2.2 equivalents of pivaloyl chloride d -
2.3-O-camphor-1,5-di-O-pivaloyl-myo-inositol (56) is formed in 40% yield. Finally, 
treatment of the same tetrol with 4 equivalents of pivaloyl chloride at room 
temperature resulted in the prevalent formation of the d -  1,4,5-tri-O-pivaloyl derivative 
(57) which may be separated from other isomers by column chromatography (Figure 
27). These three compounds have been used to synthesise myo-inositol phosphates by 
further derivatisation followed by phosphorylation.
myo-Inositol has been benzoylated selectively using 3.5 equivalents of benzoyl 
chloride in pyridine for 2h, to give three main products. [368] The ratio of the 
benzoylated products was temperature dependent and at 90°C, d l -  1,3,4,5-tetra-O- 
benzoyl-myo-inositol, 33% was the main product together with 1,3,4,6-tetra-O- 
benzoyl-myo-inositol, 13% and d l -  1,3,4,5,6 -penta-O-benzoyl-myo-inositol. The d l -  




Rj = Pivaloyl, R2 = R3 = R4 = H (55) 
Rj = R3 = Pivaloyl, R2 = R4 = H (56) 
Rj = R3 = R4 = Pivaloyl, R2 = H (57)
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benzyl trichloroacetimidate and trifluoromethane sulphonic acid followed by 
debenzoylation with sodium methoxide to give the 1,3,4,5-tetrol. The tetrol was 
phosphorylated and deprotected to give Ins(l,3,4,5)P4. Ozaki and coworkers have 
also used the benzoylating reagent benzoyl imidazole f363l in the presence of caesium 
fluoride (CsF), to benzoylate selectively, d l -  1,2:4,5-di-0-cyclohexylidene-myo- 
inositol at the 3-hydroxyl position in 65% yield and with no other regioisomer. The 
use of other benzoylating reagents gave mixtures of products, so benzoyl imidazole is 
a useful selective benzoylating reagent. Acetate and butyrate derivatives have not 
been used widely, but their use in myoinositol chemistry will be described under 
"Enzymatic Resolutions".
If the benzoylation of myoinositol is carried out using 2.5 equivalents of benzoyl 
chloride in pyridine at 90°C, 1,3,5-tri-O-benzoyl-myoinositol is readily isolated in 
15% yield by column chromatography. t369l This intermediate was enantioselectively 
acylated under kinetic conditions using a tartaric acid monoester to provide a d -  or l -  
tetra-acylated product which was transformed into D-Ins(l,3,4,5)P4 or L-Ins(l,3,4,5)P4, 
the details of which will be described in section 3.7.
3.5.3 Silicon Protective Groups
h  &
ho^ ^ t^ / - opoj2
v 0 ' f v  HO (60) T  0
Ins(l,3,4,6)P4 (61) 
R = H (58) — ►R = Bz (59) 
bis-disiloxane Figure 28
There have been several reports of hydroxyl protection using silicon protective 
groups. l,3-Dichloro-l,l,3,3-tetraisopropyldisiloxane (TIPSC12) has been used to 
protect diols. First,[370] the treatment of myo-inositol with 2.5 equivalents of TIPSC12 
in pyridine at room temperature gave the highly crystalline bis-disiloxane (58) 
derivative (Figure 28) in 66% yield. This compound was esterified at the 2- and 5- 
positions with benzoyl chloride in boiling pyridine, and the silicon protective groups 
were removed by treatment with aqueous hydrogen fluoride in acetonitrile to give 2,5- 
di-O-benzoyl-myoinositol (60) in 96% yield. This tetrol was phosphorylated and
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deprotected to give Ins(l,3,4,6)P4 (61). t37°3 Second, when DL-l,2-(9-cyclohexylidene- 
myo-inositol was treated with TrPSCl2 (1.2 equivalents) in pyridine at room 
temperature, the 3,4-TIPS derivative was formed in 90% yield. I370! This intermediate 
could be used for the synthesis of Ins(l,3,4)P3 by further protection and deprotection 
steps.
The exposed 1,2-diol of the protected d l -3  ,6-di-0-benzy 1-4,5-di-O-bis
(dibenzyloxyphospho)-myo-inositol was selectively silylated using triethylsilyl 
chloride in pyridine at 0°C. The triethylsilyl group was selectively introduced at the 
equatorial 1-hydroxyl position (95% yield) over the axial 2-hydroxyl position. 
Benzoylation at the axial 2-position (97% yield) and desilylation with acid provided 
the 1-hydroxy derivative which was phosphorylated and deprotected to give racemic 
Ins(l,4,5)P3. [371] t-Butyldiphenylsilyl chloride was used to silylate selectively d l -  
1,2:4,5-di-O-isopropylidene-myo-inositol at the 3-hydroxyl group in 60% yield. t372l 
The 6-position was esterified with (lS)-(-)-co-camphanic acid chloride and the 
individual diastereoisomers were separated by high performance liquid 
chromatography, (HPLC). The 1-0-silyl derivative was used to synthesise the chiral 
phospholipid D-myo-inositol-1 -(sodium 1,2-di-0-hexadecanoyl-.m-glycer-3-yl- 
phosphate). The silicon group was removed by treatment with tetrabutylammonium 
fluoride in tetrahydrofuran (THF).
When D-2,3-0-camphor-myo-inositol is treated with f-butyldiphenylsilyl chloride (1.1 
equivalents) in the presence of imidazole in acetonitrile, D-l-O-r-butyldiphenylsilyl-
2,3-O-camphor-myo-inositol was formed in 30% yield. When 2.2 equivalents of t -  
butyldiphenylsilyl chloride were used, then D-l,4-di-O-/-butyldiphenylsilyl-2,3-0- 
camphor-myo-inositol was formed in 50% yield.13481
3.6 Selective Hydroxyl Protection Using Dibutyltin Oxide
The difference between the reactivities of secondary hydroxyl groups in sugars and 
cyclitols is small, so inevitably substitution of a polyol leads to several products. 
There has been a dramatic increase in the use of organotin derivatives, and to a lesser 
extent organoborane derivatives, to activate selectively, one hydroxyl group over a 
neighbouring one and provide partially protected myo-inositol derivatives which have 
been difficult to obtain otherwise.
Some of the first reports of selective substitution at one hydroxyl of a vicinal diol, 
appeared using pyranosides as the source of the 1,2-diol. When the 1,2-diol was
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suspended in toluene or methanol in the presence of dibutyltin oxide or the bis- 
alkoxide, water or an alcohol was removed azeotropically, together with the formation 
of the dibutylstannylene. In non polar solvents such as toluene, dibutylstannylenes 
exist as dimers (Figure 29). The chemical shifts in the 119Sn NMR spectra of 
carbohydrate stannylenes in CDC13 are characteristic of a penta-coordinate tin, in 
which the O-Sn-O angle is approximately 80°, accommodated in a trigonal bipyramid. 
This topic has been reviewed by S. David and S. Hanessian. l373J
The alkylation of 1,2-diols has been mediated by stannylenes in the presence of CsF. 
When the stannylene has been formed the solvent was evaporated and then dried for 
several hours in vacuo at high temperature (90°C), in the presence of CsF (2.5 
equivalents). Anhydrous DMF was added followed by the alkyl halide (for example, 
benzyl bromide) to give the monoalkylated product in high yield. [374i
Caesium fluoride plays a major role in the selective alkylation reaction. Caesium 
fluoride has a highly polarisable caesium cation and an electronegative fluoride anion. 
The high reactivity of the dibutylstannylene acetal activated by Sn-O bonds, is not 
sufficient to explain the high regioselectivity. However, the polarisable caesium 
cation may activate the halogen of the alkyl halide. The activation of the Sn-O bond 
may be caused by the formation of a pentacoordinate complex, because the maximum 
yield was obtained with 2 equivalents of CsF. Both the caesium cation and the 
fluoride anion contribute towards the high regioselective and high yielding O- 
monoalkylation of the diol.
There are several examples where CsF has mediated highly regioselective alkylations 
in the synthesis of myo-inositol derivatives, d l-  1,2:5,6-Di-O-cyclohexylidene-myo 
inositol was stannylated with dibutyltin oxide across the 3,4-fran.y-diol. This tin 
complex was activated with caesium fluoride in DMF using benzyl bromide as the 
alkylating reagent, which provided DL-4-O-benzyl-1,2:5,6-di-O-cyclohexylidene-myo- 
inositol (63) in 97% yield, (Figure 30). l375l In several examples, the cis- 1,2-diol of 
myoinositol derivatives was alkylated in the presence of caesium fluoride. First, d l -
Figure 29
(62) Dibutylstannylene in 
non-polar solvent
71
l,4-di-0-benzyl-5,6-di-0-butanoyl-myo-inositol was stannylated using dibutyltin 
oxide to form the cw-stannylene which was alkylated using p-methoxybenzyl 
chloride/potassium iodide together with 2.5 equivalents of CsF in DMF to give d l - 1 -  
0-/?-methoxybenzyl-3,6-di-0-benzyl-4,5-di-0-butanoyl-my<?-inositol in 85% yield 
after crystallisation. l358l Second, allylation of d l -  1,4-di-0-allyl-6-0-benzyl-5-0-p- 
methoxybenzyl-myo-inositol using allyl bromide under similar conditions provided 
d l - 1 ,3,4-tri-0-ally l-6-0-benzyl-5-0-p-methoxybenzyl-myc>-inositol derivative in 83% 
yield. [3591 Third, allylation of d - 3 ,4,5-tri-0-ally 1-6-0-benzyl-my<9-inositol via the cis-
1,2-0-stannylene acetal with allyl bromide together with CsF provided the d - 1,3,4,5- 
tetra-0-allyl-6-0-benzyl-myo-inositol derivative in 95% yield. I376l These examples 
provide high yielding and highly regioselective mono-alkylation of a diol, which 






The last few years have seen many examples for the selective alkylation of 
polyhydroxy compounds, especially myoinositol, and its derivatives. From previous 
work, it has been demonstrated that alkylation of the cis-1,2-0-stannylene derivative 
in a six membered ring provides preferential alkylation at the equatorial site. I358J The 
solvent of choice in most of the examples was toluene, in the presence of 
tetrabutylammonium bromide or iodide. Roy Gigg and his coworkers t377l used 
acetonitrile as the solvent which was refluxed in a solid/liquid soup of myo-inositol, 
dibutyltin oxide and tetrabutylammonium bromide in the presence of molecular sieves 
in a soxhlet thimble to remove the water which was formed. The reaction of myo­
inositol with dibutyltin oxide, tetrabutylammonium bromide (2 equivalents each) and 
a large excess of allyl bromide in refluxing acetonitrile, gave many products which 
could be separated by chromatography, but no major product was formed. The 
reaction of myo-inositol with dibutyltin oxide, tetrabutylammonium bromide (3 
equivalents each) and a large excess of allyl bromide in refluxing acetonitrile gave 
fewer products. Several ether soluble derivatives were formed including d l - 1,3,4,5- 
tetra-0-allyl-myo-inositol, l,3,4,6-tetra-0-allyl-myo-inositol, and DL-l,2,3,4-tetra-0- 
allyl-myo-inositol in small quantities. However, the major product formed was the
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water soluble DL-l,3,4-tri-0-allyl-my0-inositol which was isolated in 44% yield, 
together with a small portion of l,3,5-tri-0-allyl-my0-inositol and several mono- and 
di-0-allyl compounds which were characterised as their known di-0-isopropy lidene 
derivatives. This major product has tremendous potential for the synthesis of several 
myoinositol phosphate analogues in a one pot high yielding reaction for the selective 
protection of 3 out of the 6 hydroxyl groups of myoinositol. When 5  equivalents of 
dibutyl tin oxide were used under similar conditions, fewer allylated products were 
formed and only a small amount of penta-O-allyl-myoinositol was formed. There 
were two major products: l,3,4,6-tetra-0-allyl-myoinositol, ( 2 5 % )  and d l - 1 , 3 , 4 ,5 -  
tetra-O-allyl-myoinositol, (26%), together with other minor products. The tetra-0- 
allyl derivatives have been used to prepare their respective tetrakisphosphates in only 
a few transformations starting from myoinositol, [3771
The tetrabutylammonium bromide plays a critical role in the reaction, being a very 
effective catalyst. Without the tetrabutylammonium bromide the reaction would not 
proceed or go to completion. It has been suggested t3781 that the co-ordination of the 
halide anion to the tin of the stannylene complex enhances the nucleophilicity of one 
of the bound oxygen atoms in some unknown manner. The polar aprotic nature of 
acetonitrile may also influence the nucleophilicity of the oxygen at one of the tin 
atoms.
In a more recent paper, Gigg and his coworkers 13791 have selectively alkylated racemic
1.2-0-isopropylidene-myo-inositol with excess benzyl bromide, dibutyltin oxide and 
tetrabutylammonium bromide in refluxing acetonitrile to give DL-3,4,6-tri-0-benzyl-
1.2-0-isopropylidene-myo-inositol in 40% yield and DL-3,5,6-tri-0-benzyl-l,2-0- 
isopropylidene-myo-inositol in 30% yield together with four minor components. 
When 2 equivalents of dibutyltin oxide were used, DL-3,6-di-0-benzyl-1,2-0- 
isopropylidene-myo-inositol was formed in c a .  45% yield which is less cumbersome 
than the 5-step transformation first devised by Gigg and his coworkers.13491
Selective p-methoxybenzylation of d l-  1,6-di-0-benzyl-2,3-0-isopropylidene-myo- 
inositol with dibutyltin oxide and excess p-methoxybenzyl chloride in the presence of 
tetrabutylammonium bromide gave a mixture of the 4-0-p-methoxybenzy 1 derivative 
in 64% yield and the 5-0-p-methoxybenzy 1 derivative in 23% yield, indicating a 
selectivity of 3:1 for the 4-position over the 5-position. Under the same conditions, 
but replacing p-methoxybenzyl chloride with allyl bromide no regiospecificity was 
observed. I3801 The use of the dibutylstannylene acetal to regioselectively alkylate
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myo-inositol derivatives has greatly reduced the number of transformations needed to 
provide a suitable phosphorylation precursor.
3.7 Resolution of myo-Inositol Derivatives
There have been several methods used to resolve myo-inositol phosphate precursors. 
The majority of these methods rely on the derivatisation of the racemate with a chiral 
acid derivative to form a pair of diastereoisomeric esters. These esters may be 
separated by silica gel chromatography or by crystallisation. HPLC analysis has been 
used to determine the diastereomeric purity and basic hydrolysis of the individual 
diastereoisomers regenerates the corresponding enantiomers.
Two other methods have been used, albeit infrequently, for the resolution of myo­
inositol derivatives. First, using chiral derivatives of carbohydrates and second, 
employing a chiral HPLC column. Russian scientists have used D-mannose 
orthoacetate [381J and D-glucose orthoacetate [381] derivatives to resolve racemates. The 
diastereoisomeric intermediates were separated by silica gel chromatography or 
selective crystallisation. In the early years of myo-inositol phosphate synthesis, a 
chiral HPLC column was used to separate DL-5,6-di-0-benzyl-3,4-di-0-p- 
methoxybenzyl-myo-inositol possessing a free 1,2-dihydroxy moiety. Highly efficient 
resolution of this racemate was accomplished by using a stainless steel tube packed 
with the chiral cellulose 3,5-dimethylphenylcarbamate derivative, supported on silica 
gel. Eluting with propanol/hexane (1:5) gave the L-5,6-di-0-benzyl-3,4-di-0-p- 
methoxybenzyl-myo-inositol (retention time 15min) and the D-isomer (retention time 
25min). The latter enantiomer was used to synthesise D-Ins(l,3,4)P3.135°i
The main chiral acids or acid chlorides that have been used for the resolution of myo­
inositol derivatives are: (-)-menthoxyacetyl chloride ( 6 6 ) ,  d -  and L-tartaric acid 
monoester (64,65) and finally (15)-(-)-co-camphanic acid chloride (67) and (lR)-(+)-co 
-camphanic acid chloride (68). One example of a carbamate derivative using R-(+)- 
(l-phenylethyl)isocyanate (69) has also been employed (Figure 31). The most popular 
method, by far, for resolving racemates has been the derivatisation by means of S-(-)~ 
camphanate esters. The use of enzymes (such as lipases and esterases) for the 
synthesis of myo-inositol phosphate precursors has also been utilised and will be 
discussed later.
It has been discussed above that benzoylation of myo-inositol provides a series of 
protected intermediates, including 1,3,4,5-tetra-O-benzoyl-myo-inositol and the meso
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derivative 1,3,5-tri-O-benzoyl-rayo-inositol. I369l The meso compound was selectively 
acylated with a chiral acid derivative to provide protection at the 1,3,4,5-positions. 
The readily available chiral acids such as (-)-menthoxyacetyl chloride, (-)- 
menthoxycarbonyl chloride, amino acid mixed anhydrides and isocyanates were 
unable to obtain useful selectivities. However, kinetic resolution of 1,3,5-tri-O- 
benzoyl-rayo-inositol (1 equivalent) using methyl hydrogen 2,3-O-cyclohexylidene-D- 
tartrate in the presence of methanesulphonyl chloride (1.1 equivalents), N- 
methylmorpholine (2.5 equivalents) and a catalytic amount of DMAP in THF at 0°C 
provided the diastereoisomeric monotartrates in an optimised yield of 62% with a 
diastereoisomeric excess of 96% and 1,3,5-tri-O-benzoyl-myo-inositol was recovered 
in 28% yield. The methyl hydrogen 2,3-O-cyclohexylidene-L-tartrate derivative 
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Figure 31
The major use of (-)-menthoxyacetyl chloride will be discussed in the first synthesis of 
D-Ins(l,4,5)P3. In a later synthesis of D-Ins(l,4,5)P3, racemic l,2:5,6-di-0- 
cyclohexylidene-myo-inositol was derivatised as the 3,4-di-O-menthoxyacetate, to 
provide two diastereoisomers with quite different chromatographic mobilities on TLC 
[ether/hexane (1:3) Rf = 0.87 for d - ( - ) - 1,2:5,6-di-0-cyclohexylidene-3,4-di-0- 
menthoxyacetyl-myo-inositol and for the slower moving diastereoisomer, l - 1,2:5,6-di-
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O-cyclohexylidene-3,4-di-0-menthoxyacetyl-my0-inositol an R f = 0.74. t3821 The l -  
derivative was used to prepare D-Ins(l,4,5)P3.
Vasella and coworkers 13521 have synthesised both enantiomers of Ins(l,3,4,5)P4, via 
DL-4-0-benzyl-2-O-f-butyldimethylsilyl-myoinositol orthoformate. This compound 
was treated with (R)-(+)- l-(phenylethyl)isocyanate in the presence of butyl lithium at 
-78°C to provide a mixture of diastereoisomers and unreacted starting material. In 
order to separate the diastereoisomers the product was desilylated and the 
diastereoisomers were separated by medium pressure chromatography and the 
racemate was recycled. Further derivatisation of the individual diastereoisomers gave 
d -  and L-2,6-di-0-benzyl-myoinositol which were used to synthesise d -  and l - 
Ins(l,3,4,5)P4.
The enantiomers of camphanic acid are the most popular resolving agents to date for 
the synthesis of chiral rayo-inositol phosphate precursors. Until recently, only 
(co)-camphanic acid chloride (67) was available, but in 1989 the l/?-(+)-(co)- 
camphanic acid chloride (68) became commercially available from Fluka. However, 
the lS-(-)-(co)-camphanic acid chloride is the most widely used because l/?-(+)-(co)- 
camphanic acid chloride is very expensive, (250mg, £25.70, Fluka 1993/94). lS-(-)- 
(CD)-Camphanic acid chloride is a highly crystalline reagent which is available in 
>98% optical purity. The camphanate esters that are formed may be separated by 
column chromatography (when the R{ values for the two diastereoisomers are 
different) or more appropriately by crystallisation of one diastereoisomer from the 
mixture. At least one of the camphanate derivatives is usually highly crystalline and 
the absolute configuration of the diastereoisomer may be evaluated by X-ray 
crystallography. The chiral camphanic acid may be recovered from the aqueous layer 
after saponification, by acidification followed by extraction with dichloromethane.
The first significant use of l*S-(-)-(co)-camphanic acid chloride I3831 was in the 
resolution of d l -  1 ,2,4-tri-0-benzyl-5,6-0-isopropylidene-wyo-inositol (Figure 32) to 
give a mixture of 3-O-camphanate ester derivatives. After work-up and evaporation, 
the remaining syrup was dissolved in ether and crystals appeared rapidly. After 
separating the crystals, the remaining syrup was diluted with methanol and more 
crystals appeared, which contained one diastereoisomer only in 86% yield. This 
highly crystalline compound was subsequently found to be D-l,2,4-tri-0-benzyl-3-0- 
(-)-camphanoyl-5,6-0-isopropylidene-myo-inositol (72) which was the wrong 
diastereoisomer for the synthesis of D-Ins(l,4,5)P3. Later, with the availability of 1R- 
(+)-((0)-camphanic acid chloride, the mother liquor containing mainly the non­
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crystalline l -  1,2,4-tri-0-benzyl-3-0-(-)-camphanoyl-5,6-0-isopropylidene-myo- 
inositol (71) was saponified to give l -  1,2,4-tri-O-benzyl-5,6-0-isopropylidene-my<9- 
inositol. This compound was treated with lR-(+)-(co)-camphanic acid chloride to give 
the crystalline l -  1,2,4-tri-0-benzyl-3-0-(+)-camphanoyl-5,6-0-isopropylidene-myo- 
inositol (73). The pure diastereoisomer was crystallised from ether in 80% yield. 
Saponification of this L-derivative followed by deacetonation provided D-2,3,6-tri-0- 
benzyl-wyo-inositol which was used to synthesise D-Ins(l,4,5)P3. [384l














In the synthesis of both enantiomers of 2-deoxy-2,2-difluoro-myo-inositol-1,4,5- 
trisphosphate, 15-(-)-(co)-camphanic acid chloride was employed to resolve the 
intermediate DL-3,6-di-0-benzyl-2-deoxy-2,2-difluoro-4,5-0-isopropylidene-myo- 
inositol (74) (Figure 33).[385] Thus, treatment of the racemic derivative (74) with 15- 
(-)-(co)-camphanic acid chloride provided two diastereoisomers which were separated 
by silica gel chromatography using dichloromethane as the eluting solvent.
F F
\  Bl'"P JL  \  BnO I
D-2,2Fr Ins(l,4,5)P3
BnO BnO O
Racemic (74) TLC R{ = 0.19 (75)
L-2,2F2-Ins(l,4,5)P3
BnO
TLC Rf = 0.29 (76) Figure 33
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The slower moving diastereoisomer (75) on TLC, R{ = 0.19 (60% yield) provided the 
derivative which was suitable for single X-ray crystallography I385l and was 
subsequently found to be the intermediate for the synthesis of D-2-deoxy-2,2-difluoro- 
myoinositol-1,4,5-trisphosphate. The faster moving diastereoisomer, R{ = 0.29 (64% 
yield) (76) provided the intermediate for the synthesis of L-2-deoxy-2,2-difluoro-myo­
inositol- 1,4,5-trisphosphate.
In another example, DL-l-O-allyl-2,3,6-tri-0-benzyl-myoinositol[358] was treated with 
1 S-(-)-(co)-camphanic acid chloride to give the 4,5-di-O-camphanoyl derivative. After 
work-up the syrup was taken up in ether and kept at -20°C overnight, after which time 
crystals had appeared. These were filtered and the mother liquor was redissolved in 
ether-methanol to give more crystals of d - ( + ) -  1 -0-ally 1-2,3,6-tri-0-benzyl-4,5-di- O- 
camphanoyl-myoinositol in 74% yield. Surprisingly, after leaving the mother liquor 
for several days at -20°C a solid was formed. The solid was redissolved in warm ether 
and after 2 days the other diastereoisomer crystallised in 80% yield. The D-derivative 
was used to synthesise D-myo-inositol-4,5-bisphosphate 1-phosphorothioate.
The derivative, d l -  1 ,3,4-tri-0-allyl-2-0-benzyl-myo-inositol was treated with lS-(-)- 
(m)-camphanic acid chloride to give a mixture of bis-camphanates. The two 
diastereoisomers had only slightly different mobilities by TLC, differing by an R{ = 
0.05. Crystallisation of the L-5,6-di-0-camphanoyl derivative (84% yield, R{ = 0.4) 
provided a suitable intermediate for the synthesis of L-Ins(l,3,4)P3. The other 
diastereoisomer (R{ = 0.45) was obtained by column chromatography of the mother 
liquors and provided a suitable intermediate for the synthesis of D-Ins(l,3,4)P3. [386J 
Finally, a one pot allylation of myoinositol, (described in section 3.6) provided
1.3.4.5-tetra-O-allyl-myo-inositol in 26% yield. Treatment of this diol with lS-(-)- 
(co)-camphanic acid chloride gave a mixture of 2,6-di-O-camphanates with different 
mobilities by TLC (.R{ = 0.65 and 0.70, ether-light petroleum, 4:1). The slower 
moving bis-camphanate, R{ = 0.65 was crystallised directly from the mixture of diaster 
eoisomers with ether-petroleum ether (1:1), to give the L-2,6-di-0-camphanoyl-
1.3.4.5-tetra-O-allyl-myoinositol. The other diastereoisomer (Rf = 0.70) was obtained 
by column chromatography of the mother liquors. These chiral intermediates were 
used to synthesise both enantiomers of Ins( 1,3,4,5)P4. [3871 These examples represent 
successful applications of 15-(-)-(co)-camphanic acid chloride and its enantiomer in 
the synthesis of myoinositol phosphate derivatives.
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3.7.1 The Use of Enzymes to Resolve my o-Inositol Phosphate Derivatives
The first example in which enzymes were used to resolve myoinositol phosphate 
precursors, appeared in 1988 by the Vasella group. l352l The mesoderivative 4,6-di-
0-butanoyl-myoinositol-orthoformate, (77) (prepared in 3 steps from the 
orthoformate) (Figure 34) was hydrolysed enantiospecifically by pig liver esterase 
(PLE) to give L-4-O-butanoyl-myoinositol-orthoformate (78) in 83% yield and 95% 
enantiomeric excess. One recrystallisation followed by a further 3 steps converted 
this intermediate into optically pure L-2,6-di-0-benzyl-myoinositol. However, 6 more 
protection-deprotection steps were required to convert L-4-O-butanoyl-myoinositol- 
orthoformate into D-2,6-di-0-benzyl-myoinositol. Both compounds were 
phosphorylated and deprotected to give l -  and D-Ins(l,3,4,5)P4 respectively.
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Figure 34 L-4-0-Butyryl-myo-inositol 
orthoformate (78)
Pr = Propyl
The major contribution to the synthesis of chiral myo-inositol phosphate precursors 
using enzymes has come from the laboratory of Professor C.-S. Chen. [376l The 
treatment of myoinositol with 1-ethoxycyclohexene provided three racemic di-0- 
cyclohexylidene-myoinositol derivatives. Two of these, d l - 1,2:5,6-di-O- 
cyclohexylidene-myoinositol and d l -  1,2:4,5-di-0-cyclohexylidene-myoinositol were 
acylated to form their respective di-0-acetates and di-0-butyrates. By exposure of the 
individual compounds to a number of esterases and many lipases and proteases it was 
found that DL-3,6-di-0-acyl-1,2:4,5-di-0-cyclohexylidene-myoinositols were resistant 
to deacylation whereas the DL-3,4-di-0-acyl derivatives were deacylated by most of 
the enzymes tested. Finally, two enzymes, cholesterol esterase and porcine pancreatic 
lipase showed high degrees of stereochemical discrimination. The length of the acyl 
group was also critical in the optical purity of the product, with the 3,4-di-0-butanoyl 
derivative providing a higher enantiomeric excess than the 3,4-di-0-acetate. The 
problem of a slow reaction rate with di-0-acyl derivatives was overcome by using d l -
4-0-butanoyl-l,2:5,6-di-0-cyclohexylidene myoinositol, a compound with minimised
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steric congestion and improved solubility. The exposure of DL-4-O-butanoyl-1,2:5,6- 
di-O-cyclohexylidene-myo-inositol (15g) in phosphate buffer (0.1M), containing crude 
porcine pancreatic lipase for 2days at room temperature provided two compounds. 
First, d -  1,2:5,6-di-0-cyclohexylidene-mye>-inositol (5.6g, 88% enantiomeric excess) 
and L-4-0-butanoyl-l,2:5,6-di-0-cyclohexylidene-myo-inositol (6.5g, 95%
enantiomeric excess). Both derivatives were optically pure after one recrystallisation. 
The latter derivative, was deacylated and selectively benzylated to give d - ( - ) - 6 - 0 -  
benzyl-2,3:4,5-di-0-cyclohexylidene-myo-inositol. The less stable trans-acetal was 
removed under acid conditions to give D-6-0-benzyl-2,3-0-cyclohexylidene-myo- 
inositol, which was phosphorylated and deprotected to afford D-Ins(l,4,5)P3. Further 
manipulation of provided intermediates for the synthesis of D-Ins(l,3,4)P3, and d -  
Ins(l,3,4,5)P4.1376l
dioxane U0 - ^ Z ^ 7 ^ / - 0
HO (AcO)20  ^ r i
(35) HO s 'R  = Ac (79)
Q + \ R  = H (80)
R, = H, R2 = H (81)
Ri = Ac, (82)  ► D-Ins(l,4,5)P3
_-R2 = H,R, = H (81) h o
A R2 = Ac, (83) --------»- D-Ins(l,4,6)P3
a * * Figure 35Ac = acetate &
For (80) the optical rotation is known
The kinetic resolution of d l -  1,2-O-cyclohexylidene-myo-inositol has been carried out 
by enzyme-catalysed enantioselective esterification using two hydrolytic enzymes, 
from Pseudomonas spp. (Amano Lipase P and Lipase CES). t388i d l - 1,2-0- 
Cyclohexylidene-myo-inositol (35) was dissolved in dry dioxane, together with acetic 
anhydride and the enzyme. Lipase P and Lipase CES acylated selectively the 
hydroxyl group at C-3 of the D-enantiomer (Figure 35). Lipase CES provided the 
highest optically pure derivatives, in 98% chemical yield and 98% enantiomeric 
excess for D-3-O-acetyl-1,2-O-cyclohexylidene-myo-inositol (79) and 98% chemical 
yield and >99% enantiomeric excess for l -  1,2-0-cyclohexylidene-my<9-inositol (81).
l -  1,2-O-Cyclohexylidene-rayoinositol was acylated selectively with acetic anhydride 
(6 equivalents) in the presence of dimethylacetamide (DMA) at room temperature 
with 4A sieves to afford 4-O-acylated (82) and 5-O-acylated (83) products in a ratio of
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1:1, in 74% yield. The mixture of acetylated products was subject to phosphorylation 
and separated by column chromatography. The phosphorylated D-6-O-acetyl-2,3-0- 
cyclohexylidene-myoinositol derivative provided D-Ins(l,4,5)P3 after deprotection, in 
a small number of steps, whilst the phosphorylated D-5-0-acetyl-2,3-O- 
cyclohexylidene-myoinositol derivative gave D-Ins(l,4,6)P3 in a few steps. 
Phosphorylation was carried out with Ozaki's reagent v ia  the P(HI) method outlined in 
the next section.
3.8 Phosphorylation Methods
In the early days of inositol phosphate synthesis, it was reported that phosphorylation 
of the hydroxyl groups was quite difficult. There are three main reasons for this. 
First, the reactivity of the hydroxyl functions of myoinositols is generally low 
compared with other alcohols and nucleotides because of steric crowding and 
hydrogen bonding; thus efficient phosphorylation of a vicinal 4,5-diol of Ins(l,4,5)P3 
or a vicinal 3,4,5-triol of Ins(l,3,4,5)P4 must be achieved for a successful synthesis. 
This can only be achieved using a suitable P(m) reagent or a highly reactive P(V) 
reagent. Second, strongly acidic and basic conditions must be avoided to reduce the 
chance of phosphate migration to a neighbouring hydroxyl group. Third, the resulting 
phosphate triester may form cyclic phosphates if the hydroxyl groups are not suitably 
protected.
o o o o o
PhCXM Q C C H 20 ^ | |  P h N H. I I  II II
J^P —Cl "^ p —Cl Cl BnO—P—O—P—OBn
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(84) (85) (86) (87)
Figure 36
Four P(V) reagents have been used in the synthesis of myoinositol phosphates, 
(Figure 36). These include, diphenyl phosphochloridate (84), bis(2,2,2-trichloroethyl) 
phosphochloridate (85), dianilidophosphoryl chloride (86) and tetrabenzyl 
pyrophosphate (87). Diphenyl phosphochloridate has been used to synthesise racemic 
myoinositol 1-phosphate, Ins(l)P. I389l The phosphorylation precursor, 1,2,4,5,6- 
penta- 0-benzyl-myoinositol, failed to react with either dibenzyl chlorophosphate or 
tetrabenzyl pyrophosphate, under the conditions used. The hydroxyl group was finally 
phosphorylated with diphenyl chlorophosphate in triethylamine and DMAP, followed 
by transesterification with the anion of benzyl alcohol using sodium hydride as base in 
THF to give the required hepta-Obenzyl-myoinositol-1 -phosphate derivative in 83%
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yield. Hydrogenolysis of all seven benzyl protective groups gave racemic myo­
inositol-1-phosphate, which was isolated as its crystalline biscyclohexylammonium 
salt in 95% yield. Dianilidophosphoryl chloride has been used in the first synthesis of 
Ins(l,4,5)P3. However, deprotection methods were not entirely successful so its use 
by Ozaki and coworkers was discontinued. The synthesis of Ins(l,4,5)P3 will be 












A combination of P(DI) and P(V) chemistry provided a synthesis of racemic myo­
inositol l,4-bisphosphate-5-phosphorothioate, [390] a close analogue of Ins(l,4,5)P3 
which is resistant to the action of the 5-phosphatase enzyme. The racemic diol d l -
1.2.4-tri-(9-benzyl-myo-inositol-3-[di(2,2,2-trichloroethyl) phosphate] (88) (Figure 37) 
was monophosphorylated with the sterically hindered reagent, bis(2,2,2-trichloroethyl) 
phosphochloridate in 29% yield, leaving the 5-hydroxyl group exposed (89). 
Phosphitylation of the 5-hydroxyl group was accomplished with N,N- 
diisopropylamino(2-cyanoethoxy)chlorophosphine (see below) to give the 
phosphoramidite. The reaction of the phosphoramidite in situ with 2-cyanoethanol 
and tetrazole gave the phosphite which was sulphoxidised using sulphur in pyridine to 
provide the fully protected l,4-bisphosphate-5-phosphorothioate derivative (90). A 
one step deprotection using sodium in liquid ammonia removed all the protective 
groups to give the racemic 5-phosphorothioate derivative in 88% yield, after 
purification by ion exchange chromatography.
The P(V) reagent tetrabenzyl pyrophosphate has been used to synthesise Ins(l,4,5)P3, 
Ins(l,3,4)P3 and several bisphosphates. [364] The reagent is easy to handle and a fairly 
stable crystalline compound of relatively low toxicity. The phosphorylation of d l -
2.4.5-tri-O-benzyl-myo-inositol was carried out in THF at 60°C with sodium hydride
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as base, to form the alkoxide, which was then reacted with tetrabenzyl pyrophosphate 
to form the fully protected Ins(l,3,4)P3 derivative. The benzyl protective groups were 
removed by hydrogenolysis. DL-2,4-Di-0-benzyl-myoinositol was phosphorylated 
under the same conditions as for DL-2,4,5-tri-0-benzyl-myo-inositol, in 66% yield and 
hydrogenolysis afforded Ins(l,3,4,5)P4, in 88% yield. I353l
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The second method of introducing a phosphate moiety into the myo-inositol ring 
involves the reaction of the hydroxyl group with a P(1H) reagent (Figure 38), which is 
more reactive than its P(V) counterpart. Oxidation of the P(m) intermediate with t- 
butylhydroperoxide l358l or m-CPBA t375J gives a phosphate triester intermediate 
whereas sulphoxidation with sulphur in pyridine I391l or phenacetyl disulphide t392l 
provides the phosphorothioate triester. The first P(m) reagent used to phosphitylate 
myo-inositol derivatives was Af,N-diisopropylamino(2-cyanoethoxy)chlorophosphine
(91) which will be fully described in Potter's synthesis of racemic Ins(l,4,5)P3. Reese 
and Ward I346! introduced another reagent, bis(2-cyanoethoxy)diethylaminophosphine
(92) which was used to phosphitylate the intermediate, d l -  1,2-0-cyclopentylidene-4- 
0-(2,7-dibromo-9-phenylxanthen-9-yl)-myoinositol in the presence of l//-tetrazole 
and dichloromethane as the solvent. The 1,4,5-trisphosphite triester was oxidised 
with r-butylhydroperoxide to give the 1,4,5-trisphosphate and the product was purified 
by column chromatography. Total deprotection of this intermediate was 
accomplished in a two step process. First, the base labile cyanoethoxy groups were 
removed with N1 ^ V1 /v^/^-tetramethylguanidine in ethanol-water (4:1 v/v) at 37°C for 
24h, then at room temperature for 48h to give the N 1 ^/^-tetram ethylguanidium  
salt. The cyclopentylidene acetal and 4-0(2 ,7-dibromo-9-phenylxanthen-9-y 1) groups
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were removed in ca. lh when the product was dissolved in water (pH ~ 6) at room 
temperature.
Meek and coworkers [393] used dimethoxychlorophosphine (93) in the presence of 
V,V-diisopropylethyl amine and dichloromethane as solvent, to phosphitylate the four 
vicinal hydroxyl groups of d l - 1,2-Oisopropylidene-myo-inositol. Hydrogen peroxide 
was used to oxidise the P(III) to the P(V) phosphate intermediate. The eight methyl 
groups of d l - 1,2-0-isopropylidene-3,4,5,6-tetrakis(dimethoxyphospho)-mye>-inositol 
were removed using excess bromotrimethylsilane in dry dichloromethane, followed by 
stirring in water with the autocatalysed hydrolysis of the isopropylidene group, to 
provide DL-Ins(l,4,5,6)P4. Reagent (93) was also used to phosphitylate DL-2,4-di-0- 
benzoyl-rayo-inositol which was oxidised in the same manner to give the 1,3,4,5- 
phosphorylated derivative and the methyl groups were removed using 30% hydrogen 
bromide in acetic acid followed by basic hydrolysis of the benzoate esters to give d l - 
Ins(l,3,4,5)P4.
Van Boom and coworkers t394l have used several phosphitylating reagents, one being 
the monofunctional bis(2-cyanoethoxy)chlorophosphine (94) which was used to 
prepare racemic Ins(l,3,4)P3 using V,V-diisopropylethylamine as base and acetonitrile 
as solvent, to phosphitylate DL-2,4,5-tri-0-benzyl-myo-inositol. The phosphite triester 
was oxidised with f-butylhydroperoxide to give the protected phosphate triester. The 
base-labile cyanoethoxy groups were deprotected by ammonolysis followed by 
sodium hydroxide (0.2N) in dioxane/methanol/water at 50°C and neutralised with 
Dowex 50W H+ form. The benzyl groups were cleaved by catalytic reduction using 
palladium on carbon under hydrogen to give racemic Ins(l,3,4)P3 as a free acid in 
80% yield.
Ozaki and coworkers have also used several phosphitylating reagents. However, over 
the past few years they have employed a very effective phosphitylating reagent, o- 
xylene-W,W-diethylaminophosphine (95). This was easily obtained in a one pot 
reaction with oxylenediol and hexaethylphosphorustriamide to give the product. 
Thus, treatment of l - 1,2,4-tri-O-benzyl-myo-inositol with o-xylene-V,V-diethylamino 
phosphine in the presence of l//-tetrazole followed by the addition of mCPBA 
afforded the protected tris-phosphate in 97% yield. Hydrogenolysis in methanol and 
5% palladium on carbon afforded D-Ins(l,4,5)P3 in quantitative yield as its potassium 
salt.
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Finally, the most popular reagent to date is bis(benzyloxy)diisopropylaminophosphine 
(96) which was first used by Fraser-Reid and coworkers t375l and subsequently by 
many other groups. Essentially this reagent is employed in the same way as Ozaki's 
reagent, and Fraser-Reid used it to synthesise racemic Ins(l,4,5)P3. Vasella and 
coworkers I352l also used the reagent to phosphitylate D-and L-2,4-di-0-benzyl-myo- 
inositol in the presence of l//-tetrazole and acetonitrile as solvent. The intermediate 
tetrakisphosphite was oxidised with mCPBA and deprotected by hydrogenolysis with 
palladium on carbon to give l - and D-Ins(l,3,4,5)P4 respectively in 76% yield as the 
cyclohexylammonium salt.
At present the lff-tetrazole catalysed phosphitylation of hydroxyl groups is the most 
popular and most efficient method for introducing phosphate and phosphorothioate 
groups into the myo-inositol ring. Further improvements will not be necessary 
because yields are approaching quantitative.
3.9 Six Approaches to the Synthesis of Ins(l,4,5)P3
3.9.1 Ozaki's Synthesis of D-Ins(l,4,5)P3 from my o-Inositol
Ozaki's synthesis started with DL-l,2:4,5-di-0-cyclohexylidene-myo-inositol (32) 
which was prepared in one step by treatment of myo-inositol with 1- 
ethoxycyclohexene in DMF with toluene-p-sulphonic acid as a catalyst. This 
intermediate was crystallised from the mixture which also contained d l -1,2:3,4- and 
d l - 1,2:5,6-di-Ocyclohexylidene acetals. Treatment of the mother liquor with 
ethanolic toluene-p-sulphonic acid resulted in precipitation of d l -1,2-0- 
cyclohexylidene-myo-inositol which was then subjected to cyclohexyledination as 
described for myoinositol in order to produce more d l -1,2:4,5-di-O-cyclohexylidene- 
myoinositol. The two hydroxyl groups were benzylated using benzyl chloride in 
DMF and sodium hydride as base, to afford DL-3,6-di-0-benzyl-1,2:4,5-di-O- 
cyclohexylidene-myo-inositol (97) in 90% yield. The less stable 4,5-fran.s-acetal was 
removed using ethylene glycol in chloroform in the presence of toluene-p-sulphonic 
acid as an acid catalyst to give the exposed 4,5-diol (98) in 80% yield. Allylation of 
the diol using allyl bromide and sodium hydride in DMF gave DL-4j5-di-0-allyl-3,6- 
di-O-benzyl-1,2-O-cyclohexylidene-myoinositol (99) in quantitative yield. The 
cyclohexylidene acetal was then removed by heating with 80% acetic acid for 4h to 
give DL-5,6-di-D-allyl-l,4-di-0-benzyl-my<9-inositol (100) in 88% yield. At this stage, 
optical resolution was examined and it was found that treatment of DL-5,6-di-0-allyl-
1,4-di-O-benzyl-myo-inositol with /-menthoxyacetyl chloride in pyridine at 0°C
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provided D-4,5-di-0-allyl-3,6-di-6>-benzyl-l-0-menthoxyacetyl-mjo-inositol (101a) in 
39% yield [Rf = 0.52, (ethyl acetate-hexane, 3:2)] and L-4,5-di-Oallyl-3,6-di-0- 
benzyl-l-O-menthoxyacetyl-myo-inositol (101b) in 43% yield [R{ = 0.61, (ethyl 
acetate-hexane, 3:2)]. The keynote of the resolution was that the two diastereoisomers 
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Recrystallisation of the reaction mixture from hexane in the presence of seed crystals 
also yielded the D-phosphorylation precursor. Each diastereoisomer was subjected to 
basic hydrolysis and transformed into their corresponding chiral 1,2-diols in
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quantitative yield. The absolute configuration was confirmed by transforming l - 4 , 5 -  
di-<9-allyl-3,6-di-0-benzyl-l-menthoxyacetyl-myoinositol into the known l - 1 , 4,5,6- 
tetra-O-benzyl-myoinositol, in five steps. D-4,5-Di-O-allyl-3,6-di-0-benzyl-myo 
inositol was selectively allylated at the 1-position by treatment with allyl bromide in 
the presence of sodium hydroxide in benzene, under reflux for 80min to give d -1,4,5- 
tri-O-ally 1-3,6-di-O-benzyl-myoinositol (102) in 78% yield. The 2-hydroxyl position 
was benzylated as before to give the fully protected d -1,4,5-tri-O-ally 1-2,3,6-tri-O- 
benzyl-myoinositol (103). The three allyl protective groups were eventually removed 
using Wilkinsons catalyst, [(PPh3)3RhCl] and (DABCO) in 90% aqueous ethanol for 8 
h which provided the chiral precursor D-2,3,6-tri-0-benzyl-myoinositol or, for lowest 
numbering, l -  1,2,4-tri-O-benzyl-myoinositol (104) in 59% yield. This compound has 
the necessary hydroxyl groups exposed so the penultimate stage of this synthesis was 
phosphorylation with dianilidophosphonic chloride in the presence of DMAP and 
pyridine to afford the totally protected l - 1,2,4-tri-O-benzyl-3,5,6-tris-0- 
dianilinophospho-myoinositol (105) in 41-60% yield. [395,396] Deprotection was 
accomplished in two steps by treatment of the totally protected derivative with excess 
isoamyl nitrite in a mixture of pyridine/acetic acid/acetic anhydride (1:1:1) followed 
by debenzylation at the 1-, 2- and 4-positions using 5% palladium on carbon under an 
atmosphere of hydrogen to furnish D-Ins(l,4,5)P3 in 17% yield as well as a cyclic 4,5- 
pyrophosphate in a similar yield. The phosphorylation methods were subsequently 
improved by the introduction of oxylene-N, N-diethylphosphoramidite, which was 
discussed in section 3.8.
3.9.2 Potter's Synthesis of Racemic Ins(l,4,5)P3
Following Ozaki's synthesis of D-Ins(l,4,5)P3, the second synthesis appeared a year 
later, by Potter and coworkers. [397l The advantage of this synthesis was the superior 
phosphorylation and deblocking methodology. However, a disadvantage of the 
synthesis was that the synthetic Ins(l,4,5)P3 was racemic.
The versatile intermediate d l - 1,2:4,5-di-0-isopropylidene-myoinositol (37) was 
synthesised in a three step reaction by treatment of myoinositol with 2,2- 
dimethoxypropane in DMF and toluene-p-sulphonic acid as a catalyst. Benzoylation 
in situ with benzoyl chloride in pyridine furnished DL-3,6-di-Obenzoyl-1,2:4,5-di-O- 
isopropylidene-myoinositol in 26% yield from myoinositol. The two benzoates were 
deprotected using methanolic sodium hydroxide followed by neutralisation with 
carbon dioxide and solid extraction with dichloromethane to afford d l - 1,2:4,5-di-O- 
isopropylidene-myoinositol in 94% yield. The diol was benzylated with benzyl
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bromide in DMF with sodium hydride as base to give DL-3,6-di-0-benzyl-1,2:4,5-di- 
O-isopropylidene-myoinositol (106) which was then subjected to mild acid treatment 
to remove the less stable trans diequatorial isopropylidene (55% yield) group, 
followed by allylation with allyl bromide and sodium hydride in DMF to give d l -4,5- 
di-0-allyl-3,6-di-0-benzyl-l,2-0-isopropylidene-wyo-inositol (107). The more stable 
c/.s-isopropylidene acetal was then removed under acidic conditions, methanol/1M 
HC1 (9:1) in order to expose the 1,2-diol. The 1-position was selectively protected by 
tin-mediated allylation using allyl bromide in DMF to afford DL-l,4,5-tri-0-allyl-3,6- 
di-O-benzyl-myo-inositol (108) in 73% yield. The 2-position was benzylated with 
benzyl bromide in DMF, with sodium hydride as base to give the fully protected 
compound DL-l,4,5-tri-0-allyl-2,3,6-tri-(9-benzyl-myo-inositol (109). The three allyl 
groups were removed by one of two procedures. First, a one step deprotection using 
10% palladium on carbon in the presence of toluene-p-sulphonic acid in an ethanol- 
water mixture, gave d l - 1,2,4-tri-(9-benzyl-my<9-inositol (110) in 87% yield after 
refluxing for 4h. Second, isomerisation of the allyl moiety using freshly sublimed 
potassium f-butoxide in dry DMSO gave the DL-l,4,5-tri-(9-cw-prop-l-enyl ether 
followed by acid treatment with acetone- 1M HC1 (9:1) at reflux for 30min to give d l -
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The triol (110) was phosphorylated in a 3-step procedure using a P(III) reagent 
initially developed for DNA synthesis. I398l Thus, d l -  1,2,4-tri-0-benzyl-myoinositol 
was treated with diisopropylamino(2-cyanoethoxy)chlorophosphine (91) and N,N- 
diisopropylethylamine in dichloromethane to afford the trisphosphoramidite (6p = 
150.46ppm) in ca. 90% yield. The reaction of the trisphosphoramidite with 2- 
cyanoethanol in the presence of 1/f-tetrazole provided the trisphosphite intermediate 
(111). This intermediate had 3 peaks in the phosphorus spectrum Sp = 139.6ppm for 
P-l and 140.2ppm, 141.0ppm for P-4 and P-5 (not assigned). At higher resolution 
there was a distinctive AB-coupling pattern for P-4 and P-5 5JPP = 3.4Hz coupling 
which confirmed phosphitylation of the vicinal 4,5-diol. The trisphosphite was 
oxidised with anhydrous f-butylhydroperoxide to afford the trisphosphate triesters 5p ~ 
-3.4, in quantitative yield. The fully protected phosphate, 1,2,4-tri-0-benzyl-3,5,6-tris 
[di(cyanoethoxyphospho)]-myoinositol (112) was deblocked in one step using 
sodium in liquid ammonia for 15min. The crude product was purified by ion 
exchange chromatography to provide racemic Ins(l,4,5)P3 (113) and a small sample 
was further purified by HPLC using tritiated Ins(l,4,5)P3 to permit detection.
3.9.3 Ley’s Synthesis of D-Ins(l,4,5)P3 from Benzene
There have been two different approaches for introducing protected hydroxyl groups 
with the correct stereochemistry to give Ins(l,4,5)P3, using benzene as the starting 
material. The first was a racemic synthesis, which was slightly modified to provide a 
chiral synthetic route. Both the racemic and chiral synthesis of Ins(l,4,5)P3 was 
carried out by Ley and coworkers. [400,40i]
Benzene (114) was converted into do3,5-cyclohexadiene-1,2-diol (115) in a single 
step by microbial oxidation using Pseudomonas putida. This biotransformation was 
not possible by chemical means in a single step and provided a versatile building 
block for the synthesis of polyols. ds-3,5-Cyclohexadiene-1,2-diol is now 
commercially available [Fluka, (20%), 10ml, £50.30], albeit expensive. The ds-diol 
was envisaged as the C-2-C-3 functionality of the myoinositol ring and was protected 
as the cyclic carbonate (116) by the reaction with sodium methoxide and 
dimethylcarbonate at room temperature. The A,5-trans-6io\ moiety was introduced by 
epoxidation of the mesocarbonate (116) with mCPBA which gave the desired a- 
epoxide (117) in 47% yield together with the p-epoxide in 10% yield. The resolution 
was carried out at this stage by treatment of the racemic epoxide with a catalytic 
amount of tetrafluoroboric acid-diethyl ether in the presence of (7?)-(+)-sec-phenethyl
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alcohol, to afford a (1:1) mixture of diastereoisomers in 67% yield, which were then 
separated by HPLC. The less polar diastereoisomer was utilised for the synthesis of d -  
Ins(l,4,5)P3. The free hydroxyl group of compound (118) was benzylated under mild 
conditions by stirring benzyl bromide in the presence of silver (I) oxide in DMF to 
give compound (119). In this way the C-4 and C-5 hydroxyl groups were protected in 
a similar manner so that deprotection later in the synthesis would expose the 1-, 4- and
5-hydroxyl groups in preparation for phosphorylation. The cyclic carbonate 
functionality was then hydrolysed with aqueous triethylamine in methanol, to furnish 
the diol, in which the hydroxyl groups at C-2 and C-3 were ideally placed for directed 
epoxidation across the olefin. Epoxidation with mCPBA (2 equivalents) gave the 
required P-epoxide (120) in 87% yield together with a small quantity (5%) of the a- 
epoxide, which were readily separated by column chromatography. The cw-diol at the 
C-2-C-3 positions was then protected as its isopropylidene acetal using 2,2- 
dimethoxypropane and a catalytic amount of camphorsulphonic acid in 89% yield. 
The ring opening of the P-epoxide (120) with the newly developed hydroxide 
equivalent sodium-2p-propoxy-5,5-dimethyl-1,3-dioxane (121) gave compound (122) 
as the major product in 58% yield. Catalytic hydrogenation of the 1-hydroxy 
derivative [5(/?)]-D-4-0-benzyl-2,3-Oisopropylidene-6-O-[2-(5,5-dimethyl-1,3-
dioxan-2-yl)ethyl]-5-0-(phenylethyl)-wyo-inositol (122) exposed the 1-, 4- and 5- 
hydroxyl groups which were ready for phosphorylation. The reaction of three 
equivalents of rc-butyl lithium and tetrabenzylpyrophosphate in THF and N,N- 
diisopropylethylamine furnished the myo-inositol-1,4,5-trisphosphate derivative (123) 
in 67% yield. Deprotection by hydrogenation, followed by acid treatment with 80% 
aqueous trifluoroacetic acid gave the crude product which was purified by HPLC to 
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3.9.4 Carless's Synthesis of Racemic Ins(l,4,5)P3 from Benzene
The second approach towards the synthesis of myo-inositol phosphate derivatives 
relied on the cw-hydroxylation of the all-equatorial conduritol B, which was prepared 
from benzene in the following manner (Figure 42). l402J
Benzene was subjected to Birch reduction, trans-hydroxylation, acetylation and 
dehydrobromination in an overall yield of 40% to give the trans-d\o\ (124). This 
compound was then protected as its di-(2-methoxyethoxymethyl) ether using 2- 
methoxyethoxymethyl chloride (MEM-C1) and A^A^-diisopropylethylamine as base, in 
91% yield. The 1- and 4-hydroxyl groups were introduced into the 6-membered ring 
by treatment of the diene with singlet oxygen in a [2+4] cycloaddition to give the 
endoperoxide which yielded the conduritol F derivative (125) by stereospecific 
reduction with thiourea/methanol in 70% yield. The hydroxyl group at C-l of the 
conduritol F derivative was then inverted by an oxidation-reduction transformation. 
Oxidation with pyridinium chlorochromate (PCC, 1.5 equivalents) gave two separable 
hydroxyenones, (126) in 50% and another isomer in 20% yield respectively. 
Reduction of (126) in the presence of sodium borohydride/cerium trichloride gave the 
symmetrical conduritol B derivative (127). A more efficient alternative was found by 
oxidising both 1- and 4-hydroxyl groups with PCC (3 equivalents), to give the
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enedione, which did not undergo tautomerisation to the corresponding aromatic 
system, but was reduced with sodium borohydride/cerium trichloride to give the 
conduritol B derivative in 70% yield. Benzylation of the conduritol B derivative with 
sodium hydride and benzyl bromide was achieved in 95% yield. The two remaining 
cw-hydroxyl groups were introduced using osmium tetroxide/N-methylmorpholine-//- 
oxide in 96% yield to give the myoinositol derivative (128). Selective hydroxyl 
protection at the 3-position using MEM-C1 in 60% yield followed by benzylation at 
the 2-position, gave DL-l,2,4-tri-0-benzyl-3,5,6-tri-O-(2-methoxyethoxymethyl)-myo 
inositol (129). The three MEM-protective groups were removed using 6M HC1, in 
THF at 20°C to give DL-l,2,4-tri-0-benzyl-myoinositol (110). The triol was 
phosphorylated with tetrabenzyl pyrophosphate and sodium hydride to give the totally 
protected intermediate in 47% yield. Catalytic hydrogenation, using palladium on 
carbon gave DL-Ins(l,4,5)P3 (113).
3.9.5 Falck's Synthesis of D-Ins(l,4,5)P3 from (-)-Quinic acid
D-(-)-Quinic acid (130) is a readily available, reasonably inexpensive [lOOg, £46.30 























carboxyl group. However, satisfactory solutions must be addressed for several 
outstanding issues for the synthesis of D-Ins(l,4,5)P3 from D-(-)-quinic acid. First, 
differentiation of the hydroxyl groups, second, stereospecific oxidation of both 
methylene groups, corresponding to C-4 and C- 6  of Ins(l,4,5)P3 and finally the 
removal of the carboxyl group at the C-5 position of Ins(l,4,5)P3. The realisation of 
these objectives together with the inversion of the hydroxyl group at C-l of the myo­
inositol derivative has led to the efficient chiral synthesis of D-Ins(l,4,5)P3 from d - ( - ) -  
quinic acid.[403]
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The first step was to adjust the stereochemistry at C-l to give a myo-inositol 
derivative. This was accomplished by modifying a literature procedure. (-)-Quinic 
acid was converted into the lactone by a two-step one pot lactonisation and 
cyclohexylidenation using cyclohexanone and Amberlite IR-120 acid resin, followed 
by mesylation of the tertiary alcohol to give compound (131). The lactone was
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methanolysed and the C-l hydroxyl (myo-inositol numbering) was oxidised with PCC 
and triethylamine-induced mesylate elimination provided the enone. The enone was 
reduced to the enol by delivery to the less hindered p-face using sodium borohydride, 
to provide compound (132).
The C-l hydroxyl group now had the correct equatorial orientation and this was 
protected as the p-trimethylsilylethoxymethyl (SEM) ether. The ester function was 
reduced to the primary alcohol using diisobutylaluminium hydride (DIBAL-H) at -78° 
C followed by selenation of the primary alcohol with A-(phenylseleno)phthalimide in 
the presence of tributylphosphine, to give (133). A stereoselective [2,3]-sigmatropic 
rearrangement of the allylic selenoxide followed by benzylation with benzyl bromide 
and potassium hydride gave (134) as the only product.
The methylene group at C-4 was fimctionalised by ozonolysis of (134) and the 
resulting ketone was converted into the silylenol ether (135) using r-butyldimethylsilyl 
(TBDMS) trifluoromethane sulphonate with complete regiospecificity. Hydroboration 
with borane/THF from the p-face followed by alkaline hydrogen peroxide oxidation 
provided the fully hydroxylated myo-inositol derivative (136). The TBDMS group at 
the 5-position was easily removed with fluoride whereas the SEM protective group at 
the 1-position was only removed under more drastic conditions, using 
tetrabutylammonium fluoride, in hexamethylphosphoric triamide (HMPA) at 100°C. 
Finally, phosphorylation of this chiral intermediate, L-4-D-benzyl-1,2-0- 
cyclohexylidene-myo-inositol (137) with tetrabenzylpyrophosphate followed by 
hydrogenolysis and acid treatment, gave D-Ins(l,4,5)P3 (7) in 62% yield for the 
deprotection steps.
3.9.6 Ballou's Synthesis of D-Ins(l,4,5)P3 from D-Pinitol
Another strategy that has been adopted for the synthesis of D-Ins(l,4,5)P3 used d -(+ )-  
3-O-methyl-c/n'ro-inositol, (138) or D-pinitol, as starting material. [404] D-Pinitol 
reaches 20% of the dry weight of the cold water extract of sugar pine (P i n u s  
l a m b e r t i a n a  D o u g l) stump wood. [405J
D-(+)-Pinitol was demethylated by treatment with hydroiodic acid in acetic acid to 
give D-(+)-c/nVo-inositol. The reaction of D-(+)-c/»Vo-inositol (27) with 
dimethoxycyclohexane in the presence of an acid catalyst resulted in the formation of 
D-l,2:5,6-di-0-cyclohexylidene-c/»>oinositol (139). The hydroxyl groups at C-3 and 
C-4 were benzylated using neat benzyl chloride and solid potassium hydroxide as base
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and an 18-crown-6 phase transfer catalyst to give D-3,4-di-0-benzyl-1,2:5,6-di-O- 
cyclohexylidene-c/nVo-inositol. The 3,4-di-O-benzyl derivative was treated with 80% 
acetic acid at 100°C for 2h to provide the 1,2,5,6-tetrol. This tetrol was benzoylated 
selectively at the 1-, 2- and 5-positions using benzoyl chloride at 5°C for 2 days then 
23°C for 1 day and 80°C for 18h to give l,2,5-tri-(9-benzoyl-3,4-di-0-benzyl-D-c7n><9- 
inositol (140). The axial hydroxyl group at C-6 (D-c/nro-inositol numbering) was 
inverted via the trifluoromethanesulphonate ester using sodium acetate in acetic acid 
to give a 3:1 mixture (70% yield) of l-  1,2,4-tri-0-benzoyl-5,6-tri-0-benzyl-myo- 
inositol (143) and L-l,3,4-tri-0-benzoyl-5,6-tri-(7-benzyl-myo-inositol (142). The 
reaction proceeded via a benzyloxonium ion which preferentially opens to give the 
axial benzoyl group. The intermediate (143) was the one required for the synthesis of 
D-Ins(l,4,5)P3. Thus, l-  1,2,4-tri-O-benzoyl-myo-inositol (144) was obtained by 






















Phosphorylation was accomplished by the P(IH) method, using bis(benzyloxy) 
diisopropylaminophosphine and l/Z-tetrazole in dichloromethane. Oxidation with 
mCPBA gave the totally protected 1,4,5-trisphosphate in 94% yield. Hydrogenolysis
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with 5% palladium on charcoal, followed by basic hydrolysis to saponify the benzoyl 
esters, provided D-Ins(l,4,5)P3 as its cyclohexylamine salt in 87% yield.
There are four main reviews on the chemistry of inositol phosphates. However, they 
are all several years old. [406-409]
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CHAPTER FOUR
Review Of The Structure-Activity Relationships 
t The Ins(l,4,5)P3 Receptor And The Enzymes 3- 
Kinase And 5-Phosphatase
4.1 Introduction
The second messenger Ins(l,4,5)P3 has been synthesised by many groups and by 
several different approaches, some of which were discussed in Chapter 3. Now that 
all the problems concerning the introduction of phosphate groups into the myoinositol 
ring have been overcome, the next stage is to modify the structure of Ins(l,4,5)P3 in 
order to provide analogues which may have a different effect at the Ins(l,4,5)P3 
receptor. Ins(l,4,5)P3 binds to the N-terminus of its receptor resulting in the release of 
Ca2+ ions from intracellular stores and thereafter, the second messenger must be 
destroyed. There are two avenues for the deactivation of Ins(l,4,5)P3 which have 
already been discussed in detail.
This chapter will mainly deal with small molecule Ins(l,4,5)P3 receptor agonists 
together with 3-kinase and 5-phosphatase inhibitors, which were designed, based on 
the Ins(l,4,5)P3 structure and which are modified at the hydroxyl and phosphate 
groups. No small molecule Ins(l,4,5)P3 receptor antagonist has been presented to 
date. However, a number of partial agonists have been synthesised and evaluated, and 
further modification will hopefully develop a lead to provide a small molecule, full 
antagonist. The number of analogues that have been synthesised over the last few 
years has increased, therefore only a selected number of chemical schemes will be 
presented. The emphasis will be placed on the chemical modification of the 
Ins(l,4,5)P3 structure together with the pharmacology of the molecule so as to provide 
a structure-activity relationship, and show how these modifications affect interaction 
with the receptor as well as with the enzymes 3-kinase and 5-phosphatase. Finally, 
the two Ins(l,4,5)P3 receptor antagonists, heparin and the polyanion decavanadate will 
be discussed.
4.2 Modification of the Ins(l,4,5)P3 structure
Modification of the Ins(l,4,5)P3 structure falls into two divisions. First, modulation 
of the phosphate group (Figure 45) and second, adjustment of the hydroxyl moiety in 
some manner. Phosphate groups have been modified by replacing one of the oxygen 
atoms of the phosphate with a sulphur atom so producing a phosphorothioate analogue 
(146). Generally, the phosphorothioate group is more resistant to enzyme hydrolysis 
by phosphatases therefore providing a longer half-life and a different biological 
activity from the natural substrate. The phosphorothioate group is larger than the 
phosphate moiety, thus increasing steric demand. The nucleophilic nature of the 
sulphur moiety also provides a point of attachment for environmentally-sensitive
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reporter groups, such as fluorescent and spin labels. The negative charge on the 
phosphorothioate is present on the sulphur atom rather than the oxygen atom. 
Phosphorothioate groups are more acidic than phosphates and generally less stable 
because they are prone to air oxidation. Therefore, care must be taken when handling 
compounds containing phosphorothioate groups.
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Other modifications of the phosphate moiety include the introduction of a methyl or 
methylene group onto the phosphorus atom. If a methylene group bridging the 
attached to the myo-inositol ring carbon and the phosphorus atom a 
methylenephosphonate (147) is produced. On the other hand if a methyl group is 
attached to the phosphorus atom then a methyl phosphonate (148) is produced. Most 
of the useful phosphate-modified analogues have been derived from phosphorothioate 
substitution.
Modulation of the myo-inositol hydroxyl moiety has been carried out in order to 
provide analogues which were not metabolised by the two Ins(l,4,5)P3-deactivating 
enzymes, 3-kinase and/or 5-phosphatase. The hydroxyl group has been replaced by 
simple deletion (replacing -OH by -H) in order to provide deoxy-derivatives with no 
potential H-bonding at that position. Fluoro, or difluoro analogues, have also replaced 
the hydroxyl and hydroxyl/hydrogen functions respectively, on the inositol ring. 
Fluoro analogues are H-bond acceptors only, and are a useful hydroxyl replacement to 
probe for this type of interaction. The fluorine substituent is isoelectronic with the 
hydroxyl group but is more hydrophobic. Alkylation with methyl iodide provides a 
methyl ether, where no H-bonding at that site can take place, and may deliver a 
hydrophobic interaction with the outcome of possible antagonistic activity. The 
hydroxyl groups may be inverted at the 2-, 3- and 6-positions in order to give 
analogues of Ins(l,4,5)P3. Not all the hydroxyl positions have been inverted,
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however, and such future work will provide important information on the structure- 
activity relationships. Finally, replacement of the hydroxyl function via the azide 
followed by hydrogenolysis has provided the more basic amino-moiety, with possible 
interaction with the neighbouring phosphate group in which the amino function 
presumably exists as NH3+.
4.3 myo-Inositol Tetrakisphosphates and Phosphorothioates
Not many myo-inositol tetrakisphosphate analogues have been synthesised, and 
therefore data on their interaction with the Ins(l,4,5)P3 receptor, Ins(l,3,4,5)P4 
receptor, or with the two enzymes 5-phosphatase or 3-kinase are scarce.
4.3.1 D-Ins(l,3,4,5)P4 and L-Ins(l,3,4,5)P4
D-Ins(l,3,4,5)P4 (149) L-Ins(l,3,4,5)P4 (150)
Figure 46
D-myoInositol 1,3,4,5-tetrakisphosphate (149), Ins(l,3,4,5)P4, mobilised all the 
Ins( 1,4,5)P3-sensitive Ca2+ stores in SH-SY5Y human neuroblastoma cells with an 
EC50 value of 2.05pM t218l compared with 0.14pM for Ins(l,4,5)P3. However, l-myo­
inositol 1,3,4,5-tetrakisphosphate (150), L-Ins(l,3,4,5)P4, failed to mobilise Ca2+ at 
concentrations up to 100|iM. Pig cerebellar membranes contain both Ins(l,4,5)P3 and 
Ins(l,3,4,5)P4 binding sites. In experiments using these membranes, both l -  
Ins(l,3,4,5)P4 and L-Ins(l,4,5)P3 were greater than 1000-fold weaker in displacing 
specific [3H]Ins(l,4,5)P3 at the Ins(l,4,5)P3 receptor. Whereas D-Ins(l,3,4,5)P4 (IC50 
= 762nM) was only 40-fold weaker than D-Ins(l,4,5)P3 (IC50 = 20.7nM). In contrast, 
the Ins(l,3,4,5)P4 receptor showed poor stereoselectivity. Both D-Ins(l,3,4,5)P4 and l -  
Ins(l,3,4,5)P4 showed biphasic displacement of [3H]Ins(l,3,4,5)P4, with high (2.1nM) 




In two articles, Hirata and coworkers t410>4ii] have demonstrated a role for myo-inositol 
3,4,5,6-tetrakisphosphate (151) Ins(3,4,5,6)P4, in gating Ca2+ influx. NIH/3T3 
fibroblasts possess a Ca2+ influx pathway and when these cells were held at -40mV, 
followed by the application of Ins(3,4,5,6)P4, an elevation of [Ca2+]j was observed 
lasting for 2-3min. t41°l This influx was not observed in the absence of extracellular 
Ca2+. However, when Ins(3,4,5,6)P4 was applied to ras-transformed NIH/3T3 
fibroblasts (DT) cells held at -40mV, an initial elevation of [Ca2+]j was observed 
followed by a substantial increase in the presence of extracellular Ca2+. Indeed, in 
ras-transformed NIH/3T3 fibroblasts, the application of Ins(l,3,4,5)P4 or 
Ins(l,3,4,6)P4 mimicked the bradykinin-induced increase of [Ca2+]j with little or very 
little specificity between the three. [Ca2+ influx mediated by Ins(l,3,4,5)P4 and 
Ins(l,3,4,6)P4 has been discussed in 2.7.7]. In conclusion, Ins(3,4,5,6)P4 in 
conjunction with other tetrakisphosphates may provide a mechanism to maintain 
[Ca2+]j at a certain level during cytosolic Ca2+ oscillations following agonist 
stimulation in ras-transformed NIH/3T3 fibroblast cells.
4.3.3 dl-Iiis(1,2,4,5)P4
Ozaki and coworkers were the second group to provide biological data for racemic 
Ins(l,2,4,5)P4. d l -  1 ,4-Di-O-benzyl-myo-inositol was phosphitylated with bis 
(benzyloxy)diisopropylaminophosphine followed by oxidation with mCPBA. Column 
chromatography gave the fully protected phosphorylated compound in 96% yield. 






Ins(l,2,4,5)P4 (152) in 77% yield. WV
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In the purified rat cerebellum, it was shown that DL-Ins(l,2,4,5)P4 (152) inhibited the 
binding of [3H]Ins(l,4,5)P3 with a half maximal concentration of 11.3nM, compared 
with 7.1nM for Ins(l,4,5)P3. The EC50 for Ca2+-release from nonmitochondrial pools 
of permeabilised rat basophilic leukemic (RBL) cells for Ins(l,4,5)P3 was 0.5|iM, 
whereas for DL-Ins(l,2,4,5)P4 it was 1.2|xM. Assuming that L-Ins(l,2,4,5)P4 does not 
contribute to Ca2+-release, then D-Ins(l,2,4,5)P4 is nearly as potent as Ins(l,4,5)P3 and 
substitution with a hydrophilic phosphate group at the 2-position did not appear to 
significantly decrease binding at the Ins(l,4,5)P3 receptor. DL-Ins(l,2,4,5)P4 was 
found to be a potent inhibitor of 5-phosphatase from erythrocyte ghosts. It is difficult 
to speculate whether one or both enantiomers play an important part in the inhibition 
process. A Dixon plot showed that DL-Ins(l,2,4,5)P4 behaved as a competitive 
inhibitor of 5-phosphatase with a K{ value of 1.4|iM, whereas the Km value for 
Ins(l,4,5)P3 was 16.8|xM. The compound was not recognised by 3-kinase from rat 
brain cytosol.
DL-Ins(l,2,4,5)P4 has also been synthesised by Meek and coworkers t393J and also 
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jcy/Zo-Inositol 1,2,4,5-tetrakisphosphate (159), scyllo-lns( 1,2,4,5)P4, was synthesised 
from the intermediate d l -1-0 -ally 1-3,6-di-0-benzyl-4,5-O-isopropy lidene-rayo-
inositol (153 in Figure 48). First, the unsubstituted axial 2-hydroxyl position was 
blocked with the excellent leaving group, trifluoromethane sulphonate (154) using
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trifluoromethane sulphonic anhydride in pyridine. The 2-position was set-up for SN2 
substitution, which was achieved using caesium acetate in DMF at room temperature 
to provide the equatorial scy/Zo-derivative (155). The isopropylidene group was 
removed under acidic conditions, followed by saponification of the acetate moiety to 
give (156). The allyl group of compound (156) was isomerised to the c/s-prop-l-enyl 
ether using BulOK/DMSO followed by acid hydrolysis to provide the symmetrical 
derivative l,4-di-0-benzyl-jcy//o-inositol (157). Phosphitylation of the four hydroxyl 
groups with bis(benzyloxy)diisopropylaminophosphine and l//-tetrazole followed by 
oxidation, provided the totally protected scyllo-derivative (158). Chemical reduction 
using sodium in liquid ammonia removed all ten of the benzyl protective groups to 
give the symmetrical scyllo-Ins(l,2,4,5)P4 (159) in 41% yield. t413l
scyllo-lns( 1,2,4,5)P4 was found to be a potent full agonist at the Ins(l,4,5)P3 receptor 
from saponin-permeabilised SH-SY5Y cells with an EC50 value for Ca2+-release of 
82.56nM. [cf Ins(l,4,5)P3 EC50 for Ca2+-release was 52nM]. scyllo-Ins(l,2,4,5)P4 
displaced [3H]Ins(l,4,5)P3 from specific sites on bovine adrenal cortex membranes 
with an IC50 of 14.37nM, and with a K{ value of 10.82nM. jcy//o-Ins(l,2,4,5)P4 was 
found to be a substrate for 5-phosphatase from human erythrocyte ghosts (HEG) K{ 
value of 4.3jiM and also a substrate for 3-kinase from crude rat brain homogenate 
supernatant (CRBHS) with a K{ value of 25.1pM. I414]
4.3.5 Ins(l,3,4,5)P4-3S
Two approaches to the synthesis of myoinositol 3-phosphorothioate-1,4,5- 
trisphosphate, Ins(l,3,4,5)P4-3S have been published. The first to be published was a 
synthesis of the racemate by Liu and Potter (in Figure 49), f415] to give (168) and the 
second was a chiral synthesis by Kozikowski and coworkers (in Figure 5 0 )[416] to give
(176).
The first synthesis was carried out by using myoinositol as the starting material, d l -  
l,2:4,5-Di-0-isopropylidene-myoinositol (37) was prepared in a 3-step procedure 
described by Gigg and coworkers. [344] Selective allylation at the 3-position was 
achieved using allyl bromide in the presence of barium oxide/barium hydroxide in 
63% yield. Benzylation at the 6-position using benzyl chloride and sodium hydride in 
DMF in quantitative yield provided the totally protected compound DL-3-0-allyl-6-0 
benzyl-1,2:4,5-di-0-isopropylidene-myoinositol (160). The isopropylidene groups 
were removed under acidic conditions and a p-methoxybenzyl group was introduced 
selectively at the 1-position via the stannylene acetal, in the presence of caesium
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fluoride and p-methoxybenzyl chloride in 74% yield, to give compound (161). The
4.5-O-isopropylidene acetal was reintroduced to give (162) and the free 2-hydroxyl 
was subsequently benzylated to give the fully protected derivative. The 4,5-O- 
isopropylidene acetal and the /7-methoxybenzyl group were removed using 1M HC1 
under reflux, to give dl-1-O-ally 1-2,4-di-O-benzyl-myo-inositol (163) in 90% yield. 
The allyl group was isomerised to the ds-prop-l-enyl ether (164) and the exposed 
hydroxyl groups at the 1-, 4- and 5-positions were phosphitylated using 
bis(benzyloxy)diisopropylaminophosphine in the presence of l//-tetrazole, and then 
oxidised to provide the fully protected trisphosphate (165) in 80% yield. The cis- 
prop-l-enyl ether was removed using trifluoroacetic acid in order to expose the 3- 
hydroxyl (166) and was set-up for phosphitylation at the 3-position followed by 
sulphoxidation using sulphur in pyridine to provide the totally protected 3- 
phosphorothioate-l,4,5-trisphosphate (167). The decabenzyl derivative (167) was 
deprotected in one step using sodium in liquid ammonia followed by ion exchange 
chromatography on Q-Sepharose, eluting with a gradient of triethylammonium 
bicarbonate (TEAB) buffer (0—»1M) to give DL-myo-inositol 3-phosphorothioate-
1.4.5-trisphosphate (168) in 68% yield.
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Figure 49
It has been reported l417J that Ins(l,3,4,5)P4 acts as a full agonist for Ca2+-release in the 
presence of the 3-phosphatase inhibitor, phytic acid, with an EC50 value of 2.5|iM. 
DL-Ins(l,3,4,5)P4-3S (168) was also a weak, albeit full agonist for Ca2+-release in 
permeabilised neuroblastoma cells with an EC50 of 4.7|iM which is similar to 
Ins(l,3,4,5)P4. I417l DL-Ins(l,3,4,5)P4-3S specifically displaced [3H]Ins(l,4,5)P3 from 
specific sites on bovine adrenal cortex membranes with an IC50 of 889nM, whereas 
Ins(l,4,5)P3 had an IC50 value of 4.4nM. For Ins(l,3,4,5)P4 the IC50 value was 
152nM. The analogue also appeared to be a substrate for 5-phosphatase from HEG 
and inhibited dephosphorylation of [3H]Ins(l,4,5)P3 with a Kx value of 0.14p,M. The 
3-phosphorothioate substitution will provide an important probe to investigate the 
second messenger function of Ins(l,3,4,5)P4 which is resistant to 3-phosphatase 
action.
A different approach, starting from L-quebrachitol has been reported by Kozikowski 
and coworkers. [416] L-Quebrachitol (169) was protected as the 3,4:5,6-di-0- 
isopropylidene derivative (170) using 2-methoxypropene in the presence of an acid
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catalyst in DMF at 70°C for 5h. Mesylation at the axial 1-position followed by 
demethylation at the 2-position and concomitant removal of the 3,4:5,6-di-0- 
isopropylidene groups with boron tribromide, exposed the hydroxyl groups which 
were subsequently protected at the 3, 4, 5 and 6-positions as the di-O-isopropylidene 
derivative to give L-l-0-methanesulphonyl-2,3:5,6-di-0-isopropylidene-c/»ro-inositol 
(171) which could be separated from L-3,4:5,6-di-0-isopropylidene-c/z/ro-inositol 
derivative by crystallisation. Benzylation at the 4-hydroxyl position followed by 
demethanesulphonylation with lithium aluminium hydride, exposed the 1-hydroxyl 
derivative, which was inverted to give the 3-hydroxy-myo-inositol derivative (172) by 
Swem oxidation followed by lithium borohydride reduction. The exposed hydroxyl 
group at the D-3-position was protected as a p-methoxybenzyl ether and the trans-4,5- 
O-isopropylidene group was cleaved using a catalytic amount of acetyl chloride in 
methanol. The 4,5-diol was benzoylated with benzoyl chloride in pyridine and the 
cis-1,2-<9-isopropylidene group was hydrolysed using concentrated HC1 in methanol at 
room temperature to give the diol (173). Selective benzoylation at the equatorial 1- 
hydroxyl (89% yield) followed by protection at the 2-position as a (benzyloxy)methyl 
ether gave compound (174). The benzoate groups at the 1-, 4- and 5-positions were 
removed by alkaline methanolysis and the exposed hydroxyl groups were 
phosphorylated using tetrabenzyl pyrophosphate and sodium hydride to give the fully 
protected 1,4,5-trisphosphate (175). Exposure of this compound to wet DDQ 
removed the p-methoxybenzyl ether at the 3-position in 87% yield which then allowed 
phosphitylation followed by sulphoxidation with phenylacetyl disulphide. Chemical 
reduction of all the protective groups using sodium in liquid ammonia gave d -  
Ins(l,3,4,5)P4-3S (176) which was characterised as its triethylammonium salt.
105
HO OH — O OMs OMs
L-quebrachitol (169) (170) 4 steps
v
OBOM OH














D-Ins(l,3,4,5)P4-3S displaced [3H]Ins(l,4,5)P3 from specific sites on bovine adrenal 
cortex membranes with an IC50 of 279.9nM. It was a full, albeit weak agonist with an 
EC50 value of 2.53jxM. The synthesis of another analogue, DL-Ins(l,3,4,5)P4-5S has 
also been published [392J but, no biological data have been described and will not be 
discussed any further.
4.4 Inositol Trisphosphate Analogues
4.4.1 L-c/»ro-Ins(2,3,5)P3 and L-c/iiro-Ins(l,4,6)P3
The starting material for the synthesis of L-c/nro-inositol 2,3,5-trisphosphate, [h-chiro- 
Ins(2,3,5)P3] was L-quebrachitol (169 in Figure 51). L-Quebrachitol t41Mi9] was 
demethylated using concentrated HI to provide L-c/nro-inositol (28) in 80% yield. 
The treatment of L-c/nro-inositol in the presence of four equivalents of dibutyltin 
oxide and a five-fold excess of tetrabutylammonium iodide in acetonitrile provided 
the crystalline L-2,3,5-tri-0-benzyl-c/n'r<?-inositol (177) in 32% yield. The remaining 
three hydroxyl groups were benzoylated to give L-l,4,6-tri-Obenzoyl-2,3,5-tri-0- 
benzyl-c/i/ro-inositol (178) in quantitative yield. The benzyl groups were removed by 
hydrogenation using a palladium catalyst in order to provide the phosphorylation
precursor, l-  1,4,6-tri-0-benzoyl-c/zz>o-inositol (94% yield) (179). The cheap, 
commercially available phosphitylating reagent, diethoxychlorophosphine, was used 
in the presence of dry 7V,N-diisopropylethylamine and acetonitrile to phosphitylate the 
2-, 3- and 5-hydroxyl groups followed by oxidation to the P(V) intermediate (180) 
with f-butylhydroperoxide in 73% yield. The six ethyl groups of the protected 
phosphate were removed using bromotrimethylsilane in dichloromethane, followed by 
treating the evaporated residue with water in order to provide the free phosphate. The 
benzoyl groups were hydrolysed with 0.5M NaOH, followed by treatment with 
Dowex 50(H+) resin and final purification using ion exchange chromatography on 
DEAE Sephadex A-25 to give L-c/iiro-Ins(2,3,5)P3 in 86.5% yield. A synthesis of d l - 
c/H>0-Ins(2,3,5)P3 has been carried out by Carless and Busia. t42°]
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Figure 51
If the equatorial 3-hydroxyl group of Ins(l,4,5)P3 is inverted to provide an axial 
hydroxyl group then L-c/«>o-Ins(2,3,5)P3 is produced. It was envisaged that the
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inverted hydroxyl moiety may provide an inhibitor of the 3-kinase enzyme, l -chiro- 
Ins(2,3,5)P3 was found to be a potent agonist for the release of Ca2+ from 
permeabilised SH-SY5Y cells with an EC50 of 1.4|iM. It displaced [3H]Ins(l,4,5)P3 
from specific sites on bovine adrenal cortex membranes with an IC50 of 60.4nM. The 
analogue was also a potent inhibitor of 3-kinase {Kx of 7.1p,M, then re-evaluated to a 
Kx of 0.97|lM). [421,422] Significantly, L-c/»'ro-Ins(2,3,5)P3 was a potent inhibitor of 5- 
phosphatase (Kx of 7.7|iM). Two possible explanations for 5-phosphatase inhibition 
by L-c/Hro-Ins(2,3,5)P3 were given. First, the conformation of L-c/uro-Ins(2,3,5)P3 in 
solution and/or bound to the 5-phosphatase may be sufficiently different from 
Ins(l,4,5)P3 to interfere with the catalytic mechanism of 5-phosphatase and bind to it 
in a manner similar to Ins(l,4,5)P3 as shown in (181 in Figure 51). The inhibition of 
5-phosphatase by L-c/»>o-Ins(2,3,5)P3 may result from an inverted and rotated mode 
of binding (182), where the ring pucker, the vicinal 4,5-bisphosphate and the 3- 
hydroxyl group, [represented as the 4-hydroxyl group in L-c/n>o-Ins(2,3,5)P3] may 
result. The 5-phosphate group of L-c/nro-Ins(2,3,5)P3 represented an equatorial 2- 
phosphate of Ins(l,4,5)P3. Furthermore, the two axial groups of L-c/»Vo-Ins(2,3,5)P3 
at the 1- and 6-positions, now mimic the 6- and 1-positions of Ins(l,4,5)P3.
The analogue L-chiro-lns( 1,4,6)P3 (184 in Figure 51) was also synthesised from l- 
quebrachitol via the precursor L-2,3,5-tri-0-benzyl-c/i/ro-inositol (177). [423,424] The 
hydroxyl groups at the 1-, 4- and 6-positions were phosphitylated with bis(2- 
cyanoethoxy)diisopropylaminophosphine and l//-tetrazole in dry dichloromethane, 
followed by oxidation to P(V) with f-butylhydroperoxide in 75% yield after 
chromatography. Deprotection of the totally protected compound (183) with sodium 
in liquid ammonia provided L-chiro-Ins( 1,4,6)P3 (184) in 75% yield after ion 
exchange chromatography on DEAE Sephadex A-25. This compound did not show 
any Ca2+-releasing properties from permeabilised SH-SY5Y cells, but it was a 
moderately potent inhibitor of Ins(l,4,5)P3 5-phosphatase with a Kx value of 44jiM. 
This compound did not interact with 3-kinase.
In another system, L-chiro-Jns( 1,4,6)P3 competitively inhibited the specific 5- 
phosphate dephosphorylation of Ins(l,4,5)P3 and Ins(l,3,4,5)P4 from skeletal muscle 
with Kx values of 6.35 and 1.76|iM respectively,
4.4.2 d- And L-c/H>o-Ins(l,3,4)P3, d- and L-Ins(2,4,5)P3
The synthesis of D-chiro-lns( 1,3,4)P3 (185) and L-chiro-lns( 1,3,4)P3 (186) started with 
the chiral intermediates d- and L-l,2,5-tri-D-benzoyl-3,4-di-0-benzyl-c/zzro-inositol,
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obtained from D-c/ziro-inositol and L-c/nro-inositol respectively, as described in 
section 3.9.6. The two benzyl groups from each of the two enantiomers were removed 
quantitatively by hydrogenation. Phosphitylation of the resulting triol, using 
bis(benzyloxy)diisopropylaminophosphine followed by oxidation with mCPBA, gave 
the totally protected l,3,4-tris(dibenzyloxyphospho)-2,5,6-tri-0-benzoyl-c/»><9-inositol 
in 84% yield for the D-enantiomer and 77% for the L-enantiomer. The individual 
enantiomers were deprotected by hydrogenation over a palladium on carbon catalyst 
followed by saponification with sodium hydroxide. The cyclohexylamine salt of the 
D-enantiomer was crystallised from water and 2-propanol in 71 % yield. l426l
The analogue D-c/n'ro-Ins(l,3,4)P3 was tested for Ca2+-release in permeabilised rat 
basophilic leukemic (RBL) cells using fluo-3 as the Ca2+ indicator. The EC50 value 
was found to be 4.2fiM, compared with an EC50 value of 0.17pM for Ins(l,4,5)P3. 
This value was very similar to D-Ins(2,4,5)P3 and indicated that if the 1-position of 
D-Ins(2,4,5)P3 was inverted to give an axial hydroxyl and thus D-c/nro-Ins(l,3,4)P3, 





D-myo-Ins(2,4,5)P3 (187) L-myo-Ins(2,4,5)P3 (188)
Figure 52
The analogues D-Ins(2,4,5)P3 (187) and L-Ins(2,4,5)P3 (188) were synthesised from d -  
and L-c/z/ro-inositol. The c/n'ro-inositols were transformed into 1,3,4-tri-O-benzoyl-
5,6-di-O-benzyl-myo-inositol, which were minor products resulting from inversion,
L-cfciro-Ins( 1,3,4)P3 (186)
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(see section 3.9.6). The benzyl groups were removed by hydrogenation in quantitative 
yield to provide 1,3,4-tri-O-benzoyl-L-myo-inositol, from D-chiro-inositol and 1,3,4- 
tri-O-benzoyl-D-myo-inositol, from L-c/uro-inositol. The individual triols were 
phosphorylated and deprotected as for the d- and L-c/nVo-Ins(l,3,4)P3 in order to 
provide d- and L-Ins(2,4,5)P3. [426l
The Ca2+-releasing properties of D-Ins(2,4,5)P3 in permeabilised RBL cells was found 
to be 4.3pM. The Ca2+-releasing activity of L-Ins(2,4,5)P3 was 25-fold less than for 
the D-isomer, having an EC50 value of 110|iM, albeit lower than L-Ins(l,4,5)P3 with an 
EC50 value of more than 2000|llM, i.e. no real activity. The Ca2+-releasing activity of 
L-Ins(2,4,5)P3 and L-c/uro-Ins( 1,3,4)P3 may be due to the isomers having an axial 
phosphate which may be flexible enough to allow an induced fit at the active site of 
the receptor by ring distortion or flipping. t426l
4.4.3 L-Ins(l,4,5)P3, Ins(l,3,5)P3 and DL-scyllo-Ins(l,2,4)P3
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L-Ins(l,4,5)P3 (189) was synthesised from the known chiral intermediate D-l,2,4-tri-0- 
benzyl-myo-inositol, originally prepared by Gigg and coworkers. [383^ The analogue 
was found to be a weak inhibitor of Ins(l,4,5)P3 5-phosphatase from bovine aorta with 
a value of 39pM. I427! It was poorly recognised by 3-kinase from crude bovine 
aortic cytosol, while the EC50 value was 220{iM for Ca2+-mobilisation in 
permeabilised bovine aortic smooth muscle cells. In another study,[422] L-Ins(l,4,5)P3 
inhibited Ins(l,4,5)P3 5-phosphatase from HEG with a K{ value of 15.3pM. l- 
Ins(l,4,5)P3 interacted modestly with 3-kinase from CRBHS with a K{ value of 40.3|i 
M and had an EC50 value » 3 0 |iM .
The meso-compound Ins(l,3,5)P3 (190) was also tested by Polokoff and coworkers 
[4271 and was shown to be a competitive inhibitor of 5-phosphatase, with a K-x value of 
45|iM. It was not effectively recognised by 3-kinase, with a K{ value of 1687|lM and 
did not release Ca2+ effectively, with an EC50 value of 630|iM.
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The first scyllo-inositol phosphate analogue to be synthesised was DwcyZ/o-inositol
1.2.4-trisphosphate (191), DL-scyllo-]ns( 1,2,4)P3. This analogue differs from 
Ins(l,4,5)P3 in that the axial 2-position has been inverted to provide an equatorial 
hydroxyl function. It was synthesised from DL-l-0-allyl-3,6-di-0-benzyl-4,5-O- 
isopropylidene-rayoinositol (153). The 2-position was blocked with a triflate (154) 
and then inverted with caesium acetate/DMF at room temperature in an SN2 manner to 
provide the suitable scyllo-inositol derivative (155). [428] The 4,5-O-isopropylidene 
acetal was removed by acid hydrolysis followed by saponification of the acetate group 
to provide the racemic compound DL-2-O-allyl-1,4-di-0-benzyl-scy/Zc>-inositol (156). 
This was phosphitylated with bis(benzyloxy)diisopropylaminophosphine and 1H- 
tetrazole followed by oxidation, to give the trisphosphate in 58% yield. Deprotection 
of all protective groups using sodium in liquid ammonia provided dh-scyllo- 
Ins(l,2,4)P3 (191) which was purified by ion exchange chromatography, scyllo- 
Ins(l,2,4)P3 potently induced Ca2+-mobilisation in saponin permeabilised SH-SY5Y 
cells with an EC50 value of 171nM. The analogue was also tested for its ability to 
interact with 5-phosphatase from HEG and 3-kinase from CRBHS. It was found that 
the analogue was a moderate 5-phosphatase inhibitor with a K{ value of 24.2pM but 
was susceptible to 3-kinase activity, and was rapidly metabolised by SH-SY5Y cells.
[414]
4.4.4 3-Modified Ins(l,4,5)P3-3R Analogues: R = Carboxyl, Methyl, Ethyl and n- 
Propyl
All four racemic compounds, DL-Ins( 1,4,5)P3-3-0-methylenecarboxylate (195), dl-3- 
0-methyl-Ins(l,4,5)P3 (196), DL-3-0-ethyl-Ins(l,4,5)P3 (197) and DL-3-O-w-propyl- 
Ins(l,4,5)P3 (198) were synthesised by to Liu and Potter, [429,430] using the versatile 
intermediate DL-3-O-allyl-2,6-di-0-benzyl-4,5-Oisopropylidene-1 -O-p-methoxy 
benzyl-myo-inositol (192). This intermediate was also used to synthesise myo-inositol
1.4.5-trisphosphate-3-phosphorothioate (168) and shall be the starting point for the 
synthesis of the 3-modified derivatives (Figure 54).
First, DL-Ins(l,4,5)P3-3-0-methylenecarboxylate (195), was synthesised by removing 
the 4,5-0-isopropylidene group and the 1 -O-p-methoxybenzyl ether by treatment with 
acid to give DL-l-0-allyl-2,6-di-0-benzyl-myo-inositol (163), in 90% yield. The triol 
was phosphitylated with bis(2-cyanoethoxy)diisopropylaminophosphine and 1/7- 
tetrazole to provide the trisphosphite, which was oxidised using f-butylhydroperoxide 
to give the trisphosphate (193) in 80% yield. The allyl ether was cleaved using
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sodium periodate and ruthenium trichloride hydrate to give the 3-0- 
methylenecarboxylate (194). The hydroxyl and phosphate protective groups were 
removed by treatment with sodium in liquid ammonia followed by ion exchange 
chromatography on Q-Sepharose, eluting with a gradient of (TEAB) to provide the 
pure product in 68% yield.
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Figure 54
DL-Ins(l,4,5)P3-3-0-methylenecarboxylate ( 1 9 5 ) ,  was able to mobilise Ca2+ from 
permeabilised neuroblastoma cells with a potency similar to Ins(l,3,4,5)P4 [EC50 
value of 3.5|iM for ( 1 9 5 )  and EC50 value of 2.5|iM for Ins(l,3,4,5)P4]. It had a K{ 
value of 153|iM for Ins(l,4,5)P3 3-kinase from CRBHS and was a potent inhibitor of
5-phosphatase from HEG with a K-x value of l.OpM.
DL-3-0-Methyl-Ins(l,4,5)P3 ( 1 9 6 ) ,  DL-3-0-ethyl-Ins(l,4,5)P3 ( 1 9 7 )  and d l - 3 - 0 - / i -  
propyl-Ins(l,4,5)P3 ( 1 9 8 )  analogues were again prepared from the intermediate d l - 3 -  
0-allyl-2,6-di-0-benzyl-4,5-0-isopropylidene-l-0-p-methoxybenzyl-myo-inositol 
( 1 9 2 ) .  However, in order to synthesise 3-0-alkyl derivatives, the allyl function was 
removed by isomerising to the prop-l-enyl ether using Wilkinsons catalyst, 
[(Ph3)P]3RhCl in the presence of DABCO, in 93% yield. The prop-l-enyl ether was 
removed using mercuric chloride and mercuric oxide in an acetone/water mixture. 
The alkyl groups were introduced at the 3-position using methyl, ethyl and /z-propyl 
iodide, with sodium hydride as base in DMF. The 4,5-0-isopropylidene group and the 
1 - 0-p-methoxybenzyl ether were removed by refluxing in 1M HC1 to produce the 
corresponding triols. Each of the triols were phosphitylated in the same way as for the 
synthesis of Ins(l,4,5)P3-3-0-methylenecarboxylate and purified by ion exchange
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chromatography on Q-Sepharose, eluting with a gradient of TEAB and quantified by 
the Briggs phosphate assay. t43°3
DL-3-O-Methyl Ins(l,4,5)P3 has an EC50 value of 4|iM whereas DL-3-O-ethyl and d l - 3 -
O-n-propyl derivatives have an EC50 value greater than lOOpM. Therefore any 
hydrophobic group greater than a methyl group has a catastrophic effect on Ca2+- 
release. All three alkylated analogues were potent HEG 5-phosphatase inhibitors with 
DL-3-O-methyl Ins(l,4,5)P3 having a K{ value of 3.3|xM and a K{ value for CRBHS 3- 
kinase inhibition of 192|iM. The DL-3-O-ethyl and DL-3-O-w-propyl derivatives were 
potent HEG 5-phosphatase inhibitors, with Kx values of 11.4|iM and 8.0|xM 
respectively.
4.4.5 D-Ins(l,4,6)P3 and D-Ins(l,3,6)P3
myo-Inositol tetrakisphosphate, Ins(l,3,4,6)P4 (61) has been discovered in nature and 
has also been shown to release Ca2+ ions, albeit weakly. I217^ Ins(l,3,4,6)P4 has also 
been shown to be a partial agonist at the Ins(l,4,5)P3 receptor in SH-SY5Y 
neuroblastoma cells [216] and more recently in rat brain microsomes. f431] [The action 
of Ins(l,3,4,6)P4 as a partial agonist will be discussed in section 4.9.1].
In order to discover further information concerning the essential features of the 
activity of Ins( 1,3,4,6)P4, two myoinositol trisphosphates, D-Ins(l,4,6)P3 (199) and d- 
Ins(l,3,6)P3 (200) [L-Ins(l,3,4)P3] can be derived by removing the phosphate at the d- 
3 and d - 4  positions and provide the same ring pucker conformation as D-Ins(l,4,5)P3 
with different orientations of the hydroxyl moiety. Similarly L-Ins(l,4,6)P3 (201) and 
L-Ins(l,3,6)P3 (202) may be considered as having the same ring pucker conformation 
as L-Ins(l,4,5)P3 but with different hydroxyl orientations.
The synthesis of D-Ins(l,4,6)P3 by Ozaki and coworkers has briefly been discussed in 
section 3.7.1. They found that D-Ins(l,4,6)P3 had a rotation [a]D = -8.9° (c = 0.90, 
H20), as the sodium salt.[432] However, the pH was not stated. Hirata and coworkers 
[433] found that D-Ins(l,4,6)P3 bound to the Ins(l,4,5)P3 receptor of rat basophilic 
leukemic cells (RBL) some 16-fold less potently than Ins(l,4,5)P3, but was 125-fold 
less potent at releasing Ca2+ as Ins(l,4,5)P3. The potency of D-Ins(l,4,6)P3 with 
respect to binding was found to be the same as for Ins(l,3,4,6)P4. Thus the phosphate 
groups at the 1-, 4- and 6-positions in the D-configuration was essential for activity, d- 
Ins(l,4,6)P3 was assayed for 5-phosphatase activity from erythrocyte ghosts and 
inhibited the enzyme with a K{ value of 9.2|iM. D-Ins(l,4,6)P3 was also as potent as
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Ins(l,4,5)P3 in inhibiting the phosphorylation of [3H]Ins(l,4,5)P3 but although no 
clear values for this inhibition were tabulated, it appeared to be less than 5|iM.
L-Ins(l,3,6)P3 (202) D-Ins(l,3,6)P3 (200)
Figure 55
D-Ins(l,3,4)P3 (202) was reported by Ozaki and coworkers to have a specific rotation 
[a]D of -6° (isolated as the hexa-ammonium salt, but no biological data was given at 
that time. Later, Gou and Chen £4341 and Chen and coworkers [376] reported a 
chemoenzymatic synthesis of D-Ins(l,3,4)P3 (as the hexa-potassium salt) which had a 
[a]D of +14° (c = 2, H20 , pH 8.2). This caused confusion, so Potter and coworkers 
[435] unambiguously synthesised both enantiomers of Ins(l,3,4)P3. It was found that d -  
Ins(l,3,4)P3 had a [a]D of +37° (c= 2, 1M TEAB, pH 7.8) and L-Ins(l,3,4)P3 had a 
[a]D of -40° (c = 0.42, 1M TEAB, pH 7.8) both calculated for the free acid. It was 
found that Gou and coworkers were correct in the assignment of the optical rotation, 
which may cast doubt on the work of Ozaki and coworkers.
Hirata and coworkers t433l have reported some biological data for the synthetic l -  
Ins(l,3,4)P3 (which was synthesised according to Ozaki and coworkers l350l). It was 
found that L-Ins(l,3,4)P3 could bind to the Ins(l,4,5)P3 receptor from rat basophilic 
leukemic (RBL) cells some 90-fold weaker than Ins(l,4,5)P3, but was 3000-fold 
weaker at Ca2+-release and the EC50 value could not be determined. The poor binding 
and Ca2+-release experiments may call into question the true identity of Ozaki's l -  
Ins(l,3,4)P3, unless L-Ins(l,3,4)P3 is a partial agonist in this particular cell type? l -  
Ins(l,3,4)P3 was found to have a value of 27.4|iM and was less potent than d -  
Ins(l,4,6)P3 at inhibiting 3-kinase. However, in contrast, the two enantiomers of 
Ins(l,3,4)P3 (Figure 55) (synthesised according to Potter and coworkers) [4351 were 
examined in Limulus ventral photoreceptors. [435] It was shown that D-Ins(l,3,4)P3
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was much less efficient for Ca2+-release than D-Ins(l,4,5)P3 or L-Ins(l,3,4)P3. In 
addition, and unlike D-Ins(l,4,5)P3, L-Ins(l,3,4)P3 showed repetitive bursts of 
depolarisation which continued for up to 5min, suggesting that L-Ins(l,3,4)P3 was 
metabolised more slowly than D-Ins(l,4,5)P3. In conclusion, the biological actions of 
D-Ins(l,3,4)P3 should be re-examined.
4.5 myo-Inositol Phosphorothioates, Chemistry and Pharmacology
The same protected precursors that have been used for the synthesis of myoinositol 
phosphates can also be used to synthesise myo-inositol phosphorothioates. The 
difference being the P(m) phosphite is oxidised with sulphur in pyridine t391l or 
phenacetyl disulphide, C392l to give the fully protected phosphorothioate triester. 
Deprotection of the fully protected phosphorothioate takes place by chemical 
reduction using sodium in liquid ammonia followed by further purification by ion 
exchange chromatography to afford the pure deprotected compound.
X =Y = Z = S (203)
X = Y = 0 ;Z  = S (204)
X = 0 ;Y  = Z = S (205)
X = S;Y  = Z = 0  (206)
Figure 56
The first reported Ins(l,4,5)P3 analogue was racemic myo-inositol 1,4,5- 
trisphosphorothioate Ins(l,4,5)PS3 (203). This was synthesised in the same way as 
racemic Ins(l,4,5)P3 [391] except that oxidation of the trisphosphite was effected with 
sulphur in pyridine instead of r-butylhydroperoxide. The deprotection of the
phosphorothioate was then carried out in one step using sodium in liquid ammonia, 
and purified by ion exchange chromatography to give Ins(l,4,5)PS3. Several other 
myo-inositol phosphorothioate analogues have been synthesised and evaluated, 
(Figure 56). These include the following: DL-myo-inositol l,4-bisphosphate-5- 
phosphorothioate DL-Ins(l,4,5)P3-5S (204), DL-myo-inositol 1-phosphate-4,5-
bisphosphorothioate DL-Ins(l,4,5)P3-4,5S2 (205) and DL-myo-inositol 4,5-
bisphosphate-1-phosphorothioate DL-Ins(l,4,5)P3-lS (206) all of which are based on 
Ins(l,4,5)P3. After the synthesis and biological evaluation of DL-Ins(l,4,5)PS3 a closer 
analogue, DL-Ins(l,4,5)P3-5S was synthesised and evaluated. [390,436] ft was found that 
substitution with a phosphorothioate only at the 5-position slightly decreased the 
effective Ca2+-mobilising properties with an EC50 value of 0.8|iM compared to 0.11 \i 
M for Ins(l,4,5)P3, t437l in permeabilised SH-SY5Y human neuroblastoma cells, d l -
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Ins(l,4,5)P3-5S was also a potent inhibitor of 5-phosphatase from HEG with a K-x 
value of 6.8}iM, but appeared to be a substrate for the 3-kinase enzyme from CRBHS 
and inhibited the phosphorylation of [3H]Ins(l,4,5)P3 with a K{ value of 5|iM. d l -  
Ins(l,4,5)P3-4,5S2 was prepared in a similar way to DL-Ins(l,4,5)P3-5S, using d l - 1 ,2 ,4 -  
tri-0-benzyl-3-0-[di(2,2,2-trichloroethoxyphospho)]-myo-inositol as the starting 
material. [438] This intermediate was phosphitylated at the free hydroxyl 4- and 5- 
positions followed by oxidation with sulphur in pyridine, deblocked and purified in 
the same way as DL-Ins(l,4,5)P3-5S in order to give DL-Ins(l,4,5)P3-4,5S2. This 
analogue mobilised Ca2+ from SH-SY5Y neuroblastoma cells with an EC50 value of 
1.2}iM slightly higher than DL-Ins(l,4,5)P3-5S, but lower than DL-Ins(l,4,5)PS3 (EC50 
value of 2.5|iM) indicating that sequential phosphorothioate replacement decreases 
the Ca2+-mobilising ability, albeit slightly. The analogue was a potent inhibitor of 5- 
phosphatase from HEG with a K{ value of 1 .4 j iM  and was found to be a cosubstrate 
for 3-kinase from CRBHS inhibiting the metabolism of Ins(l,4,5)P3 with a K{ value of 
46jxM. DL-Ins(l,4,5)P3-4,5S2 has also been used to prepare the analogue d l-myo­
inositol 1-phosphate-4,5-pyrophosphate DL-Ins(l,4,5)P3-(PP) which provided further 
evidence for the free rotation of the crucial 4,5-bisphosphate motif. This analogue 
showed no Ca2+-releasing activity and little inhibition of 3-kinase and 5-phosphatase: 
(3-kinase, K{ value of >100|iM and 5-phosphatase Kx value of 200jiM). I422l
Increasing the number of phosphorothioate groups in the molecule tended to increase 
the EC50 value as well as increasing its resistance to 5-phosphatase from HEG. 
However, DL-Ins(l,4,5)P3-4,5S2 was slightly more potent than DL-Ins(l,4,5)PS3 (Ki 
value of 1.7|iM) and was a poor inhibitor of 3-kinase from CRBHS with a Kt value of 
230jiM. This indicated the specificity of a phosphate moiety over a phosphorothioate 
group for 3-kinase interaction. Another analogue, DL-myo-inositol 4,5-bisphosphate-
1-phosphorothioate DL-Ins(l,4,5)P3-lS, has also been synthesised in racemic [439] and 
optically active I358J form. The phosphorothioate group at this position offers a point 
of attachment for reporter groups such as fluorescent and spin labels, due to the 
nucleophilic nature of the sulphur atom. DL-Ins(l,4,5)P3-lS was modified by coupling 
with the fluorescent reporter group nitrobenzoxadiazole (NBD) moiety at the 1- 
position to provide DL-NBD-Ins(l,4,5)P3. It was found that the analogue could bind to 
the Ins(l,4,5)P3 cerebellar receptor with high affinity and it released Ca2+ potently 
with an EC50 value only 6-fold higher than for Ins(l,4,5)P3. Other research groups 
have modified the 1-position and 2-hydroxyl by attaching probes or affinity matrices, 
but this will not be discussed any further. This research has been reviewed in two 
references. t408’409]
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4.5.1 Biology and Application of Ins(l,4,5)PS3
DL-Ins(l,4,5)PS3 is recognised by Ins(l,4,5)P3 receptors from many cell-types and is a 
full agonist for Ca2+ release and is resistant to all known Ins(l,4,5)P3 metabolic 
pathways. The function of Ins(l,4,5)P3 in the red blood cell is unknown at present 
even though phosphoinositide breakdown is well established. It is known that in 
permeabilised red blood cells, Ins(l,4,5)P3 elicits the transient release of Ca2+, 
disorganisation of the spectrin network and reversible shape changes, which were 
measured by immunofluorescence, t440! However, DL-Ins(l,4,5)PS3, being resistant to 
metabolic degradation, gave a sustained Ca2+ release and irreversible shape changes 
and disorganisation of the spectrin network. Thus the Ins(l,4,5)P3 pathway plays a 
pivotal role in the shape maintenance of red blood cells.
A further application of DL-Ins(l,4,5)PS3 has been to demonstrate the 'quantal' release 
of Ca2+ by Ins(l,4,5)P3 in permeabilised hepatocytes. I441l It was demonstrated that 
the amount of Ca2+ released from the Ins(l,4,5)P3-sensitive Ca2+ store iwas dependent 
on the concentration of Ins(l,4,5)P3. Submaximal concentrations of Ins(l,4,5)P3 or 
DL-Ins(l,4,5)PS3 failed to empty Ca2+ stores completely and this was not due to 
deactivation of the stimulus nor receptor desensitisation because of the enzymatic 
stability of DL-Ins(l,4,5)PS3.
The horseshoe crab Limulus, possesses microvillar photoreceptors which release Ca2+ 
on exposure to light, via the Ins(l,4,5)P3 pathway. DL-Ins(l,4,5)PS3 has been used to 
investigate the mechanisms that terminate Ca2+ mobilisation in ventral photoreceptors 
of Limulus. DL-Ins(l,4,5)PS3 generated unusual sustained repetitive oscillations of 
Ca2+-dependent membrane potential which may persist for tens of minutes. I442! 
Finally, in rat pancreatic acinar cells, DL-Ins(l,4,5)PS3 has been used to distinguish 
between Ins(l,4,5)P3-sensitive and Ins(l,4,5)P3-insensitive non-mitochondrial 
MgATP-dependent Ca2+ pools. [443J The analogue was used to keep the Ins(l,4,5)P3- 
sensitive Ca2+ store empty and so no Ca2+-reuptake occurred into the Ins(l,4,5)P3- 
insensitive pool. However, in permeabilised rat parotid acinar cells, there is evidence 
to show Ca2+-reuptake into Ins(l,4,5)P3-sensitive and thapsigargin-sensitive Ca2+ store 
in the presence of DL-Ins(l,4,5)PS3. [444]
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The analogue L-c/izro-inositol 1,4,6-trisphosphorothioate (207), L-chiro-Ins( 1,4,6)PS3, 
was synthesised in the same way as L-chiro-lns( 1,4,6)P3 except that sulphoxidation 
occurred (using sulphur in pyridine) to give the totally protected phosphorothioate 
triester, in 90% yield. t424l Deprotection using sodium in liquid ammonia and 
purification by ion-exchange chromatography on Q-Sepharose Fast Flow, gave l- 
chiro-Ins( 1,4,6)PS3 in 70% yield. The analogue did not interact with the Ins(l,4,5)P3 
receptor from electrically permeabilised SH-SY5Y human neuroblastoma cells and 
was poorly recognised by the 3-kinase from CRBHS with a K{ value >100jxM. 
However, L-chiro-lns( 1,4,6)PS3 which has little similarity to Ins(l,4,5)P3 inhibited 5- 
phosphatase from HEG with a K{ value of 0.3pM which makes it a potent and 
selective 5-phosphatase inhibitor. An explanation for this inhibition has been 
proposed [422] which considered the c/uro-inositol ring to flip so that the 1- and 6- 
phosphorothioate groups were equatorial but the 4-phosphorothioate, and the 2-, 3- 
and 5-hydroxyl groups axial (208 in Figure 57). Molecular modelling has shown good 
overlay between the phosphorothioates of L-chiro-Jns( 1,4,6)PS3 and the phosphates of 
Ins(l,4,5)P3, the major difference being the pseudo-axial 1-phosphorothioate 
compared to Ins(l,4,5)P3. In another important study, I425] L-chiro-lns( 1,4,6)PS3 
competitively inhibited the dephosphorylation of Ins(l,4,5)P3, but surprisingly, was 
found to inhibit the cleavage of the 5-phosphate group from Ins(l,3,4,5)P4
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noncompetitively with apparent K{ values of 0.67 and 0.43|iM respectively. This 
analogue was the first phosphorothioate of Ins(l,4,5)P3 to show noncompetitive 
kinetics for inhibition of Ins(l,4,5)P3 metabolism. These experiments suggest that 
Ins(l,3,4,5)P4 and L-c/u>0-Ins(l,4,6)PS3 may bind to different regions on the 5- 
phosphatase from porcine skeletal muscle. Although the noncompetitive inhibition 
may indicate enzyme inactivation by L-chiro-lns( 1,4,6)PS3, or the presence of soluble 
type I 5-phosphatase in muscle.
L-myo-Inositol 1,4,5-trisphosphorothioate, L-Ins(l,4,5)PS3 (209) was synthesised from 
d- 1,2,4-tri-(9-benzyl-myo-inositol which in turn was obtained from the L-enantiomer 
of l-0-allyl-2,3,6-tri-0-benzyl-myoinositol. f424] Thus, the allyl group was first 
isomerised to give the cw-prop-l-enyl ether using potassium r-butoxide in dry DMSO 
followed by acid hydrolysis to provide D-l,2,4-tri-O-benzyl-my0-inositol. The triol 
was phosphitylated with bis(2-cyanoethoxy)diisopropylaminophosphine and 1H- 
tetrazole followed by sulphoxidation using sulphur in pyridine to give the fully 
protected trisphosphorothioate triester in 99% yield. Deprotection and purification as 
for other phosphorothioates gave L-Ins(l,4,5)PS3 in 91% yield. This analogue did not 
interact with the Ins(l,4,5)P3 receptor from electrically permeabilised SH-SY5Y 
human neuroblastoma cells and was poorly recognised by 3-kinase from CRBHS with 
a K{ value of 108|iM. However, L-Ins(l,4,5)PS3 was a potent inhibitor of 5- 
phosphatase from HEG preparation with a K{ value of 0.43pM. Thus, there was a 
250-fold enantiomeric selectivity over 3-kinase inhibition and a 35-fold increase in 
affinity of over L-Ins(l,4,5)P3 for 5-phosphatase inhibition.
The meso compound myo-inositol 1,3,5-trisphosphorothioate, Ins(l,3,5)PS3 (210), 
was synthesised using the symmetry of the orthoformate structure.[424] The hydroxyl 
groups at the 2-, 4- and 6-positions were p-methoxybenzylated with p-methoxybenzyl 
chloride in DMF and sodium hydride as base to give 2,4,6-tri-O-p-methoxybenzyl- 
myoinositol orthoformate in 78% yield. The 1-, 3- and 5-positions were exposed by 
refluxing the protected intermediate in a mixture of 2M HC1 and methanol (1:20) to 
give 2,4,6-tri-O-p-methoxybenzyl-myoinositol in 85% yield. The 1,3,5-triol was 
phosphitylated with bis(benzyloxy)diisopropylaminophosphine and l//-tetrazole in 
dichloromethane followed by sulphoxidation with sulphur in pyridine to give the 
totally protected 1,3,5-trisphosphorothioate. Deprotection and purification over Q- 
Sepharose gave pure Ins(l,3,5)PS3 in 91% yield.
Ins(l,3,5)PS3 (210), did not interact with the Ins(l,4,5)P3 receptor from electrically 
permeabilised SH-SY5Y human neuroblastoma cells. This analogue was poorly
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recognised by the 3-kinase from CRBHS with a Kx value of 247|iM, but was 
efficiently recognised by 5-phosphatase from (HEG) preparation with a Kx value of 
0.52|iM. This showed a 475-fold specificity of 5-phosphatase over 3-kinase for 
Ins(l,3,5)PS3.
4.6 Fluoro- and other Halogenated Ins(l,4,5)P3 Analogues
There have been several reports of racemic and chiral fluorinated myoinositol 
phosphate analogues, together with other 3-modified halogen (Cl, Br) analogues.
4.6.1 3-X-modified Ins(l,4,5)P3 Analogues (X = F, Cl, Br)
The main compound of interest has been D-3-deoxy-3-fluoro-myoinositol 1,4,5- 
trisphosphate (217 in Figure 58) D-3F-Ins(l,4,5)P3 which was prepared from d - 3 -  
deoxy-3-fluoro-myoinositol (211). This intermediate was prepared from the chiral 
starting material L-quebrachitol. When L-quebrachitol was treated with neat 
diethylaminosulphur trifluoride (DAST) at 20°C a mixture of D-3-deoxy-3-fluoro-l-0- 
methyl-myoinositol and d - 3 -deoxy-3-fluoro-4-O-methyl-myo-inositol was produced. 
The methyl group of both compounds was removed using boron tribromide in 
dichloromethane to provide D-3-deoxy-3-fluoro-myoinositol (211) in 35-50% overall 
yield.
When D-3-deoxy-3-fluoro-myo-inositol was treated with 2-methoxypropene and 
camphorsulphonic acid in DMF at 80°C for 40h a mixture of 1,2:4,5-(212) and 
l,2:5,6-di-0-isopropylidene acetals were produced (83% yield) in a ratio of 2:3 
respectively. Only 3-fluoro-l,2:4,5-di-0-isopropylidene-myo-inositol (212) was used 
in the synthesis and the other regioisomer was recycled. The free 6-hydroxyl group 
was benzylated to give (213) and the trans-acetal was selectively cleaved using HC1 in 
methanol in order to expose the 4- and 5-hydroxyl groups which were then 
benzoylated using benzoyl chloride and DMAP in pyridine to provide derivative (214) 
in (92% yield). The cis-1,2-0-isopropylidene acetal was removed with acetic 
acid/water/THF (2:1:1), 80°C for 14h in 92% yield, followed by selective 
benzoylation at the 1-position using benzoyl chloride/pyridine at 0°C for 12h in 92% 
yield. The exposed 2-hydroxyl group was protected as the ethoxyethyl derivative in 
86% yield which gave the fully protected compound (215). Basic hydrolysis of the 
three benzoate ester groups at d - 1 - ,  4- and 5-positions using methanolic potassium 
carbonate 23°C for 14h exposed the hydroxyl groups at these positions in 83% yield. 
Phosphorylation was accomplished using tetrabenzylpyrophosphate and sodium
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hydride in DMF at 0°C for 8-1 Oh to give the totally protected phosphorylated 
intermediate (216) in 95% yield. The ethoxyethyl moiety was cleaved using toluene- 
/7-sulphonic acid in methanol (23°C for 14h) in 82% yield. Debenzylation was 
accomplished by hydrogenolysis over platinum oxide and titration with NaOH gave 
the stable hexasodium salt of D-3F-Ins(l,4,5)P3. I446! The analogues D-3-chloro-myo- 
inositol 1,4,5-trisphosphate, [D-3Cl-Ins(l,4,5)P3] and D-3-bromo-rayo-inositol 1,4,5- 
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The EC50 value for Ins(l,4,5)P3 was found to be 52.1nM for the release of Ca2+ from 
SH-SY5Y human neuroblastoma cells. D-3F-Ins(l,4,5)P3 was found to have an EC50 
value of 120.2nM, D-3Cl-Ins(l,4,5)P3 an EC50 value of 639.8nM and D-3Br- 
Ins(l,4,5)P3 an EC50 value of llOOnM. For the 3-modified halogen derivatives of 
Ins(l,4,5)P3, one may suggest that the Ins(l,4,5)P3 receptor is sensitive to steric bulk, 
similar to the 3-0-alkylated Ins(l,4,5)P3 molecules (discussed in section 4.4.4). A 
fluorine substituent has a volume of 10.1 A3, chlorine 19.4A3 and bromine has a 
volume of 25.2A3. Moreover, the increase in bulk volume at the 3-position, switches 
from being Ins(l,4,5)P3-like [seen for D-3F-Ins(l,4,5)P3] to being Ins(l,3,4,5)P4-like 
[seen for D-3Br-Ins(l,4,5)P3] with D-3Cl-Ins(l,4,5)P3 being intermediate in size, 
between Ins(l,4,5)P3 and Ins(l,3,4,5)P4. It may be concluded that the phosphorylation 
of Ins(l,4,5)P3 -» Ins(l,3,4,5)P4 may act to dissect the function of these two 
molecules at the Ins(l,4,5)P3 receptor. I447!
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The analogue D-3F-Ins(l,4,5)P3 has also been tested on the enzymes 5-phosphatase 
and 3-kinase. It appeared to be resistant to 3-kinase from CRBHS with a K-t value of 
8.6pM. However, D-3F-Ins(l,4,5)P3 was hydrolysed by 5-phosphatase from HEG at a 
similar rate to that for Ins(l,4,5)P3 but inhibited the dephosphorylation of 
[3H]Ins(l,4,5)P3 with a K{ value of 3.9pM.
D-3F-Ins(l,4,5)P3 has recently been used as a tool in order to investigate Ca2+-influx in 
rat hepatocytes. Microinjection of Ins(l,3,4,5)P4, Ins(l,4,5)P3 or D-3F-Ins(l,4,5)P3 
indicated that Ins(l,4,5)P3 rather than Ins(l,3,4,5)P4 is responsible for Ca2+-influx. 
When the agonist vasopressin activated PLC, an influx of Mn2+ was observed which 
was independent of intracellular Ca2+ stores, if the depletion was delayed by using low 
agonist concentration or heparin. It was proposed [448] that Ins(l,4,5)P3 was able to 
stimulate Ca2+-influx by two pathways. Thus Ins(l,4,5)P3 activates receptor-operated 
Ca2+-channels directly. The Ca2+-influx resulting from this is followed by 
Ins(l,4,5)P3-induced depletion of Ca2+ stores, producing a 'store-dependent-entry1.
4.6.2 2-Modified Fluoro-Inositol Phosphates
The intermediate d l - 1 -0-ally 1-3,6-di-0-benzy 1-4,5-0-isopropylidene-ray£>-inositol 
(153) was prepared from myo-inositol in several transformations according to Gigg 
and coworkers. [3831 This intermediate was used to synthesise all the 2-fluorinated 
inositol trisphosphate analogues in this section. 2-Deoxy-2-fluoro-jcy//o-inositol
1,4,5-trisphosphate (222 in Figure 59) was synthesised in 5 steps from this 
intermediate. First, the allyl group was isomerised using potassium f-butoxide in dry 
DMSO for 3h to give the cw-prop-l-enyl ether (218) in quantitative yield. The 
equatorial fluorine group was introduced using DAST (3 equivalents) in dry 
dichloromethane via an SN2 reaction to give DL-3,6-di-0-benzyl-2-deoxy-2-fluoro-4,5- 
0-isopropylidene-s,cy//<9-inositol (219) in 68% yield, t385! The acid sensitive 4,5-0- 
isopropylidene group and the cw-prop-l-enyl were removed under acidic conditions 
[1M HCl-methanol, (1:5)], to give the racemic 1,4,5-triol (220) in 89% yield. 
Phosphitylation with bis(2-cyanoethoxy)diisopropylaminophosphine and l//-tetrazole 
followed by oxidation with r-butylhydroperoxide provided the trisphosphate triester 
(221) which was not isolated. The protective groups were removed using sodium in 
liquid ammonia, and purified by ion exchange chromatography to give racemic 2-F- 
jcy//o-Ins(l,4,5)P3 (222) in 34% yield. It was found to be a full agonist for the release 
of Ca2+ from permeabilised SH-SY5Y human neuroblastoma cells with an EC50 value 
of 0.77|iM. The analogue was found to be a substrate albeit a poor one for 5-
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phosphatase from HEG with a Kx value of 0.7|iM, but was resistant to 3-kinase from 
CRBHS with a Kx value of 8.8|iM. t449l
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DL-2-Deoxy-2,2-difluoro-myo-inositol 1,4,5-trisphosphate ( 2 2 7 ) ,  dl-2,2F 2-scyllo- 
Ins(l,4,5)P3 was synthesised from the same intermediate ( 1 5 3 ) ,  and subsequently 
resolved to give the d - ( 2 2 8 )  and l - ( 2 2 9 )  enantiomers (in Figure 60). [385] The 2- 
hydroxyl group was oxidised using DMSO/acetic anhydride in 94% yield in order to 
provide the 2-inosose derivative ( 2 2 3 ) .  The 2-deoxy-2,2-difluoro moiety was 
introduced using excess DAST (4 equivalents) in dry dichloromethane (79% yield) to 
give compound ( 2 2 4 ) .  The allyl group was isomerised to a mixture of cis- and trans- 
prop-l-enyl ethers (9:2) using Wilkinson's catalyst to give ( 2 2 5 )  in 75% yield and the 
acid sensitive protective groups were removed under acidic conditions to provide the 
triol ( 2 2 6 ) .  The exposed 1-, 4- and 5-hydroxyl groups were phosphoiylated and 
deprotected in the same way as for 2¥-scyllo-Jns( 1,4,5)P3 to give dl-2,2F2- 
Ins(l,4,5)P3.
Chiral d - ( 2 2 8 )  and L-2,2F2-Ins(l,4,5)P3 ( 2 2 9 )  were synthesised by resolving DL-3,6-di-
0-benzyl-2-deoxy-2,2-difluoro-4,5-0-isopropylidene-my<9-inositol ( 7 4 ) ,  using lS-(-)- 
co-camphanic acid chloride. [3851 The diastereoisomeric camphanate ester derivatives 
were separated by flash chromatography (described in section 3.7). The camphanate 
was then hydrolysed under basic conditions in >90% yield for both compounds, and 
the 4,5-0-isopropylidene group was removed under acidic conditions followed by 
phosphorylation/deprotection as for 2F-scyllo-lns( 1,4,5)P3 to give the resolved 






D-2,2F2-Ins( 1,4,5)P3 (228) L-2,2F2-Ins(l,4,5)P3 (229)
Figure 60
The EC50 value for DL-2,2F2-Ins(l,4,5)P3 was found to be 0.4lpM, for the d -  
enantiomer 0.2 lpM  and for the L-enantiomer 53|xM. Thus, the D-enantiomer is a full 
agonist for Ca2+-release from SH-SY5Y human neuroblastoma cells and is 250-fold 
more potent than the L-enantiomer, indicating the stereospecificity for the d -  
enantiomer at the Ins(l,4,5)P3 receptor, t449! The three compounds were then tested 
for 5-phosphatase HEG preparation and 3-kinase CRBHS. DL-2,2F2-Ins(l,4,5)P3 
showed inhibition of 5-phosphatase with a K-x value of 26pM [the Km value for 
Ins(l,4,5)P3 had a value of 40|iM in this study]. D-2,2F2-Ins(l,4,5)P3 was a substrate 
for 5-phosphatase and inhibited [3H]Ins(l,4,5)P3 dephosphorylation with a K{ value of 
60fiM. However, L-2,2F2-Ins(l,4,5)P3 was resistant to 5-phosphatase with a K{ value 
of 19pM.
The 3-kinase enzyme recognised D-2,2F2-Ins(l,4,5)P3 as a substrate with high affinity 
which inhibited the phosphorylation of [3H]Ins(l,4,5)P3 competitively with a K{ value 
of 6.6|iM. However, L-2,2F2-Ins(l,4,5)P3 was a potent inhibitor of 3-kinase and 
inhibited the phosphorylation of [3H]Ins(l,4,5)P3 with a K{ value of 11.5|iM, which 
compares favourably with Ins(l,4,5)P3 with a Km value of 3.2pM. t45°l
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DL-2F-Ins( 1,4,5 )P3 (236)
A final 2-modified fluorinated analogue, DL-2-deoxy-2,-fluoro-mye>-inositol 1,4,5-
v
trisphosphate DL-2F-Ins(l,4,5)P3 (236 in Figure 61), has been successfully synthesised. 
[428] T tie  intermediate DL-l-O-allyl-3,6-di-O-benzyl-4,5-0-isopropylidene-scy//<9- 
inositol (230) was used as the intermediate to synthesise DL-2F-Ins(l,4,5)P3. The allyl 
group was isomerised using potassium f-butoxide in dry DMSO to give the cis-prop-
1-enyl ether (231). The 2-hydroxyl was then set-up for SN2 via the 
trifluoromethanesulphonate (232) followed by fluoride inversion using anhydrous 
tetrabutylammonium fluoride to restore the rayo-configuration in 69% yield. The 
observation that ^ n p  was 29.5Hz in the spectrum of d l -  1 -O-as-prop-1 -enyl-2-deoxy-
2-fluoro-3,6-di-0-benzyl-4,5-(9-isopropylidene-myo-inositol (233) confirmed the 
inversion of the 2-position back to the myo-configuration. Removal of the acid 
sensitive protective groups gave the triol (234) and phosphitylation [using 
bis(benzyloxy)diisopropylaminophosphine and l//-tetrazole] followed by oxidation 
with r-butylhydroperoxide, provided the fully protected trisphosphate (235). 
Deprotection with sodium in liquid ammonia gave DL-2F-Ins(l,4,5)P3 (236) in 41% 
yield. The racemic compound has an EC50 value of 104.7nM, [Ins(l,4,5)P3 had a 
value of 51.6nM] from SH-SY5Y human neuroblastoma cells. DL-2F-Ins(l,4,5)P3 was 
also resistant to 5-phosphatase inhibition and had a K{ value of 14.4|iM, but was 
susceptible to 3-kinase activity, and inhibited phosphorylation of [3H]Ins(l,4,5)P3 
with a K-x value of 3.0pM.
Other fluorinated inositol phosphates have been synthesised including DL-6-deoxy-6- 
fluoro-myo-inositol 1,4,5-trisphosphate by Ley and coworkers I4011 together with d l - 6 -  
deoxy-6-fluoro-c/»'ro-inositol 2,3,5-trisphosphate by Carless and coworkers [451J and
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DL-2-deoxy-2,2-difluoro-myo-inositol 1,3,4-trisphosphate by Prestwich and coworkers. 
I452l All three of these compounds have no biological data associated with the 
synthesis.
4.7 D-6-Deoxy-Ins(l,4,5)P3
D-6-Deoxy-myo-inositol 1,4,5-trisphosphate D-6-deoxy-Ins(l,4,5)P3 (237), was 
synthesised from D-galactose (D. Dubreuil, J. Cleophax, B. V. L. Potter and S. D. 
Gero, unpublished data). However, Ley and coworkers have synthesised this 
analogue in racemic form from benzene. I401! Briefly, the intermediate, epoxy acetal 
(238) which was derived from the versatile cw-l,2-diol was treated with lithium 
aluminium hydride in ether at reflux temperature to give the 6-deoxy compound (239) 
in 76% yield, together with a small quantity (12%), of the other regioisomer. The 
benzyl groups were removed by hydrogenolysis to give compound (240) and the 
exposed hydroxyl groups at 1-, 4- and 5-positions were phosphorylated with 
tetrabenzylpyrophosphate in the presence of n-butyl lithium. Deprotection of the 
benzylphosphate and isopropylidene protective groups took place using 
bromotrimethylsilane in dichloromethane followed by the addition of water to give d l -
6-deoxy-Ins(l,4,5)P3 (241 in Figure 62). Ley and coworkers have also made d l - 6 -  
deoxy-6-C-methyl-Ins(l,4,5)P3 by the same route, but using lithium 
dimethyl(cyano)copper (I) to open the epoxide in a nucleophilic fashion to give a 
product which was treated in the same way to obtain the deprotected phosphate. Only 
DL-6-0-methyl-Ins(l,4,5)P3 has been evaluated, which was found to be a weak 
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The biological data for D-6-deoxy-Ins(l,4,5)P3 demonstrated the importance of the 6- 
hydroxyl group in binding to the Ins(l,4,5)P3 receptor and is recognised by the 
enzymes 3-kinase and 5-phosphatase. D-6-Deoxy-Ins(l,4,5)P3 was a full agonist for 
Ca2+-release in permeabilised SH-SY5Y neuroblastoma cells with an EC50 value of 
6.4jiM, which was 70-fold less than for Ins(l,4,5)P3 (EC50 value of 0.09|iM). This 
difference indicated the importance of the 6-hydroxyl group in binding to the 
Ins(l,4,5)P3 receptor. D-6-Deoxy-Ins(l,4,5)P3 inhibited [32P]Ins(l,4,5)P3 
dephosphorylation by 5-phosphatase from HEG with a K{ value of 76pM. l453J The Km 
value for Ins(l,4,5)P3 was found to be 40fiM f427^ and thus D-6-deoxy-Ins(l,4,5)P3 had 
an apparent 2-fold weaker affinity for 5-phosphatase than Ins(l,4,5)P3. This result 
agrees with the work carried out by Polokoff and coworkers [427l in which the 
minimum structural requirements for substrate hydrolysis by 5-phosphatase (from 
aortic smooth muscle) was suggested to be a free hydroxyl at the 6-position and 
phosphate groups at the 1-, 4- and 5-positions. The 6-hydroxyl group may provide a 
catalytic role in the mechanism of 5-phosphatase dephosphorylation in a similar 
manner to the synthetic 2- and 6-deoxy analogues of Ins(l)P and their interaction with 
myo-inositol monophosphatase. [4541
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The 3-kinase from CRBHS showed far greater selectivity than the less specific 5- 
phosphatase enzyme. D-6-Deoxy-Ins(l,4,5)P3 inhibited the phosphorylation of 
[3H]Ins(l,4,5)P3 [K{ value of 5.7^iM; Ins(l,4,5)P3 had K{ value of 3.2^iM]. Thus the 
analogue binds very well to the 3-kinase but increasing the steric bulk at the 6- 
position (by methylation) decreased its affinity, (IC50 value of 319|iM). However, d -  
6-deoxy-Ins(l,4,5)P3 mobilised Ca2+ ions with different kinetics to Ins(l,4,5)P3 and is 
probably a substrate for the enzyme.
In conclusion, the 6-hydroxyl group, while not essential for Ca2+-release, certainly has 
a role in binding to the receptor, or fixing the conformation of the phosphate groups of 
Ins(l,4,5)P3.
4.7.1 D-3-Deoxy, D-2,3-Dideoxy and D-2,3,6-Trideoxy Ins(l,4,5)P3
The three deoxy compounds were all synthesised from the same starting material, l -  
quebrachitol. t455^ L-Quebrachitol (169 in Figure 63) was treated with 2- 
methoxypropene in the presence of camphorsulphonic acid and DMF to form the 
3,4:5,6-di-0-isopropylidene derivative (242). The sodium alkoxide was formed at the 
1-position followed by the addition of carbon disulphide and methyl iodide to provide 
the corresponding S'-methyldithiocarbonate, which was deoxygenated using n- 
tributyltin hydride in the presence of the radical initiator azobisisobutyronitrile 
(AIBN) in toluene to give the D-3-deoxy derivative (243) (myo-inositol numbering). 
The methyl and isopropylidene groups were then removed using boron tribromide to 
give D-3-deoxy-myoinositol (244) [(-)-vibumitol]. The D-3-deoxy derivative was 
treated with 2-methoxypropene and catalytic camphorsulphonic acid in DMF to give a 
mixture of D-3-deoxy-1,2:4,5-di-0-isopropylidene-myo-inositol and the 1,2:5,6- 
regioisomer. Benzylation of the mixture gave the 6-O-benzyl (245) and 4-O-benzyl 
derivatives. The fraws-isopropylidene acetal was removed using a catalytic amount of 
HC1 and the two hydroxyl groups were benzoylated, at which stage the regioisomers 
were separated by chromatography, which provided D-4,5-di-0-benzoyl-6-0-benzyl-3- 
deoxy-1,2-O-isopropylidene-myoinositol (246) for further manipulation. The cis-1,2-
O-isopropylidene acetal was removed under acidic conditions [1M aqueous HC1, 
methanol/THF (4:1)], in order to expose the cis- 1,2-hydroxyl. Selective benzoylation 
using benzoyl chloride/DMAP/pyridine, 0°C, for 28h, provided the 1,4,5-tri-O- 
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Figure 63 D-2,3,6-trideoxy-Ins(l,4,5)P3 (257)
First, D-3-deoxy-myo-inositol 1,4,5-trisphosphate (249), D-3-deoxy Ins(l,4,5)P3, was 
synthesised by protecting the 2-position as the ethoxyethyl ether to give (248) using 
ethyl vinyl ether and pyridinium toluene-p-sulphonate, the benzoyl groups were 
removed using methanolic potassium carbonate to expose the hydroxyl groups at the
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1-, 4- and 5-positions in 94% yield. Phosphorylation using tetrabenzylpyrophosphate 
and sodium hydride in DMF gave the totally protected phosphorylated compound in 
50% yield. Hydrogenation using palladium on carbon, followed by dissolution in 
water, provided the title compound (249) which was isolated as the sodium salt in 
56% yield.
Second, D-2,3-dideoxy-myo-inositol 1,4,5-trisphosphate (253), D-2,3-dideoxy 
Ins(l,4,5)P3 was synthesised using the same the intermediate (247). The 2-hydroxyl 
group was set-up for deoxygenation using the phenoxythiocarbonyl derivative (250), 
by treatment with phenyl chlorothiocarbonate in the presence of DMAP. Compound
(250) was treated with tributyltin hydride and AIBN to give the 2,3-dideoxy derivative
(251). Debenzoylation as for the 3-deoxy Ins(l,4,5)P3, followed by phosphorylation 
and deprotection, gave D-2,3-dideoxy Ins(l,4,5)P3 (253).
Third, D-2,3,6-trideoxy Ins(l,4,5)P3 (257) was synthesised from the 2,3-dideoxy 
derivative (251). Debenzylation of compound (251), exposed the 6-hydroxyl which 
was treated with phenyl chlorothiocarbonate in the presence of DMAP to give (254) 
and deoxygenation as before gave the protected D-2,3,6-trideoxy-myo-inositol 
derivative (256). The benzoate groups were removed with methanolic potassium 
carbonate and phosphorylated as for the other two deoxy derivatives to give d-2,3,6- 
trideoxy Ins(l,4,5)P3 (257).
The analogues D-3-deoxy Ins(l,4,5)P3 and D-2,3-dideoxy Ins(l,4,5)P3 were full 
agonists for Ca2+-release at the Ins(l,4,5)P3 receptor from permeabilised SH-SY5Y 
neuroblastoma cells with EC50 values of 155.7 and 185.7nM respectively, which was 
only 3-fold less than Ins(l,4,5)P3 with had an EC50 value of 52.1nM. However, d- 
2,3,6-trideoxy Ins(l,4,5)P3 was a poor agonist for Ca2+-release with an EC50 value > 
10,000nM. This evidence further identifies the critical role of the 6-hydroxyl in 
binding to the Ins(l,4,5)P3 receptor whilst the 2- and 3-positions appear to be less 
important from this data.
D-3-Deoxy Ins(l,4,5)P3 and D-2,3-dideoxy Ins(l,4,5)P3 were evaluated for HEG 5- 
phosphatase and CRBHS 3-kinase activity. [4561 Both D-3-deoxy Ins(l,4,5)P3 and d- 
2,3-dideoxy Ins(l,4,5)P3 were found to be substrates for 5-phosphatase displacing 
[3H]Ins(l,4,5)P3 with K-x values of 11.5 and 16.5|iM. These values are very similar to 
those found by Hirata and coworkers 14571 for DL-2-deoxy Ins(l,4,5)P3 which had a 
value of 12.9|iM and was also a substrate. The 3-kinase enzyme is substrate specific
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and both D-3-deoxy and D-2,3-dideoxy Ins(l,4,5)P3 were found to be resistant to 3- 
kinase activity as predicted with K{ values of 25pM and 19pM respectively.
In summary, the deoxy derivatives have been useful in demonstrating the role of the 6- 
hydroxyl group in binding to the receptor and the less critical roles of the 2- and 3- 
hydroxyl groups for this purpose. The 6-deoxy analogue is also resistant to 5- 
phosphatase indicating a role for the 6-hydroxyl group in 5-phosphatase-catalysed 
dephosphorylation.
4.8 O ther Analogues
Several other analogues have been prepared and evaluated, two of which are 
phosphonates. First, the 5-methylenephosphonate analogue of Ins(l,4,5)P3 (260 in 
Figure 64) was prepared from the commercially available chiral starting material (-)- 
quinic acid [458] and second, DL-myo-inositol l,4-bisphosphate-5-methylphosphonate 
(262 in Figure 65) was prepared from intermediate (54). [459] The 5- 
methylenephosphonate was prepared from intermediate (134), which was also used by 
Falck and coworkers to prepare D-Ins(l,4,5)P3. [403^ The 2-
(trimethylsilyl)ethoxymethyl ether (SEM), protective group was removed with 
tetrabutylammonium fluoride in (hexamethylphosphoric triamide) HMPA at 100°C 





D-Ins( 1,4)P2-5-methylenephosphonate (260) OH O
Figure 64
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across the alkene provided the anti-Markovnikov adduct. This intermediate 
underwent smooth oxidative elimination to provide the endocyclic allylic bromide to 
give compound (258) in 95% yield. Michaelis-Becker phosphorylation of the allylic 
bromide using excess sodium dibenzyl phosphite in the presence of 18-crown-6 in 
toluene, followed by hydroboration of the alkene with mCPBA, provided compound 
(259) as a single isomer in 95% yield. The 1- and 4-phosphate groups were 
introduced using the phosphite method [bis(benzyloxy)diisopropylaminophosphine 
and l//-tetrazole] followed by oxidation with mCPBA to furnish the fully protected 
phosphate. Hydrogenation over palladium on carbon followed by acid hydrolysis of 
the 2,3 - 0-cy cl ohexy li dene acetal gave the 5-methylenephosphonate analogue (260) in 
67% yield, isolated as the sodium salt.
The phosphonate analogue elicited contraction of permeabilised bovine tracheal 
smooth muscle, with a 5-10 fold lower potency than D-Ins(l,4,5)P3. The compound 
was also 5-phosphatase resistant, and in bovine adrenal microsomes was equally 
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The 5-methylphosphonate analogue (262) was prepared by van Boom and coworkers 
I459! from the 1,4-bisphosphate derivative (54). Thus, phosphonylation of the 5- 
hydroxyl with excess bis[6-(trifluoromethyl)benzotriazol-l-yl]-methylphosphonate 
(261) gave, after 15min at 20°C, the putative [6-(trifluoromethyl)benzotriazol-l-yl]- 
methyl phosphonate intermediate. This was treated in situ with benzyl alcohol and N- 
methylimidazole to give after lh at 20°C, the fully protected Ins(l,4,5)P3 analogue as 
a mixture of diastereoisomers. Hydrogenolysis gave the methylphosphonate analogue 
which was isolated as the sodium salt. Biological evaluation initially indicated that 
the racemic analogue was an antagonist at the Ins(l,4,5)P3 receptor from
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permeabilised platelets. However, this finding has not been confirmed by any 
biological publication.
The three phosphates of Ins(l,4,5)P3 have been replaced by sulphates and 
sulphonamides.[460] d l -  1,2,4-Tri-O-benzyl-myo-inositol (110) (Figure 66) was treated 
with triethylamine-sulphur trioxide complex at 50°C for 16h in DMF, followed by 
hydrogenolysis over palladium on carbon in DMF-water (4:1) to give myo-inositol
1,4,5-trissulphate (263) in 86% yield. The 1,4,5-trissulphamoylated derivative was 
prepared by treating d l -  1,2,4-tri-0-benzyl-my<9-inositol (110) and sulphamoyl chloride 
with sodium hydride in DMF at 0°C for 2h. Debenzylation by hydrogenolysis 
provided myo-inositol 1,4,5-trissulphamate (264) in 84% yield from the starting triol. 
Neither of these compounds displayed any binding to the Ins(l,4,5)P3 receptor from 
platelets. 3- Azido-3 -deoxy-myo-inositol 2,4,5-trisphosphate has also been prepared 
(not shown) and did not show any interesting biological activity for 3-kinase nor Ca2+- 
release. However, it was a substrate for 5-phosphatase inhibiting the 
dephosphorylation of [3H]Ins(l,4,5)P3 with a K{ value of 36.3pM. I456l
Benzene 1,2,4-trisphosphate t461l has been prepared by phosphorylating benzene 1,2,4- 
triol with dibenzylphosphochloridate in the presence of Af,AT-diisopropylethylamine. 
The benzyl groups were removed using 70% trifluoroacetic acid in dichloromethane, 
and purified by reverse phase HPLC, to give pure benzene 1,2,4-trisphosphate. The 
analogue interacted with the Ins(l,4,5)P3 receptor but did not release Ca2+. The 
analogue showed inhibition of 5-phosphatase with an IC50 value of 32|iM (from 
adrenal cortex microsomes) and an IC50 value for 3-kinase inhibition of 6.1|iM (from 
adrenal cortex cytosol).




Figure 66 DL-Ins-1,4,5-trissulphonamide (264)
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4.9 Partial Agonists at the Ins(l,4,5)P3 Receptor
The term partial agonist was first used in order to provide an explanation for agonists 
which display a large range of intrinsic activities at the same receptor depending on 
the conditions and model used. [4621 The term efficacy is used to distinguish between 
the agonist binding to the receptor measured by its equilibrium constant, and the 
ability of the agonist to produce a response (for example Ca2+-release) once it has 
bound. For example, in a specific tissue, two different agonists acting on the same 
receptor may generate different maximal responses from the same tissue. At 100% 
receptor occupancy one agonist may produce a smaller effect than another agonist and 
in parallel with this idea arrived the concept of spare receptors. A high efficacy 
agonist will produce a maximum response when it occupies only a small fraction of 
receptors, there are in other words, 'spare receptors'. However, an agonist with low 
efficacy will not produce a maximum response even when all the receptors are 
occupied. The difference between agonists, partial agonists and antagonists may 
become a matter of efficacy. Antagonists have zero efficacy, partial agonists have low 
variable efficacy and agonists have high efficacy. In this last section partial agonists 
will be discussed with respect to Ca2+-release and finally, antagonists, which may be 
useful as tools for pharmacological interaction.
4.9.1 Ins(l,3,4,6)P4
The naturally occurring /weso-compound myo-inositol 1,3,4,6-tetrakisphosphate, (64) 
Ins(l,3,4,6)P4 was synthesised by deprotection of 2,5-di-<9-benzyl-l,3,4,6-tetra[di(2- 
cyanoethoxyphospho)]-myo-inositol, first by hydrolysis of the base-labile cyanoethoxy 
groups followed by hydrogenation of the benzyl groups at the 2- and 5-positions. It 
was found that Ins(l,3,4,6)P4 mediated Ca2+-release from the Ins(l,4,5)P3 receptor of 
SH-SY5Y human neuroblastoma cells. However, (64) was also found to be a partial 
agonist with an EC50 value of 5.92pM compared to Ins(l,4,5)P3 with an EC50 value of 
0.12|iM. *2161 Thus, Ins(l,3,4,6)P4 is 50-fold less potent at Ca2+-release and only 
released a maximum of 80-90% of the Ca2+ pool that is normally released by 
Ins(l,4,5)P3. Furthermore, Ins(l,3,4,6)P4 behaves a full agonist at other Ins(l,4,5)P3 
receptors. The reason for the observed partial agonism of Ins(l,3,4,6)P4 at SH-SY5Y 
human neuroblastoma cells and more recent in rat brain microsomes [431] is not 
obvious. By further modification of this structure one will hopefully produce an 
analogue with even lower efficacy and therefore closer to an antagonist.
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The important functional aspects for Ca2+-release are a vicinal D-4,5-bisphosphate and 
an adjacent 6-hydroxyl to increase the binding at the Ins(l,4,5)P3 receptor. A 
phosphate group at the 1-position further enhances binding to the receptor. The meso- 
Ins(l,3,4,6)P4 does not have a free 6-hydroxyl or a D-4,5-bisphosphate. However, the 
molecule may bind to the Ins(l,4,5)P3 receptor in one of two orientations which 
maximise similarity to Ins(l,4,5)P3 (Figure 67). In the first binding mode (265) the 4-, 
1- and 6-phosphate groups may represent a pseudo D-l,4,5-trisphosphate with the 5- 
hydroxyl mimicking the 6-hydroxyl group of Ins(l,4,5)P3. The pseudo 2-position is 
phosphorylated and equatorial but this does not affect the Ca2+-releasing activity as 
exemplified by the activity of racemic Ins(l,2,4,5)P4 and scyllo-Ins(l,2,4,5)P4. The 
pseudo 3-position of Ins(l,3,4,6)P4 is now axial and may play a part in the partial 
agonist behaviour. In the second orientation (266), the pseudo D-l,4,5-trisphosphate 
moiety is provided by the 3-, 6- and 1-phosphates from Ins(l,3,4,6)P4 with an 
equatorial 3-hydroxyl [5-hydroxyl from Ins(l,3,4,6)P4] and the pseudo 6-position is 
occupied by the axial 2-hydroxyl of Ins(l,3,4,6)P4. It is difficult to determine which 
orientation or both is involved in this partial agonist behaviour.
Ins(l,3,4,6)P4 was also found to be a poor inhibitor of 3-kinase from CRBHS with a 
K-x value of 150|iM. However, it was found to be a substrate, and like other 
tetrakisphosphates tested, Ins(l,3,4,6)P4 had a high affinity for 5-phosphatase from 
HEG, and inhibited [3H]Ins(l,4,5)P3 dephosphorylation with a K{ value of 7.7|iM .[422]
O o
first binding mode (265)
Figure 67 O o
second binding mode (266)
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4.9.2 L-c/n>0-Ins(2,3,5)PS3 and D-6-deoxy-Ins(l,4,5)PS3
L-c/nro-Inositol 2,3,5-trisphosphorothioate (267 Figure 68) [L-c/n‘ro-Ins(2,3,5)PS3] 
was synthesised in a similar manner to L-c/»re>-Ins(2,3,5)P3 described in section 4.4.1. 
Essentially, l -  1,4,6-tri-O-benzoyl-c/i/ro-inositol was phosphitylated with bis(2- 
cyanoethoxy)diisopropylaminophosphine and l//-tetrazole, followed by 
sulphoxidation with sulphur in pyridine. Work up and purification by flash 
chromatography gave the protected trisphosphorothioate in 90% yield. All the 
protective groups were removed by sodium in liquid ammonia reduction followed by 
final purification by ion exchange chromatography to provide L-c/nVc>-Ins(2,3,5)PS3 
(267) in 70% yield.[4631 D-6-Deoxy-myo-inositol 1,4,5-trisphosphorothioate, (268), d -  
6-deoxy-Ins(l,4,5)PS3, was synthesised by phosphitylating D-2,3-0-cyclohexylidene- 
6-deoxy-myo-inositol l464l using bis(benzyloxy)diisopropylaminophosphine and 1H- 
tetrazole, followed by sulphoxidation with sulphur in pyridine. The phosphorothioate 
protective groups were removed using sodium in liquid ammonia and the cis-2,3-0- 
cyclohexylidene acetal was removed using H+ Dowex ion exchange resin. The 
residue was purified by ion exchange chromatography over DEAE Sephadex-A25 
resin and eluted with TEAB to give D-6-deoxy-Ins(l,4,5)PS3 (268).
The binding and Ca2+-mobilising properties of L-c/z/ro-Ins(2,3,5)PS3 and D-6-deoxy- 
Ins(l,4,5)PS3 with the Ins(l,4,5)P3 receptor from permeabilised SH-SY5Y human 
neuroblastoma cells were investigated. It was found using radioligand assays, that 
both analogues were able to compete with [3H]Ins(l,4,5)P3 for specific sites on 
adrenal cortical membranes, albeit weaker than Ins(l,4,5)P3. Both these analogues 
could compete at the Ins(l,4,5)P3 receptor with Kd values of 500nM for l -chiro- 
Ins(2,3,5)PS3 and 5300nM for D-6-deoxy-Ins(l,4,5)PS3, whereas Ins(l,4,5)P3 had a Km 
value of 6.5nM. The intrigue of these analogues was that they showed low efficacy, 
releasing only 34% of the Ca2+ with respect to Ins(l,4,5)P3 for L-c/i/ro-Ins(2,3,5)PS3, 
and 42% for D-6-deoxy-Ins(l,4,5)PS3. Both compounds were able to inhibit the 
response of Ins(l,4,5)P3-induced Ca2+-release with K-x values of 6|iM and 33pM
L-c/ifro-Ins(2,3,5)PS3 (267) D-6-deoxy-Ins(l,4,5)PS3 (268)
Figure 68
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respectively for L-c/nro-Ins(2,3,5)PS3, and D-6-deoxy-Ins(l,4,5)PS3 which were very 
similar to the EC50 values of 5.3|xM and 16fiM respectively. These two compounds 
represent analogues with low efficacy and are valuable leads in the synthesis of 
compounds with zero efficacy and thus zero Ca2+-release. By further structural 
modification both at the phosphate and at the hydroxyl function, a better tool may be 
found in order to investigate the structure-activity relationships of the Ins(l,4,5)P3 
receptor. The reasons why these two compounds show lower efficacy than normal are 
not clear. However, two features that both these compounds have in common are: 
first, both analogues are phosphorothioates, with a pseudo d - 1,4,5-configuration and 
second, both have a single structural modification at a hydroxyl group, l -chiro- 
Ins(2,3,5)PS3 has an inverted 3-hydroxyl and D-6-deoxy-Ins(l,4,5)PS3 has a deleted 6- 
hydroxyl moiety. The substitution of phosphates for phosphorothioates leads to an 
increase in size, hydrophobicity and charge distribution. One or all of which may 
participate to produce a response of lower efficacy. Another second messenger, cyclic 
adenosine monophosphate (cyclic AMP) has been substituted with a phosphorothioate 
to produce the only known competitive antagonist, Rp adenosine 3',5'-cyclic- 
monophosphorothioate !4651 and Rp adenosine 3',5'-cyclic-monophosphorodithioate I466] 
of the several hundreds of analogues that have been synthesised. L-c/uVo-Ins(2,3,5)P3 
was also found to be a partial agonist in permeabilised platelets where it released only 
42.3% of the Ca2+-pool that was available to Ins(l,4,5)P3. f4631
Both these compounds have been tested for resistance to 5-phosphatase from HEG 
and 3-kinase from CRBHS. It was found that L-c/uroIns(2,3,5)PS3 was the most 
potent inhibitor of 5-phosphatase with a K{ value of 0.23jiM, and was a potent 
inhibitor of 3-kinase with a K{ value of 0.82p.M. [422] D-6-Deoxy-Ins(l,4,5)PS3 was 
found to be resistant to 3-kinase and 5-phosphatase enzymes with K-x values of 7.9|i.M 
and 1.4|iM respectively.[422]
4.9.3 D-3-Amino-3-deoxy Ins(l,4,5)P3 and scy//o-Ins(l,2,4,5)PS4
D-3-Amino-3-deoxy-myo-inositol 1,4,5-trisphosphate (269), D-3-amino-3-deoxy- 
Ins(l,4,5)P3 was prepared by Kozikowski and coworkers, [4671 and scyllo-inositol
1,2,4,5-tetrakisphosphorothioate (270), scyllo-Ins(l,2,4,5)PS4, was prepared by 
D. Lampe (Ph.D thesis 1993). I413l
D-3-Amino-3-deoxy-Ins(l,4,5)P3 was prepared from D-3-azido-3-deoxy-myo-inositol. 
Briefly, D-3-azido-3-deoxy-myo-inositol was treated in the same way as for D-3-deoxy- 
3-fluoro-myo-inositol in order to obtain the totally protected phosphorylated d - 3 -
137
azido-3-deoxy-myo-inositol derivative. Hydrogenation over palladium on carbon 
under acidic conditions removed all the protective groups and reduced the D-3-azido 
group to give the D-3-amino-3-deoxy-Ins(l,4,5)P3 (269). scyllo-lns( 1,2,4,5)PS4 was 
prepared from the meso-compound 1,4-di-O-benzyl-^cyZ/o-inositol [the same 
intermediate that was used to prepare scyllo-Ins(l,2,4,5)P4]. Phosphitylation of the 
four hydroxyl groups using bis(benzyloxy)disopropylaminophosphine followed by 
sulphoxidation (sulphur in pyridine) gave the totally protected 
tetrakisphosphorothioate. Deprotection using sodium in liquid ammonia provided 
scyllo-Ins(l,2,4,5)PS4 in 18% yield.
D-3-Amino-3-deoxy-myo-inositol 1,4,5-trisphosphate mobilised Ca2+ from saponin- 
permeabilised SH-SY5Y neuroblastoma cells. The experiments were carried out at 
three different pH values, 6.8, 7.2 and 7.6. It was found that the EC50 values varied 
both with Ins(l,4,5)P3 and D-3-amino-3-deoxy-Ins(l,4,5)P3. However, at pH 6.8 the 
EC50 value for Ins(l,4,5)P3 was 255nM but the EC50 value for D-3-amino-3-deoxy- 
Ins(l,4,5)P3 was 3676nM and D-3-amino-3-deoxy-Ins(l,4,5)P3 released only 80% of 
the possible Ins(l,4,5)P3-sensitive Ca2+ pool. At pH 7.2 and 7.6 the analogue was a 
full agonist with EC50 values of 1070nM and 149InM respectively. In addition the 
analogue was able to fully displace [3H]Ins(l,4,5)P3 from binding sites on rat 
cerebellum membranes at pH 6.8 and 7.6 indicating that the analogue fully interacted 
with the Ins(l,4,5)P3 receptor. No data on the interaction of this analogue with the 
enzymes 3-kinase or 5-phosphatase have been published.
scyllo-Ins(l,2,4,5)PS4 was also demonstrated to be a partial agonist in saponin 
permeabilised SH-SY5Y neuroblastoma cells. scyllo-Jns( 1,2,4,5)PS4 was able to 
mobilise 80% of the Ca2+ from the Ins(l,4,5)P3-sensitive Ca2+ pool with an EC50 value 
of 1.6|iM.[414] scyllo-lns( 1,2,4,5)PS4 displaced [3H]Ins(l,4,5)P3 from binding sites on 
bovine adrenal cortex membranes with an IC50 value of 424.6nM. The compound can 
only bind in one orientation because it is symmetrical, and the phosphorothioate 
substitution is critical for partial agonism because scyllo-lns( 1,2,4,5)P4 was a full
D-3-amino-Ins(l,4,5)P3 (269) scyllo-lns( 1,2,4,5)PS4 (270)
Figure 69
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agonist at the same Ins(l,4,5)P3 receptor. jcy//o-Ins(l,2,4,5)PS4 was also found to be 
a potent inhibitor of 5-phosphatase from HEG with a K{ value of 0.3jiM and of 3- 
kinase from CRBHS with a K{ value of 56.7|iM.
4.9.4 The Ins(l,4,5)P3 Receptor Antagonists Heparin and Decavanadate
COjH







Figure7 0  -glucosaminyl -a -1-unit
Heparin (Figure 70) is a heteroglycan, containing alternating sulphated units of 
glucuronic acid and glucosamine in a straight chain of 30-70 glycose units. Heparin is 
highly acidic due to the sulphate groups and a powerful anticoagulant. Heparin was 
the first antagonist at the Ins(l,4,5)P3 receptor to be recognised, binding with with 
reasonable potency resulting in the inhibition of Ca2+-mobilisation from several 
systems, including bovine adrenal cortex with an IC50 value of lOjig/ml I456l and 
4.5|ig/ml in rat liver microsomes. l456l Heparin has been used to purify the 
Ins(l,4,5)P3 receptor using heparin-agarose affinity chromatography which has been 
discussed in section 2.6.1. It is easy to speculate that the charged sulphate groups of 
heparin may interact with the Ins(l,4,5)P3 receptor which is normally responsible for 
for binding phosphate groups, since N-desulphation of heparin decreased the 
antagonistic activity. t468l
Another molecule that was found to be a competitative antagonist, was decavanadate, 
which inhibited Ca2+-release from intracellular stores with a K{ value of 1.2pM. t469J 
The molecule is anionic with low specificity, and was able to bind to both the 
Ins(l,4,5)P3 and Ins(l,3,4,5)P4 recognition sites. Orthovanadate was not a
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competititive antagonist but tetravanadate has been reported to inhibit phospholipase 
C. I47°l
Table 6 provides a summary of modifications to Ins(l,4,5)P3 both at the phosphate 
and hydroxyl functions with respect to the Ins(l,4,5)P3 receptor-ligand interaction and












Large substituents allowed 
without loss of activity. 
Deletion decreases activity.
Bulky groups are tolerated. 
Hydroxyl group deletion and 
inversion also tolerated, 
together with fluoro- and 
phosphorylated derivatives.
Deoxy-, fluoro- and amino- 
groups bind to the receptor. 
Inversion to give chiro- 
derivative also recognised, but 
hydrophobic substituents 
larger than OMe fail to 
mobilise calcium.
No 4-modified compounds 
have been made.
4,5-Bisphosphate is essential 
for recognition. Ins(l,5)P2 and 
Ins(l,4)P2 do not bind to 
receptor.
Removal of the hydroxyl 
reduces affinity 70-fold. 
Methylation reduces the 
affinity even further.
3-Kinase Interaction
1-Phosphate is important 
however not essential. 
Ins(4,5)P2 is a weak 
substrate.
The axial hydroxyl is 
important for recognition, 
although 2-deoxy 
Ins(l,4,5)P3 is a substrate. 
Inversion of the hydroxyl 
group reduces affinity 5- 
fold. Phosphorylation —> 
Ins(l,2,4,5)P4 removes 
recognition.
Deoxy-, fluoro- and chiro- 
derivatives are potent 
inhibitors of 3-kinase.
No 4-modified compounds 
have been made. 
Ins(l,4,5)P3-5S is slowly 
phosphorylated by enzyme.
6-Deoxy-Ins(l,4,5)P3 is a 






is a weak substrate.
2-Deoxy-Ins( 1,4,5)P3 
is a good substrate. 
However, substitution 
with a phosphate gives 
a good inhibitor.
Deoxy- and fluoro- 
Ins(l,4,5)P3 are good 
substrates, chiro- 
Ins(2,3,5)P3 is a potent 
inhibitor.
No 4-modified analo - 
gues have been made. 











5.1 Aims of the Project
The biology of myoinositol phosphates has developed immensely over the last decade. 
Since the first critical paper which was published in 1983, there have been 
approximately 500 biological publications per annum from 1987 to the present. 
However, the number of chemical papers lags behind because of the initial problems 
encountered with the synthesis of myoinositol phosphates which did not commence 
until 1987. Thus, there is a need to produce analogues which will disrupt the enzymes 
3-kinase and 5-phosphatase and synthesise a full antagonist which will be used to 
investigate the structure-fimction requirements of the Ins(l,4,5)P3 receptor.
In the work described in this thesis, fourteen myoinositol phosphate analogues were 
prepared and fully characterised, thirteen of which were based on myoinositol and one 
based on the planar benzene ring with phosphates arranged in a pseudo 1,4,5- 
trisphosphate orientation.
The first target compounds to be synthesised were DL-3,6-di-0-benzoyl Ins(l,2,4,5)P4 
(276) and DL-Ins(l,2,4,5)P4, (152) which were initially made in racemic form. The latter 
compound was then resolved from a suitable intermediate in order to provide d -  and l -  
enantiomers of Ins(l,2,4,5)P4, once the biological data for the racemic mixture had been 
evaluated. D-Ins(l,2,4,5)PS4 was also synthesised, in order to investigate if it had 
properties similar to those of scyllo-lns( 1,2,4,5)PS4, which is a partial agonist at the 
Ins(l,4,5)P3 receptor which was discussed in section 4.9.3.
Methylation of the hydroxyl groups at the 2- and 5-positions of Ins(l,3,4,6)P4 indicated 
that these positions were important for binding at the Ins(l,4,5)P3 receptor because the 
resulting compound did not interact with the receptor. The corresponding 2,5-di-0- 
methyl Ins(l,3,4,6)PS4 analogue was also prepared in order to investigate its interaction 
with the enzymes 3-kinase and 5-phosphatase. The phosphorothioate analogue 
Ins(l,3,4,6)PS4 was prepared to see if it was a partial agonist like Ins(l,3,4,6)P4, in SH- 
SY5Y human neuroblastoma cells.
The structure of Ins(l,3,4,6)P4 was then dissected to give two compounds, in order to 
investigate which part of the molecule provided the partial agonist effect present in SH- 
SY5Y human neuroblastoma cells. The two analogues D-Ins(l,4,6)P3 and L-Ins(l,3,4)P3 
have the Ins(l,4,5)P3 motif, but the orientations of certain hydroxyl groups were
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different (this was discussed in section 4.4.5). Only one molecule was synthesised by 
the author, namely Ins(l,4,6)P3. First, DL-Ins(l,4,6)P3 was made in order to investigate 
its Ca2+-releasing properties together with its phosphorothioate counterpart. A route 
was then undertaken in order to prepare both the d -  and L-enantiomers of Ins(l,4,6)P3 
together with D-Ins(l,4,6)PS3, because DL-Ins(l,4,6)PS3 was found to be a partial agonist 
with low efficacy in rabbit platelets.
Finally, the analogue based on the benzene ring, benzene 1,2,4-trisphosphate (360), was 
synthesised as a potential inhibitor of 5-phosphatase and 3-kinase. Later it was also 
tested on the p85 monoclonal antibody of immunoprecipitated Ptdlns 3-kinase and was 
the first Ins(l,4,5)P3-like molecule to inhibit this enzyme.































DL-3,6-Di-0-benzoyl-Ins( 1,2,4,5)P4 (276) DL-Ins(l,2,4,5)P4 (152)
Figure 71
The aim of preparing DL-3,6-di-0-benzoyl Ins(l,2,4,5)P4 (276) and DL-Ins(l,2,4,5)P4 
(152) (Figure 71) was first, to establish the effect of a phosphate group at the 2-position
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and second, to investigate the effect of blocking the 3- and 6- hydroxyl groups on Ca2+- 
release, and establish what effect these compounds have on the Ins(l,4,5)P3 
metabolising enzymes, 3-kinase and 5-phosphatase.
d l -  1,4-Di-O-benzoyl-myo-inositol (272) was the phosphorylation precursor which was 
used to synthesise (276) and (152). This tetrol was synthesised in a three step two pot 
reaction. Thus, DL-3,6-di-0-benzoyl-1,2:4,5-di-0-isopropylidene-myoinositol (36) was 
prepared in 30% yield using the method developed by Gigg and coworkers, in the 
following way. I344! A mixture of myo-inositol (21), 2,2-dimethoxypropane and a 
catalytic amount of toluene-p-sulphonic acid was stirred in DMF at 100°C for 2h. The 
mixture was cooled to 0°C and pyridine was added to the mixture followed by benzoyl 
chloride. Stirring was continued for a further 2h and the resulting thick yellow-brown 
soup was filtered into a sinter funnel. The mixture was then washed with pyridine to 
remove any unreacted benzoyl chloride and water to dissolve the pyridinium 
hydrochloride. The remaining solid was then washed with acetone to remove water and 
contaminating organic material, and finally ether to give a compact white powder. The 
crude compound was insoluble in the washing solvents and pure enough for the 
synthesis of d l -  1,2:4,5-di-0-isopropylidene-myo-inositol (37), described in section 
5.3.1. However, a small quantity of (36) was recrystallised from hot DMF for the !H 
NMR, melting point and synthesis of the intermediate (272). DL-3,6-Di-0-benzoyl-
I,2:4,5-di-0-isopropylidene-myo-inositol (36) was unusual because it was highly 
insoluble in organic solvents at room temperature. The JH NMR spectrum was poorly 
resolved in d6-DMSO, but surprisingly a small quantity (~ 5mg) was soluble in 0.5ml of 
CDC13. The melting point for compound (36) was 328-330°C, and unusually high for a 
myo-inositol derivative. The !H NMR spectrum for compound (36) showed downfield 
shifts [in comparison to (37)] for C-6-H and C-3-H at 5 = 5.61 (dd, J = 6.78 and
II.17Hz) and 8 = 5.43 (dd, J = 4.21 and 10.63Hz), respectively, due to carbonyl 
deshielding from the benzoyl group.
The washings provided several other compounds, including DL-3,4-di-0-benzoyl- 
1,2:5,6-di-O-isopropy lidene-myo-inositol and DL-3,4,5,6-tetra-0-benzoyl-1, 2 - 0 -
isopropylidene-myo-inositol. Recently, these were separated in the following manner. 
[47i] x h e  combined filtrate and washings were partitioned between water and 
dichloromethane, the organic layer was separated and concentrated in  v a c u o .  The 
solubility of d l - 3  ,4-di- O-benzoyl-1,2:5,6-di-O-isopropylidene-myo-inositol in methanol 
was much higher than d l - 3  ,4,5,6-tetra-O-benzoyl-1,2-O-isopropylidene-myo-inositol. 
Thus, the mixture was washed with methanol and the two compounds were then 
isolated in 28% and 13% yield respectively.
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The relatively insoluble dl- 3 ,6-di-O-benzoyl-l,2:4,5-di-Oisopropylidene-myo-inositol 
(36) was suspended in 80% acetic acid and heated under reflux for 30min, after which 
time a clear solution was seen. The mixture was cooled, and poured into an ice-water 
mixture to cause precipitation. The solid was filtered off and washed thoroughly with 
ether to give DL-l,4-di-0-benzoyl-myo-inositol (272). Compound (272) was insoluble 
in all protic solvents, including hot ethanol and methanol. However, precipitation from 
DMF-water provided the pure tetrol in 93% yield which had a melting point of 253°C. 
The !H NMR in d6-DMSO indicated that the 1- and 4-positions were protected and at 
positions 2-, 3-, 5- and 6-, the ring hydrogens coupled to their respective hydroxyl 
groups. This tetrol was also synthesised by Meek and coworkers, f393l but full 
experimental details were not given.
I
141.8ppml41.3ppm 140.4ppm 139.8ppm
^ ----------  76.90Hz__________►
Figure 72
The cheap commercially available P(III) reagent diethoxychlorophosphine (273), (8p = 
+167ppm), was used to phosphitylate DL-l,4-di-0-benzoyl-myo-inositol (272). The 
tetrol was dissolved in a mixture of dry DMF and dry 7V,Af-diisopropylethylamine and 
stirred under nitrogen. The mixture was cooled to 0°C and diethoxychlorophosphine
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was added slowly over a 5min period and stirred for lh  at room temperature. At this 
stage, the 31P NMR spectrum of (274) operating at 36.2MHz with a sweep width of 
2500KHz, showed eight peaks resulting from two 5JPP AB coupling systems centered 
around 8 = +141.8 and +141.3ppm (for the 4,5-positions) and +140.4 and 139.8ppm (for 
the 1,2-positions) for each doublet of the AB coupling pattern. This AB spectrum is 
shown in Figure 72 which demonstrated phosphitylation of a pair of vicinal diols at the
I,2-positions, where 5JPP = 1.83Hz and 5JPP = 3.66Hz for the 4,5-positions.
Oxidation of the 1,2,4,5-tetrakisphosphite with r-butylhydroperoxide provided DL-3,6-di- 
O-benzoyl-1,2,4,5-tetrakis(diethoxyphospho)-my<9-inositol (275) and destroyed the two 
AB patterns shifting the phosphate signals upfield to -1.53, -2.11, -2.18 and -2.49ppm in 
the 31P-1H-decoupled spectrum. Surprisingly the tetrakisphosphate was isolated as a 
crystalline solid, m.p. 122-123°C (from ethyl acetate-hexane).
The 400MHz !H NMR spectrum of crystalline (275) resolved the myoinositol ring 
hydrogens which overlapped at 270 MHz. The triplet at 8 = 5.90 was identified as C-6- 
H whilst the two triple doublets at 5 = 5.29 (J = 2.13, 10.07Hz) and 8 = 5.25 (J = 2.44, 
9.16Hz) were C-2-H and C-3-H. Two quartets, at 8 = 5.15 and 8 = 4.79 represent 
C-4-H and C-l-H, C-5-H respectively, and indicated that these positions were 
phosphorylated.
The eight ethyl groups of (275) were removed by a simple transetherification reaction. 
The tetrakisphosphate was dissolved in dry dichloromethane and bromotrimethylsilane 
was added dropwise under nitrogen and stirred at room temperature overnight. The 
trimethylsilyl moieties replaced the ethyl functions to give bromoethane as a by-product. 
The transesterification reaction was quantitative by 31P NMR for the deprotection of the 
octaethylphosphate because the four peaks at -1.53, -2.11, -2.18 and -2.49ppm 
disappeared and four new signals appeared at -12.4, -13.2, -15.1 and -17.3ppm, which 
indicated an upfield shift due to the trimethylsilyl groups attached to the phosphate. The 
eight silicon protective groups were then hydrolysed quantitatively by the addition of 
water to give DL-3,6-di-0-benzoyl Ins(l,2,4,5)P4 (276) (Figure 71). A small sample was 
purified by ion exchange chromatography using a gradient of TEAB on Q-Sepharose 
Fast Row to give the pure compound (276) in 81% yield. The four phosphorus signals 
had moved downfield to -0.22 (d, J = 9.76Hz), -0.39 (d, J = 10.68Hz), -0.49 (d, J =
I I.9Hz) and -0.79 (d, J = 8.83Hz).
DL-Ins(l,2,4,5)P4 (152) was prepared by hydrolysis of the two benzoate esters of 
compound (276) with 1M aqueous sodium hydroxide at 60°C for lh. An elevated
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temperature was used because the ester groups appeared to be resistant to basic 
hydrolysis at room temperature. After lh the pH was adjusted to ~ 6 with Dowex (H+ 
form) which was then filtered off and the benzoic acid was removed by washing the 
aqueous solution with dichloromethane. Pure DL-Ins(l,2,4,5)P4 (152) was obtained after 
ion exchange chromatography, which eluted at ca. 550mM TEAB buffer.
PPM
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Figure 73
The 31P NMR (Figure 73) shows four singlets in the 3 1H-decoupled spectrum and 
four doublets for the 31P NMR •H-coupled spectrum, +1.31 (d, J = 8.00Hz), +1.15 (d, J 
= 7.90Hz), +1.04 (d, J = 9.9Hz) and -0.04 (d, J = 6.0Hz). In the ‘H NMR spectrum,
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C-2-H was obscured by the HDO peak at 8 = 4.80, C-4-H was a quartet at 8 = 4.29 (J = 
9.16Hz) but C-l-H and C-5-H overlapped at 8 = 3.97-4.04 and both were 
phosphorylated. Positions C-3-H and C-6-H were not phosphorylated and were 
observed as a doublet, (J = 10.07Hz) and a triplet, (J = 9.46Hz) respectively.
5.2.1 Pharmacology
DL-3,6-Di-0-benzoyl Ins(l,2,4,5)P4 (276) and DL-Ins(l,2,4,5)P4 (152) have been 
examined for their ability to displace [3H]Ins(i,4,5)P3 from membranes prepared from 
bovine adrenal cortexes. I472l Compound (152) (Figure 74) displaced [3H]Ins(l,4,5)P3 
(15-30Ci/mM, NEN), with a value of 26.4nM ±1.8 whereas compound (276) did not 
compete (>3fiM). As expected, (276) was devoid of Ca2+-mobilising activity from 
45Ca2+-preloaded SH-SY5Y human neuroblastoma cells permeabilised with saponin 
(>100|iM). However, it was found (by R. A. Wilcox) I472l that (152 in Figure 75) 
released 45Ca2+ potently from intracellular stores with an EC50 value of 165nM, 
compared to an EC50 value of 52nM for Ins(l,4,5)P3.
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Both compounds were tested for their ability to interact with the enzymes 5-phosphatase 
from HEG and 3-kinase from CRBHS. Compound (276) had a low affinity for 3- 
kinase, with a Kx value of 105|iM [cf. Km for Ins(l,4,5)P3 = 1.5p.M], and inhibited the 
dephosphorylation of [3H]Ins(l,4,5)P3 with a K{ value of 15.9|iM [cf. Km for 
Ins(l,4,5)P3 = 31.8p.M]. Compound (152) did not inhibit [3H]Ins(l,4,5)P3 
phosphorylation (>300|iM), but was a potent inhibitor of Ins(l,4,5)P3 5-phosphatase, 
with a Kx value of 2.9fiM, under conditions where IOjiM of Ins(l,4,5)P3 (2.5nM) 
liberated 1.4nmol ± 0.5 of inorganic phosphate monitored colorimetrically as described 
previously. l473l Ins(l,4,5)P3 5-phosphatase did not liberate inorganic phosphate when 
incubated with either compound (10|iM, 2.5nM). However, initial experiments (carried 
out by R. A. Wilcox) f472J monitoring the temporal aspects of Ca2+-release from saponin- 
permeabilised SH-SY5Y neuroblastoma cells with the Ca2+ sensitive dye, Fluo-3 (lfiM) 
indicated the rate of reuptake of Ca2+ was slightly slower than for Ins(l,4,5)P3, 
















These results indicate that introduction of a bulky negatively charged phosphate group 
at the 2-position only slightly decreases Ca2+-release from saponin-permeabilised SH- 
SY5Y neuroblastoma cells. However, the affinity for 5-phosphatase increased like 
other tetrakisphosphates such as Ins(l,3,4,5)P4. However, the affinity decreased for 3- 
kinase in comparison to Ins(l,4,5)P3. The benzoate groups of DL-3,6-di-0-benzoyl 
Ins(l,2,4,5)P4 sterically interact with the enzyme 5-phosphatase, and decreased the 
binding affinity compared to DL-Ins(l,2,4,5)P4 by approximately 6-fold.
5.3 The Synthesis of d- and L-Ins(l,2,4,5)P4 and D-Ins(l,2,4,5)PS4
5.3.1 Synthesis of DL-l,4-Di-0-Benzyl-5,6-Di-0-/7-Methoxybenzyl-wyo-Inositol
The enantiomers of Ins(l,2,4,5)P4 were synthesised by a different route to the racemic 
mixture. The reason for the synthesis of these two compounds was first, to establish 
which isomer was responsible for the inhibition of the enzyme 5-phosphatase and 
second, to discover the true EC50 value for D-Ins(l,2,4,5)P4 in comparison to 
Ins(l,4,5)P3 and scyllo-Ins(l,2,4,5)P4. It is also known that L-Ins(2,4,5)P3 can release 
Ca2+ from intracellular stores (see section 4.4.2) albeit with a low potency (EC50 value 
of llOjiM) and thus it would be interesting to discover if L-Ins(l,2,4,5)P4 made some 
contribution to the Ca2+-releasing properties observed for DL-Ins(l,2,4,5)P4. scyllo- 
Ins(l,2,4,5)PS4, described in section 4.9.3 was a partial agonist at the Ins(l,4,5)P3 
receptor and a single modification to give an axial phosphorothioate group produced d- 
Ins(l,2,4,5)PS4 which may also be a partial agonist.
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The racemic compound, dl- 1,4-di-0-benzyl-5,6-di-0-p-methoxybenzyl-myo-inositol 
(279 in Figure 76) has been synthesised by another group using a different route. [474]
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d l - 3 ,6-Di-O-benzoyl-l,2:4,5-di-0-isopropylidene-my<?-inositol (36) was prepared as 
described in section 5.2. Basic hydrolysis of the two benzoyl groups was followed by 
neutralisation with carbon dioxide and addition of water, which was then evaporated in 
vacuo to give the crude product, d l -  1,2:4,5-Di-0-isopropylidene-myo-inositol (37) was 
extracted from the mixture with dichloromethane. It was found that if the crude solid 
contained moisture at this stage, a poor yield was obtained, and the extracted diol (37) 
was contaminated with benzoic acid. The crude mixture was then recrystallised from 
ethyl acetate to give the pure diol (37). Benzylation of this intermediate with benzyl 
bromide and sodium hydride in DMF gave the highly crystalline DL-3,6-di-0-benzyl- 
l,2:4,5-di-0-isopropylidene-myo-inositol (106). The less stable trans acetal was 
removed selectively in 80% yield using a catalytic amount of toluene-p-sulphonic acid 
and ethane 1,2-diol (one equivalent) in dichloromethane at room temperature. The 
reaction was quenched with triethylamine at the instant the solution became cloudy due 
to the formation of d l -  1,4-di-O-benzyl-myo-inositol. The mixture was worked up and 
purified by flash chromatography to provide d l -  1,4-di-0-benzyl-2,3-O-isopropylidene- 
myoinositol (277) in 80% yield and was the first stage in the route where 
chromatography was employed. This compound has also been prepared by Gigg and 
coworkers under different acidic conditions in 55% yield from compound (106). A 
second, more efficient method for making this compound, required the synthesis of d l -
1,2-0-isopropylidene-myo-inositol prepared from myoinositol, 2,2-dimethoxypropane a 
catalytic amount of toluene-p-sulphonic acid in DMSO at 90°C, in 79% yield, d l - 1 ,2 -  
O-Isopropylidene-myoinositol was then treated with two equivalents of dibutyltin 
oxide, tetrabutylammonium bromide in acetonitrile at reflux temperature. Work up and 
flash chromatography gave compound (277) in 62% yield. I475]
The hydroxyl groups at the 4- and 5-positions were alkylated with p-methoxybenzyl 
chloride in DMF with sodium hydride as base. Work up and purification by flash 
chromatography provided the pure compound (278) as a syrup. The !H NMR spectrum 
showed two singlets at 8 = 3.77 and 3.79ppm for the -OMe group of the p- 
methoxybenzyl moieties. The cis 1,2-O-isopropylidene group was removed by careful 
acid treatment with 1M aqueous HC1 in methanol (1:9) at 50°C for 30min, after which 
the p-methoxybenzyl groups were intact and the acetal had been removed to give 
compound (279). Caution must be taken at this stage, because prolonged treatment of a 
compound containing a p-methoxybenzyl function with acid will result in its hydrolysis. 
With the presence of a cis 1,2-diol in compound (279) it was envisaged that introduction 
of a chiral acid at the equatorial 1-position would result in the formation of two 
diastereoisomers which may be separated by selective crystallisation or 
chromatography.
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5.3.2 Optical Resolution of DL-l,4-Di-0-Benzyl-5,6-0-/?-Methoxybenzyl-myo 
Inositol
(1S')-(+)-0-Acetylmandelic acid (280) was chosen for resolution of the cis 1,2-diol 
because it is relatively cheap (£23.70 for 5g) and is 99% pure by GLC (Aldrich 
1994/95). Unlike the enantiomers of camphanic acid chloride (discussed in section 3.7) 
both (R)- and (5)-enantiomers are available at a similar price.
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(5')-(+)-0-Acetylmandelic acid has not been widely used for the resolution of myo­
inositol derivatives, so we took the opportunity to investigate its potential as a resolving 
agent. The resolutions in this thesis were successful, and the two diastereoisomers 
resulting from each racemic mixture were easily separated by flash chromatography.
The treatment of DL-l,4-di-0-benzyl-5,6-0-p-methoxybenzyl-myo-inositol (279) with 
(5)-(+)-0-acetylmandelic acid (280) (1.03 equivalents) in the presence of DMAP and
1,3-dicyclohexylcarbodiimide (DCC) at -20°C afforded two diastereoisomers (281) and 
(282) in 36% and 37% yield respectively (Figure 77). By keeping the temperature at -20 
°C with dry ice, there was no acylation by NMR of the 2-position, thus selectivity was 
achieved and work up was easy. The simplicity of the resolution lies in the ease with 
which the two diastereoisomers were separated by flash chromatography. The two 
diastereoisomers (281) and (282) had Rf values of 0.44 and 0.34 respectively 
(chloroform-acetone, 30:1). Both diastereoisomers were obtained as crystalline solids 
m.p. (281): 120-121°C and (282): 147-148°C and both had positive rotations [a]D = 
+12° and [a]D = +42° for (281) and (282) respectively.
The hydrogen at position one (shifted downfield due to esterification at the 1-hydroxyl 
position) could not be identified in either diastereoisomer (Figure 78) because the 
methylene AB coupling pattern of the benzyl group overlapped with the dd for C-l-H. 
However, C-2-H was identified as a broad doublet at 8 = 4.15 (J = 1.83Hz) for 
compound (281) and at 5 = 4.40 for compound (282) as a broad doublet (J = 1.83Hz). 
The C-2-OH signal was also significant because it was seen at 8 = 2.16 for compound
(281) and at 8 = 2.69 for (282) which indicated that the hydrogen and hydroxyl groups 
at C-2 were more deshielded than for the less polar diastereoisomer (281). The unique 
singlet at 8 = 5.94 for (281) and at 8 = 5.98 for (282) of CH3C 0 2Ctf(Ph)C02- is 
indicative of the high purity of the diastereoisomers.
Base catalysed deacylation of the two diastereoisomers gave pure enantiomers (283) and
(284) where [a]D = -25° and +25° respectively. Melting points were only slightly 
higher than for the racemic mixture, (m.p. 133-134°C for both enantiomers). The two 
chiral 1,2,4,5-tetrols were prepared by acid hydrolysis of the of the p-methoxybenzyl 
ethers in 1M HCl-ethanol (1:2) at reflux temperature for 4h. Deprotection of the p- 
methoxybenzyl groups with DDQ or CAN would have caused problems because the 
product is very polar and insoluble in solvents such as dichloromethane or ethyl acetate, 
thus work up and extraction of the product would have been difficult. After 4h the 
mixture was cooled and the solvents were evaporated in vacuo. The resulting solid was 
filtered and recrystallised from ethanol to give the pure enantiomers d-(285) and l-3,6-
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di-O-benzyl-myo-inositol (286) which had specific rotations of +16° and -16° 
respectively. The melting point of the racemic mixture (lit. f3441 205-207°C) was much 





The >H NMR spectrum of compound (285) in d6-DMSO is shown in Figure 79. The 
expansions below the full spectrum show the myo-inositol ring hydrogens, four of which 
are coupling to their respective hydroxyl groups, and two which are protected at 
positions 3- and 6-. Following D20  exchange, four of the ring hydrogen signals 
collapsed to give a triplet at 5 = 3.97 (C-2-H), a triplet at 8 = 3.58 (C-4-H), a dd at (8 = 
3.31) C-3-H, and a triplet at 8 = 3.13 (C-5-H). This tetrol was the precursor for the 
synthesis of D-Ins(l,2,4,5)P4 and the enantiomer from the more polar diastereoisomer
(282), l- 3 ,6-di-O-benzyl-myo-inositol (286), was the precursor of L-Ins(l,2,4,5)P4.
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5.3.3 Preparation of Bis(benzyloxy)diisopropylaminophosphine
The phosphitylating reagent for the synthesis of most of the myo-inositol phosphates and 
phosphorothioates was bis(benzyloxy)diisopropylaminophosphine (96 in Figure 80). 
Af,N-Diisopropylaminodichlorophosphine (289) was prepared by Tanaka and coworkers 
[476] by careful addition of two equivalents of N,iV-diisopropylamine (288), dropwise, to 
an ethereal solution of phosphorus trichloride (287) at -78°C. The product was isolated 
by filtering the hydrochloride salt under nitrogen, which was then washed with more dry 
ether and evaporated to give a viscous moisture-sensitive syrup. The product was 
purified by distillation under reduced pressure (8p = +169.4ppm) and was stored as a 
crystalline solid at -20°C.
PClj + 
(287)
NH N - P C t
(288) (289)
.OBn




Benzyl alcohol (2 equivalents) was then added to a solution of 7/,//-diisopropyl 
aminodichlorophosphine in the presence of triethylamine and dichloromethane at -78°C 
and stirred for a further 2h at room temperature. The best result was obtained when 
more dichloromethane was added to the mixture so the reaction went to completion and 
an excess of benzyl alcohol was not present which would cause problems with the 
phosphitylation procedure. The product was then isolated by filtering the 
triethylammonium chloride salt, and the dichloromethane layer was washed with a 
saturated aqueous solution of sodium hydrogen carbonate. The organic layer was then 
dried over magnesium sulphate, filtered and evaporated to give a thick syrup in 96% 
yield Rf = 0.78, (hexane-triethylamine, 10:1). Purification by chromatography was not 
necessary, because the !H NMR spectrum showed a clean sample without 
contamination from benzyl alcohol or triethylamine and the 3*P-lH-decoupled NMR 
spectrum showed a single peak at 5p = +147.86ppm. The purity of the reagent (96) was 
evident from the phosphitylation procedure.
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D-Ins(l,2,4,5)P4 X = 0(295) 
D-Ins(l,2,4,5)PS4 X = S (298)
L-Ins(l,2,4,5)P4 (296)
Figure 81
Phosphitylation of two pairs of vicinal diols (an axial-equatorial pair and an equatorial- 
equatorial pair) would be very difficult with some P(V) reagents due to their low 
reactivity and formation of undesirable cyclic phosphates. The most efficient method 
for introducing phosphates and phosphorothioates into the myoinositol ring was to stir a
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mixture of phosphitylating reagent (96) (2 equivalents per hydroxyl) and l//-tetrazole (4 
equivalents per hydroxyl) in dry dichloromethane to form the tetrazolide intermediate 
(290 in Figure 81). The 31P NMR at this stage showed a single peak at 8 = +126.73ppm 
for (290) and no signal at 8 = +147.86ppm for the phosphitylating reagent. Any 
moisture present in the solvent would be indicated by the presence of 77-phosphonate at 
8 = +7.54ppm. For a successful phosphitylation procedure very little phosphonate 
should be present.
The procedure was carried out for both enantiomers in the same way. Thus, in separate 
experiments the enantiomers of 3,6-di-O-benzy 1-myo-inositol (285,286) were added to 
the tetrazolide (290) in dichloromethane and stirred for a further 5min at room 
temperature. The 31P NMR spectrum again showed eight peaks and the distinctive five 
bond phosphorus-phosphorus spin-spin coupling systems for (291,292) (5Jj 2 = 1.83Hz; 
5J45 = 3.66Hz) and is shown in Figure 72. Oxidation of the tetrakisphosphite 
intermediate with /wCPBA at 0°C destroyed the two AB coupling patterns and provided 
the fully protected d-(293) and L-3,6-di-0-benzyl-l,2,4,5-tetrakis(dibenzyloxyphospho)- 
wyo-inositol (294) in 94% and 88% yields respectively, after work up and purification 
by flash chromatography. The chosen solvent systems were important because 
chloroform-acetone (5:1) removed the phosphonate impurities and the pure enantiomers 
were eluted with ethyl acetate-pentane (2:1). The use of mCPBA superseded t- 
butylhydroperoxide because of lower yields resulting from the formation of other by­
products present on the baseline. The problem of low yields and other by-products has 
been highlighted by Yu and Fraser-Reid. f375l The specific rotations for (293) and (294) 
were [a]D = -3.5° (c = 2 in CH2C12) and [a]D = +3.3° (c = 1.26 in CH2C12) respectively.
A deprotection strategy was employed to remove all the benzyl groups in one step with 
freshly cut sodium in distilled liquid ammonia and in the absence of a protic solvent. 
Under these conditions, the solution of sodium in liquid ammonia remained a deep blue 
colour due to electron solvation of the sodium. Dioxan was used to dissolve the 
compound because at -33°C it solidified, thus fixing the compound and holding it in 
solution. Unsatisfactory results have been obtained using THF as the solvent. The 
chemical reduction was complete within 2min, after which methanol was added to 
quench the reaction. The ammonia was evaporated under a stream of nitrogen and the 
crude mixture was dissolved in water. As a result of a clean deprotection there was a 
distinctive smell of 1,2-diphenylethane, generated as a by-product and which has a 
woody odour.
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Purification of crude D-Ins(l,2,4,5)P4 (295) and L-Ins(l,2,4,5)P4 (296) was carried out by 
ion exchange chromatography on Q-Sepharose Fast How. Both compounds eluted at 
ca. 700 mM TEAB buffer and were isolated in 40% and 22% yields respectively. The 
proton and phosphorus NMR spectra for L-Ins(l,2,4,5)P4 are given in Figure 82. The 
31P NMR spectrum showed four distinct signals at 5 = +1.78 (d, J 10.1Hz), 5 = +1.44 (d, 
J 6.7Hz), 8 = +1.20 (d, J 6.7Hz) and 8 = +0.67 (d, J 6.7Hz). The »H NMR showed five 
peaks accounting for six protons, 8 = 4.71 (1H, d, obscured by HDO peak) for C-2-H, 8 
= 4.30 (1H, q, J 9.52Hz) for C-4-H, 4.03 (2H, q, J 9.34Hz) for C-l-H and C-5-H, 3.90 
(1H, t, J 9.53Hz) and 3.72 (1H, d, J 9.71 Hz), the extra peak at 8 = 3.66 is probably an 
amine impurity from the triethylamine. The specific rotations using TEAB as a solvent 
were [oc]D = -27.2° for (295) and [a]D = +25.8° for (296).
SJM98.31Pdec.
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Figure 82
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D-rayo-Inositol 1,2,4,5-tetrakisphosphorothioate (298) was prepared via the 
tetrakisphosphite which was oxidised with sulphur to give the tetrakisphosphorothioate. 
The usual method for sulphoxidation contained a mixture of an excess of sulphur 
suspended in pyridine with the phosphite. The reaction is usually stirred overnight, 
followed by work up and chromatography. At this stage, the excess sulphur is difficult 
to remove completely. However, a fast sulphoxidation procedure (within 5min) was 
developed which provides clean fully blocked phosphorothioate compounds without 
such contamination with sulphur. At the tetrakisphosphite stage, the dichloromethane 
was evaporated to give a thick syrup. A mixture of dry DMF (2ml) and dry pyridine 
(lml) was added together with sulphur (2 equivalents per phosphite). Sulphoxidation 
was complete within 5min, the excess sulphur was removed by filtration through cotton 
wool in a Pasteur pipette and the solvents were evaporated in vacuo at room 
temperature. Caution must be taken at this stage, because desulphurisation occurred 
when evaporation of the solvent was carried out at 70°C to give the symmetrical 
tetrabenzyl thiopyrophosphate at (8 = +56ppm), but no problem was encountered if 
evaporation was carried out at room temperature. The resulting syrup was diluted with 
ethyl acetate, washed with brine, dried and purified by flash chromatography (ether- 
pentane, 1:2) to give the fully blocked d - 3 ,  6-di-0-benzyl-1,2,4,5- 
tetrakis[di(benzyloxyphosphorothio)]-myoinositol (297) as a clean syrup, having a 
specific rotation of -5.3° (c = 1.9 in CH2C12). Deprotection of (297) with sodium in 
liquid ammonia and final purification by ion exchange chromatography on Q-Sepharose 
Fast Flow eluted at ca. 700mM TEAB to provide D-Ins(l,2,4,5)PS4 in 33.2% yield. The 
specific rotation was similar to that of D-Ins(l,2,4,5)P4 where [a]D = -25.8° (c = 0.31 in 
TEAB, at pH = 8.6). The !H NMR of D-Ins(l,2,4,5)PS4 showed five peaks similar to 
that of D-Ins(l,2,4,5)P4 where 5 = 4.83 (1H, d, J 9.46Hz) for C-2-H, 8 = 4.46 (1H, q, J 
11.92Hz) for C-4-H, 4.18 (2H, q, J 9.77Hz) for C-l-H and C-5-H, 3.86 (1H, t, J 9.46Hz) 
and 3.61 (1H, d, J 9.71Hz). The 31P NMR showed four signals at 8 = 51.47 (d, J 
12.18Hz), 8 = 50.64 (d, J 10.26Hz), 8 = 50.20 (d, J 11.54Hz) and 8 = 49.14 (d, J 
11.54Hz). The coupling constants for phosphorothioates coupling to a ring proton are 
usually larger than for the phosphate counterparts. The tetrakisphosphates and 
tetrakisphosphorothioate also gave satisfactory accurate -ve FAB spectra.
5.3.5 Pharmacology
At present these analogues have not been pharmacologically evaluated in terms of 
recognition by the Ins(l,4,5)P3 receptor and the interaction with the enzymes 3-kinase 
and 5-phosphatase.
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A simple way to establish the absolute configuration of D-3,6-di-0-benzyl-myo-inositol 
would be to resolve d l -  1 ,2:4,5-di-0-isopropylidene-my<?-inositol followed by 
benzylation and acidic hydrolysis of the isopropylidene groups to give the individual 
enantiomers. The resolution of d l -  1 ,2:4,5-di-0-isopropylidene-ray<9-inositol has been
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previously accomplished using (S)-(-)-co-camphanic acid chloride as the chiral auxiliary. 
In this resolution, the 3-position was blocked using f-butyldiphenylsilyl chloride and the 
6-position was acylated with the chiral auxiliary and separation was carried out by 
tedious HPLC. Thus, a simple resolution to provide the chiral diol would be 
appropriate, because single X-ray crystal analysis of the 6-0-camphanate has been 
determined, and derived from this, the specific rotation, [a]D = +22° and melting point 
(159-161°C) for L-l,2:4,5-di-0-isopropylidene-myo-inositol has been established. I477! 
Moreover, in a recent article, in which D-l,2:4,5-di-0-isopropylidene-ray<?-inositol was 
synthesised from D-mannitol, the melting point was found to be 176-177°C with [a]D = 
-21.7°. t478] Thus, the specific rotation is in agreement for both enantiomers, but there 
appears to be some discrepancy over the melting point.
The isolation of the pure enantiomer d -  1,2:4,5-di-0-isopropylidene-myo-inositol (301) 
was carried out in the following manner and is outlined in Figure 83. d l - 1,2:4,5-Di-O- 
isopropylidene-myo-inositol (37), DCC and a catalytic amount of DMAP were stirred in 
dry dichloromethane at 0°C. (5)-(+)-0-Acetylmandelic acid (280) (1.25 equivalents per 
hydroxyl) in dichloromethane was added dropwise and the mixture was stirred at room 
temperature for a further 24h. The mixture was filtered through celite to remove the 
DCU and it was found TLC (including chloroform-acetone mixtures) did not separate 
the two diastereoisomers. The mixture of diastereoisomers was dissolved in hot 
methanol and allowed to cool. Figure 84 shows the mixture of diastereoisomers after 
one recrystallisation. One compound was in abundance by a factor of 2.5. Three further 
recrystallisations from the same solvent gave the pure diastereoisomer shown in Figure 
85. The lH NMR of the mixture of diastereoisomers in Figure 84 demonstrated several 
important features. First, the !H NMR of the minor compound showed a methyl singlet 
(from the isopropylidene acetal) at 8 = 1.00. Usually, the range for the methyl 
resonance for this type of functional group is 8 = 1.30-1.65. In the mixed spectrum the 
two C-5-H resonances were identified at 8 = 3.22 and 3.44 as two dd, for the major and 
minor compounds. Two other hydrogen resonances were also well separated at 8 = 4.54 
and 4.33 for C-2-H and at 8 = 4.15 and 3.78 for C-l-H for the major and minor 
diastereoisomers respectively and for the pure compound (299 in Figure 85) these minor 
peaks were not present. The unique peak to assess the purity of the diastereoisomer in 
Figure 85 was the hydrogen of the chiral acetylmandelates (at 8 = 6.00 and 6.12) 
[CH3C 0 2C//(Ph)C02-]. The ]H NMR spectrum of the mixture (in Figure 84) showed a 
distinct singlet at 8 = 6.05 which arose from the minor component and which was not 











The yield was not particularly high (36.5%) for the recovery of a single diastereoisomer. 
However, this has not been optimised at present. The rotation was constant after a total 
of four recrystallisations, [a]D = +64° together with the melting point (212-214°C). 
Basic hydrolysis of the two acyl groups followed by chromatography and 
recrystallisation of the diol from ethyl acetate gave d - 1,2:4,5-di-O-isopropylidene-myo- 
inositol (301) [a]D = -22° with a melting point of 174-176°C. These physical properties 
agreed with the data published by Chiara and Martm-Lomas. t478] Gigg and coworkers 
[4 7 5] have synthesised l -  1,2:4,5-di-6Msopropylidene-myo-inositol by a different route, 
[a]D = +23.3°, (m.p. 175-177°C). The dispute over the melting point of the chiral diol 
has now been resolved because the value (159-161°C) stated by Young and coworkers 
I477! was incorrect. The hydroxyl groups at C-3-H and C-6-H were then benzylated to 
give D-3,6-di-0-benzyl-l,2:4,5-di-0-isopropylidene-myo-inositol (302), ([a]D = -44°, 
m.p. 157-159°C). Recently, Gigg and coworkers [47S1 synthesised L-3,6-di-0-benzyl- 
l,2:4,5-di-0-isopropylidene-myo-inositol, [a]D = +85°, which had a melting point of 
159-161 °C. The acetal protecting groups at the 1,2- and 4,5-positions were removed by 
acid hydrolysis and the solvents were evaporated in vacuo. The resulting solid was 
recrystallised from ethanol to give D-3,6-di-0-benzyl-myo-inositol (285), which was 
identical to the NMR and had the same melting point and specific rotation described 
previously for (285) in section 5.3.4.
5.4 Modification of the Ins(l,3,4,6)P4 Structure
Ins(l,3,4,6)P4 is a partial agonist at the Ins(l,4,5)P3 receptor from SH-SY5Y human 
neuroblastoma cells. Modifying the Ins(l,3,4,6)P4 structure, may lead to the 
development of a full antagonist. In other systems however, for example in platelets, 
this tetrakisphosphate was shown to be a full agonist, thus receptor selectivity has also 
been achieved. Acting on this important finding, we decided to explore the roles of the 
hydroxyl groups and phosphate moieties of the myoinositol ring. First, if the 2- and 5- 
positions of Ins(l,3,4,6)P4 were methylated any polar interaction between the hydroxyl 
groups and the Ins(l,4,5)P3 receptor protein would be removed, introducing steric 
hindrance, and this would demonstrate the importance of one or both of the hydroxyl 
groups at these positions. Second, replacing the phosphate groups with 
phosphorothioates at all four positions may provide a partial agonist with a lower 
efficacy than Ins(l,3,4,6)P4, for reasons discussed in 4.9.3.
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The two meso tetrols were synthesised from the same crystalline intermediate, DL-l,4-di- 
0-allyl-3,6-di-0-p-methoxybenzyl-myo-inositol (306 in Figure 86) which was prepared 
in three steps from d l -  1,2:4,5-di-0-isopropylidenermyo-inositol. The diol was alkylated 
with allyl bromide using sodium hydride as base in DMF. The reaction proceeded 
smoothly to give a single product by TLC, ether (R{ = 0.8). The literature t349! stated that 
the pure compound was crystallised from the mixture. However, it was found that a 
pure compound was only isolated if there was little allyl bromide left after the reaction 
was complete. Crystallisation of DL-3,6-di-(9-allyl-1,2:4,5-di-O-isopropylidene-myo- 
inositol (303) occurred only at -20°C in the freezer because the product was highly 
soluble in the crystallising solvent (i.e. pentane) at room temperature. DL-l,4-Di-0- 
allyl-myo-inositol (304) was prepared by treating the fully protected derivative (303) 
with 80% acetic acid at reflux temperature for 30min. The acid was evaporated in 
vacuo to give a white solid which was then dissolved in hot ethanol, cooled and kept in 
the freezer until crystals appeared. It was envisaged that selective p- 
methoxybenzylation at the 3- and 6-positions would give a protected 1,3,4,6- 
intermediate which could be alkylated at the 2- and 5-positions to provide the 1,3,4,6- 
tetrol precursor. Thus, selective p-methoxybenzylation occurred by refluxing dibutyltin 
oxide (2.5 equivalents) with d l -  1,4-di-0-allyl-m_yo-inositol (304) in toluene under reflux 
to form the cis-1,2 and the fran.s-4,5-dibutylstannylene derivative. The toluene was 
evaporated and DMF was added to the syrup together with CsF (5 equivalents) and p-
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methoxybenzyl chloride (3 equivalents) and the reaction was then stirred overnight. 
The role of the CsF in this type of selective reaction has been discussed in Chapter 3. 
TLC (ethyl acetate-hexane, 1:1) showed two products, DL-l,4-di-0-allyl-3,6-di-O-p- 
methoxybenzyl-myo-inositol (306) (isolated in 24% yield) (Rf = 0.56) and DL-l,4-di-0- 
allyl-2,5-di-0-p-methoxybenzyl-myo-inositol (305) (isolated in 12% yield) (R{ = 0.40). 
It was impossible to judge by TLC whether or not most of the dibutyltin acetal 
derivative collapsed to reform DL-l,4-di-0-allyl-mye>-inositol, because of the 
overlapping R{ values of the decomposed tin residues and the tetrol. This procedure was 
repeated several times and gave the same result. The protected derivatives d l -1,3,4,5- 
tetra-O-allyl-myo-inositol and 1,3,4,6-tetra-O-allyl-myo-inositol have also been 
synthesised in one step from myo-inositol and discussed in Chapter 3. However, both 
these compounds were syrups and not as easy to handle as compounds (305) and (306) 
which were crystalline solids. The diol (306) was methylated with methyl iodide using 
sodium hydride as the base in DMF. DL-l,4-Di-0-allyl-3,6-di-(9-p-methoxybenzyl-2,5- 




The allyl and p-methoxybenzyl protective groups were then removed in one step. The 
most efficient method for the deprotection was by refluxing a mixture of compound
(307) in ethanol-water together with palladium on carbon and toluene-/?-sulphonic acid 
overnight. The palladium on carbon was removed by filtering the solution through 
celite and the solvents were evaporated. Recrystallisation of the crude mixture from 
ethanol gave the meso compound 2,5-di-O-methyl-myo-inositol (308). Whilst this work 
was being carried out, Gigg and coworkers [3771 also prepared 2,5-di-O-methyl-myo- 
inositol (308) which had a melting point of 270°C, but we found that compound (308) 
decomposed between 266-268°C which was not observed by Gigg and coworkers. The 
!H NMR of this compound in d6-DMSO is shown in Figure 87. The ]H NMR spectrum 
indicated the presence of a symmetrical compound. There was a triplet at 5 = 2.65 for 
C-5-H (J 9.0Hz), a ddd, at 5 = 3.19, for C-l-H and C-3-H (J 2.56, 5.31, 9.89Hz), C-2-H 
was a broad singlet at 5 = 3.35 and there was a dt at 6 = 3.36 for C-4-H and C-6-H (J 
4.95, 10.1Hz). Only two peaks were identified as doublets at 8 = 4.57 (J = 5.13Hz) and 
5 = 4.67 (J = 4.76Hz), both hydroxyl groups exchanged with D20 . A singlet at 8 = 3.44 
was identified as the two methyl groups at the 2- and 5-positions. This intermediate was 
used for the synthesis of 2,5-di-0-methyl-my<9-inositol-1,3,4,6-tetrakisphosphate and the 
phosphorothioate analogue.
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2,5-Di-O-benzyl-myo-inositol (311 in Figure 88)  was prepared in three steps from d l -
l,4-di-0-allyl-3,6-di-0-p-methoxybenzyl-myo-inositol (306). Thus, (306) was 
benzylated using benzyl bromide and sodium hydride in DMF. Work up and 
purification gave the fully protected compound (309) as a highly crystalline solid in 
92% yield. Several methods were attempted to deprotect the allyl and p-methoxybenzyl 
groups. First, palladium on charcoal at reflux temperature in an ethanol-water mixture 
and in the presence of toluene-p-sulphonic acid. Second, a two step deprotection, first 
with DDQ in (water-dichloromethane, 1:15), followed by deallylation with palladium on 
charcoal. Neither method was satisfactory for removing both protective groups.
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However, a successful two step deprotection strategy was finally employed using freshly 
sublimed potassium f-butoxide in dry DMF at 85°C for 2.5h. The reaction isomerised 
the allyl moiety to the cw-prop-l-enyl ether, which was then rendered susceptible to 
acidic hydrolysis. The R{ value of the 1,4-di-0-cis-prop-1 -enyl derivative (310) was 
identical to that of (309), but treatment of a small quantity of the mixture with acid gave 
a lower spot on TLC (not recorded). The compound was extracted from the mixture, 
purified by chromatography and recrystallised from hexane to give compound (310) in 
83% yield. The !H NMR spectrum showed that the 1,4-di-0-ds-prop-1 -enyl groups had 
formed because the coupling constants for CH3//C=C//-0-Ins were recorded at 8 = 6.08 
and 6.26ppm and had coupling constants of 6.23 and 6.41 Hz respectively, whereas if a 
trans-prop-1 -enyl ether had formed the coupling constant would have been in the order 
of ca. 15Hz. The ris-prop-l-enyl ether and the p-methoxybenzyl group were both acid 
sensitive so treatment of the derivative with 10% TFA in dichloromethane would cleave 
both protective groups whilst leaving the benzyl ethers intact. Thus, addition of the 
compound to the acid resulted in a red-orange solution which was stirred overnight. 
The only product which was detected by TLC resulted from deprotection of the p- 
methoxybenzyl group which stained purple in the presence of phosphomolybdic acid. 
The acidic solution was evaporated and the resulting slurry was coevaporated with water 
and ethanol. A white solid precipitated from the solution and was washed with water, 
acetone and finally ether to remove any impurities. The solid was crystallised from 
DMF-ethanol to give 2,5-di-O-benzyl-rayo-inositol (311). Whilst this work was in 
progress, the same compound was prepared by Gigg and coworkers, I3871 but no !H 
NMR data for the compound were given. Gigg and coworkers prepared 2,5-di-O- 
benzyl-myo-inositol by benzylating 1,3,4,6-tetra-O-allyl-rayo-inositol followed by 
deallylation with palladium on charcoal in the presence of acid. The analytical data 
(microanalysis) presented by this group t387J was slightly high for the carbon (+0.85%) 
but the melting point was 270-272°C, and in good agreement with ours (271-273°C).
The *H NMR spectrum of 2,5-di-O-benzyl-myo-inositol (311) is shown in Figure 89 and 
shows a symmetrical pattern similar to 2,5-di-O-methyl-myo-inositol. A triplet at 8 =
3.03 for C-5-H (J = 9.16Hz) and a small triplet at 8 = 3.60 for C-2-H (J = 2.57Hz). At 8 
= 3.33 there is a ddd, (J = 2.57, 4.77 and 9.71Hz) for C-l-H and C-3-H and at 8 = 3.60 
there is a dt (J = 5.13 and 9.34Hz) for C-4-H and C-6-H, both signals integrating for two 
hydrogens. The two doublets at 8 = 4.75 (J = 4.77Hz) for C-l-OH and C-3-OH and at 8 
= 4.83 (J = 5.12Hz) for C-4-OH and C-6-OH both exchanged with D20 . However, the 
addition of D20  caused precipitation of the compound which was easily recovered by 
filtration. A mass spectrum for this compound could not be obtained because of its 
inherent insolubility in m-nitrobenzyl alcohol, glycerol and thioglycerol. 2,5-Di-O-
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benzyl-myo-inositol was used to prepare myoinositol 1,3,4,6-tetrakisphosphorothioate 
[Ins(l,3,4,6)PS4] (320).
> « i.y 12 T J I) 6 i / J « J J I 3 »
Figure 89










(BO)2P O y ^ X ^ >





II (EtO)2PO I 
(EtO)2PO ^





2 ,5 -Di-O-methyl-myo-inositol (308 in Figure 90) was dissolved in dry DMF and dry 
N,N-diisopropylethylamine. The mixture was cooled, diethoxychlorophosphine was
added dropwise and and stirred for 45min to give the 1,3,4,6-tetrakisphosphite 
intermediate (312). Oxidation of the P(HI) intermediate was carried out using t- 
butylhydroperoxide to give compound (313). Purification by flash chromatography was 
not necessary since aqueous work up provided the pure compound as a glass.
0 0 - 1
Figure 91
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The eight ethyl groups were removed from the protected tetrakisphosphate by a two 
step, one-pot process. Compound (313) was dissolved in dry dichloromethane and 
bromotrimethylsilane was added to the mixture under nitrogen and stirred overnight. In 
this reaction the eight ethyl groups of compound (313) were replaced by trimethylsilyl 
functions in quantitative yield by 31P NMR, in a transetherification process with the 
production of bromoethane. The solvents were evaporated and water was added to the 
residue in order to hydrolyse the temporary trimethylsilyl moieties. The final product 
was purified by ion exchange chromatography on Q-Sepharose Fast Flow using a 
gradient of 200-1000mM TEAB buffer. The title compound (314) eluted at ca. 500mM 
buffer and characterised as its glassy triethylammonium salt.
The !H NMR and 31P-1H NMR (decoupled and coupled) are given in Figure 91 There 
were only two peaks in the 31P-1H (decoupled) spectrum at 5 = 0.00 and - 0.58ppm as a 
consequence of the symmetry through the C-2-H and C-5-H bonds. The 31P-1H 
(coupled) spectrum shows two doublets centered at 8 = 0.00 (J = 9.9Hz) and - 0.58 (J = 
8.0Hz). The lH NMR spectrum shows two methyl groups at 5 = 3.51 and 3.57 together 
with the C-5-H which was hidden under the methyl singlet at 8 = 3.57. C-2-H was a 
broad singlet at 8 = 3.97 and C-l-H and C-3-H were as a triplet at 8 = 4.06 (J = 9.52Hz) 
as well as C-4-H and C-6-H being identified as a quartet at 8 = 4.28 (J = 9.40Hz). A 
sample of the compound gave a satisfactory accurate -ve FAB mass spectrum.
5.4.3 Synthesis of 2,5-Di-0-MethyI my o-Inositol 1,3,4,6-Tetrakisphosphorothioate
The reagent, bis(benzyloxy)diisopropylaminophosphine (96) was used to phosphitylate
2,5-di-O-methyl-myo-inositol (308 in Figure 92). A mixture of l//-tetrazole and 
bis(benzyloxy)diisopropylaminophosphine was stirred in DMF for lh  to give the 
tetrazolide. The formation of this complex in DMF was somewhat slower than in 
dichloromethane, with the appearance of two peaks at 8 = +126.12 and 8 = +127.47ppm 
in the 31P-1H NMR (decoupled) spectrum. The tetrol was then added to the tetrazolide 
complex and the mixture was stirred for a further 2h. The 31P-1H NMR (decoupled) 
spectrum at this stage showed two peaks centered at 8 = +141.26 and 8 = +139.45ppm 
which indicated a phosphitylated myoinositol derivative. However, at high resolution, 
a single AB spin coupling pattern was observed (315 in Figure 93) with a 5JPP = 3.90Hz. 
Sulphoxidation of this intermediate with sulphur S8, in (pyridine-DMF, 1:2), gave the 
protected intermediate (316) within 15min. This was the first time that sulphoxidation 
was carried out in this mixture which was an improvement on sulphur in pyridine only. 
The technique was improved for the synthesis of other phosphorothioates, e.g. 
Ins(l,2,4,5)PS4, which was discussed previously, together with all phosphorothioates
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which follow. The sulphur was filtered off and the solvent carefully evaporated in 
vacuo. The protected phosphorothioate (316) was purified by flash chromatography and 
isolated in 82% yield as a clean syrup. The 31P-1H NMR (coupled and decoupled) 
spectra for (316) are shown in Figure 94. This shows two singlets (decoupled) at 5 = 
67.09 and 5 = 69.1 lppm, which was the area observed for protected phosphorothioates. 
The 31P-1H NMR coupled spectrum shows two doublet of quintets, (J = 8 and 9.9Hz, 
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The octabenzyl derivative (316) was deprotected with sodium in liquid ammonia 
followed by purification on Q-Sepharose eluting at ca. 800mM TEAB buffer in 25% 
yield and was characterised as the triethylammonium salt. The product (317) exhibited 
a similar *H NMR spectrum to the phosphate derivative (314) and the 31P-!H NMR 
spectra (in Figure 95) shows two singlets at 8 = 46.7 and 8 = 48.8ppm, for the 31P-1H- 
decoupled spectrum, and the inset 31P-^-coupled spectrum shows two doublets (J = 
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5.4.4 Synthesis of myo-Inositol 1,3,4,6-Tetrakisphosphorothioate
A mixture of the phosphitylating reagent (96) and l//-tetrazole was stirred in dry DMF 
for lh. 2,5-Di-O-benzyl-myo-inositol (311 in Figure 96) was added to the mixture and 
stirred for lh. A similar AB spin coupling pattern to compound (315) was observed 
with 5JPP = 4.27Hz. Sulphur and pyridine-DMF (1:2) were added, and the mixture was 
stirred for lOmin. The sulphur was filtered and the solvents were evaporated in vacuo. 
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Deprotection of the compound with sodium in liquid ammonia followed by purification 
by ion exchange chromatography gave Ins(l,3,4,6)PS4 (320) in 46% yield. The 31P-!H 
NMR spectra were similar to the 2,5-di-O-methyl derivative (317) except the chemical 
shifts were slightly different; 8 = 46.7 (d, J = 12.2Hz) and 8 = 42.4ppm, (d, J = 9.8Hz).
5.4.5 Pharmacology
The three meso compounds, 2,5-di-O-methyl Ins(l,3,4,6)P4 (314) 2,5-di-O-methyl 
Ins(l,3,4,6)PS4 (317) and Ins(l,3,4,6)PS4 (320) have been evaluated. I422l It is known 
that Ins(l,3,4,6)P4 is a partial agonist with high intrinsic activity l216i mobilising 85% of 
the 45Ca2+ mobilised by Ins(l,4,5)P3 from electrically permeabilised SH-SY5Y human 
neuroblastoma cells with an EC50 value of 19.6pM. Methylating the hydroxyl groups of 
Ins(l,3,4,6)P4 gave 2,5-di-O-methyl Ins(l,3,4,6)P4 (314) and removed all 45Ca2+-
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mobilising activity in a fashion similarly observed for 3,6-di-O-benzoyl Ins(l,2,4,5)P4 
(276). This result indicated the importance of one or both hydroxyl groups which were 
critical for interacting with the Ins(l,4,5)P3 receptor. Similarly, substitution of all the 
phosphates with phosphorothioate functions gave 2,5-di-O-methyl Ins(l,3,4,6)PS4 (317) 
and Ins(l,3,4,6)PS4 (320) [from Ins(l,3,4,6)P4] which were poor agonists at the 
Ins(l,4,5)P3 receptor, mobilising <15% of the maximal dose of Ins(l,4,5)P3 at 30jiM. 
The important information here is that none of these compounds antagonised the 45Ca2+- 
release activity of Ins(l,4,5)P3.
The three compounds were also tested for their interaction with the enzymes 3-kinase 
from CRBHS and 5-phosphatase from HEG. For comparison Ins(l,4,5)P3 had a Km 
values of 0.85|iM and 13.8}iM for 3-kinase and 5-phosphatase respectively. Both 2,5- 
di-O-methyl derivatives (314) and (317) were poorly recognised by the 3-kinase with K-x 
values of >100|iM and 105|iM respectively. However, Ins(l,3,4,6)PS4 was recognised 
by 3-kinase with a K{ value of 46fiM. This value was similar to scyllo-Ins(l,3,4,6)PS4 
t414l which had a Kt value of 56.7pM and was discussed in Chapter 4. Ins(l,3,4,6)PS4 
had an increased affinity for 5-phosphatase with a K{ value of 1.9|iM compared to 
Ins(l,3,4,6)P4 with value of 7.7pM. Methylation at the 2- and 5-positions gave 
compounds (314) and (317) which had K-t values of 15.9|iM and 1.4|iM respectively. 
Thus tetrakisphosphates, generally have a higher affinity for 5-phosphatase over 
trisphosphates and replacing phosphates with phosphorothioates resulted in increased 
affinity for 5-phosphatase from HEG.
5.5 Introduction to the Synthesis of DL-Ins(l,4,6)P3 and DL-Ins(l,4,6)PS3
D-Ins(l,4,6)P3 may be derived from Ins(l,3,4,6)P4 by removing the phosphate group at 
the 3-position to give a compound with a pseudo d-1,4,5 motif with inverted hydroxyl 
groups at the pseudo 2- and 3-positions, as described in Chapter 4. First, DL-Ins(l,4,6)P3 
was synthesised in order to establish any properties of Ca2+-release, followed by its 
phosphorothioate, DL-Ins(l,4,6)PS3 (336) which proved to be a promising lead in the 
development of a full antagonist. After the synthesis of the racemic mixture, the 
individual enantiomers were successfully made using (S)-(+)-(9-acetylmandelic acid 
which was used to resolve a precursor to d-(346) and L-2,3,5-tri-0-benzyl-my<?-inositol 
(345).
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5.5.1 The Synthesis of DL-l,2,5-Tri-0-BenzyI-myo-Inositol
DL-3,6-Di-0-allyl-l,2:4,5-di-0-isopropylidene-m_yo-inositol (303) was used as the 
starting material for the synthesis of DL-l,2,5-tri-0-benzyl-my<9-inositol (328). For this 
racemic synthesis, all the intermediates are drawn in the L-configuration so the 




































DL-3,6-Di-O-allyl-l,2:4,5-di-0-isopropylidene-myo-inositol (303) was prepared from d l -  
l,2:4,5-di-0-isopropylidene-rayoinositol (37) by allylating the 3- and 6-hydroxyl 
groups with allyl bromide and sodium hydride in DMF. The less stable trans 
isopropylidene acetal was removed selectively using a catalytic amount of toluene-p- 
sulphonic acid and one equivalent of ethane 1,2-diol, in dichloromethane with stirring. 
The temperature was kept at 0°C (with ice) for lOmin after which the cooling was
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removed and the reaction mixture was allowed to warm to room temperature whilst 
stirring. It was found that the nature of the protective group at positions 3- and 6-, 
influenced the rate of hydrolysis of the 4,5-trans isopropylidene acetal. If ester groups 
were present, the rate of hydrolysis of the trans acetal was slow. When positions 3- and 
6- were blocked with benzyl groups the rate of hydrolysis was smooth and complete 
within 45min, whereas cooling was necessary when the allyl group occupied these 
positions, in order to prevent the formation of excess d l -  1,4-di-O-allyl-myo-inositol 
(304) and therefore to control the formation of d l -  1,4-di-0-allyl-2,3-(9-isopropylidene- 
myo-inositol. When the solution became cloudy (after 40min), triethylamine was added 
to quench the reaction and water was added to the solution, d l -  1,4-Di-0-allyl-my<9- 
inositol (304) was soluble in water and a small amount of starting material (303) and 
product (321) were present in the organic layer. The organic solvent was evaporated to 
give a solid and the mixture was recrystallised from ethyl acetate-hexane to give pure 
d l -  1,4-di-0-allyl-2,3-0-isopropyhdene-myo-inositol (321) in 68% yield. No starting 
material was detected after recrystallisation because it was soluble in all organic 
solvents at room temperature.
The trans diol was now exposed and it was envisaged that the 6-position would be more 
reactive towards tin-mediated alkylation over the 5-position. Thus, treatment of the diol 
(321) with a mixture of dibutyltin oxide, tetrabutylammonium iodide, p-methoxybenzyl 
chloride and acetonitrile in the presence of 4A sieves (in a Soxhlet) for 48h at reflux 
temperature gave three products. The major product was found to be DL-l,4-di-0-allyl- 
2,3-0-isopropylidene-6-0-p-methoxybenzyl-myo-inositol (324) R{ = 0.40 (ether-hexane, 
3:2) which was isolated in 52% yield. The !H NMR spectra in CDC13 distinctly shows 
the hydroxyl at the 5-position coupling to the ring hydrogen, 5 = 3.43, as a ddd, (J = 
2.02, 8.24 and 8.24Hz) and upon D20  exchange the ddd collapsed to a dd, (J = 8.24 and 
8.24Hz). C-5-H is usually the most upfield hydrogen and thus the C-6-OH has been 
benzylated. Also formed was d l -  1,4-di-0-allyl-2,3-0-isopropylidene-5-0-p- 
methoxybenzyl-myo-inositol (323) R{ = 0.22 (ether-hexane, 3:2), isolated in 31% yield. 
The !H NMR spectra showed coupling of C-6-H to its hydroxyl, at 5 = 3.94, as a dt, (J = 
1.46 and 9.71Hz) and upon D20  exchange the dt collapsed to a triplet (J = 9.53Hz), thus 
C-5-OH was alkylated. At Rf = 0.50 (ether-hexane, 3:2), d l -  1,4-di-O-allyl-2,3-0- 
isopropylidene-5,6-di-0-p-methoxybenzyl-myo-inositol (322) was isolated in 14% 
yield. Surprisingly, the only crystalline solid was the 5-O-p-methoxybenzyl derivative, 
which formed crystals several centimetres in length which could be recrystallised from 
hexane, (m.p. 70-72°C). The three products were easily separated by flash 
chromatography using the same solvent system as for the TLC system.
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The major compound was treated in one of two ways in order to obtain the required d l -
1,2,5-tri-O-benzyl-myo-inositol (328). First, the 2,3-0-isopropylidene was hydrolysed 
under acidic conditions, using methanol-1M HC1 (9:1) which was kept at 50°C for 
30min. Under these mild acidic conditions the p-methoxybenzyl group was not affected 
and d l -  1,4-di-0-allyl-6-O-p-methoxybenzyl-my<9-inositol (325) was isolated in 80% 
yield after crystallisation from ethyl acetate-hexane. The three hydroxyl groups at 
positions 2-, 3- and 5-, were alkylated with benzyl bromide using sodium hydride as 
base in DMF. Work up and purification by column chromatography gave a syrup which 
was dissolved in hot hexane and crystallised on cooling to give the fully protected 
compound, d l -  1,4-di-0-allyl-2,3,5-tri-0-benzyl-6-0-p-methoxybenzyl-myo-inositol
(326) in 85% yield (m.p. 53-54°C).
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d l -  1,4-Di-0-allyl-2,3-(9-isopropylidene-6-(9-p-methoxybenzyl-myo-inositol (324 in
Figure 98) was benzylated with benzyl bromide and sodium hydride in DMF to afford 
the totally protected compound d l -  1,4-di-0-allyl-5-0-benzyl-2,3-0-isopropylidene-6-0- 
p-methoxybenzyl-myo-inositol (329) as a syrup, in 93% yield, after column 
chromatography. The cis 2,3-acetal was removed with methanol-1M HC1 (9:1), at 50°C 
for 30min. Work up and crystallisation (from ether-hexane) gave d l -  1,4-di-O-ally 1-5-0- 
benzyl-6-O-p-methoxybenzyl-myo-inositol (330) (m.p. 87-88°C) in 88% yield. This 
compound had a cis 1,2-diol and was ideal for resolution at this stage using (S)-(+)-0- 
acetylmandelic acid and will be described later. The hydroxyl groups were benzylated 
at the 2-, 3- and 5-positions to give the known, fully protected d l -  1,4-di-0-allyl-2,3,5- 
tri-0-benzyl-6-0-/?-methoxybenzyl-myo-inositol (326). This compound was then 
deprotected in one of two ways, the latter being the most successful. First, a two step
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deprotection strategy was employed using DDQ (in dichloromethane-water, 15:1) in 
order to cleave the p-methoxybenzyl group. An interesting colour change took place. 
Initially the colour of DDQ was mustard-yellow which immediately turned green on 
contact with the solvent mixture. As the reaction proceeded, the solution changed to a 
red-brown colour. After ca. lh the solution was filtered and the precipitate was salmon- 
pink in colour. The distinctive odour of p-methoxybenzaldehyde was another positive 
sign that the p-methoxybenzyl ether had been cleaved by DDQ. All other protective 
groups were intact to give, after work up, DL-l,4-di-0-allyl-2,3,5-tri-O-benzyl-myo 
inositol (327) in 87% yield as a syrup. The two allyl groups were removed in a one pot 
deprotection reaction using 10% palladium on charcoal, together with toluene-p- 
sulphonic acid in an ethanol-water mixture at the reflux temperature for 5h. 
Unfortunately the mixture was refluxed for too long, and other debenzylated products 
present on the baseline were observed by TLC. Deallylation with palladium on carbon 
gave d l -  1,2,5-tri-O-benzyl-myoinositol (328) in 40% yield after work up and 
chromatography.
Second, the allyl groups at the 1- and 4-positions were isomerised with potassium t- 
butoxide in dry DMSO to give the cis 1,4-di-O-prop-1 -eny 1 derivative (331) in 80% 
yield after work up and purification by chromatography. For this reaction the 
isomerisation was easy to follow because the starting material (R{ = 0.50, in ether- 
hexane, 1:1) had a lower R{ value than the product (R{ = 0.72, in ether-hexane, 1:1). The 
melting point (89-91°C) was also higher than for the allyl derivative, and generally, if 
one allyl moiety is isomerised to a c/s-prop-l-enyl group the melting point increases by 
15-20°C. The smell of DMSO was still apparent even after chromatography and 
difficult to remove, however, satisfactory analytical data was achieved for the product 
DL-2,3,5-tri-0-benzyl-6-0-/7-methoxybenzyl-l,4-di-(9-cw-prop-l-enyl-myo-inositol 
(331). The next step was was a one pot acidic hydrolysis of the cw-prop-l-enyl and the 
p-methoxybenzyl ethers. Thus treatment of compound (331) with ethanol-1M aqueous 
HC1 (2:1) for 4h hydrolysed the acid sensitive protecting groups. The solvents were 
evaporated in vacuo and were purified by column chromatography to give DL-l,2,5-tri- 
Obenzyl-myoinositol (328).
The !H NMR spectrum of d l -  1,2,5-tri-O-benzyl-myoinositol in CDC13 is shown in 
Figure 99. The three hydroxyl signals are very broad, 8 = 1.65-2.65, but the hydrogens 
of the myoinositol ring are well separated as shown on the expansion. The C-5-H is a 
triplet and is deshielded most 8 = 3.23, (J = 9.16Hz). The two dd, at 8 = 3.30 (J = 2.39 
and 9.71Hz) and 8 = 3.40 (J = 2.57 and 9.71Hz) are C-l-H and C-3-H. The two triplets 
at 8 = 3.82 (J = 9.52Hz) and 8 = 4.12 (J = 9.52Hz) are C-4-H and C-6-H, whilst the
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unique triplet at 8 = 4.06 is C-2-H. The 2-D COSY spectrum was most informative 
when it was run in d6-DMSO, (Figure 100). The hydroxyl groups were coupled to the 
ring hydrogens of DL-l,2,5-tri-0-benzyl-myo-inositol (328). Since the compound was 
racemic, the tri-O-benzyl compound will be named DL-l,2,5-tri-0-benzyl-myc>-inositol, 
therefore the hydroxyl groups at positions 3-, 4- and 6 are exposed. The triplet at 8 = 
3.97 is C-2-H because of the small coupling between two axial-equatorial positions. 
The signal furthest upfield is a triplet at 8 = 3.09 (J = 9.15Hz) and the C-l-H is a dd, at 8 
= 3.29, because the hydroxyl group is not exposed and there is no extra coupling in d6- 
DMSO. The ddd, at 8 = 3.33 corresponds to position C-3-H because of the extra 
coupling in d6-DMSO and has cross peaks with the dt, corresponding to C-4-H at 8 =
3.64 and finally C-6-H is also a dt, at 8 = 3.80. Both these dt signals gave cross peaks 
with the triplet corresponding to C-5-H. Thus the correct hydroxyl positions are 
exposed for phosphitylation to give DL-Ins( 1,4,6)P3 (334) and DL-Ins(l,4,6)PS3 (336).





5.5.2 Synthesis of DL-Ins(l,4,6)P3
The treatment of bis(benzyloxy)diisopropylaminophosphine (96) with l//-tetrazole in 
dry dichloromethane gave the tetrazolide complex (290) indicated by the 31P NMR 
spectrum at 5 = +126.73ppm. The addition of DL-l,2,5-tri-0-benzyl-mye>-inositol (328) 
to the tetrazolide produced the familiar AB spin coupling pattern together with a singlet 
at 5 = +141.6ppm for the phosphitylated C-4-OH. The AB system was assigned to the 
phophitylated 1,6-bisphosphite triester system (5 = +140.2 and +142.3ppm, 5JPP = 
3.66Hz) in Figure 101. The AB system implies phosphitylation of the vicinal diol and
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the presence of unreacted tetrazolide complex indicated complete phosphitylation, since 
the tetrazolide complex is very reactive toward nucleophiles, including water. 
Oxidation of the trisphosphite triester with r-butylhydroperoxide gave the fully protected 
derivative, DL-l,2,5-tri-0-benzyl-3,4,6-tris[di(benzyloxyphospho)]-myoinositol (333) as 
a syrup in 85% yield after work up and purification by flash chromatography. The 
important step in the work up was the wash with sodium metabisulphite solution which 
removed the excess r-butylhydroperoxide. The compound was deprotected using 
sodium in liquid ammonia. The crude product was purified by ion exchange 
chromatography on Q-Sepharose fast flow using a gradient of TEAB as eluent to give 
pure DL-Ins( 1,4,6)P3 (334 in Figure 102) in 60% yield as its glassy triethylammonium 
salt. The 31P and lH NMR data will be discussed for the chiral compound. The accurate 
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5.5.3 Synthesis of DL-Ins(l,4,6)PS3
The tetrazolide complex was formed in the same way as for the synthesis of d l -  
Ins(l,4,6)P3 and the triol was added to the tetrazolide (290) in the same way in order to 
form the trisphosphite triester (332) with the formation of the familiar AB spin coupling 
pattern. However, at this stage the dichloromethane was evaporated and the syrup was 
dissolved in dry DMF (2ml) and dry pyridine (1ml), followed by the addition of sulphur 
(2 equivalents per phosphite). The reaction was complete within 5min, the excess 
sulphur was filtered, and the solvents were evaporated in vacuo. Work up and 
purification by flash chromatography provided the fully protected d l -  1,2,5-tri-O-benzyl- 
3,4,6-tris[di(benzyloxyphosphorothio)]-myo-inositol (335) as a sulphur free syrup in 
81% yield. Deprotection of the fully blocked compound with sodium in liquid ammonia 
followed by purification by ion exchange chromatography over Q-Sepharose Fast Flow, 
eluting with a gradient of TEAB buffer at ca. 600mM to give DL-Ins(l,4,6)PS3 (336 in 
Figure 102) as the triethylammonium salt. The 31P and *H NMR data will be discussed 
for the chiral compound.
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5.5.4 Pharmacology
DL-Ins(l,4,6)P3 and DL-Ins(l,4,6)PS3 have been evaluated for their Ca2+-releasing 
properties. However, Ozaki and coworkers have tested D-Ins( 1,4,6)P3 for Ca2+-release 
and its interaction with 3-kinase and 5-phosphatase, which was described in Chapter 4.
DL-Ins( 1,4,6)P3 was evaluated as a Ca2+-mobilising agonist in permeabilised rabbit 
platelets, in comparison to Ins(l,4,5)P3 and Ins(l,3,4,6)P4. Ozaki and coworkers have 
previously demonstrated that D-Ins(l,4,6)P3 released Ca2+ from intracellular stores. 






For this assay, rabbit platelets were isolated and washed according to Murphy and 
coworkers. [479] The platelets (109/ml) were suspended in an "intracellular like" buffer 
containing 5mM ATP and permeabilised by treatment with saponin (40jig/ml) for lmin. 
The washed platelets were loaded with 45Ca2+ for 60min and stimulated with the inositol 
phosphate analogue for 3min at room temperature. The remaining cell-associated 
45Ca2+ was then determined by rapid filtration. The dose response curves for d l -  
Ins(l,4,6)P3 are shown in Figure 103. The EC50 values (mean ± SEM) were 0.18 ± 0.1 p 
M for Ins(l,4,5)P3, 2.07 ± 0.08pM for DL-Ins(l,4,6)P3 and 9.67 ± 0.50|iM for 
Ins(l,3,4,6)P4. DL-Ins(l,4,6)P3 (334) was some 11-fold less potent than Ins(l,4,5)P3 but 
5-fold more potent than Ins(l,3,4,6)P4 in its ability to release Ca2+. Only the d -  
enantiomer of DL-Ins(l,4,6)P3 will release Ca2+, as the L-enantiomer does not have a d -
4,5-bisphosphate moiety. Thus, D-Ins(l,4,6)P3 (199) should only be five to six times 
less potent at Ca2+-release than Ins(l,4,5)P3. l48°l DL-Ins(l,4,6)P3 was also evaluated as 
an inhibitor of 5-phosphatase from HEG and was found to inhibit [3H]Ins(l,4,5)P3 
dephosphorylation with a K{ value of 17.8pM.
The Ca2+-release activity for dl-Lis(1,4,6)PS3 was evaluated in the same way as for d l -  
Ins(l,4,6)P3 and the dose response curves are shown in Figure 104. In marked contrast 
to DL-Ins(l,4,6)P3 the phosphorothioate analogue released a maximum of 21.2% ± 0.40 
(n = 3) of the Ca2+-released by Ins(l,4,5)P3. For comparison, L-c7*z>0-Ins(2,3,5)PS3 and 
5cy//o-Ins(l,2,4,5)PS4 released 42.3 ± 6% (n = 3) and 61.7 ± 11% (n = 3) respectively. 
Of the three phosphorothioate analogues described above, only DL-Ins(l,4,6)PS3 
exhibited antagonism at the Ins(l,4,5)P3 receptor. Coincubation of DL-Ins(l,4,6)PS3 
(300nM-100|iM) with 0.3}iM of Ins(l,4,5)P3 at 0°C produced a dose dependent 
inhibition of Ins(l,4,5)P3-induced 45Ca2+-release, such that 100pM of DL-Ins(l,4,6)PS3 
produced approximately 50% inhibition, (in Figure 104). This analogue was the first 
description of an antagonist at the Ins(l,4,5)P3 receptor in platelets. This molecule 
possesses the best antagonistic properties so far described, which, by further 
modification will hopefully lead to a full antagonist. The precursors to the chiral d -  
enantiomer have been resolved and pure D-Ins(l,4,6)PS3 has been synthesised, but the 
pharmacology on this compound has not been carried out. J. Al-Hafidh, carried out the 
biological testing of DL-Ins(l,4,6)P3 and DL-Ins(l,4,6)PS3 at the University of Bath.
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5.6 Resolution of DL-l,2,5-Tri-0-BenzyI-myo-Inositol Precursors
From the previous section DL-l,4-di-0-allyl-5-0-benzyl-6-O-p-methoxybenzyl-m;ye>- 
inositol (330) was synthesised from d l-  1,2:4,5-di-0-isopropylidene-my<9-inositol and the 
cis-2,3-diol was resolved successfully with (5)-(+)-0-acetylmandelic acid to provide the 
enantiomers o f 1,2,5-tri-O-benzyl-myo-inositol. This was carried out in the following 
manner.
A mixture of dl- 1,4-di-O-allyl-5-0-benzyl-6-O-p-methoxybenzyl-mye>-inositol (330), 
(5)-(+)-0-acetylmandelic acid (328) (1.04 equivalents) and a catalytic amount of DMAP 
in dichloromethane was stirred at -20°C, (in Figure 105). DCC in dichloromethane was 
added dropwise over a period of 1.5h, the cooling was removed and the mixture was 
stirred overnight at room temperature. TLC (pentane-ethyl acetate, 2:1) showed two 
products, Rf = 0.28 and 0.40. The precipitate of DCU was removed by filtration through 
celite and the clear solvent was evaporated to give a syrup. The mixture was purified by 
flash chromatography to give the two diastereoisomers. No problems were encountered 
in the purification process, in which there was little overlap during chromatography. Of 
the two diastereoisomers, D-l-<9-[S-(+)-0-acetylmandelyl]-3,6-di-0-allyl-5-O-benzyl-4-
O-p-methoxybenzyl-myo-inositol (337), was isolated as the less polar isomer (R{ = 0.40) 
in 36.5% yield as a syrup [a]D = -8°, and L-l-0-[S-(+)-O-acetylmandelyl]-3,6-di-0- 
allyl-5-0-benzyl-4-0-p-methoxybenzyl-myo-inositol (338), as the more polar, (R{ = 
0.28) [isolated as a crystalline solid in 35% yield, m.p. 103-105°C, (from ethanol), and 
[oc]D = +59°]. A single X-ray crystal structure was attempted, however, the shape of the 
unit crystal and weak diffraction patterns made it difficult for a successful crystal 
structure determination. Establishing the absolute configuration of the two 
diastereoisomers will be discussed later.
The !H NMR spectra for the two diastereoisomers is shown in Figure 106. The upper 
spectrum represents compound (337) and the lower spectrum compound (338). Unlike 
the resolution of the tetrabenzyl derivative used for the chiral synthesis of d -  and l -  
Ins(l,2,4,5)P4, there were fewer distinct differences between the signals of the 
diastereoisomers in the aromatic region and the unique hydrogen (as a singlet) of the 
acetylmandelate moiety CH3C 02C//(Ph)C02- overlapped with the allyl hydrogen Ins-O- 
CH2C//=CH2 signal in the spectra. A closer look at the upper spectrum revealed two 
allyl groups overlapping (at ~ 5 = 5.9) (Ins-0-CH2C//=CH2) which is the usual shift for 
this functional group. However, for the more polar diastereoisomer the multiplet at 6 = 
5.91 only integrated for one hydrogen. The other hydrogen from Ins-0-CH2CH=CH2
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and presumably attached at the C-6 position was shifted upfield to 5 = 5.30, presumably 
due to the shielding affect of the acetylmandelate phenyl moiety.
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C-l-H of the less polar diastereoisomer has been shifted downfield, due to the carbonyl 
deshielding effect of the acetylmandelate, which was be identified as a dd, 8 = 4.77, J = 
2.56 and 10.26Hz. Thus selective acylation occurred at the 1-position. The dd, for the 
slower running compound by TLC was not be seen, however, C-2-H of the more polar 
diastereoisomer (338) showed a broad singlet at 8 = 4.29, thus C-l-OH was selectively 
acylated in both diastereoisomers. The hydroxyl group at C-2 for compound (338) 8 =
2.65 is more shielded than for the slower moving diastereoisomer at 8 = 2.90. The 13C 
NMR spectra did not show any significant differences in chemical shift values between 
similar groups.
The individual diastereoisomers were then deacylated with methanolic sodium 
hydroxide solution to give L-l,4-di-0-allyl-5-(9-benzyl-6-0-p-methoxybenzyl-myo- 
inositol (339), (from the faster moving diastereoisomer) in 90% yield, after work up and 
crystallisation from ethyl acetate-hexane. The specific rotation was [a]D = -51°, and the 
melting point (111-113°C) was 24°C higher than for the racemic material. The d -  
enantiomer, d -  1,4-di-Oallyl-5-Obenzyl-6-0-/?-methoxybenzyl-myoinositol (340), was 
obtained in the same way, and isolated in 98% yield. The specific rotation was equal 
and opposite (+51°) and the melting point was found to be the same (111-112°C). The 
hydroxyl groups at the cis 2,3-diol of each enantiomer were benzylated using benzyl 
bromide and sodium hydride in DMF, to give the fully protected compounds (341) and 
(342) in 78% and 94% yields respectively. The melting point for both enantiomers was 
72-73°C and 19°C higher than for the racemic derivative. Both specific rotations were 
equal and opposite such that compound (341) was [a]D = -19° and compound (342) 
[a]D = +19°. The allyl and p-methoxybenzyl groups were cleaved in a two step process 
for each enantiomer. First, the two allyl groups of each compound were isomerised 
using freshly sublimed potassium /-butoxide in anhydrous DMSO for 5h at 50°C. TLC 
(ether-hexane, 1:1) showed complete conversion of starting material R{ = 0.50 into a 
single product Rf = 0.72, indicating the formation of the 1,4-di-O-ds-prop-1 -enyl 
derivative (343,344) which were not isolated. The individual enantiomers were 
extracted and the acid sensitive ds-prop-l-enyl and p-methoxybenzyl groups were 
cleaved under acid conditions using 1M aqueous HC1 in ethanol (1:2) at reflux 
temperature for 3h. The solvents were evaporated in vacuo and the resulting solids were 
purified by flash chromatography to give L-2,3,5-tri-(9-benzyl-myo-inositol (345), used 
for the synthesis of L-Ins(l,4,6)P3 and D-2,3,5-tri-(9-benzyl-myo-inositol (346), used for 
the synthesis of D-Ins(l,4,6)P3. The two triols were isolated in 67% yield for (345) and 
in 71% yield for (346). The melting point (176-177°C) for both enantiomers was also 
higher than the racemate by 16°C and the specific rotations [a]D = -34° and [a]D = +34° 
were equal and opposite. The NMR data were the same as for the racemic material.
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The chiral triols were essentially synthesised in the same way as for the racemic mixture 
and summarised in Figure 107. The difference was in the chromatography solvent 
which was changed to chloroform-acetone (10:1). It was found that this system easily 
separated the phosphonate impurities from the required totally protected product. The 
specific rotations also provided a problem because both compounds appeared to read 
zero on the polarimeter. Thus the readings have been reported as 0° ± 1° for each of the
195
totally protected compounds (349) and (350). This specific rotation was then carried out 
at other wavelengths and the same result was found.
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Figure 108
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Deprotection of the enantiomers with sodium in liquid ammonia followed by 
purification on Q-Sepharose Fast Flow using a gradient of TEAB as buffer, gave d- 
Ins(l,4,6)P3 (199) in 34% yield and L-Ins(l,4,6)P3 (201) in 60% yield. The rotations for 
the respective compounds at pH 8.6 in 1M TEAB buffer were [a]D = -29.1° and [a]D = 
+25.0°. The size of the rotation in TEAB buffer was much larger than in water, 
probably due to the interaction of the triethylamine moiety with the phosphate groups 
and was also observed for the tetrakisphosphates. The literature values, which have just 
been published, for D-Ins(l,4,6)P3 and L-Ins(l,4,6)P3 were [a]D = -8.9° (c = 0.90, H20) 
and [a]D = +9.4° (c = 0.85, H20), prepared by a totally different route by Ozaki and 
coworkers. Thus the sign of the rotation of each enantiomer (199,201) agreed with that 
prepared by Ozaki and coworkers. *4321
The !H and 31P NMR spectra for D-Ins(l,4,6)P3 are given in Figure 108. For the *H 
NMR spectrum at 5 = 3.44, (t, J = 9.15Hz for C-5-H) a 5 = 3.58, (dd, J = 9.77 and 
2.5Hz, for C-3-H), whilst C-l-H was at 8 = 3.93, (br dt, J = 9.46 and 2.5Hz). The two 
overlapping signals at 8 = 4.07 were C-2-H as a broad singlet and C-4-H (q, J = 
9.16Hz). C-6-H was deshielded more than C-4-H and appeared at 8 = 4.20 (q, J = 
9.16Hz). The 31P NMR (162MHz) showed three singlets in the 31P-1H-decoupled 
spectrum and as doublets in the ]H-3^ -coupled spectrum, 8 = -0.03 (d, J = 9.52Hz), 8 = 
+0.39 (d, J = 8.79Hz) and 8 = +0.97 (d, J = 8.3Hz). Both compounds gave satisfactory 
accurate -ve FAB spectra.
5.6.2 Synthesis of D-Ins(l,4,6)PS3
The phosphitylating procedure was carried out as for the racemic compound, and the 
route is shown in Figure 107. Sulphoxidation was carried out in the same way as for the 
racemic compound in order to obtain the totally protected D-trisphosphorothioate (351). 
The work up and purification steps for the protected intermediate were also the same as 
for the racemic compound. The specific rotation was low because the polarimeter 
indicated a zero reading as for the protected chiral phosphates, thus a rotation of 0° ± 1° 
was registered at 589nm and at other wavelengths. Deprotection of the fully blocked 
compound using sodium in liquid ammonia followed by purification on Q-Sepharose, 
eluting with a gradient of TEAB buffer gave D-Ins(l,4,6)PS3 (352) in 36.5% yield. The 
specific rotation for D-Ins(l,4,6)PS3, was found to be -26.9° at pH 8.6 in TEAB buffer 







The !H NMR spectrum for D-Ins(l,4,6)PS3 is given in Figure 109 and was the best 
recorded spectrum for a water soluble myo-inositol phosphate or phosphorothioate 
analogue prepared by the author. The spectrum shows six clear signals at 8 = 3.42 (t, J 
= 9.16Hz for C-5-H) and 8 = 3.56 (dd, J = 2.75, 9.77Hz for C-3-H) and both these 
positions were unphosphorylated. The next three signals were the phosphorylated 
hydroxyl positions at 8 = 3.99 (dt, J = 2.74, 9.77Hz for C-l-H), 8 = 4.24 (q, J = 9.46Hz 
for C-4-H) and 8 = 4.36 (q, J = 9.76Hz for C-6-H) and C-2-H was seen at 8 = 4.42 as a 
singlet. The 31P NMR spectra for D-Ins(l,4,6)PS3 are given in Figure 110. The 31P 
spectrum showed three sharp singlets and as doublets in the 1H-31P coupled spectrum, at 
8 = +47.31 (d, J = 11.45Hz), and 8 = +48.24 (d, J = 11.44Hz) and 8 = +50.00 (d, J = 





5.6.3 Establishing the Absolute Configuration D-2,3,5-Tri-0-Benzyl-myo-Inositol
A literature search was used to find a possible target compound that could be 
synthesised in a small number of steps in order to identify the absolute configuration of 
D-2,3,5-tri-0-benzyl-my<9-inositol (346). From the literature, we found d -  and l - 1,2,4,5- 
tetra-O-benzyl-myo-inositol whose rotations were [a]D = -4.3° and +3.9° respectively, 
which had a melting point of 105-107°C. [3861 Gigg and coworkers determined the 
absolute configuration of these two compounds from the known derivatives d -  and l -
2,4,5-tri-O-benzyl-myo-inositol, by selective benzylation at the 1-position to give the 























l -  1,2,4,5-Tetra-O-benzyl-wyo-inositol (355 in Figure 111) was synthesised from d - 1 ,4 -  
di-0-allyl-2,3,5-tri-0-benzyl-6-0-p-methoxybenzyl-myo-inositol (342). The p- 
methoxybenzyl group was removed from (342) by acidic hydrolysis using 1M HC1- 
ethanol (1:2) at reflux temperature for 4h. The solvents were evaporated in vacuo 
followed by work up and purification by flash chromatography to provide D-l,4-di-0- 
allyl-2,3,5-tri-O-benzyl-ray0-inositol (353) in 91% yield as a syrup, [a]D = -3° (c = 9 in 
CH2C12). The exposed 6-hydroxyl group was then benzylated with benzyl bromide and 
sodium hydride in DMF to give D-l,4-di-0-allyl-2,3,5,6-tetra-0-benzyl-myo-inositol
(354) in 90% yield after work up and flash chromatography. Gigg and coworkers [386J 
prepared racemic (354) which was isolated as a syrup, however, chiral (354) was a low 
melting point solid, 63-65°C (from pentane and had a rotation of [a]D = +18° (c = 1 in 
CH2C12). The allyl groups were then removed in a one pot reaction using palladium on 
carbon in the presence of toluene-p-sulphonic acid at reflux temperature for 2h in 
ethanol-water (6:1, 30ml). First the allyl group was isomerised to a mixture of the cis
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and trans-prop-l-enyl deivatives, and second the prop-l-enyl derivatives were 
hydrolysed with toluene-p-sulphonic acid. The mixture was filtered through celite and 
the solvents were evaporated. The residue was then purified by flash chromatography 
(ethyl acetate-dichloromethane, 1:1) to give pure D-2,3,5,6-tetra-0-benzyl-myc>-inositol
(355) in 61% yield, which is the same as L-l,2,4,5-tetra-0-benzyl-raye>-inositol. The 
specific rotation was found to be [a]D = +4.0° (c = 2 in CH2C12), and agreed well with 
the literature value [386J of [a]D = +3.9° (c = 1 in CHC13). The melting point of the 
compound was also similar, (103-105°C) and in good agreement with the literature 
value of, 105-107°C.
After this work had been completed, the synthesis of d -  and L-Ins(l,4,6)P3 by a different 
route was published and the sign of the rotational values were the same for each 
enantiomer, although the size of the rotation was different due to the nature of the 
counterions and solvent used for this determination.
5.7 Synthesis of Benzene 1,2,4-Trisphosphate
An analogue loosely based on the arrangement of the phosphate groups at the 1-, 4- and 
5-positions was benzene 1,2,4-trisphosphate (360). In this analogue, the 4-, 1- and 2- 
positions represent the 1-, 4- and 5-positions of Ins(l,4,5)P3 respectively. However, 
there are no hydroxyl groups at the 3-, 5- and 6-positions of the benzene ring.
The synthesis of benzene 1,2,4-trisphosphate (360 in Figure 112) was carried out in a 
few steps using commercially available starting materials. Benzene 1,2,4-triol (356) 
was obtained from Aldrich Chemical Company and was in the form of an amorphous 
grey powder. When the triol (356) was added to a mixture of dry N,N- 
diisopropylethylamine in dry dichloromethane, the solution changed immediately to a 
blood red colour. The solution was then cooled to -78°C with a dry ice-acetone cooling 
bath. Diethoxychlorophosphine was then added dropwise and the hydroxyl groups were 
phosphitylated when the solution changed from blood red to a pale yellow colour. At 
the 1,2,4-trisphosphite triester stage (357) an AB 31P-3ip coupling pattern was observed 
for the 1- and 2-positions, J12 = 6.10Hz, centered around 6 = +134ppm and 8 = 
+133.2ppm for the 4-position. The cooling was then removed and the excess 
phosphitylating reagent was hydrolysed with water (2ml) after which the trisphosphite
(357) was oxidised to the trisphosphate (358) with f-butylhydroperoxide and the AB 
coupling pattern was destroyed. After work up and flash chromatography the pure 





























The six ethyl groups of l,2,4-tris(diethoxyphospho)-benzene (358) were removed in a 
two step process. First, an excess of bromotrimethylsilane was added to a solution of
(358) in dry dichloromethane. The reaction was stirred overnight, after which the 
protective ethyl groups had been replaced with trimethylsilyl moieties, in quantitative 
yield as judged by 31P NMR. The three phosphorus peaks for (358) at 8 = -3.61, -3.92 
and -4.28ppm were shifted upfield to 5 = -22.14, -22.61 and -23.35ppm for (359). The 
lower boiling solvents were evaporated and the silicon protective groups were then 
removed from (359) by the addition of water (1ml).
Final purification of the product was achieved by elution from Q-Sepharose Fast Row 
using a linear gradient of TEAB buffer, 0-1000mmol. Benzene 1,2,4-trisphosphate 
(360) was eluted between 200-500mM buffer and was evaporated to give a glassy 
triethylammonium salt in 86% yield. The Briggs phosphate test was only used for the 
quantitative test because (360) was detected using the UV monitor. The three signals in 
the 31P NMR spectrum of (360 in Figure 113) showed three singlets at -3.61, -3.92 and 
-4.28ppm. A satisfactory accurate -ve FAB mass spectrum was also obtained for (360).
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Attempts were made to synthesise benzene 1,2,4-trisphosphorothioate. However, when 
sulphoxidation of the trisphosphite was carried out using sulphur in pyridine-DMF, the 
only product that formed judged by 31P NMR was the symmetrical thiopyrophosphate at 
5 = +56ppm. This compound will be synthesised later by a different approach using 
another sulphurising reagent.
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5.7.1 Pharmacology
Benzene 1,2,4-trisphosphate (360) has been prepared by another group l461! and by a 
different method using P(V) phosphorylation and the phosphorylated intermediate was 
not purified or characterised. It was found by these workers that this compound 
inhibited 3-kinase phosphorylation of [3H]Ins(l,4,5)P3 with an IC50 = 6.1|iM (from 
bovine adrenal cortex). It also inhibited the dephosphorylation of [3H]Ins(l,4,5)P3 with 
an IC50 = 32pM (from adrenal cortex microsomes) which indicated in this system at 
least, the affinity of (360) for Ins(l,4,5)P3 phosphatase was similar to or slightly higher 
than Ins(l,4,5)P3. This compound was also found to be a very weak antagonist at the
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Ins(l,4,5)P3 receptor, IC50 = 428|iM from a microsomal preparation. Thus, further 
modification of this structure may lead to a full antagonist.
The benzene 1,2,4-trisphosphate we prepared was tested on 5-phosphatase from HEG 
preparations, and had a Kx value of 7|iM, (carried out by S. T. Safrany at Leicester 
University). No data on 3-kinase activity were available. However, this compound was 
tested on Ptdlns 3-kinase, an enzyme which phosphorylates the minor phospholipid 
PtdIns(4,5)P2 to give PtdIns(3,4,5)P3. It was found (by S. Ward at Bath University), that 
(360) inhibited Ptdlns 3-kinase activity in p85 mAb (monoclonal antibody) 
immunoprecipitates with an IC50 value of 25pM ± 2.5. It was also found that l -chiro- 
Ins(2,3,5)P3 and L-c/»Vo-Ins(2,3,5)PS3 discussed earlier also inhibited the Ptdlns 3- 
kinase activity in p85 mAb immunoprecipitates with an IC50 value of 5|iM ±3.5 and 20 
pM ± 5. The results for these experiments are shown in Figure 114. This is the first 
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5.8 Outlook
In 1883 Ringer [176] discovered that cardiac muscle could not continue to beat in vitro if 
a minimum concentration of extracellular Ca2+ was absent. Exactly a century later a 
paper presented in Nature ^  described the linkage between the binding of the water
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soluble molecule Ins(l,4,5)P3 and the release of Ca2+ from intracellular stores. Since 
1983, the role of Ins(l,4,5)P3 and its metabolism has asked more questions than has 
given answers, but has also provided new avenues for research, although its importance 
as a mobiliser of Ca2+ ions should not be undermined. The response of the receptor to 
Ins(l,4,5)P3 in different cell types, in terms of receptor binding and Ca2+-release may 
provide new targets for drug design, once the inherent hydrophilic properties of 
Ins(l,4,5)P3 analogues have been overcome and new lipophilic molecules have been 
synthesised.
Specific small molecule antagonists for certain cell types, would be invaluable as tools 
for investigating the response downstream of the receptor, following the consequences 
of zero Ca2+-release in vivo, and may give some indication of specific function for that 
receptor-type. Analogues that have been described in this thesis, in particular d l -  
Ins(l,4,6)PS3, have contributed to the development of small molecule antagonists, 
although this molecule is a partial agonist. Further modification will be necessary to 
provide a full antagonist. The development of specific and potent small molecule 3- 
kinase and 5-phosphatase inhibitors would be invaluable, together with inhibitors of 
enzymes further downstream of Ins(l,4,5)P3. Once an inhibitor has been synthesised, it 
must pass across the cell membrane in order to reach its target, and cell permeable 




6 General Information For Experimental
Unless stated, myo-inositol derivatives were racemic and are drawn in the d -  
configuration. The naming of the d -  and L-enantiomers were not interchanged so that the 
experimental is easy to follow. Thin layer chromatography (TLC) was performed on pre­
coated plates (Merck TLC aluminium sheets silica 60 F254) : the product was visualised by 
spraying with phosphomolybdic acid in methanol, followed by heating. Flash 
chromatography refers to the procedure developed by Still and coworkers I483] and was 
carried out on sorbsil C60 silica gel.
The NMR spectra for the nuclei 31P, ]H and 13C were recorded on a Jeol FX-90Q GX270, 
GX400 or GLIEX400 spectrometers. Chemical shifts were measured in parts per million 
(ppm) relative to tetramethylsilane (TMS), deuterium oxide (D20 ) or dimethyl 
sulphoxide-d6 (d6-DMSO). The NMR of samples recorded in D20  were approximately 
pH 4-5. The 31P NMR shifts were measured in ppm relative to external 85% phosphoric 
acid. Coupling constants, J were measured in hertz (Hz) and the following abbreviations 
are used: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, ex = 
exchanged with D20  and Cq = quaternary carbon. Melting points (uncorrected) were 
determined using a Reichert-Jung Thermo Galen Kofler block, using two glass plates. 
Microanalysis was carried out by the University of Bath microanalysis service. Low 
resolution mass spectra were recorded by the University of Bath Mass Spectrometry 
Service using +ve and -ve Fast Atom Bombardment (FAB) with 3-nitrobenzyl alcohol 
(NBA) as the matrix. High resolution accurate mass spectrometry was carried out by the 
SERC Mass Spectrometry Service in Swansea. Optical rotations were measured using an 
Optical Activity Ltd. AA-10 polarimeter using 1ml, 2.5ml or 5ml cells. All rotations 
were measured out at ambient temperature.
Chemicals were purchased from Aldrich, Fluka, Lancaster and Fisons chemical 
companies. Ether refers to diethyl ether, light petroleum refers to the boiling range of 40- 
60°C and evaporation refers to solvent removed under reduced pressure. The term in 
vacuo, refers to the removal of solvent on a cold finger rotary evaporator at ImmHg or 
below. Ether, A^N-dimethylformamide (DMF), dichloromethane, and ethyl acetate were 
distilled from phosphorus pentoxide and stored over 4A sieves. Triethylamine and N,N- 
diisopropylethylamine were distilled from calcium hydride. Af,A-Diisopropylamine was 
distilled from sodium hydroxide pellets and pyridine was distilled from potassium 
hydroxide pellets. Phosphorus trichloride was purified by refluxing for lh followed by
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distillation and potassium f-butoxide was purified by sublimation at 225°C/lmmHg. 
Benzyl alcohol and DMSO were purchased in anhydrous form and stored over 4A sieves. 
Sodium hydride was 60% pure and used in a dispersion oil.
Ion exchange chromatography was performed on an LKB-Pharmacia Medium Pressure 
Ion Exchange Chromatograph using Q-Sepharose and gradients of triethylammonium 
bicarbonate (TEAB) as eluent. Fractions containing phosphate and phosphorothioate 
were assayed by a modification of the Briggs phosphate test f484l in the following way. 
For the quantitative test, each sample was assayed by pipetting a known volume of 
sample into a test tube, which was heated to dryness. Three drops of concentrated 
sulphuric acid were added to each tube, which was heated in an oven at 175°C for lh. 
The tubes were allowed to cool, and water (250|il) was added to each sample in order to 
dissolve the residue. A solution of ammonium molybdate (500|il) [(12.5%w/v) in water 
together with concentrated sulphuric acid (8ml)] was added, followed by 250pl of 
hydroquinone solution [(0.5%w/v) in water (20ml) and one drop of concentrated sulphuric 
acid] which was then shaken, and finally 250pl of sodium sulphite solution [(20%w/v) in 
water (20ml)] was added. The mixture was heated to reflux temperature for 10s and a 
blue colour indicated the presence of inorganic phosphate. For the quantitive assays the 
solutions were transferred to volumetric flasks and made up to 10ml with milliQ water. 
The UV absorbance at 340nm was recorded using 3ml matched quartz cells. The 
concentration was calculated from two standard curves and drawn from UV absorbance 
values of known concentrations of KH2P 04 which were treated as above and measured at 
340nm. 0.1M and 1M HC1 was in the form of an aqueous solution.
6.1 The Synthesis o f DL-3,6-Di-0-Benzoyl m y0-Inositol-l,2,4,5-Tetrakisphosphate 
and DL-my0-Inositol-l,2,4,5-Tetrakisphosphate
6.1.1 DL-3,6-Di-0-benzoyl-l,2:4,5-di-O-isopropyIidene-my0-inositol (36)
The title compound was prepared according to Gigg and coworkers.[344]
A mixture of myo-inositol (lOOg, 0.55mol), DMF (500ml), 2,2-dimethoxypropane 
(400ml, 3.25mol) and toluene-p-sulphonic acid (2.0g, 10.5mmol), was stirred at 100-120° 
C for 2h. Triethylamine (20ml), was added to the clear cooled solution and the lower 
boiling solvents were evaporated at 50°C. Pyridine (300ml, 3.71 mol) was added to the 
DMF solution, followed by benzoyl chloride (400ml, 2.58mol), added dropwise, with 
stirring at 0°C over 30min. After a further 2h the solid was collected and washed
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successively with pyridine, water, acetone and ether to give the crude product (36). 
Yield, (77.54g, 29.8%).
m.p. 328-330°C (from DMF); (lit. ^  328-330°C).
5h (CDC13; 270MHz) 1.30, 1.43, 1.51, 1.64 (12H, 4s, CMe2), 3.73 (1H, dd, J 9.34, 10.99, 
H-5, Ins), 4.38 (1H, dd, J 5.13, 10.26, H-l, Ins), 4.41 (1H, dd, J 3.3, 9.71, H-4, Ins), 4.79 
(1H, t, J 4.4, H-2, Ins), 5.43 (1H, dd, J 4.22, 10.63, H-3, Ins), 5.61 (1H, dd, J 6.78, 11.17 
H-6, Ins), 7.26-7.62 (6H, m, Ins-0-C(0)Ph), 8.08-8.16 (4H, m, Ins-O-C(O)P^).
6.1.2 DL-l,4-Di-(9-benzoyl-/nyo-inositol (272)
DL-3,6-Di-0-benzoyl-1,2:4,5-di-0-isopropylidene-myo-inositol (36) (9.36g, 20mmol) was 
suspended in 80% acetic acid (200ml). The mixture was heated under reflux for 0.5h, 
cooled, and poured into an ice-water mixture (1000ml). The precipitated solid was 
filtered, washed thoroughly with ether and recrystallised from DMF-water to give the title 
compound (272). Yield, (7.25g, 93%).
m.p. 253°C (from DMF-water).
(Found: C, 61.9; H, 5.11. C20H20O8 requires C, 61.85; H, 5.15).
5h (d6-DMSO; 270MHz) 3.48 (1H, dt, J 4.65, 9.3, H-5, Ins), 3.73 (1H, ddd, J 2.25, 6.9, 
9.52, H-3, Ins), 3.93 (1H, dt, J 5.49, 9.53, H-6, Ins), 4.07 (1H, br t, J 2.00, H-2, Ins), 4.83 
(1H, dd, J 2.00, 10.00, H-l, Ins), 4.97 (1H, d, J 6.6, D20  ex, Ins-OH), 5.25-5.33 (2H, m, 
D20  ex, Ins-OH), 5.35 (1H, t, J 9.9, H-4, Ins), 5.38 (1H, d, J 4.2, D20  ex, Ins-OH), 7.50- 
7.69 (6H, m, Ins-0-C(0)/>/i), 8.00-8.09 (4H, m, Ins-0-C(0)P/i).
8C (d6-DMSO; 68MHz) 69.83, 70.77, 70.93, 73.07, 75.70, 76.28 (6d, CH, wyo-inositol 
ring carbons), 129.34, 130.12, 130.25, 130.64, 133.85, 134.14 (6d, Ins-0-C(0)Ph), 
131.13 (s, Cq, Ins-0-C(0)Ph\ 166.58 (s, Cq, Ins-0-C(0)Ph).




A mixture of DL-l,4-di-0-benzoyl-myoinositol (272) (0.776g, 2mmol), dry DMF (10ml) 
and dry 7V,N-diisopropylethylamine (2.8ml, 16mmol), was stirred under an atmosphere of 
nitrogen at room temperature. The solution was cooled in an ice bath and 
diethoxychlorophosphine (273) (2.32ml, 16mmol) was added dropwise over a period of 
5min and then warmed to room temperature. After stirring for lh, 70% t- 
butylhydroperoxide, (3ml, 21.8mmol) was added to the reaction mixture at -78°C to give 
the crude product, R{ = 0.20 (ethyl acetate). The solvents were evaporated in vacuo and 
the remaining solid was partitioned between water and dichloromethane (50ml of each). 
The organic layer was washed with 10% sodium metabisulphite solution, brine (20ml of 
each) and finally water (2x20ml). The organic layer was dried over magnesium sulphate 
and evaporated to give a solid. The crude product was purified over silica gel (ethyl 
acetate) and the solvent was evaporated to give the pure title compound (275). Yield, 
(1.547g, 83%).
m.p. 122-123°C (from ethyl acetate-hexane).
(Found: C, 46.1; H, 6.03. C36H56O20P4 requires C, 46.35; H, 6.00).
5h (CDC13; 400MHz) 0.82-0.88 (9H, m, Ins-0-P(0)0CH 2C //3), 1.20-1.33 (15H, m, Ins- 
0-P(0)0C H 2Ctf3), 3.52-3.85 (6 H, m, Ins-0-P(0)0C//2CH3), 4.01-4.21 (10H, m, Ins-O- 
P (0)0C tf2CH3), 4.79 (2H, q, J 9.46, H-l and H-5, Ins), 5.15 (2H, q, J 9.16, 9.46, H-4, 
Ins), 5.25 (1H, td, J 2.44, 9.16, H-2 or H-3, Ins), 5.29 (1H, td, J 2.13, 10.07, H-2 or H-3, 
Ins), 5.90 (1H, t, J 10.07, H-6 , Ins), 7.43-7.59 (6 H, m, Ins-0-C(0)P/i), 8.17-8.24 (4H, m, 
Ins-O-C(O)PZi).
5C (CDC13; 6 8 MHz) 15.24, 15.34, 15.79, 15.89 (4q, Ins-0-P(0)0CH 2CH3), 63.66, 63.79, 
64.22 (3t, Ins-0-P(0)0CH2CH3), 70.02,73.27, 75.05, 75.37, 76.35 (5d, CH, myo-inositol 
ring carbons), 129.02, 129.70 (2s, Cq, Ins-O-C(O)P^), 128.11, 128.21, 130.12, 130.38, 
133.14, 133.37 (6 d, Ins-0-C(0)F7i), 165.32 (s, Cq, Ins-0-C(0)Ph).
SP (CDC13; 162MHz) -1.53, -2.11, -2.18, -2.49 0H-31P decoupled).




0.1 mmol) in dry dichloromethane (5ml), was stirred at room temperature under an 
atmosphere of nitrogen. Bromotrimethylsilane (0.264ml, 2mmol), was added to the dry 
dichloromethane, and the mixture was stirred overnight. The solvents were evaporated 
and the residue was stirred with water (2ml), for lh. Final purification of a third of the 
compound was carried out by ion exchange chromatography, on Q-Sepharose, using a 
buffer gradient of TEAB 200-1000mmol and flow rate 5ml/min. The fractions which 
gave a positive Briggs test and eluted at ca. 500mmol buffer, were pooled to give pure 
(276). Yield, (27pmol, 81%).
5h (D20 ; 270MHz) 4.54-4.62 (2H, m, H-l and H-5, Ins), 4.80 (1H, H-4, Ins, obscured by 
HDO peak), 5.07 (1H, d, J 10.25, H-3, Ins), 5.23 (1H, d, J 10.07, H-2, Ins), 5.61 (1H, t, J
9.89, H-6 , Ins), 7.47-7.66 (6 H, m, Ins-0-C(0)Ph), 8.09-8.16 (4H, m, Ins-0-C(0)Ph).
8 C (D20 ; 6 8 MHz) 71.51,72.39, 73.88, 74.95 (4d, CH, myo-inositol ring carbons), 128.56,
128.98 (2s, Cq, Ins-0-C(0)P/i), 128.04, 128.79, 129.54, 129.70, 133.22 (5d, CH, Ins-O- 
C (0 )Ph), 167.52, 167.74 (2s, Cq, Ins-O-C(O)Ph).
8 p (D20 ; 162MHz) -0.22 (d, J 9.76, -CH-O-PO32), -0.39 (d, J 10.68, -CH-O-PO32), - 
0.49 (d, J 11.9, -CH-O-PO32-), -0.79 (d, J, 8.83, -CH-O-PO32 ).
m/z (-ve ion FAB) 707 [M - H, (100%)] 460 (12%) 387 (30%) 232 (95%) 177 (20%) 
159 (44%) 97 (30%).
Accurate mass spectrum requires: (M - H)_ = 706.9732. Found 706.9730.
6.1.5 DL-myo-Inositol-l,2,4,5-tetrakisphosphate (152)
Crude DL-myo-inositol-3,6-di-0-benzoyl-l,2,4,5-tetrakisphosphate (276) (0.1mmol), was 
heated with 1M sodium hydroxide (3ml), at 60°C for lh. Dowex (H+ form) was added 
with water (30ml), until the pH was ~ 6 . The Dowex was filtered off, washed with water 
(2x20ml), and the benzoic acid was removed by washing with dichloromethane (2x30ml). 
The aqueous layer was then concentrated and the residue was purified by ion exchange
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chromatography, using a gradient of TEAB (0-1000mmol). The pure title compound 
(152) eluted at ca. 550mmol TEAB. Yield, (80p,mol, 80%).
8 H (D20 ; 400MHz) 3.70 (1H, d, J 10.07, H-3, Ins), 3.90 (1H, t, J 9.46, H-6 , Ins), 3.97-
4.04 (2H, m, H-l and H-5, Ins), 4.29 (1H, q, J 9.16, H-4, Ins), 4.80 (1H, H-2, Ins, 
obscured by HDO peak).
8 C (D20 ; 6 8 MHz) 69.86, 70.86, 73.91, 74.88, 76.41, 77.71 (6 d, CH, myo-inositol ring 
carbons).
8 P (D20 ; 162MHz) +1.31 (d, J 8.00, -CH-O-PO32), +1.15 (d, J 7.90, -CH-O-PO32*), 
+1.04 (d, J 9.9, -CH-O-PO32 ), -0.04 (d, J 6.00, -CH-O-PO32 ).
m/z (-ve ion FAB) 499 [M - H, (100%)] 481(5%) 401(5%) 154(10%) 97(7%).
Accurate mass spectrum requires: (M - H)~ = 498.9210. Found 498.9210.
6.2 Synthesis of d -  and L-myo-Inositol-l,2,4,5-Tetrakisphosphate and D-myo-Inositol-
1,2,4,5-Tetrakisphosphorothioate
6.2.1 DL-l,2:4,5-Di-0-isopropyIidene-myo-inositoI (37)
The title compound was prepared by the method of Gigg and coworkers. I344!
A mixture of DL-3,6-di-0-benzoyl-l,2:4,5-di-0-isopropylidene-myo-inositol (36) (40g, 
84mmol), sodium hydroxide (12g, 300mmol) and methanol (500ml), was heated under 
reflux for lh. The colourless solution was cooled, neutralised with carbon dioxide, 
diluted with water (200ml) and evaporated to dryness. The residue was extracted with 
dichloromethane (6x200ml), concentrated then recrystallised from ethyl acetate to give 
the title compound (37), R{ = 0.2 (ether). Yield, (17.8g, 82%).
m.p. 171-173°C (from ethyl acetate); (lit. I344! 171-173°C).
8 h (CDC13; 400MHz) 1.38, 1.46, 1.48, 1.54 (12H, 4s, CMex), 2.83 (1H, d, J 8.24, D20  ex, 
Ins-OH), 3.20 (1H, br s, D20  ex, Ins-OH), 3.33 (1H, t, J 10.07, H-5, Ins), 3.84 (1H, t, J 
9.77, H-4, Ins), 3.90 (1H, br d, J 7.94, D20  ex, dd, J 6.41, 10.68, H-6 , Ins), 4.03 (1H, br
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dd, J 4.58, 8.55, D20  ex, dd, J 4.27, 10.07, H-3, Ins), 4.08 (1H, dd, J 5.19, 6.1, D20  ex, 
dd, J 5.79, 5.5, H-l, Ins) 4.49 (1H, t, J 5.5, H-2, Ins).
5C (CDC13; 100MHz) 25.80, 25.85, 26.85, 26.92 (4q, CMe2\  69.70, 74.71, 77.63, 77.92, 
78.14, 81.86 (6 d, CH, myo-inositol ring carbons), 110.26, 112.67 (2s, Cq, CMe2).
6.2.2 DL-3,6-Di-(?-benzyl-l,2:4,5-di-CMsopropylidene-my0-inositol (106)
The title compound was prepared according to Gigg and coworkers. I344!
A mixture of DL-l,2:4,5-di-C-isopropylidene-myo-inositol (37) (9.1g, 35mmol), DMF 
(200ml) and sodium hydride (4.8g, 200mmol), was stirred at room temperature. Benzyl 
bromide (11.9ml, 0.1 mol), was added dropwise to the stirred solution and after 2h, TLC 
(ether-light petroleum, 1:1) showed a new spot Rf = 0.60. Methanol (50ml), was added 
dropwise to destroy the excess sodium hydride, water (2 0 0 ml) was added to the mixture 
and the product was extracted with ether (2x200ml). The ether layer was washed again 
with water (2 x2 0 0 ml), dried over magnesium sulphate, filtered and evaporated to give a 
white crystalline solid (106). Yield, (14.0g, 91%).
m.p. 152-154°C (from hexane); (lit. f344! 153-155°C).
8 h (CDC13; 270MHz) 1.31, 1.38, 1.46, 1.49 (12H, 4s, CMe2), 3.34 (1H, t, J 9.52, H-5, 
Ins), 3.67 (1H, dd, J 6.4, 10.4, H-4, Ins), 3.74 (1H, dd, J 4.2, 10.0, H-3, Ins), 3.98-4.07 
(2H, m, H-l and H-6 , Ins), 4.29 (1H, t, J 4.4, H-2, Ins), 4.76-4.91 (4H, m, Ins-0-C//2Ph), 
7.23-7.40 (10H, m, Ins-0-CH2Ph).
5C (CDC13; 6 8 MHz) 25.81, 26.95, 27.76 (3q, CMe2\  71.71, 71.84 (2t, Ins-0-CH2Ph),
74.24, 76.54, 77.03, 78.72, 79.76, 80.96 (6 d, CH, myo-inositol ring carbons), 109.76,
111.99 (2s, Cq, CMe2), 127.30, 127.69, 127.79, 128.05, 128.18, 128.25 (6 d, Ins-O- 
CH2P/i), 137.78, 138.07 (2s, Cq, Ins-0-CH2P/i).
6.2.3 DL-l,4-Di-C-benzyl-2,3-C-isopropyIidene-myo-inositol (277)
DL-3,6-Di-0-benzyl-l,2:4,5-di-O-isopropylidene-my<9-inositol (106) (5.28g, 12mmol), 
was dissolved in dichloromethane (100ml), followed by the addition of a catalytic amount
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of toluene-/?-sulphonic acid (2 0 mg, 0 .1  mmol) and one equivalent of ethane 1 ,2 -diol 
(0.565ml, 12mmol). The mixture was stirred at room temperature until the solvent 
became slightly turbid. TLC (ether) showed a major product R{ = 0.30, a trace product Rf 
= 0.06, and a trace of starting material Rf = 0.80. Triethylamine (2ml) was added to the 
reaction mixture and the solvent was evaporated. Purification by flash chromatography 
(dichloromethane-ethyl acetate, 1:1), gave the title compound (277). Yield, (3.84g, 80%).
m.p. 160-161°C (from ethyl acetate); (lit. t3491 161-163°C).
5h (CDC13; 270MHz) 1.33, 1.48 (6 H, 2s, CMe2), 2.96 (1H, br s, D20  ex, Ins-OH), 3.01 
(1H, br s, D20  ex, Ins-OH), 3.35 (1H, t, J 9.34, H-5, Ins), 3.51 (1H, d, J 10.25, H-3 Ins), 
3.52 (1H, t, J 9.9, H-6 , Ins), 3.92 (1H, t, J 9.52, H-4, Ins), 4.06 (1H, dd, J 5.31, 6.78, H-l, 
Ins), 4.27 (1H, dd, J 4.21, 5.13, H-2, Ins), 4.68, 4.91 (2H, AB, J 11.54, Ins-0-Ctf2Ph), 
4.77 (2H, s, Ins-0-Ctf2Ph), 7.24-7.41 (10H, m, Ins-0-CH2P/i).
5C (CDC13; 6 8 MHz) 25.88, 27.99 (2q, CMe2\  72.55, 73.27 (2t, Ins-0-CH2Ph), 71.51,
72.97, 73.98, 76.93, 79.17, 81.89 (6 d, CH, myo-inositol ring carbons), 109.85 (s, Cq, 




A mixture of DL-l,4-di-0-benzyl-2,3-0-isopropylidene-myo-inositol (277) (2.8g, 7mmol) 
and sodium hydride (0.72g, 30mmol) was dissolved in dry DMF (50ml). p- 
Methoxybenzyl chloride (2.9ml, 20mmol), was added dropwise at room temperature and 
stirred for 2h. TLC (ether-petroleum ether, 2:1) showed a new spot, Rf = 0.40. The 
excess sodium hydride was destroyed with methanol (1 0 ml) and the solvents were 
evaporated in vacuo. The remaining syrup was partitioned between water (100ml) and 
ether (100ml), washed with 0.1M HC1 (100ml), a saturated aqueous solution of sodium 
hydrogen carbonate (100ml), and water (100ml). The organic layer was dried over 
magnesium sulphate, the remaining syrup was purified by flash chromatography (ether- 
petroleum ether, 2:1) and the product was isolated as a syrup. Yield, (3.60g, 80%).
(Found: C, 73.0; H, 6.64. C42H480 8 requires C, 73.12; H, 6.87).
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5h (CDC13; 270MHz) 1.35, 1.51 (6 H, 2s, CMe2), 3.39 (1H, t, J 8.79, H-5, Ins), 3.67 (1H, 
dd, J 3.61, 8 .8 , H-3 or H-l, Ins), 3.74-3.80 (1H, obscured, H-3 or H -l, Ins), 3.77 (3H, s, 
Ins-0-CH2PhOMe), 3.79 (3H, s, Ins-0-CH2PhOAfe), 3.92 (1H, t, J 8.61, H-4 or H-6 , Ins),
4.09 (1H, t, J 6.60, H-4 or H-6 , Ins), 4.25 (1H, dd, J 4.03, 5.31, H-2, Ins), 4.71-4.88 (8 H, 
m, Ins-0-CZ/2Ph), 6.84 (4H, 2d, J 9.1 Ins-0-CH2P/iOMe), 7.21-7.41 (14H, m, Ins-O- 
CH2Ph and Ins-0-CH2P/iOMe).
8 C (CDC13; 6 8 MHz) 25.53, 27.59 (2 q, CMe2), 55.04 (q, Ins-0-CH2PhOMe), 73.10, 73.65, 
74.73 (3t, Ins-0-CH2Ph and Ins-O-CH2PhOMe), 74.37, 77.00, 78.91, 80.47, 81.70, 82.35 
(6 d, CH, myo-inositol ring carbons), 109.56 (s, Cq, CMe2), 113.52, 113.58, 114.10,
127.30, 127.63, 127.72, 127.82, 128.05, 128.21, 129.44 (lOd, Ins-0-CH2P/i and Ins-O- 
CH2P/iOMe), 131.78, 130.61 (2s, Cq, Ins-0-CH2P/iOMe), 138.04, 138.40 (2s, Cq, Ins-O- 
CH2P h \ 158.96 (s, Cq, Ins-0-CH2P/iOMe).
m/z (-ve ion FAB) 549 [M - benzyl (8 %)] 519 [M - p-methoxybenzyl (40%)] 335 
(10%) 258(30%) 137 [-0-CH2PhOMe (100%)] 107 [-0-CH2Ph (70%)].
6.2.5 DL-l,4-Di-C-benzyl-5,6-di-0-p-methoxybenzyl-myo-inositol (279)
DL-3,6-Di-C-benzyl-1,2 -0 -isopropylidene-4 ,5 -di-(9 -/7-methoxybenzyl-myo-inositol (278) 
(2.25g, 3.5mmol), was dissolved in a mixture of methanol-lM HC1 (9:1, 30ml), which 
was kept at 50°C for 30min. TLC (ether) showed a new spot R{ = 0.40. Sodium 
hydrogen carbonate (2 g), was added and the solvents were evaporated under reduced 
pressure. The product was extracted with dichloromethane (3x100ml), and the organic 
solvent was evaporated to give a solid. The crude product was purified by flash 
chromatography (ether-chloroform, 3:1), to give the title compound (279). Yield, (1.9g, 
90%).
m.p. 130-132°C (from ethyl acetate-hexane); (lit. £4741 130.4-130.6°C).
5h (CDC13; 270MHz) 2.53 (1H, d, J 4.4, D20  ex, Ins-OH), 2.62 (1H, s, D20  ex, Ins-OH),
3.43 (2H, overlapping, H-3 and H-l, Ins), 3.44 (1H, t, J 9.34, H-5, Ins), 3.78 (3H, s, Ins- 
0-CH2PhOMe), 3.79 (3H, s, Ins-0-CH2PhOAfe), 3.81 (1H, t, J 9.34, H-4 or H-6 , Ins), 
3.94 (1H, t, J 9.53, H-4 or H-6 , Ins), 4.25 (1H, br s, H-2, Ins), 4.70-4.96 (8 H, m, Ins-O- 
Ctf2Ph), 6.83 (2H, d, J 8 .8 , Ins-0-CH2P/iOMe), 6.84 (2H, d, J 8 .8 , Ins-0-CH2P/iOMe), 
7.21-7.36 (14H, m, Ins-0-CH2P/i and Ins-0-CH2P/iOMe).
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5C (CDC13; 6 8 MHz) 55.04 (q, Ins-0-CH2PhOMe), 72.68, 75.34, 75.50 (3t, Ins-0-CH2Ph 
and Ins-O-CH2PhOMe), 69.15, 71.71, 80.01, 81.28, 81.37, 82.93 (6 d, CH, myoinositol 
ring carbons), 113.74, 127.82, 127.89, 128.54, 129.41, 129.54 (5d, Ins-0-CH2P/i and Ins- 
0-CH 2P/iOMe), 130.68, 130.84 (2s, Cq, Ins-0-CH2P/zOMe), 138.49, 138.81 (2s, Cq, Ins- 
0-CH 2P/i), 159.12 (s, Cq, Ins-0-CH2P/iOMe).
m/z (-ve ion FAB) 753 [M + NBA, (40%)] 599 [M - H, (100%)] 509 [M - benzyl, 
(10%)] 479 [M - p-methoxybenzyl, (20%)] 335 (15%) 137 [-0-CH2PhOMe, (30%)] 
107 [-0-CH2Ph, (30%)].
6.2.6 d-(281) And L-l-0-[S-(+)-0-acetylmandeIyI]-3,6-di-0-benzyl-4,5-di-0-p- 
methoxybenzyl-myo-inositol (282)
A mixture of d l -  1,4-di-0-benzyl-5,6-di-0-p-methoxybenzyl-myo-inositol (279) (2.5g, 
4.17mmol), .5-(+)-0-acetylmandelic acid (280) (0.835g, 4.3mmol) and DMAP (0.03g, 
0.25mmol), was stirred in dichloromethane, (15ml) at -20°C (dry ice alone). DCC 
(0.877g, 4.33mmol) in dichloromethane (5ml) was added dropwise over 90min with 
stirring. The reaction mixture was stirred at room temperature overnight after which, 
TLC (chloroform-acetone, 30:1) showed two products, R{ = 0.44 and 0.34. The mixture 
was filtered through celite and washed thoroughly with dichloromethane (100ml). The 
solvent was evaporated to give a white solid and the individual diastereoisomers were 
separated by flash chromatography, (chloroform-acetone, 30:1) to give (281) Rf = 0.44, 
(36% yield) and (282) R{ = 0.34, (37% yield).
(281) m.p. 120-121°C (from ethanol).
(282) m.p. 147-148°C (from ethanol).
(281) [a]D = +12° (c = 1 in CH2C12).
(282) [a]D = +42° (c = 1 in CH2C12).
(281) (Found: C, 71.1; H, 6.27. C46H48On requires C, 71.10; H, 6.23).
(282) (Found: C, 70.8; H, 6.22. C46H48On requires C, 71.10; H, 6.23).
(281) 5h (CDC13; 400MHz) 2.16 (1H, s, D20  ex, Ins-OH), 2.19 (3H, s, Ins-02C-CH- 
(OAc)Ph), 3.44 (1H, dd, J 2.45, 9.46, H-3, Ins), 3.49 (1H, t, J 9.46, H-5, Ins), 3.77 (3H, s, 
Ins-OCH2PhOMe), 3.78 (3H, s, Ins-OCH2PhOMe), 3.91 (1H, t, J 9.46, H-4, Ins), 4.05 
(1H, t, J 10.07, H-6 , Ins), 4.15 (1H, br d, J 1.83, H-2, Ins), 4.61-4.81 (9H, m, Ins-
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OCtf2Ph, Ins-OCtf2PhOMe, and H-l, Ins), 5.94 (1H, s, Ins-02C-Ctf-(OAc)Ph), 6.82 (2H, 
d, J 8.54, Ins-OCH2P/*OMe), 6.83 (2H, d, J 8.85, Ins-OCH2P/zOMe), 7.17-7.44 (19H, m, 
Ins-OCH2P/i, Ins-OCH2P/iOMe and Ins-02C-CH-(0Ac)P/i).
5C (CDC13; 100MHz) 20.70 (q, Ins-02C-CH-(0Ac)Ph, -OC(0)CH3), 55.25 (q, Ins- 
OCH2PhOMe), 67.32, 74.78, 75.25, 78.42, 79.61, 80.72, 82.73 (7d, CH, mjo-inositol ring 
carbons and Ins-02C-CH-(0Ac)Ph), 72.80, 75.46, 75.58 (3t, Ins-OCH2Ph and Ins- 
OCH2PhOMe), 113.77 (d, Ins-OCH2P/*OMe), 127.34, 127.52, 127.76, 127.91, 128.29,
128.47, 128.82, 129.26, 129.42, 129.55 (lOd, Ins-OCH2Ph, Ins-OCH2P/zOMe and Ins- 
0 2C-CH-(0Ac)P/i), 130.76, 130.81, 133.37, 137.71, 138.31 (5s, Cq, Ins-OCH2P/i, Ins- 
OCH2P/zOMe and Ins-02C-CH-(OAc)P/i), 159.14, 159.18 (2s, Ins-OCH2P/zOMe), 
168.27, 170.75 (2s, Cq, Ins-02C-CH-(0Ac)Ph, -0C(0)CH3).
m/z (-ve ion FAB) 929 [M + NBA, (30%)] 775 [M - H, (58%)] 599 (50%) 193 (55%) 
149 (100%).
(282) ^  (CDC13; 400MHz) 2.17 (3H, s, Ins-02C-CH-(0Ac)Ph), 2.69 (1H, s, D20  ex, Ins- 
OH), 3.43 (1H, t, J 9.46, H-5, Ins), 3.49 (lH,dd, J 2.75, 9.77, H-3, Ins), 3.75 (3H, s, Ins- 
OCH2PhOMe), 3.77 (3H, s, Ins-OCH2PhOA/e), 3.93 (1H, t, J 9.77, H-4, Ins), 4.00 (1H, t, 
J 9.77, H-6 , Ins), 4.14, 4.46 (2H, AB, J 10.99, Ins-OC//2Ph or Ins-OCtf2PhOMe), 4.40 
(1H, br d, J 1.83, H-2, Ins), 4.61-4.84 (7H, m, Ins-OC//2Ph, Ins-OC//2PhOMe, and H-l, 
Ins), 5.98 (1H, s, Ins-02C-Ctf-(0Ac)Ph), 6.75 (2H, d, J 8.54, Ins-OCH2PAOMe), 6.82 
(2H, d, J 8.85, Ins-OCH2P/iOMe), 6.83-7.46 (19H, m, Ins-OCH2P/i, Ins-OCH2P/iOMe 
and Ins-02C-CH-(0Ac)P/i).
8 C (CDC13; 100MHz) 20.65 (q, Ins-02C-CH-(0Ac)Ph, -OC(0)CH3), 55.23, 55.27 (2q, 
Ins-OCH2PhOM^), 67.43, 74.94, 75.40, 78.40, 79.79, 80.74, 82.70 (7d, CH, myo-inositol 
ring carbons and Ins-02C-CH-(OAc)Ph), 72.80, 74.98, 75.58 (3t, Ins-OCH2Ph and Ins- 
OCH2PhOMe), 113.68, 113.75 (2d, Ins-OCH2P/zOMe), 127.19, 127.25, 127.89, 128.02, 
128.49, 128.84, 129.41, 129.50 (8 d, Ins-OCH2P^, Ins-OCH2P/*OMe and Ins-02C-CH- 
(OAc)P/z), 130.65, 130.83, 132.92, 137.63, 138.20 (5s, Cq, Ins-OCH2P/i, Ins- 
OCH2P/iOMe and Ins-02C-CH-(0Ac)P/z), 159.08, 159.16 (2s, Ins-OCH2P/iOMe),
168.58, 170.66 (2s, Cq, Ins-02C-CH-(OAc)Ph, -0C(0)CH3).




A mixture of D-l-O-[S-(+)-0-acetylmandelyl]-3,6-di-0-benzyl-4,5-di-0-/?-methoxy 
benzyl-myo-inositol (281) (0.956g, 1.23mmol), sodium hydroxide (0.40g, lOmmol) and 
methanol (100ml) was heated at reflux temperature for 30min. The mixture was cooled 
and neutralised with carbon dioxide. The resulting solid was diluted with water (50ml) 
and evaporated to dryness in vacuo. The crude product was extracted with 
dichloromethane (4x100ml) which was then evaporated to give a solid (283), R{ = 0.40 
(ether). Yield, (0.729g, 99%).
m.p. 133-134°C (from ethyl acetate-hexane).
[oc]D = -25° (c = 1 in CH2C12).
(Found: C, 72.1; H, 6.77. C36H40O8 requires C, 71.98; H, 6.71).
The mass spectrum and NMR data were identical to (279).
6.2.8 L-3,6-Di-(7-benzy 1-4,5-di-0-p-methoxybenzyl-myo-inositol (284)
A mixture of L-l-<9-[S-(+)-O-acetylmandelyl]-3,6-di-O-benzyl-4,5-di-0-p-methoxy 
benzyl-rayo-inositol (282) (0.929g, 1.19mmol), sodium hydroxide (0.40g, lOmmol) and 
methanol (100ml) was heated at reflux temperature for 30min. Work up as for the d -  
enantiomer gave the title compound (284) R{ = 0.40 (ether). Yield, (0.655g, 91%).
m.p. 133-134°C (from ethyl acetate-hexane).
[a]D = +25° (c = 1 in CH2C12)
(Found: C, 72.0; H, 6 .8 6 . C36H40O8 requires C, 71.98; H, 6.71).
The mass spectrum and NMR data were identical to (279).
6.2.9 D-3,6-Di-0-benzyl-myo-inositol (285)
d-3 ,6 -Di-0-benzyl-4,5-di-O-p-methoxybenzyl-myo-inositol (283), (0.624g, 1.04mmol) 
was suspended in 1M HCl-ethanol (60ml, 1:2). The mixture was heated at reflux 
temperature for 4h, cooled and the solvents were evaporated in vacuo. The resulting solid 
was filtered and washed with water (10ml) and ether (2x10ml). The solid was then
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recrystallised from ethanol to give the pure title compound (285), Rf = 0.60 (chloroform- 
methanol, 6:1). Yield, (0.323g, 8 6 %).
m.p. 172-173°C (from ethanol).
[a]D = +16° (c = 1 in methanol).
(Found: C, 6 6 .6 ; H, 6.73. C20H24O6 requires C, 66.65; H, 6.71).
8 h (d6-DMSO; 400MHz) 3.11 (1H, dd, J 2.44, 9.77, H-3, Ins), 3.15 (1H, dt, J 4.89, 8.85, 
D20  ex, t, J 9.15, H-5, Ins), 3.31 (1H, ddd, J 2.44, 6.72, 9.46, D20  ex, dd, J 2.44, 9.77, H- 
1, Ins), 3.44 (1H, t, J 9.46, H-6 , Ins), 3.60 (1H, dt, J 2.44, 5.8, D20  ex, t, J 2.44, H-2, Ins), 
4.51, 4.60 (2H, AB, J 12.21, Ins-0-Ctf2Ph), 4.67 (1H, d, J 6.71, DzO ex, Ins-OH), 4.74- 
4.81 (4H, m, Ins-OH and Ins-0-C//2Ph), 4.84 (1H, d, J 4.89, D20  ex, Ins-OH), 7.11-7.44 
(10H, m, Ins-0-CH2P/z).
8 C (d6-DMSO; 100MHz) 69.73, 72.25, 73.59, 75.03, 79.79, 81.82 (6 d, CH, myo-inositol 
ring carbons), 70.72, 71.43 (2t, Ins-0-CH2Ph), 126.92, 127.08, 127.48, 127.52, 127.63,
127.85, 127.99 (7d, Ins-0-CH2/>/i), 139.32, 139.94 (2 s, Cq, (7d, Ins-0-CH2P/i).
m/z (-ve ion FAB) 513 [M + NBA, (100%)] 359 [M - H, (75%)] 291 (50%) 228(30%).
6.2.10 L-3,6-Di-0-benzyI-myo-inositol (286)
L-3 ,6 -Di-0 -benzyl-4 ,5 -di-O-p-methoxybenzyl-my<9-inositol (284), (0.590g, 0.98mmol) 
was suspended in 1M HCl-ethanol (60ml, 1:2). The mixture was heated at reflux 
temperature for 4h, cooled and the solvents were evaporated in vacuo. The resulting solid 
was filtered and washed with water (10ml) and ether (2x10ml). The solid was then 
recrystallised from ethanol to give the pure title compound (286), R{ = 0.60 (chloroform- 
methanol, 6:1). Yield, (0.293g, 83%).
m.p. 172-173°C (from ethanol).
[a]D = -16° (c = 1 in methanol).
(Found: C, 66.4; H, 6.73. C20H24O6 requires C, 66.65; H, 6.69).
The mass spectrum and NMR data were identical to (285).
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6.2.11 A,A-DiisopropyIaminodichlorophosphine (289)
The title compound was prepared according to Tanaka and coworkers. f476J 
Dry A,A-diisopropylamine (288) (141ml, l.Omol) in dry ether (150ml) was added 
dropwise to a stirred solution of phosphorus trichloride (287) (44ml, 0.5mol) in dry ether 
(100ml) at -78°C. More dry ether (500ml) was added and the mixture was stirred for a 
further 15h at room temperature. The precipitated amine salt was then filtered and 
washed with 500ml of ether and evaporated to give an oil. The crude mixture was 
distilled, b.p. 62-63°C at 7mmHg (lit. b.p. 62-63°C at 7mmHg). Yield, (68.3g, 6 8 %). 
The product (289) was stored at -20°C.
5h (CDC13; 90MHz) 1.27 (12H, d, J 6.78, (Me)2C(H)N-PCl2), 3.93 (2H, septet, J 7.44, 
(Me)2C(//)N-PCl2).
5P (CDC13; 36.2MHz) +169.4 OH-decoupled).
6.2.12 Bis(benzyloxy)diisopropylaminophosphine (96)
The title compound was prepared by the method of Yu and Fraser-Reid. I375]
A mixture of 7V,7/-diisopropylaminodichlorophosphine (289) (23.59g, 0.116mol) in dry 
dichloromethane and dry triethylamine (34.8ml, 0.249mol) was stirred at -78°C under an 
atmosphere of nitrogen. Anhydrous benzyl alcohol (23.8ml, 0.23mol) was added 
dropwise and stirred for a further 2h. The amine salt was filtered and washed with a 
further two portions of dichloromethane (2x200ml). The organic layer was then washed 
with saturated sodium hydrogen carbonate (300ml) and water (300ml). The organic layer 
was dried over magnesium sulphate, filtered and evaporated to give a thick oil R{ = 0.78 
(hexane-triethylamine, 10:1) and the title compound (96) was pure by NMR. Yield, 
(38.46g, 96%).
5h (CDC13; 270MHz) 1.20 (12H, d, J 6.78, (Me)2C(H)N-PCl2), 3.60-3.80 (2H, m, 
(Me)2C(//)N-POCH2Ph), 4.65-4.82 (4H, m, -C//2Ph), 7.22-7.36 (10H, m, -CU2Ph).
8 C (CDC13; 6 8 MHz) 24.48, 24.61 (2q, (Me)2C(H)N-POCH2Ph), 42.9 (d, (Me)2C(H)N- 
POCH2Ph), 65.16, 65.45 (2t, -CH2Ph), 126.88, 127.11, 128.11 (3d, -CH2Ph).
8 P (CDC13; 36.2MHz) +147.86 ^P^H-decoupled).
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6.2.13 D-3,6-Di-0-benzyl-l,2,4,5-tetrakis[di(benzyIoxyphospho)]-my0-inositoI (293)
A mixture of bis(benzyloxy)diisopropylaminophosphine (96) (0.69g, 2mmol) and 1H- 
tetrazole (0.28g, 4mmol) in dry dichloromethane (5ml), was stirred at room temperature 
for 15min in order to form the tetrazolide intermediate (290). d - 3 ,6 -Di-O-benzyl-myo- 
inositol (285) (0.108g, 0.30mmol), was added to (290), and stirred for a further lOmin. 
The reaction mixture was cooled to 0°C and mCPBA (0.8g, 2.3mmol), (50-60%) was 
added and stirred for a further 30min. The mixture was diluted with ethyl acetate (50ml) 
and washed with 10% sodium metabisulphite (50ml), 1M HC1 and a saturated solution of 
sodium hydrogen carbonate then brine and water (50ml of each). The organic layer was 
separated then dried over magnesium sulphate and evaporated to give a syrup. The 
product was purified by flash chromatography, R{ = 0.20, (chloroform-acetone, 5:1) then 
(ethyl acetate-pentane, 2:1), in order to obtain the pure title compound (293) as a syrup. 
Yield, (0.395g, 94%).
[a]D = -3.5° (c = 2 in CH2C12).
(Found: C, 65.2; H, 5.54. C76H760 18P4 requires C, 65.14; H, 5.47).
5h (CDC13; 400MHz) 3.55 (1H, d, J 9.76, H-3, Ins), 3.98 (1H, t, J 9.46, H-6 , Ins), 4.41 
(1H, t, J 9.46, H-5, Ins), 4.48-5.11 (22H, m, Ins-0-(0)P0-Ctf2Ph, Ins-0-C//2Ph, H -l, H- 
4, Ins), 5.43 (1H, d, J 8 .8 6 , H-2, Ins), 6.94-7.41 (50H, m, Ins-0-(0)P0-CH2/>fc, Ins-O- 
CH 2Ph).
5C (CDC13; 100MHz) 69.18, 69.23, 69.29, 69.24, 69.42, 69.47, 69.53, 69.60, 69.65, 74.37 
(lOt, Ins-0-(0)P0-CH 2Ph, Ins-0-CH2Ph), 72.24, 74.37, 74.63, 75.43, 77.38, 78.66 (6 d, 
CH myo-inositol ring carbons), 127.19, 127.39, 127.57, 127.74, 127.85, 127.96, 128.09, 
128.16, 128.29, 128.45, 128.51, 128.65 (12d, Ins-0-(0)P0-CH2P/i, Ins-0-CH2P/z),
135.48, 135.55, 135.60, 135.73, 135.78, 135.84, 135.91, 136.01, 136.46, 137.94 (10s, Cq, 
Ins-0-(0)P0-CH2P/i, Ins-O-CH 2Ph).
5P (CDC13; 162MHz) -1.16, -1.66, -1.71, -2.07 (3ip-iH-decoupled). 
m/z (+ve ion FAB) 1401 [M + H, (7%)] 181(5%) 107(2%) 91(100%).
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6.2.14 L-3,6-Di-O-benzyl-l,2,4,5-tetrakis[di(benzyIoxyphospho)]-my0-inositol (294)
A mixture of bis(benzyloxy)diisopropylaminophosphine (96) (0.69g, 2mmol) and 1H- 
tetrazole (0.28g, 4mmol) in dry dichloromethane (5ml), was stirred at room temperature 
for 15min in order to form the tetrazolide intermediate (290). L-3,6-Di-0-benzyl-myo- 
inositol (286) (0.108g, 0.30mmol), was added to (290), and stirred for a further lOmin. 
The reaction was cooled to 0°C and mCPBA (0.8g, 2.3mmol), (50-60%) was added and 
stirred for a further 30min. The product (294) was extracted and purified by 
chromatography in the same way as (293). Yield, (0.37g, 8 8 %).
[oc]D = +3.3° (c = 1.26 in CH2C12).
(Found: C, 65.0; H, 5.72. C76H760 18P4 requires C, 65.14; H, 5.47).
The mass spectrum and NMR data were identical to (293).
6.2.15 d-myo-Inositol 1,2,4,5-tetrakisphosphate (295)
Ammonia (80ml), was distilled into a three neck flask and small pieces of freshly cut 
sodium metal (0.80g, 34.8mmol), were added until the solution remained blue. The dry- 
ice condenser was moved across to the reaction flask and ammonia (40ml), was gently 
transferred to the flask by heating. Small slithers of sodium (0.40g, 17.4mmol), were 
added to the ammonia until the colour remained blue once again. 3,6-Di-O-benzyl-
l,2,4,5-tetrakis[di(benzyloxyphospho)]-myo-inositol (293) (0.178g, 126|Limol), was
dissolved in dry dioxan (1ml), which was then added to the sodium in liquid ammonia. 
The reaction was left for 2min and quenched with methanol (20ml). The ammonia was 
evaporated under a stream of nitrogen and MilliQ water was then added to the residue 
which was evaporated to dryness in vacuo. The deprotected phosphate (295) was purified 
by ion exchange chromatography on Q-Sepharose using a gradient of TEAB buffer 0- 
lOOOmmol and eluted at ca. 800mmol. Yield, (50.02|iimol, 40%).
[a]D = -27.2° (c = 0.50 in TEAB, pH = 8 .6 ).
5h (D20 ; 400MHz) 3.59 (1H, d, J 9.77, H-3, Ins), 3.76 (1H, t, J 9.46, H-6 , Ins), 3.90 (2H, 
q, J 9.15, H-l, H-5, Ins), 4.16 (1H, q, J 9.46, H-4, Ins), 4.59 (1H, d, J 9.77, H-2, Ins).
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8 P (D20 ; 162MHz) +0.65 (d, J 9.28, -CH-O-PO32), +0.27 (d, J 9.04, -CH-O-PO32), - 
0.01 (d, J 9.04, -CH-O-PO32 ), -0.33 (d, J, 8.06, -CH-O-PO32).
m/z (-ve ion FAB) 499 [M -H , (100%)] 419(5%) 159(10%) 97(9%).
Accurate mass spectrum requires: (M - H)“ = 498.9208. Found 498.9226.
6.2.16 l-ray 0 -Inositol 1,2,4,5-tetrakisphosphate (296)
L-3,6-Di-O-benzyl-l,2,4,5-tetrakis[di(benzyloxyphospho)]-ray0-inositol (294) (0.1Og, 71|i 
mol), was deprotected as for (295) to give pure L-rayo-inositol 1,2,4,5-tetrakisphosphate
(296) after ion exchange chromatography. Yield, (15.56p.mol, 22%). The NMR spectra 
were slightly different due to the different pH of product in the NMR tube.
[oc]D = +25.8° (c = 0.31 in TEAB, pH = 8 .6 ).
5h (D20 ; 270MHz) 3.72 (1H, d, J 9.71, H-3, Ins), 3.90 (1H, t, J 9.53, H-6 , Ins), 4.03 (2H, 
q, J 9.34, H -l, H-5, Ins), 4.30 (1H, q, J 9.52, H-4, Ins), 4.71 (1H, bd, J 9.71, H-2, Ins).
8 P (D20 ; 109MHz) +1.78 (d, J 10.1, -CH-O-PO32), +1.44 (d, J 6.7, -CH-O-PO32), +1.20 
(d, J 6.7, -CH-O-PO3 2 ), +0.67 (d, J, 6.7, -CH-O-PO32).
m/z (-ve ion FAB) 499 [M - H, (100%)] 419 (10%) 159 (10%) 97 (10%).
Accurate mass spectrum requires: (M - H)' = 498.9208. Found 498.9187.
6.2.17 D-3,6-Di-0-benzyl-l,2,4,5-tetrakis[di(benzyloxyphosphorothio)]-myo-inositol
(297)
A mixture of bis(benzyloxy)diisopropylaminophosphine (96) (0.69g, 2mmol) and 1/7- 
tetrazole (0.28g, 4mmol) in dry dichloromethane (5ml), was stirred at room temperature 
for 15min in order to form the tetrazolide intermediate (290). D-3 ,6 -Di-0 -benzyl-my<9- 
inositol (285) (0.108g, 0.30mmol), was added to (290), and stirred for a further lOmin. 
The dichloromethane was evaporated to give a thick syrup, pyridine (1ml), dry DMF 
(2ml) and sulphur (0.096g, 3mmol) were added to the syrup and the mixture was then
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stirred for 5min after which time sulphoxidation was complete by NMR and TLC, Rf = 
0.50 (ether-pentane, 2:1). The excess sulphur was then filtered off, the solvents were 
evaporated in vacuo, and the syrup was dissolved in ethyl acetate (20ml). The solution 
was washed with 0.1M HC1, TEAB, brine and finally water (20ml each). The organic 
layer was dried over magnesium sulphate, filtered and purified by flash chromatography 
(ether-pentane, 2:1), to give (297) as a syrup. Yield, (0.373g, 85%).
[ot]D = -5.3° (c = 1.9 in CH2C12).
(Found: C, 62.1; H, 5.44. C76H760 18P4S4 requires C, 62.29; H, 5.23).
6 h (CDC13; 400MHz) 3.61 (1H, d, J 9.77, H-3, Ins), 4.07 (1H, t, J 9.16, H-6 , Ins), 4.39 
(1H, t, J 11.29, H-5, Ins), 4.50-5.17 (21H, m, Ins-0-(S)PO-C//2Ph, Ins-0-C//2Ph, H-l, H- 
4, Ins), 5.28 (1H, q, J 9.15, H-4, Ins), 5.58 (1H, d, J 8 .8 6 , H-2, Ins), 6.94-7.41 (50H, m, 
Ins-0-(S)PO-CH2P/i, Ins-O-CH 2Ph).
5C (CDC13; 100MHz) 69.58, 69.66, 69.73, 70.08, 71.94, 72.01, 73.95, 74.01 (8 t, Ins-O- 
(S)PO-CH2Ph, Ins-O-CH2Ph), 75.27, 75.35, 75.44, 77.80, 78.44, 79.42 (6 d, CH myo­
inositol ring carbons), 126.37, 126.86, 127.56, 127.72, 127.91, 127.99, 128.22, 128.34 
(8 d, Ins-0-(S)PO-CH2Ph, Ins-O-CH2Ph), 135.53, 135.59, 135.71, 135.77, 135.88,
135.97, 136.52, 137.36 (8 s, Cq, Ins-0-(S)PO-CH2P/z, Ins-0-CH2P/z).
5p (CDC13; 162MHz) +67.70, +68.31, +68.51, +68.96 (31P-!H-decoupled).
m/z (-ve ion FAB) 1371 [M - Bn, (7%)] 1281 [M - 2Bn, (1.5%)] 695(0.5%) 479(10%) 
293(100%) 96(5%).
6.2.18 D - m y o -Inositol 1,2,4,5-tetrakisphosphorothioate (298)
D-3,6-Di-C-benzyl-l,2,4,5-tetrakis[di(benzyloxyphosphorothio)]-myo-inositol (297) 
(0.090g, 61.4p.mol), was deprotected as for (295) to give pure D-myo-inositol 1,2,4,5- 
tetrakisphosphorothioate (298) after ion exchange chromatography on Q-Sepharose Fast 
Flow, using a TEAB buffer gradient of 0-1000mmol. Yield, (20.4jimol, 33.2%).
[a]D = -25.8° (c = 0.31 in TEAB, pH = 8 .6 ).
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5h (D20 ; 400MHz) 3.61 (1H, d, J 9.46, H-3, Ins), 3.86 (1H, t, J 9.46, H-6 , Ins), 4.18 (2H, 
q, J 9.77, H-l, H-5, Ins), 4.46 (1H, q, J 11.29, H-4, Ins), 4.83 (1H, d, J 11.59, H-2, Ins).
5P (D20 ; 162MHz) +49.14 (d, J 11.54, -CH-0-P(S)022), +50.20 (d, J 11.54, -CH-O- 
P(S)02 2 ), +50.64 (d, J 10.26, -CH-0-P(S)02 2 ), +51.47 (d, J, 12.18, -CH-0-P(S)022).
m/z (-ve ion FAB) 499 [M - H, (100%)] 419(10%) 159(10%) 97(10%).
Accurate mass spectrum requires: (M - H)‘ = 498.9208. Found 498.9187.
6.3 Establishing the Absolute Configuration of D-3,6-Di-0-Benzyl-myo-Inositol
6.3.1 Synthesis of D-3,6-di-0-[S-(+)-0-acetylmandelyl]-l,2:4,5-di-0-isopropylidene- 
m yo-inositol (299)
A mixture of d l -  1,2 :4 ,5 -di-0 -isopropylidene-my<9-inositol (37) (2.08g, 8 mmol), DCC 
(4.13g, 20mmol) and DMAP (0.05g, 0.4mmol) in dry dichloromethane (50ml) was stirred 
at 0°C under an atmosphere of nitrogen. 5-(+)-0-Acetylmandelic acid (3.88g, 20mmol) 
in dry dichloromethane (30ml) was added dropwise over 15min and the mixture was 
stirred overnight. The precipitated DCU was filtered through celite and the filtrate was 
evaporated to give a solid. The mixture of diastereoisomers were purified by flash 
chromatography R{ = 0.30 (chloroform-acetone, 16:1) but could not be separated. The 
mixture was recrystallised four times from methanol to give a single pure diastereoisomer 
(299) (0.89lg, 36.5%) in an unoptimised yield.
(299) m.p 212-214°C.
(299) [oc]D = +64° (c = 1 in CH2C12).
(299) (Found: C, 62.7; H, 5.88. C32H360 12 requires C, 62.74; H, 5.92).
(299) 5h (CDC13; 270MHz) 1.21, 1.29, 1.32, 1.57 (12H, 4s, CMe2\  2.17, 2.18 (6 H, 2s, 
Ins-02C-CH-(OAc)Ph), 3.23 (1H, dd, J 9,34, 11.01, H-5, Ins), 4.04 (1H, t, J 10.45, H-4, 
Ins), 4.15 (1H, dd, J 4.77, 6.61, H-l, Ins), 4.54 (1H, t, J 4.58, H-2, Ins), 5.08 (1H, dd, J 
4.22, 10.63, H-3, Ins), 5.22 (1H, dd, J 6 .6 , 10.99, H-6 , Ins), 6.01 (1H, s, Ins-02C-C//- 
(OAc)Ph), 6.11 (1H, s, Ins-02C-C//-(OAc)Ph), 7.33-7.52 (10H, m, Ins-02C-CH- 
(OAc)P/i).
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5C (CDC13; 6 8 MHz) 20.59, 20.72, 25.72, 26.56 (4q, CMe%), 26.69, 27.73 (2q, Ins-02C- 
CH-(OAc)Ph, -0C(0)CH3), 71.34, 74.05, 74.34, 74.48, 75.04, 75.67, 76.37, 78.65 (8 d, 
Ins-02C-CH-(0Ac)Ph and 6  CH myo-inositol ring carbons), 110.72, 112.61 (2s, CMe2),
127.92, 128.17, 128.54, 128.59, 129.07, 129.20 (6 d, Ins-02C-CH-(OAc)P/i), 167.74,
168.40, 169.85, 170.54 (4s, Ins-02C-CH-(OAc)Ph, -0C(0)CH3).
m/z (+ve ion FAB) 613 [M + H, (50%)] 555(30%) 149(90%) 107(100%).
6.3.2 D-l,2:4,5-Di-0-isopropylidene-myo-inositol (301)
A mixture of D-3,6-di-0-[S-(+)-<9-acetylmandelyl]-1,2:4,5 -di-CMsopropylidene-my0 - 
inositol (299) (0.74g, 1.21mmol), sodium hydroxide (0.40g, lOmmol) and methanol 
(100ml) was heated at reflux temperature for 30min. The mixture was cooled and 
neutralised with carbon dioxide. The solid was then diluted with water (50ml) and 
evaporated to dryness in vacuo. The crude product was extracted with dichloromethane 
(4x100ml) and the solvent was evaporated to give a white solid. The title compound 
(301) was purified by flash chromatography (ethyl acetate-dichloromethane, 1:1), Rf = 
0.20, (ether), dried over magnesium sulphate and evaporated to give the product. The 
solid was recrystallised from ethyl acetate to give (301). Yield, (0.27lg, 8 6 %).
m.p. 174-176°C (from ethyl acetate); (lit. 14781 176-177°C).
[a]D = -22° (c = 1 in acetonitrile); (lit. I478l -21.7°, c = 0.46 in acetonitrile).
(Found: C, 55.6; H, 7.88. C12H20O6 requires C, 55.4; H, 7.75).
The NMR data were identical to (37).
6.3.3 D-3,6-Di-0-benzyl-l,2:4,5-di-0-isopropylidene-my0-inositol (302)
A mixture of D-l,2:4,5-di-0-isopropylidene-myoinositol (301) (0.209g, 0.80mmol), 
DMF (10ml) and sodium hydride (0.096g, 4mmol), was stirred at room temperature. 
Benzyl bromide (0.2ml, 2mmol) was added and stirred for a further 2h. TLC (ether-light 
petroleum, 1:1) then showed a new spot Rf = 0.60. Methanol (2ml) was added to destroy 
the excess sodium hydride and the solvents were evaporated in vacuo. The residue was 
partitioned between water and ether (30ml each) and the organic layer was evaporated to 
give a solid. The title compound (302) was purified by flash chromatography (ether- 
pentane, 1:2) and recrystallised from hexane. Yield, (0.319g, 91%).
226
m.p. 157-159°C (from hexane); (lit. l475l 159-161°C, for L-enantiomer).
[a]D = -44° (c = 1 in CH2C12); (lit. [475l +85°, c = 1 in CHC13, for L-enantiomer).
(Found: C, 71.1; H, 7.35. C26H320 6 requires C, 70.89; H, 7.32).
The NMR data were identical to (106).
6.3.4 D-3,6-Di-O-benzyl-my0-inositol (285)
A mixture of D-3 ,6 -di-Obenzyl-l,2 :4 ,5 -di-0 -isopropylidene-ray<9-inositol (302) (0.274g, 
0.62mmol) and methanol-lM HC1 (50ml, 9:1), were heated at reflux temperature for 
30min. The solution was cooled and the solvents were evaporated to give a solid which 
was recrystallised from ethanol, R{ = 0.60 (chloroform-methanol, 6:1). Yield, (0.213g, 
95%).
m.p. 172-173°C (from ethanol).
[a]D = +16° (c = 1 in methanol).
The mass spectrum and NMR data were identical to (285) described previously.
6.4 Synthesis of 2,5-di-O-Methyl-my0-Inositol 1,3,4,6-Tetrakisphosphate, 2,5-Di-0- 
Methyl-myo-Inositol 1,3,4,6-Tetrakisphosphorothioate and myo-Inositol 1,3,4,6- 
Tetrakisphosphorothioate
6.4.1 DL-3,6-Di-O-allyl-l,2:4,5-di-(9-isopropyIidene-my0-inositol (303)
The title compound was prepared by the method of Gigg and coworkers. I349!
A mixture of d l -  1,2:4,5-di-<9-isopropylidene-rayo-inositol (37) (18.2g, 70mmol), DMF 
(200ml) and sodium hydride (4.8g, 200mmol), was stirred at room temperature. Allyl 
bromide (17.3ml, 200mmol) was added dropwise over a lOmin period and the mixture 
was stirred at room temperature for 3h. TLC (ether), showed a new product Rf = 0.80 and 
excess allyl bromide (R{ = 0.95). The reaction was cooled with ice and the excess sodium 
hydride was destroyed with methanol (20ml). The mixture was diluted with water 
(300ml) and the title compound extracted with ether (6x200ml). The ether solution was
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dried over magnesium sulphate and evaporated to give a solid. The solid was purified by 
flash chromatography to give the pure title compound (303). Yield, (20.50g, 8 6 %).
m.p. 85-86°C (from pentane); (lit. I349] 85-86°C).
8 h (CDC13; 270MHz) 1.38, 1.43, 1.45, 1.54 (12H, 4s, CMe2\  3.35 (1H, dd, J 9.34, 10.62, 
H-5, Ins), 3.66 (1H, dd, J 6.6,10.62, H-4, Ins), 3.80 (1H, dd, J 4.21, 10.26, H-3, Ins), 3.98 
(1H, t, J 9.89, H-6 , Ins), 4.09 (1H, dd, J 5.0, 6.41, H-l, Ins), 4.20-4.37 (4H, m, Ins-O- 
CH2CH=CH2), 4.47 (1H, t, J 4.5, H-2, Ins), 5.17-5.36 (4H, m, Ins-0-CH2CH=C7f2), 5.87-
6.05 (2H, m, Ins-0-CH2C//=CH2).
6.4.2 DL-l,4-Di-O-aIlyI-my0-inositol (304)
The title compound was prepared by the method of Gigg and coworkers. t485l 
DL-3,6-Di-0-allyl-l,2:4,5-di-0-isopropylidene-myo-inositol (303) (17g, 50mmol) was 
dissolved in 80% acetic acid (200ml) and the mixture was heated under reflux for 30min. 
The mixture was then cooled and the acetic acid was evaporated in vacuo to give a solid. 
The solid was co-evaporated in vacuo with water (100ml), to remove any remaining 
acetic acid. The resulting solid was recrystallised from ethanol to give the title compound
(304). Yield, (10.92g, 84%).
m.p. 136-137°C (from ethanol); (lit. I485l 137-139°C).
5h (d6-DMSO; 270MHz) 2.96 (1H, dd, J 2.38, 9.7, H-l, Ins), 3.01 (1H, dt, J 4.58, 8.79, 
H-5, Ins), 3.16-3.28 (2H, m, H-3 and H-4, Ins), 3.48 (1H, dt, J 4.76, 9.34, H-6 , Ins), 3.85 
(1H, br s, H-2, Ins), 3.97-4.28 (4H, m, Ins-0-C//2CH=CH2), 4.53 (1H, d, J 6.22, D20  ex, 
Ins-OH), 4.62 (1H, d, J 3.67, D20  ex, Ins-OH), 4.67 (1H, d, J 4.76, D20  ex, Ins-OH), 
4.69 (1H, d, J 4.77, D20  ex, Ins-OH), 5.01-5.33 (4H, m, Ins-0-CH2CH=C//2), 5.83-6.00 
(2H, m, Ins-0-CH2C//=CH2).
6.4.3 DL-l,4-Di-0-allyl-3,6-di-0-j7-methoxybenzyl-wyo-inositol (306) and DL-l,4-di-0- 
allyl-3,5-di-0-/?-methoxybenzyI-myo-inositol (305)
A mixture of d l -  1,4-di-O-allyl-myo-inositol (304) (5.2g, 20mmol) and dibutyltin oxide 
(12.5g, 50mmol) was suspended in toluene (400ml) and heated under reflux for 2.5h 
whilst removing water in a Dean and Stark apparatus. The solution was cooled and the
228
toluene was evaporated under reduced pressure. The crystalline tin complex was dried at 
130°C under reduced pressure for a further 0.5h. DMF (150ml) and CsF (15.19g, 
lOOmmol), were added to the tin complex and the suspension was stirred vigorously 
under nitrogen. p-Methoxybenzyl chloride (12.53g, 60mmol) was added dropwise and 
the reaction was monitored by TLC (ether). After 24h at room temperature, TLC showed 
two products, R{ = 0.40 and 0.56. The DMF solution was evaporated in vacuo and the 
residue was partitioned between a saturated aqueous solution of sodium hydrogen 
carbonate (300ml) and dichloromethane (300ml). The solution was stirred for 30min and 
the precipitated tin derivatives were filtered through celite. The celite was then washed 
with dichloromethane (2x100ml). The organic layer was separated and washed with 
water, saturated brine and water again (200ml of each). The dichloromethane solution 
was dried over magnesium sulphate and evaporated to give an oil. The mixture was 
purified by flash chromatography (ether-light petroleum, 2 :1) to give the title compounds, 
(306), (2.4lg, 24%) and (305) (1.2g, 12%).
(306) m.p. 115-117°C (from ethyl acetate-hexane).
(305) m.p. 94-95°C (from ethyl acetate-hexane).
(306) (Found: C, 66.9; H, 7.28. C28H360 8 requires C, 67.17; H, 7.25).
(305) (Found: C, 67.1; H, 7.20. C28H360 8 requires C, 67.17; H, 7.25).
(306) 5h (CDC13; 270MHz) 2.62 (2H, br s, D20  ex, Ins-OH), 3.24 (1H, dd, J 2.56, 9.52, 
H-3 or H -l, Ins), 3.30 (1H, dd, J 2.56, 9.52, H-3 or H-l, Ins), 3.41 (1H, t, J 9.34, H-5, 
Ins), 3.68 (1H, t, J 9.34, H-4 or H-6 , Ins), 3.76 (1H, t, J 9.52, H-4 or H-6 , Ins), 3.77 (3H, 
s, Ins-0-CH2PhOMe), 3.79 (3H, s, Ins-0 -CH2PhOMe), 4.04-4.42 (5H, m, Ins-O- 
CH2CH=CH2 and H-2, Ins), 4.58-4.85 (4H, m, Ins-0-Ci/2PhOMe), 5.14-5.33 (4H, m, 
Ins-0-CH2CH=C//2), 5.87-6.05 (2H, m, Ins-0-CH2C//=CH2), 6.84-6.90 (4H, m, Ins-O- 
CH2P/iOMe), 7.24-7.31 (4H, m, Ins-0-CH2P/zOMe).
5C (CDC13; 6 8 MHz) 55.2 (q, Ins-0-CH2PhOMe), 71.61, 72.29, 74.30, 75.15 (4t, Ins-O- 
CH2CH=CH2 and Ins-0-CH2PhOMe), 67.75, 74.21, 79.20, 79.40, 80.21, 80.27 (6 d, CH, 
myo-inositol ring carbons), 113.8 (d, Ins-0-CH2P/zOMe), 116.79, 117.38 (2t, Ins-O- 
CH2CH=CH2), 129.44, 129.64 (2d, Ins-0-CH2P/iOMe), 130.00 (s, Cq, Ins-O- 
CH2P/iOMe), 135.28, 134.67 (2d, Ins-0-CH2CH=CH2), 159.32 (s, Cq, Ins-O- 
CH2P/iOMe).
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m/z (-ve ion FAB) 653 [M + NBA, (35%)] 499 [M - H, (100%)] 379 [M - CH2PhOMe,
(30%)].
(305) 8 h (CDC13; 270MHz) 2.48 (1H, br s, D20  ex, Ins-OH), 2.57 (1H, br s, D20  ex, Ins- 
OH), 3.13 (1H, dd, J 2.75, 9.70, H-3 or H-l, Ins), 3.25 (1H, t, J 9.34, H-5, Ins), 3.33(1H, 
dd, J 2.74, 9.52, H-3 or H-l, Ins), 3.76 (1H, t, J 9.52, H-4 or H-6 , Ins), 3.79 (3H, s, Ins-O- 
CH2PhOMe), 3.80 (3H, s, Ins-0-CH2PhOMe), 3.94 (1H, t, J 9.52, H-4 or H-6 , Ins), 4.06-
4.43 (5H, m, Ins-0-C/f2CH=CH2 and H-2 Ins), 4.60-4.85 (4H, m, Ins-0-Ctf2PhOMe), 
5.16-5.34 (4H, m, Ins-0-CH2CH=C//2), 5.87-6.05 (2H, m, Ins-0-CH2C//=CH2), 6.85- 
6.90 (4H, m, Ins-0-CH2P/*OMe), 7.25-7.32 (4H, m, Ins-0-CH2P/*OMe).
5C (CDC13; 6 8 MHz) 55.23 (q, Ins-0-CH2PhOAte), 75.08, 74.43, 72.42, 71.26 (4t, Ins-O- 
CH2CH=CH2 and Ins-0-CH2PhOMe), 67.17, 72.00, 78.78, 79.46, 80.56, 82.41 (6 d, CH, 
myo-inositol ring carbons), 113.84 (d, Ins-0-CH2P/iOMe), 116.57, 117.74 (2t, Ins-O- 
CH2CH=CH2), 129.48, 129.61 (2d, Ins-0-CH2P/zOMe), 130.06, 130.84 (2s, Cq, Ins-O- 
CH2P/iOMe), 134.50, 135.28 (2d, Ins-0-CH2CH=CH2), 159.32, 159.32 (2s, Cq, Ins-O- 
CH2P/iOMe).
m/z (-ve ion FAB) 653 [M + NBA, (100%)] 499 [M - H (35%)] 460 [M - CH2CH=CH2, 
(20%)] 379 [M - CH2PhOMe (20%)] 335 (20%) 123 (40%).
6.4.4 DL-l,4-Di-0-allyl-3,6-di-0-/?-methoxybenzyl-2,5-di-0-methyl-myo-inositol (307)
A mixture of sodium hydride (0.48g, 20mmol) and d l -  1,4-di-0-allyl-3,6-di-(9-/?- 
methoxybenzyl-myo-inositol (306) (2.0g, 4mmol) was stirred in DMF (50ml) at room 
temperature. Methyl iodide (1.25ml, 20mmol) was added dropwise and the mixture was 
stirred for 3h. TLC (ether), showed one spot Rf = 0.80. The excess sodium hydride was 
destroyed with methanol (10ml) and the DMF solution was evaporated in vacuo. The 
product was taken up in ether (100ml), washed with water (50ml), brine (50ml) and water 
again (50ml). The organic layer was dried over magnesium sulphate, evaporated and 
purified by flash chromatography (ether-hexane, 2:1). The resulting syrup was 
recrystallised from hexane to give (307). Yield, (1.91g, 90%).
m.p. 93-94°C (from hexane).
(Found: C, 68.4; H, 7.73. C30H40O8 requires C, 68.15; H, 7.73).
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$h (CDC13; 270MHz) 3.04 (1H, t, J 9.25, H-5, Ins), 3.14 (1H, dd, J 2.38, 9.89, H-3 or H- 
1, Ins), 3.33 (1H, dd, J 2.20, 9.89, H-3 or H-l, Ins), 3.60 (3H, s, Ins-OMe), 3.64 (3H, s, 
Ins-OMe), 3.66-3.73 (3H, m, H-2, H-4, H-6 , Ins), 3.78 (3H, s, Ins-0-CH2PhOMe), 3.79 
(3H, s, Ins-0-CH2PhOAfe), 4.04-4.39 (4H, m, Ins-0-Ctf2CH=CH2), 4.40-4.85 (4H, m, 
Ins-0-C//2PhOMe), 5.14-5.32 (4H, m, Ins-0-CH2CH=Ctf2), 5.85-6.07 (2H, m, Ins-O- 
CH2C//=CH2), 6.85-6.90 (4H, m, Ins-0-CH2P/iOMe), 7.25-7.32 (4H, m, Ins-O- 
CH2P/zOMe).
5C (CDC13; 6 8 MHz) 55.10 (q, Ins-0-CH2PhOMe), 61.05, 61.20 (2 q, Ins-OM?), 71.76,
72.58, 74.27, 75.33 (4t, Ins-0-CH2CH=CH2 and Ins-O-CH2PhOMe), 77.53, 80.04, 80.14, 
81.21, 81.24, 85.36 (6 d, CH, myo-inositol ring carbons), 113.61 (d, Ins-0-CH2P/zOMe),
116.34, 116.73 (2t, Ins-0-CH2CH=CH2), 129.15, 129.65 (2d, Ins-0-CH2P/iOMe),
130.40, 131.07 (2s, Cq, Ins-0-CH2P/iOMe), 134.44, 135.89 (2d, Ins-0-CH2CH=CH2), 
159.04, 159.09 (2s, Cq, Ins-0-CH2P/iOMe).
m/z (-ve ion FAB) 681 [M + NBA, (60%)] 513 [M - Me, (60%)] 485 (43%) 440 (52%) 
335(50%) 276(45%) 258(48%) 154(100%) 120(62%).
6.4.5 2,5-Di-O-methyl-myo-inositoI (308)
A mixture of DL-l,4 -di-0 -allyl-3 ,6 -di-0 -/7-methoxybenzyl-2 ,5 -di-0 -methyl-myo-inositol
(307) (1.056g, 2mmol) and palladium on activated charcoal, (10% Fluka, 0.30g) and 
toluene-p-sulphonic acid (0.10g, 0.52mmol) was dissolved in a mixture of ethanol (55ml) 
and water (5ml) and refluxed for 24h. TLC (chloroform-methanol 3:1), showed a single 
product Rf = 0.2. The solution was filtered through celite and recrystation from ethanol 
gave the title compound (306). Yield, (0.32 lg, 77%).
m.p. 266-268°C (from ethanol); (lit. I377! 270°C).
(Found: C, 46.1; H, 7.70. C8H160 6 requires C, 46.13; H, 7.75).
5h (d6-DMSO; 270MHz) 2.65 (1H, t, J 9.0, H-5, Ins), 3.19 (2H, ddd, J 2.56, 5.31, 9.89, 
H-3 and H -l, Ins), 3.35 (1H, br s, H-2, Ins), 3.36 (2H, dt, J 4.95, 10.1, H-4 and H-6 , Ins),
3.44 (6 H, s, Ins-0M e\ 4.57 (2H, d, J 5.13, D20  ex, -OH), 4.67 (2H, d, J 4.76, D20  ex, - 
OH).
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8 C (d6-DMSO; 6 8 MHz) 72.16, 72.58, 83.48, 85.72 (4d, CH, myo-inositol ring carbons),
51.29, 59.90 (2 q, Ins-OMe).
6.4.6 DL-l,4-Di-0-allyl-2,5-di-O-benzyl-3,6-di-0-/?-methoxybenzyl-my0-inositol (309)
A mixture of DL-l,4 -di-O-allyl-3 ,6 -di-(9 -p-methoxybenzyl-my0 -inositol (306) (2.0g, 
4mmol) and sodium hydride (480mg, 20mmol) was stirred in dry DMF (20ml). Benzyl. 
bromide (1.19ml, lOmmol) was added dropwise to the stirred solution at room 
temperature. After 2h TLC (ether-hexane, 2:1) showed one spot, Rf = 0.60. Methanol 
(5ml), was added to destroy the excess sodium hydride and the solvent was evaporated in 
vacuo. The resulting syrup was partitioned between water and ether, washed with brine 
then water (100ml of each). The organic layer was dried over magnesium sulphate, 
filtered and evaporated to give a syrup. Flash chromatography (ether-hexane, 2:1) 
removed the remaining benzyl bromide to give the title compound (309). Yield, (2.94g, 
92%).
m.p. 91-92°C (from hexane).
(Found: C, 74.3; H, 7.04. C42H480 8 requires C, 74.07; H, 7.11).
5h (CDC13; 270MHz) 3.21 (1H, dd, J 2.00, 9.90, H-3 or H-l, Ins), 3.27 (1H, dd, J 2.00,
9.90, H-3 or H-l, Ins), 3.37 (1H, t, J 9.34, H-5, Ins), 3.77 (3H, s, Ins-0-CH2PhOMe), 3.79 
(3H, s, Ins-0-CH2PhOMe), 3.90 (1H, t, J 9.34, H-4 or H-6 , Ins), 3.96 (1H, t, J 9.89, H-4 
or H-6 , Ins), 3.97 (1H, br s, H-2, Ins), 4.00-4.12 (2H, m, Ins-0-Ci/2CH=CH2), 4.27-4.43 
(2H, m, Ins-0-C//2CH=CH2), 4.53, 4.59 (2H, AB, J 11.36, Ins-0-C/f2PhOMe or Ins-O- 
CH2Ph), 4.71,4.80 (2H, AB, J 10.26, Ins-0-C//2PhOMe or Ins-0-C//2Ph), 4.84 (4H, br s, 
Ins-0-O72Ph0Me and/or Ins-0-C//2Ph), 5.12-5.33 (4H, m, Ins-0-CH2CH=C//2), 5.84-
6.03 (2H, m, Ins-0-CH2C//=CH2), 6.81 (2H, d, J 8 .6 , Ins-0-CH2P/*OMe), 6 .8 6  (2H, d, J 
8 .6 , Ins-0-CH2P/zOMe), 7.21-7.41 (14H, m, Ins-0-CH2P/iOMe and Ins-0-CH2P/z).
5C (CDC13; 68MHz) 55.23 (q, Ins-0-CH2PhOM<?), 71.58, 72.52, 73.95, 74.53, 75.44, 
75.86 (6 t, Ins-O-CH2CH=CH2, Ins-O-CH2PhOMe and Ins-0-CH2Ph), 74.44, 80.50, 
80.66, 81.28, 81.44, 83.65 (6 d, CH, myo-inositol ring carbons), 113.71 (d, Ins-O- 
CH2P/zOMe), 116.57 (t, Ins-0-CH2CH=CH2), 127.24, 127.47, 127.76, 127.86, 128.08,
128.31, 129.09, 129.77 (8 d, Ins-0-CH2P/*OMe and Ins-0-CH2P/i), 130.61, 131.13 (2s, 
Cq, Ins-0-CH2P/zOMe), 134.99, 135.51 (2d, Ins-0-CH2CH=CH2), 138.95, 139.01 (2s, 
Cq, Ins-0-CH2P/i), 158.12 (s, Cq, Ins-0-CH2P/iOMe).
r
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A mixture of DL-l,4-di-0-allyl-2,5-di-0-benzyl-3,6-di-0-/?-methoxybenzyl-myoinositol 
(309) (2.38g, 3.38mmol) and sublimed potassium f-butoxide (1.57g, 14mmol) in dry 
DMF (40ml), was stirred at 85°C for 2h under an atmosphere of nitrogen. TLC (ether- 
hexane, 2:1), showed one spot, Rf = 0.60, which was the same as starting material. The 
reaction was then cooled, water (1 0 0 ml), was added and the product extracted with 
dichloromethane (4x100ml). The organic layer was dried over magnesium sulphate, 
filtered and purified by flash chromatography, (ether-hexane, 2 :1), to give the title 
compound (310). Yield, (1.90g, 83%).
m.p. 108-110°C (from hexane).
(Found: C, 74.3; H, 7.07. C42H480 8 requires C, 74.07; H, 7.11).
5h (CDC13; 270MHz) 1.64 (3H, dd, J 1.47, 6.96, Ins-0-CH=CHC7/3), 1.66 (3H, dd, J 
1.65, 7.14, Ins-0-CH=CHC//3), 3.32 (1H, dd, J 2.57, 9.71, H-3 or H -l, Ins), 3.42 (1H, t, J
9.34, H-5, Ins), 3.51 (1H, dd, J 2.20, 9.70, H-3 or H-l, Ins), 3.77 (3H, s, Ins-O- 
CH2PhOAfe), 3.79 (3H, s, Ins-0-CH2PhOMe), 3.98 (1H, br s, H-2, Ins), 4.02 (1H, t, J 
9.53, H-4 or H-6 , Ins), 4.14 (1H, t, J 9.89, H-4 or H-6 , Ins), 4.35 (1H, dq, J 6.76, Ins-O- 
CH=C//CH3), 4.44 (1H, dq, J 6.76, Ins-0-CH=CtfCH3), 4.51-4.82 (8 H, m, Ins-O- 
Ctf2PhOMe and Ins-0-C//2Ph), 6.08 (1H, dd, J 1.65, 6.23, Ins-0-C/7=CHCH3), 6.26 (1H, 
dd, J 1.65, 6.41, Ins-0-C/7=CHCH3), 6.84-6.90 (4H, m, Ins-0-CH2P/iOMe), 7.22-7.41 
(14H, m, Ins-0-CH2P/*OMe and Ins-0-CH2Pft).
5C (CDC13; 6 8 MHz) 9.33, 9.40 (2q, Ins-0-CH=CHCH3), 55.23 (q, Ins-0-CH2PhOMe),
72.29, 74.46, 75.30, 75.73 (4t, Ins-O-CH2PhOMe and Ins-0-CH2Ph), 75.99, 78.42, 80.36, 
82.57, 82.92, 84.39 (6 d, CH, myoinositol ring carbons), 98.14, 100.77 (2d, Ins-O- 
CH=CHCH3), 113.71 (d, Ins-0-CH2P/iOMe), 127.36, 127.59, 127.82, 128.11, 128.27,
129.24, 129.96 (7d, Ins-0-CH2P/iOMe and Ins-0-CH2P/i), 130.35, 130.80 (2s, Cq, Ins-O- 
CH2P/iOMe), 138.59, 138.75 (2s, Cq, Ins-0-CH2P/i), 145.75, 147.77 (2d, Ins-O- 
CH=CHCH3), 159.18 (s, Cq, Ins-0-CH2P/iOMe).
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m/z (-ve ion FAB) 833 [M + NBA, (100%)] 559 [M - p-methoxybenzyl, (15%)] 470
(20%) 336(20% ) 272(45% ) 182(60%).
6.4.8 2,5-Di-O-benzyl-myo-inositol (311)
2 ,5 -Di-O-benzyl-3 ,6 -di-<9 -/?-methoxybenzyl-l,4 -di-0 -cw-prop-l-enyl-my0 -inositol (310) 
(0.42g, 0.62mmol), was stirred in a mixture of dichloromethane-trifluoroacetic acid 
[20ml, (10:1)] at room temperature overnight. TLC (ether), showed the presence of a p- 
methoxybenzyl derivative only, and the orange-red solution was evaporated to dryness. 
The mixture was coevaporated with water then ethanol (10ml of each) to remove traces of 
acid, after which a fine white solid precipitated from the solution. The solid was filtered 
and washed successively with water, acetone and finally ether (2 0 ml of each) to give 
(311). Yield, (0.17g, 76%).
m.p. 271-273°C (from DMF-ethanol); (lit. ^  270-272°C).
(Found: C, 66.4; H, 6.64. C2oH240 6 requires C, 66.67; H, 6.67).
5„ (d6-DMSO; 270MHz) 3.03 (1H, t, J 9.16, H-5, Ins), 3.33 (2H, ddd, J 2.57, 4.77, 9.71, 
H-3 and H-l, Ins), 3.60 (2H, dt, J 5.13, 9.34, H-4 and H-6 , Ins), 3.73 (1H, t, J 2.75, H-2, 
Ins), 4.75 (2H, d, J 4.77, D20  ex, Ins-OH-1 and Ins-OH-3), 4.78 (4H, s, Ins-0-Ctf2Ph), 
4.83 (2 H, d, J 5.12 D20  ex, Ins-OH-4 and Ins-OH-6 ), 7.20-7.43 (10H, m, Ins-0-CH2P/i).
§c (d6-DMSO; 6 8 MHz) 73.75, 74.17 (2t, Ins-0-CH2Ph), 72.19, 73.07, 81.83, 84.23 (4d, 
CH, myo-inositol ring carbons), 127.01, 127.53, 127.92, 127.98 (4d, Ins-0-CH2P/i),
139.92, 140.01 (2 s, Cq, Ins-0-CH2P/i).
6.4.9 2,5-Di-0-methyI-l,3,4,6-tetrakis(diethoxyphospho)-/wyo-inositol (313)
A mixture of 2,5-di-O-methyl-wyo-inositol (308) (0.104g, 0.5mmol) and dry 
diisopropylethylamine (0.7ml, 4mmol) was dissolved in dry DMF (5ml) and kept under 
nitrogen at -78°C. Diethoxychlorophosphine (273) (0.58ml, 4mmol), (90-95%) was 
added dropwise to the stirred solution and left for 45min. The mixture was oxidised with 
f-butylhydroperoxide (1ml, 7.3mmol) at -78°C and stirred for a further 30min at room 
temperature. The DMF was evaporated in vacuo and the remaining syrup was partitioned 
between water (50ml) and dichloromethane (50ml). The organic layer was washed with
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1 0 % sodium metabisulphite solution (2 0 ml), brine (2 0 ml) and finally water (2 x2 0 ml). 
The organic layer was dried over magnesium sulphate and evaporated to give (313) Rf = 
0.40 (chloroform-methanol, 3:1). Yield, (0.286g, 76%).
8 h (CDC13; 270MHz) 1.26-1.39 (24H, m, Ins-0-P(0)OCH2Ctf3), 3.23 (1H, t, J 9.43, H-5, 
Ins), 3.57 (3H, s, Ins-OMe), 3.63 (3H, s, Ins-O Me), 4.12-4.27 (18H, Ins-O- 
P (0 )0 0 7 2CH3, H-3 and H-l, Ins), 4.40 (1H, br s, H-2, Ins), 4.74 (2H, q, J 9.46, H-4 and 
H-6 , Ins).
5C (CDC13; 6 8 MHz) 16.05, 16.15 (2q, Ins-0-P(0)OCH2CH3), 59.64, 61.78 (2q, Ins- 
OMe), 63.89, 63.99, 64.09, 64.22, 64.31, 64.44, 64.51 (7t, Ins-0-P(0)0CH 2CH3), 75.70, 
76.28, 76.41, 76.51, 78.00, 80.79 (6 d, CH, myo-inositol ring carbons).
8 P (CDC13; 109MHz) -2.63 (10H, q, J 7.47, -CH-0-P(0)0CH 2CH3), -3.15 (10H, q, J 7.46 
-CH-0-P(0)OCH2CH3).
m/z (+ve ion FAB) 753 [M + H, (100%)] 725 [M - 2Me + H, (18%)] 291 (48%) 235 
(38%) 130(32%).
Accurate mass spectrum requires: (M + H)+ = 753.2182. Found 753.2231.
6.4.10 2,5-Di-0-methyl-myo-inositol 1,3,4,6-tetrakisphosphate (314)
2,5-Di-C-methyl-l ,3,4,6-tetrakis(diethoxyphospho)-wyo-inositol (313) (0.25g,
0.33mmol), was dissolved in dry dichloromethane (5ml) and kept under a blanket of 
nitrogen at room temperature. Trimethylsilyl bromide (0.703ml, 5.3mmol), was added 
dropwise and the solution was stirred for 16h at room temperature. Evaporation gave a 
residue which was dissolved in water (5ml), then stirred for lh to give the title compound 
(314) in quantitative yield by 31P NMR. A small portion was purified by ion exchange 
chromatography, using a buffer gradient of 200-1000mmol of TEAB and a flow rate of 
5ml/min. The amount of product was determined by a quantitative Briggs test. Yield, 
(43.5|imol) which eluted at 500mmol buffer.
8 n (D20 ; 270MHz) 3.51 (3H, br s, Ins-0Me), 3.57 (4H, br s, Ins-OMe and H-5, Ins), 3.97 
(1H, br s. H-2, Ins), 4.06 (2H, t, J 9.52, H-3 and H-l, Ins), 4.28 (2H, q, J 9.40, H-4 and H- 
6 , Ins).
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8 C (D20 ; 6 8 MHz) 59.64, 61.39 (2q, Ins-OAfe), 73.97, 75.66, 75.76, 76.21, 80.01, 81.60 
(6 d, CH, myo-inositol ring carbons).
5P (D20 ; 162MHz) 0.00 (1H, d, J 9.9, -CH-O-PO32), -0.58 (1H, d, J 8.0, -CH-O-PO32).
m/z (-ve ion FAB) 527 [M - H, (100%)] 447 (35%) 250 (40%) 97 (64%).
Accurate mass spectrum requires: (M - H)" = 526.9520. Found 526.9520.
6.4.11 2,5-Di-0-methyl-l,3,4,6-tetrakis[di(benzyIoxyphosphorothio)]-myo-inositoI 
(316)
A mixture of bis(benzyloxy)diisopropylaminophosphine (96) (0.69g, 2mmol) and 1H- 
tetrazole (350mg, 5mmol) was stirred in DMF (5ml) for lh. 2,5-Di-O-methyl-myo- 
inositol (308) (0.052g, 0.25mmol), was added to the mixture which was stirred for a 
further 2h. TLC (ether-petroleum ether, 2:1), showed a major product Rf = 1.00 for the 
phosphite. Sulphur (0.096g, 3mmol) and dry pyridine (2ml) were added and the mixture 
stirred for 15min after which TLC (ether-petroleum ether, 2:1), showed a new spot R{ = 
0.60. The excess sulphur was filtered and the solvents were evaporated in vacuo to give a 
syrup. The title compound (316) was purified by flash chromatography (ether-petroleum 
ether, 2:1) and isolated as a syrup. Yield, (0.27g, 82%).
(Found: C, 58.3; H, 5.21. C64H680 14P4S4 requires C, 58.53; H, 5.22).
5„ (CDC13; 270MHz) 2.23 (1H, t, J 9.34, H-5, Ins), 3.31 (3H, s, Ins-0Me), 3.50 (3H, s, 
Ins-0M e\ 4.33 (2H, dt, 2.02, 9.89, H-3 and H-l, Ins), 4.61 (1H, br s, H-2, Ins), 5.00-5.14 
(18H, m, Ins-0-P(S)0-C//2Ph, H-4 and H-6 , Ins), 7.20-7.37 (40H, m, Ins-0-P(S)0- 
CU2Ph).
5C (CDC13; 6 8 MHz) 61.29, 61.33 (2q, Ins-0M e\ 69.47, 70.09 (2t, Ins-0-P(S)0-CH2Ph), 
76.02, 77.00, 77.25, 79.10, 79.30, 80.66 (6 d, CH, myo-inositol ring carbons), 127.69, 
127.82, 127.89, 127.95, 128.08, 128.24 (6 d, Ins-0-P(S)0-CH2P/i), 135.18, 135.28,
135.41, 135.48, 135.57, 135.67, 135.80 (7s, Ins-0-P(S)0-CH2P/i, Cq).
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5P (CDC13; 162MHz) +69.11 (dtt, J 8.0, 9.9, 9.9, -C //-0-P(S)0C//2Ph), +67.09 (dtt, J 
7.9, 9.9, 9.9, -C//-0-P(S)0C//2Ph).
m/z (+ve ion FAB) 1314 [M + H, (0.15%)] 725 (0.1%) 430 (0.48%) 181 (10%) 91 
( 100%).
6.4.12 2 ,5 -Di-0 -methyl-my0 -inositol 1,3,4,6-tetrakisphosphorothioate (317)
Ammonia (80ml), was distilled into a three neck flask and small slithers of freshly cut 
sodium metal (0.80g, 34.8mmol), were added until the solution remained blue. The dry- 
ice condenser was moved across to the reaction flask and ammonia (40ml), was gently 
transferred to the flask by heating. Small slithers of sodium (0.40g, 17.4mmol), were 
added to the ammonia until the colour remained blue. 2,5-Di-0-methyl-l,3,4,6- 
tetrakis[di(benzylphosphorothio)]-myo-inositol (316), (0.10g, 76pmol), in dry dioxan 
(lml) was added to the sodium in liquid ammonia. The reaction was left for 2min and 
quenched with methanol (20ml). The ammonia was evaporated in a stream of nitrogen, 
MilliQ water was then added to the residue which was evaporated to dryness in vacuo. 
The deprotected phosphorothioate (317) was purified by ion exchange chromatography 
using a buffer gradient of O-lOOOmrriol and eluted at ca. 800mmol. Yield, (19.2jimol, 
25%).
5h (D20 ; 270MHz) 3.32 (1H, t, J 9.52, H-5, Ins), 3.60 (3H, s, Ins-OM e\ 3.64 (3H, s, Ins- 
OMe), 4.15 (1H, t, J 2.38, H-2, Ins), 4.23 (2H, ddd, J 2.3, 10.26, 10.26, H-3 and H-l, Ins), 
4.60 (2H, q, J 10.00, H-4 and H-6 , Ins).
8 C (D20 ; 6 8 MHz) 59.57, 61.65 (2q, Ins-0M e\ 74.07, 76.44, 80.14, 82.02 (4d, CH, myo­
inositol ring carbons).
5p (D20 ; 109MHz) +46.7 (d, J 10.1), +48.8 (d, J 10.1).
m/z (-ve ion FAB) 591 [M - H, (100%)] 557 (50%) 460 (62%) 308 (48%) 175 (50%) 
95 (95%).




A mixture of bis(benzyloxy)diisopropylaminophosphine (96) (0.69g, 2mmol) and 1H- 
tetrazole (0.35g, 5mmol) in DMF (2ml) was stirred for lh. 2,5-Di-O-benzyl-myo-inositol 
(311) (0.90g, 0.25mmol), was added to the mixture and stirred for a further lh. TLC 
(ether-petroleum ether, 1:2), showed a major product Rf = 1.00 for the phosphite. Sulphur 
(0.096g, 3mmol) and dry pyridine (2ml) were added and stirred for lOmin after which 
TLC (ether-petroleum ether, 1:2), showed a new spot R{ = 0.40. The excess sulphur was 
filtered and the solvents were evaporated at room temperature in vacuo. The title 
compound was purified by flash chromatography (ether-petroleum ether, 1 :2 ) and isolated 
as a syrup. Yield, (0.26g, 71%).
(Found: C, 62.5; H, 5.32. C76H760 14P4S4 requires C, 62.29; H, 5.23).
5h (CDC13; 400MHz) 3.59 (1H, t, J 9.15, H-5, Ins), 4.42-4.48 (3H, m, H -l, H-2 and H-3, 
Ins), 4.78-5.07 (20H, m, Ins-0-P(S)0-C/f2Ph and Ins-0-Ctf2Ph), 5.38 (2H, dt, J 9.15, 
12.52, H-4 and H-6 , Ins), 6.86-7.37 (50H, Ins-0 -P(S)0 -CH2P/i and Ins-0-CH2P/z).
8 C (CDC13; 6 8 MHz) 69.99, 70.19, 70.25, 70.54, 70.74, 74.01, 75.83 (7t, Ins-0-P(S)0- 
CH2Ph, Ins-0-CH2Ph), 76.51, 76.93, 77.84, 79.30 (4d, CH, myo-inositol ring carbons), 
127.01, 127.27, 127.53, 127.66, 128.21, 128.37, 128.57, 128.63, 128.73, 128.80, 128.86, 
128.93 (12d, Ins-0-P(S)0-CH2P/i and Ins-0-CH2P/i), 135.74, 135.87, 135.93, 136.06, 
136.13, 136.23, 136.36, 136.49, 138.75, 138.85 (10s, Cq, Ins-0-P(S)0-CH2P/i and Ins-O- 
CH2Ph).
8 p (CDC13; 109MHz) +66.78 (dtt, J 9.34, 9.52), +69.57 (dtt, J 9.71, 11.44). 
m/z (-ve ion FAB) 591 [M - Bn, (5.5%)] 1281 (1%) 293 (100%) 95 (30%).
6.4.14 myo-Inositol 1,3,4,6-tetrakisphosphorothioate (320)
Ammonia (80ml), was distilled into a three neck flask and small slithers of freshly cut 
sodium metal (800mg, 34.8mmol), were added until the solution remained blue. The dry- 
ice condenser was moved across to the reaction flask and ammonia (40ml), was 
transferred to the flask by heating. Small slithers of sodium (400mg, 17.4mmol), were
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added to the ammonia until the colour remained blue. A solution of 2,5-di-O-benzyl-
l,3,4,6-tetrakis[di(benzylphosphorothio)]-myo-inositol (319), (0.059g, 76pmol) in dry 
dioxan (1ml), was added to the sodium in liquid ammonia. The reaction was left for 
2min and quenched with methanol (20ml). The ammonia was evaporated in a stream of 
nitrogen, MilliQ water was then added to the residue which was evaporated to dryness in 
vacuo. The deprotected phosphorothioate (320) was purified by ion exchange 
chromatography using a buffer gradient of 0 - 1 0 0 0 mmol and eluted at ca. 800mmol. 
Yield, (18.5fimol, 46%).
8 h (D20 ; 270MHz) 3.61 (1H, t, J 8.98, H-5, Ins), 4.16 (1H, dt, J 2.95, 9.52, H-l and H-3, 
Ins), 4.51 (2H, q, J 9.89, H-4 and H-6 , Ins), 4.99 (1H, br s, H-2, Ins).
5p (D20 ; 109MHz) +42.4 (d, J 12.25), +45.09 (d, J 9.77).
m/z (-ve ion FAB) 563 [M - H, (100%)] 529 (15%) 232 (20%) 95 (95%).
Accurate mass spectrum requires: (M - H)" = 562.8295 Found 562.8314.
6.5 Synthesis of DL-myo-Inositol 1,4,6-Trisphosphate and DL-myo-Inositol 1,4,6- 
Trisphosphorothioate
6.5.1 DL-l,4-Di-0-aIlyl-2,3-O-isopropylidene-my0-inositoI (321)
A mixture of DL-3,6-di-0-allyl-l,2:4,5-di-0-isopropylidene-myo-inositol (301) (10.7g, 
31.47mmol) toluene-p-sulphonic acid (0.10g, 0.5mmol) and ethane 1,2-diol (1.75ml, 
31.47mmol), in dichloromethane (100ml), was stirred at 0°C in an ice bath for lOmin.
The ice bath was removed and the mixture was stirred for a further 30min until the
solution became slightly cloudy. Triethylamine (2ml), was added to the cloudy solution 
followed by water (100ml). The starting material and product were separated leaving d l -
1,4 -di-O-allyl-myo-inositol in the water layer. The product Rf = 0.30 (ether), was 
separated and the organic layer was evaporated to give the title compound and starting 
material which was recrystallised from ethyl acetate-hexane to give the pure tide 
compound (321). Yield, (6.4g, 6 8 %).
m.p. 130°C; (lit. 130-132°C).
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5h (CDC13; 270MHz) 1.37, 1.54 (6 H, 2s, CMe2\  3.10 (2H, s, D20  ex, Ins-OH), 3.36 (1H, 
t, J 9.53, H-5, Ins), 3.49 (1H, t, J 9.53, H-6 , Ins), 3.49 (1H, dd, J 2.56, 9.53, H-3, Ins), 
3.89 (1H, t, J 9.34, H-4, Ins), 4.08 (1H, dd, J 5.31, 6.78, H-l, Ins), 4.17-4.39 (4H, m, Ins- 
0 -C //2CH=CH2), 4.43 (1H, dd, J 3.97, 5.31, H-2, Ins), 5.16-5.36 (4H, m, Ins-O- 
CH2CH=C//2), 5.87-6.05 (2H, m, Ins-0-CH2C//=CH2).
8 C (CDC13; 6 8 MHz) 25.91, 27.99 (2q, CMe2), 71.64, 72.29 (2t, Ins-O-CH2CH=CH2),
71.38, 72.94, 73.88, 76.80, 79.20, 81.63 (6 d, CH, myo-inositol ring carbons), 109.88 (s, 
Cq, CMe2), 117.38, 118.06 (2t, Ins-0-CH2CH=CH2), 134.60, 134.73 (2d, Ins-O- 
CH2CH=CH2).
6.5.2 Selective alkylation of 3,6-di-0-alIyl-l,2-0-isopropylidene-myo-inositol (using 
/7-methoxybenzyl chloride) (322,323,324)
A mixture of DL-l,4-di-0-allyl-2,3-0-isopropylidene-myo-inositol (321) (4.5g, 15mmol), 
acetonitrile (300ml), dibutyltin oxide (5g, 20mmol), tetrabutylammonium iodide (7.38g, 
20mmol) and /7-methoxybenzyl chloride (5.42ml, 40mmol) was heated under reflux in a 
Soxhlet apparatus containing molecular sieves (4A, 30g), for 48h.
The reaction mixture was cooled, the solvent was evaporated and the orange residue was 
partitioned between water (250ml) and ether (250ml). The organic layer was separated 
and stirred with a saturated solution of sodium hydrogen carbonate (250ml), for lh. The 
solid was removed by filtration through celite, washed with ether and the organic layer 
was dried over magnesium sulphate. TLC (ether-hexane, 3:2) showed five spots, p- 
Methoxybenzyl iodide, R{ = 0.70; p-methoxybenzyl chloride, R{ = 0.60; DL-l,4-di-0-allyl-
2 .3 -0 -isopropylidene-5 ,6 -di-0 -/7-methoxybenzyl-myo-inositol, Rf = 0.50 (322); d l - 1 ,4 -  
di-0 -allyl-2 ,3 -0 -isopropylidene-6 -0 -/7-methoxybenzyl-wyo-inositol, R{ = 0.40 (324) and 
DL-l,4 -di-0 -allyl-2 ,3 -O-isopropylidene-5 -0 -/7-methoxybenzyl-myo-inositol, Rf = 0.22 
(323) which were separated by flash chromatography, to give the products as syrups, d l -
1.4 -Di-0 -allyl-2 ,3 -0 -isopropylidene-5 -0 -/7-methoxybenzyl-myo-inositol, (323) was then 
recrystallised from hexane. Yields, (322) (1.15g, 14%), (324) (3.27g, 52%), (323) (1.96g, 
31%).
(323) m.p. 70-72°C (from hexane).
(322) (Found: C, 69.0; H, 7.54. C31H40O8 requires C, 68.85; H,7.46).
(323) (Found: C, 65.7; H, 7.79. C23H330 7 requires C, 65.68; H, 7.68).
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(324) (Found: C, 65.6; H, 7.61. C23H33 0 7 requires C, 65.68; H, 7.68).
(322) 5h (CDC13; 270MHz) 1.37, 1.54 (6 H, 2s, CMe2), 3.34 (1H, t, J 9.16, H-5, Ins), 3.49 
(1H, dd, J 3.66, 8.80, H-3, Ins), 3.65 (1H, dd, J 6.96, 9.52, H-6 , Ins), 3.79 (3H, s, Ins-O- 
C //2PhOMe), 3.80 (3H, s, Ins-0-C//2PhOMe), 3.84 (1H, t, J 8.80, H-4, Ins), 4.07 (1H, dd, 
J 5.68, 6.77, H-l, Ins), 4.18-4.33 (4H, m, Ins-0-C//2CH=CH2), 4.38 (1H, dd, J 3.84, 5.55, 
H-2, Ins), 4.70, 4.72 (2H, AB, J 10.44, Ins-0-C//2PhOMe), 4.71, 4.77 (2H, AB, J 10.44, 
Ins-0-C//2PhOMe), 5.15-5.36 (4H, m, Ins-0-CH2CH=C//2), 5.89-6.03 (2H, m, Ins-O- 
CH2C//=CH2), 6.85 (2H, d, J 8.61, Ins-0-CH2P/iOMe), 6 .8 6  (2H, d, J 8.79, Ins-O- 
CH2P/zOMe), 7.27 (2H, d, J 8.61, Ins-0-CH2P/zOMe), 7.28 (2H, d, J 8.61, Ins-O- 
CH2P/iOMe).
5C (CDC13; 6 8 MHz) 25.68, 27.60 (2q, CMe2), 55.07 (q, Ins-0-CH2PhOAfe), 72.36, 72.78 
74.79 (3t, Ins-O-CH2CH=CH2 and Ins-0-CH2PhOMe), 74.79, 76.93, 78.91, 80.37, 81.73,
82.15 (6 d, CH, myo-inositol ring carbons), 109.66 (s, Cq, CMe2), 113.39, 113.58 (2d, Ins- 
0-CH2P/iOMe), 116.63, 117.41 (2t, Ins-0-CH2CH=CH2), 129.25, 129.51, 129.67 (3d, 
Ins-0-CH2P/iOMe), 130.64 (s, Cq, Ins-0-CH2P/iOMe), 134.83, 135.05 (2d, Ins-O- 
CH2CH=CH2), 159.06 (s, Cq, Ins-0-CH2P/iOMe).
m/z (-ve ion FAB) 693 [M + NBA, (10%)] 555 (33%) 525(60%) 379(20%) 137 [-0- 
CH2PhOMe, (95%)] 121 [-CH2PhOMe, (100%)].
(324) 8 h (CDC13; 270MHz) 1.37, 1.55 (6 H, 2s, CMe2), 2.72 (1H, d, J 2.02, D20  ex, Ins- 
OH), 3.43 (1H, ddd, J 2.02, 8.24, 8.24, D20  ex, dd, J 8.24, 8.24, H-5, Ins), 3.58 (2H, m, 
H-3 and H-6 , Ins), 3.74 (1H, t, J 8.24, H-4, Ins), 3.79 (3H, s, Ins-0-CH2PhOAfe), 4.07 
(1H, dd, J 5.68, 6.78, H-l, Ins), 4.17-4.36 (4H, m, Ins-0-C//2CH=CH2), 4.39 (1H, dd, J
3.85, 5.49, H-2, Ins), 4.70, 4.82 (2H, AB, J 10.80, Ins-0-C/72Ph0Me), 5.15-5.34 (4H, m, 
Ins-0-CH2CH=C/f2), 5.87-6.03 (2H, m, Ins-0-CH2Ctf=CH2), 6 .8 8  (2H, d, J 8.60, Ins-O- 
CH2P/iOMe), 7.31 (2H, d, J 8.60, Ins-0-CH2P/*OMe).
Sc (CDC13; 6 8 MHz) 25.62, 27.56 (2q, CMe2), 55.07 (q, Ins-0-CH2PhOMe), 72.07, 72.13, 
74.30 (3t, Ins-O-CH2CH=CH2 and Ins-O-CH2PhOMe), 73.43, 74.43, 77.00, 78.78, 79.98, 
81.24 (6 d, CH, myo-inositol ring carbons), 109.72 (s, Cq, CMe2), 113.71 (d, Ins-O- 
CH2P/iOMe), 117.09, 117.44 (2t, Ins-0-CH2CH=CH2), 128.48 (d, Ins-0-CH2P/zOMe), 
130.42 (s, Cq, Ins-0-CH2P/iOMe), 134.63, 134.73 (2d, Ins-0-CH2CH=CH2), 159.12 (s, 
Cq, Ins-0-CH2P/zOMe).
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m/z (-ve ion FAB) 573 [M + NBA, (50%)] 419 [M - H, (28%)] 379 (38%) 299 [M -
CH2PhOMe, (100%)] 258(38% ) 137(72%) 121(80%).
(323) 6 h (CDC13; 270MHz) 1.37, 1.52 (6 H, 2s, CMe2), 2.68 (1H, d, J 1.47, D20  ex, Ins- 
OH), 3.23 (1H, t, J 9.16, H-5, Ins), 3.50 (1H, dd, J 3.84, 9.70, H-3, Ins), 3.50 (1H, dd, J
6.77, 9.16, H-6 , Ins), 3.79 (3H, s, Ins-0-CH2PhOMe), 3.94 (1H, dt, J 1.46, 9.71, D20  ex, 
t, J 9.53, H-4, Ins), 4.10 (1H, dd, J 5.31, 6.78, H-l, Ins), 4.17-4.37 (4H, m, Ins-O- 
Ctf2CH=CH2), 4.41 (1H, dd, J 3.85, 5.31, H-2, Ins), 4.66, 4.81 (2H, AB, J 10.80, Ins-O- 
Ctf2Ph), 5.15-5.34 (4H, m, Ins-0-CH2CH=C//2), 5.87-6.03 (2H, m, Ins-0-CH2C//=CH2), 
6 .8 6  (2H, d, J 8.79, Ins-0-CH2P/iOMe), 7.31 (2H, d, J 8.80, Ins-0-CH2P/*0Me).
8 C (CDC13; 6 8 MHz) 25.75, 27.75 (2q, CMe2), 55.77 (q, Ins-0-CH2PhOAfe), 71.74, 72.62, 
74.63 (3t, Ins-O-CH2CH=CH2 and Ins-0-CH2PhOMe), 71.35, 73.75, 76.64, 79.14, 81.24,
82.09 (6 d, CH, myoinositol ring carbons), 109.79 (s, Cq, CMe2), 113.78 (d, Ins-O- 
CH2P/iOMe), 116.86, 117.86 (2t, Ins-0-CH2CH=CH2), 129.64 (d, Ins-0-CH2P/iOMe),
130.45 (s, Cq, Ins-0-CH2P/iOMe), 134.70, 134.92 (2d, Ins-0-CH2CH=CH2), 159.22 (s, 
Cq, Ins-0-CH2P/iOMe).
m/z (-ve ion FAB) 573 [M + NBA, (100%)] 419 [M - H, (18%)] 379(15%) 335 (20%) 
299 [M - CH2PhOMe, (100%)] 137 (72%).
6.5.3 DL-l,4 -Di-0 -alIyl-6 -O-/?-methoxybenzyI-my0 -inositol (325)
A mixture of DL-l,4-di-0-allyl-2,3-0-isopropylidene-6-0-p-methoxybenzyl-myo-inositol
(323) (2.72g, 6.47mmol), and 1M HCl-methanol (90ml, 1:9), was heated at 50°C for 
30min. The reaction mixture was cooled and TLC showed consumption of starting 
material to give a new spot R{ = 0.20 (ether). Sodium hydrogen carbonate (5g) was added 
and the solvents were evaporated. The residue was partitioned between water (50ml) and 
dichloromethane (50ml), the organic layer was separated, dried over magnesium sulphate, 
filtered and evaporated to dryness. The remaining solid was recrystallised from ethyl 
acetate-hexane to give (325). Yield, (1.97g, 80%).
m.p. 120-122°C (from ethyl acetate-hexane).
(Found: C, 62.9; H, 7.46. C20H28O7 requires C, 63.12; H, 7.42).
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5h (CDC13; 270MHz) 2.66, 2.85 (3H, 2s, D20  ex, Ins-OH), 3.32 (1H, dd, J 2.75, 9.53, H- 
3 or H -l, Ins), 3.44 (2H, dd, H-3 or H-l, and H-5 obscured, Ins), 3.59 (1H, t, J 9.34, H-4 
or H-6 , Ins), 3.72 (1H, t, J 9.34, H-4 or H-6 , Ins), 3.80 (3H, s, Ins-0-CH2PhOAfe), 4.17-
4.36 (5H, m, Ins-0-Cff2CH=CH2, and H-2, Ins), 4.64, 4.86 (2H, AB, J 10.81, Ins-O- 
C //2PhOMe), 5.16-5.35 (4H, m, Ins-0-CH2CH=Ctf2), 5.87-6.04 (2H, m, Ins-O- 
CH2C//=CH2), 6 .8 8  (2H, d, J 8.61, Ins-0-CH2P/iOMe), 7.31 (2H, d, J 8.61, Ins-O- 
CH2P/zOMe).
5C (CDC13; 6 8 MHz) 55.23 (q, Ins-0-CH2PhOMe), 71.38, 73.82, 75.15 (3t, Ins-O- 
CH2CH=CH2 and Ins-0-CH2PhOMe), 69.34, 71.51, 74.40, 79.59, 80.43, 80.60 (6 d, CH, 
myo-inositol ring carbons), 113.87 (d, Ins-0-CH2F7i0Me), 117.15, 117.57 (2t, Ins-O- 
CH2CH=CH2), 129.61 (d, Ins-0-CH2P/iOMe), 130.64 (s, Cq, Ins-0-CH2/ViOMe), 
134.41, 135.05 (2d, Ins-0-CH2CH=CH2), 159.25 (s, Cq, Ins-0-CH2P/iOMe).
m/z (-ve ion FAB) 533 [M + NBA, (65%)] 379 [M - H, (100%)] 303 (35%) 272(20%) 
182(25%) 167(30%).
6 .5 .4  DL-3,6-Di-0-allyl-l,2,5-tri-0-benzyl-4-0-/?-methoxybenzyl-#ny0-inositol ( 3 2 6 )
A mixture of d l -  1 ,4-di-0-allyl-6-0-p-methoxybenzyl-myo-inositol ( 3 2 5 )  (1.52g, 4mmol) 
and sodium hydride (0.864g, 36mmol) was stirred in dry DMF (40ml). Benzyl bromide 
(1.78ml, 15mmol), was added dropwise and the solution was stirred for a further 2h. 
TLC (ether-light petroleum, 1:1) showed one spot Rf = 0.50. The excess sodium hydride 
was destroyed with methanol (1 0 ml) and the solvents were evaporated in vacuo to give a 
syrup. The syrup was partitioned between water (100ml) and ether then washed with 
0.1M HC1 (50ml), a saturated aqueous solution of sodium hydrogen carbonate (100ml) 
and water (100ml). The organic layer was dried over magnesium sulphate, filtered and 
the solvent evaporated. The remaining syrup was purified by flash chromatography to 
give the title compound ( 3 2 6 ) .  Yield, (2.20g, 85%).
m.p. 53-54°C (from hexane).
(Found: C, 75.9; H, 7.19. C^H^O-j requires C, 75.65; H, 7.13).
5h (CDC13; 270MHz) 3.22 (1H, dd, J 2.20, 9.71, H-3 or H -l, Ins), 3.29'(1H, dd, J 2.2, 
9.89, H-3 or H-l, Ins), 3.38 (1H, t, J 9.34, H-5, Ins), 3.77 (3H, s, Ins-0-CH2PhOAfe), 3.92 
(1H, t, J 9.53, H-4 or H-6 , Ins), 3.97 (1H, t, J 9.53, H-4 or H-6 , Ins), 3.99 (1H, t, J 2.2, H-
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2, Ins), 4.08-4.10 (2H, m, Ins-0-C//2CH=CH2), 4.27-4.43 (2H, m, Ins-0-Ctf2CH=CH2), 
4.57-4.85 (8 H, m, Ins-0-Ctf2Ph and Ins-0-C//2PhOMe), 5.11-5.34 (4H, m, Ins-O- 
CH2CH=C//2), 5.84-6.04 (2H, m, Ins-0-CH2Ctf=CH2), 6.83 (2H, d, J 8.61, Ins-O- 
CH2P/iOMe), 7.22-7.42 (17H, m, Ins-0-CH2P/i and Ins-0-CH2P/iOMe).
6 C (CDC13 6 8 MHz) 55.20 (q, Ins-0-CH2PhOMe), 71.58, 72.82, 73.95, 74.53, 75.44, 
75.83 (6 t, Ins-0-CH2CH=CH2, Ins-0-CH2Ph and Ins-O-CH2PhOMe), 74.27, 80.60, 
80.73, 81.25, 81.38, 83.58 (6 d, CH, myo-inositol ring carbons), 113.68 (d, Ins-O- 
CH2P/iOMe), 116.57 (t, Ins-0-CH2CH=CH2), 127.24, 127.44, 127.50, 127.73, 127.83,
128.05, 128.28, 129.74 (8 d, Ins-0-CH2P/i and Ins-0-CH2P/iOMe), 131.07 (s, Cq, Ins-O- 
CH2P/iOMe), 134.89, 135.38 (2d, Ins-0-CH2CH=CH2), 138.49, 138.91 (2s, Cq, Ins-O- 
CH2P/i), 159.09 (s, Cq, Ins-0-CH2P/iOMe).
m/z (-ve ion FAB) 803 [M + NBA, (100%)] 696 (35%) 665 (55%) 559 [M - benzyl, 
(25%)] 485(40%) 440(35%) 318(68%) 287(60%) 178(30%) 124(25%).
6.5.5 DL-3,6-Di-O-aIIyl-l,2,5-tri-0-benzyl-my0-inositol (327)
A mixture of DL-3,6-di-0-allyl-l,2,5-tri-0-benzyl-4-0-/?-methoxybenzyl-myc>-inositol
(326) (1.70g, 2.61mmol) and DDQ (1.047g, 4.61mmol) in dichloromethane-water (20ml, 
19:1) was stirred at room temperature for lh. The precipitate was filtered and the organic 
layer was diluted with dichloromethane (150ml) and washed with 10% solution of 
sodium metabisulphite (3x 100ml), a saturated solution of sodium hydrogen carbonate 
(100ml) and water (100ml). The organic layer was dried over magnesium sulphate, 
filtered and evaporated. The crude product was purified by flash chromatography to give
(327) as a syrup, P f = 0.30 (ether-light petroleum, 1:1). Yield, (1.20g, 87%).
(Found: C, 74.7; H, 7.11. C41H460 7 requires C, 74.67; H, 7.22 ).
5h (CDC13; 270MHz) 2.25 (1H, s, D20  ex, Ins-OH), 3.09 (1H, dd, J 2.20, 9.89, H-3 or H- 
1, Ins), 3.31 (1H, t, J 9.15, H-5, Ins), 3.32 (1H, dd, J 2.20, 9.76 H-3 or H-l, Ins), 3.90 
(1H, t, J 9.52, H-4 or H-6 , Ins), 3.93-4.10 (4H, Ins-0-C//2CH=CH2, H-2 and H-4, or H-6 , 
Ins), 4.28-4.44 (2H, m, Ins-0-C//2CH=CH2), 4.62, 4.69 (2H, AB, J 11.91, Ins-0-C//2Ph), 
4.79, 4.83 (2H, AB, J 12.27, Ins-0-C//2Ph), 4.85, 4.91 (2H, AB, J 11.17, Ins-0-C//2Ph), 
5.12-5.30 (4H, m, Ins-0-CH2CH=Ctf2), 5.80-6.05 (2H, m, Ins-0-CH2C//=CH2), 7.21- 
7.41 (15H, m, Ins-0-CH2P/i).
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5C (CDC13; 6 8 MHz) 71.06, 72.88, 73.91, 74.50,75.28 (3t, Ins-O-CH2CH=CH2 and Ins-O- 
CH2Ph), 72.55, 73.49, 79.69, 80.92, 81.15, 83.29 (6 d, CH, myo-inositol ring carbons), 
116.50 (t, Ins-0-CH2CH=CH2), 127.30, 127.46, 127.56, 127.72, 127.85, 128.08, 128.34 
(7d, Ins-O-CH2P/0, 134.47, 135.31 (2d, Ins-0-CH2CH=CH2), 138.40, 138.75, 138.82 (3s, 
Cq, Ins-O-CH2Ph).
m/z (-ve ion FAB) 583 [M + NBA, (100%)] 576 (30%) 529 [M - H (8 %)] 303 (35%) 
489(18%) 322(12%) 273(10%) 184(10%).
6.5.6 DL-l,2,5-Tri-O-benzyI-my0-inositol (328)
A mixture of DL-3,6-di-O-ally 1-1,2,5-tri-O-benzyl-myo-inositol (327) (0.8g, 1.78mmol), 
toluene-/?-sulphonic acid (0 .2 0 g, lmmol) and 1 0 % palladium on activated charcoal 
(0.25g) in ethanol-water (35ml, 5:2), was heated under reflux for 5h. TLC (ether), 
showed a spot at R{ = 0.30 and debenzylation products at the baseline. The palladium on 
activated charcoal was filtered through celite to give a colourless solution, and the 
solvents were evaporated. The title compound (328) was purified by flash 
chromatography (dichloromethane-ethyl acetate, 1:1). Yield, (0.30g, 40%).
m.p. 161-162°C (from ethyl acetate-hexane).
(Found: C, 71.9; H, 6.71. C27H30O6 requires C, 71.96; H, 6.49).
5h (CDC13; 270MHz) 1.65-2.65 (3H, very br, D20  ex, Ins-OH), 3.23 (1H, t, J 9.16, H-5, 
Ins), 3.30 (1H, dd, J 2.39, 9.71, H-l, Ins), 3.40 (1H, dd, J 2.75, 9.71, H-3, Ins), 3.82 (1H, 
t, J 9.52, H-4 or H-6 , Ins), 4.06 (1H, t, J 2.57, H-2, Ins), 4.12 (1H, t, J 9.52, H-4 or H-6 , 
Ins), 4.58-4.98 (6 H, m, Ins-0-Ctf2Ph), 7.25-7.40 (15H, m, Ins-0-CH2P/i).
8 C (d6-DMSO; 6 8 MHz) 71.51, 74.01 (2t, Ins-0-CH2Ph), 72.16, 72.42, 72.84, 78.42,
80.43, 84.29 (6 d, CH, myo-inositol ring carbons), 127.04, 127.14, 127.33, 127.56, 127.98,
128.08, 128.21 (7d, Ins-0-CH2P/i), 139.20, 139.79, 139.92 (3s, Cq, Ins-0-CH2P/i).
m/z (-ve ion FAB) 603 [M + NBA, (100%)] 379 [M - H, (85%)] 359 [M - benzyl 




A mixture of DL-l,4-di-0-allyl-2,3-0-isopropylidene-6-0-p-methoxybenzyl-myo-inositol
(324) and sodium hydride (1.2g, 50mmol) was stirred in dry DMF (150ml) at room 
temperature. Benzyl bromide (2.37ml, 20mmol) was added dropwise which was then 
stirred for 2h after which TLC (ether-hexane, 1:1) showed a product, Rf = 0.44. The 
excess sodium hydride was destroyed with methanol ( 1 0 ml) and the solvents were 
evaporated in vacuo. The residue was partitioned between ether (300ml) and water 
(200ml) and the organic layer was washed with brine and water (200ml each). The 
organic layer was dried over magnesium sulphate and the solvent was evaporated. Flash 
chromatography (ether-hexane, 1 :1) of the crude product provided the title compound 
(329) as a syrup. Yield, (7.1 g, 93%).
(Found: C, 70.4; H, 7.64. C30H38O7 requires C, 70.55; H, 7.51).
6 h (CDC13; 270MHz) 1.38, 1.55 (6 H, 2s, CMex), 3.36 (1H, t, J 9.16, H-5, Ins), 3.61 (1H, 
dd, J 3.84, 8.97, H-3, Ins), 3.67 (1H, dd, J 6.96, 9.52, H-4, Ins), 3.79 (3H, s, Ins-O- 
CH2PhOMe), 3.86 (1H, t, J 8.79, H-6 , Ins), 4.08 (1H, dd, J 5.68, 6.78, H-l, Ins), 4.20-
4.37 (4H, m, Ins-0-C/72CH=CH2), 4.38 (1H, dd, J 3.85, 5.50, H-2, Ins), 4.68-4.83 (4H, 
Ins-0-C//2PhOMe and Ins-0-C//2Ph), 5.15-5.34 (4H, m, Ins-0-CH2CH=C//2), 5.88-6.02 
(2H, m, Ins-0-CH2C/f=CH2), 6.85 (2H, d, J 8.79, Ins-0-CH2P/zOMe), 7.25-7.37 (7H, m, 
Ins-0-CH2P/zOMe and Ins-0-CH2P/*).
5C (CDC13; 6 8 MHz) 25.82, 27.75 (2q, CMe2\  55.25 (q, Ins-0-CH2Ph0Me), 72.51, 72.93, 
74.91, 75.91 (4t, Ins-O-CH2CH=CH2, Ins-0-CH2Ph and Ins-0-CH2PhOMe), 74.60, 
77.08, 77.55, 79.08, 80.52, 82.26 (6 d, CH, rayo-inositol ring carbons), 109.84 (s, Cq, 
CMe2), 113.80 (d, Ins-0-CH2P/iOMe), 116.80, 117.50 (2t, Ins-0-CH2CH=CH2), 127.58, 
128.02, 128.31, 129.68 (4d, Ins-O-CH2Ph and Ins-0-CH2P/*OMe), 130.83 (s, Cq, Ins-O- 
CH2P/iOMe), 134.99, 135.21 (2d, Ins-0-CH2CH=CH2), 138.69 (s, Cq, Ins-O-CH2P/0,
159.12 (s, Cq, Ins-0-CH2P/iOMe).




(329) (6.54g, 12.82mmol) was dissolved in methanol-lM HC1 (100ml, 9:1), and the 
mixture was stirred at 50°C for 45min after which TLC (ether), showed one product, Rf = 
0.52. The reaction was cooled and 1M TEAB (20ml) was added. The solvents were 
evaporated to give a white solid. The solid was partitioned between dichloromethane 
(2 0 0 ml) and water (2 0 0 ml), and the organic layer was dried over magnesium sulphate, 
which was filtered and the solvent was evaporated to give a solid, (330). Yield, (5.3g, 
88%).
m.p. 87-88°C (from ether-hexane).
(Found: C, 68.7; H, 7.27. C27H3 4 0 7 requires C, 68.9; H, 7.29).
5h (CDC13; 270MHz) 2.76 (2H, s, D20  ex, Ins-OH), 3.32 (1H, dd, J 2.93, 9.52, H -l, Ins),
3.38 (1H, t, J 9.34, H-5, Ins), 3.61 (1H, br d, J 9.52, D20  ex, dd, J 3.84, 9.52, H-3, Ins), 
3.69 (1H, t, J 9.52, H-4 or H-6 , Ins), 3.78 (3H, s, Ins-0-CH2PhOM?), 3.87 ( 1H, t, J 9.52, 
H-4 or H-6 , Ins), 4.18-4.44 (5H, m, Ins-0-C//2CH=CH2 and H-2, Ins), 4.70-4.90 (4H, 
Ins-0-C//2PhOMe and Ins-0-C//2Ph), 5.14-5.35 (4H, m, Ins-0-CH2CH=C//2), 5.87-6.02 
(2H, m, Ins-0-CH2C/7=CH2), 6.83 (2H, d, J 8.79, Ins-0-CH2P/*OMe), 7.24 (2H, d, J
8.43, Ins-0-CH2P/zOMe), 7.27-7.35 (7H, m, Ins-0-CH2P/iOMe and Ins-0-CH2P/i).
5C (CDC13; 6 8 MHz) 55.19 (q, Ins-0-CH2PhOMe), 71.71, 74.27 75.52 (3t, Ins-O- 
CH2CH=CH2, Ins-O-CH2Ph and Ins-O-CH2PhOMe), 69.31, 71.65, 79.79, 80.89, 81.20, 
83.10 (6 d, CH, myo-inositol ring carbons), 113.73 (d, Ins-0-CH2P/zOMe), 117.09, 117.48 
(2t, Ins-0-CH2CH=CH2), 127.50, 127.70, 128.30, 129.61 (4d, Ins-0-CH2P/i and Ins-O- 
CH2P/iOMe), 130.84 (s, Cq, Ins-0-CH2P/iOMe), 134.56, 134.99 (2d, Ins-O- 
CH2CH=CH2), 138.63 (s, Cq, Ins-0-CH2P/z), 159.16 (s, Cq, Ins-0-CH2P/zOMe).
m/z (-ve ion FAB) 419 [M + NBA, (80%)] 469 [M - H, (100%)] 429(15%) 273(15%) 
124(10%).
6.5.9 DL-l,4-Di-0-allyl-2,3,5-tri-0-benzyl-6-O-/?-methoxybenzyI-my0-inositol (326)
Benzyl bromide (0.83ml, 7mmol) was added to d l -  1,4-di-0-allyl-5-0-benzyl-6-O-p- 
methoxybenzyl-myo-inositol (330) (1.5g, 3.19mmol) and sodium hydride (0.48g,
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20mmol) in dry DMF (20ml). The solution was stirred for 2h, after which TLC (ether- 
hexane, 1:1) showed a product Rf = 0.50. The excess sodium hydride was destroyed with 
methanol and the solvents were evaporated in vacuo. The residue was partitioned 
between dichloromethane and water (1 0 0 ml of each), the organic layer was dried over 
magnesium sulphate, filtered and the solvent was evaporated to give the crude product. 
Flash chromatography, (ether-hexane, 1:1) gave the pure title compound (326). Yield, 
(1.73g, 83%).
The NMR and mass spectrum data for compound (326) have been described previously in
6.5.5.
6.5.10 d l - 2 , 3 , 5 - T ri-0-benzyl-6-0-/?-methoxybenzyl- 1,4-di-O-cis-prop-1 -enyl-myo­
inositol (331)
A mixture of DL-l,4-di-(9-allyl-2,3,5-tri-Obenzyl-6-0-p-methoxybenzyl-mye>-inositol 
(326) (1.5g, 2.3mmol) and freshly sublimed potassium f-butoxide (3.66g, 30mmol) in dry 
DMSO (20ml) was kept at 50°C for 5h under an atmosphere of nitrogen. TLC (ether- 
hexane, 1:1) showed conversion of stating material R{ = 0.50 into a single product R{ = 
0.72. The dark mixture was cooled and a saturated solution of potassium chloride (50ml) 
was added and the product was extracted with ether (4x50ml). The organic layer was 
dried over magnesium sulphate and evaporated to give a solid. The crude product was 
purified by flash chromatography (ether-hexane, 1:2) to give the title compound (331). 
Yield, (1.2g, 80%).
m.p. 89-91°C (from hexane).
(Found: C, 75.6; H, 7.18. C41H460 7 requires C, 75.65; H, 7.13).
5h (CDC13; 270MHz) 1.64 (3H, dd, J 1.65, 6.59, Ins-0-CH=CH-C//3), 1.67 (3H, dd, J
1.47, 6.41, Ins-0-CH=CH-Ctf3), 3.33 (1H, dd, J 2.38, 9.71, H-3 or H-l, Ins), 3.42 (1H, t, 
J 9.34, H-5, Ins), 3.51 (1H, dd, J 2.2, 9.89, H-3 or H-l, Ins), 3.76 (3H, s, Ins-O- 
CH2PhOMe), 4.02 (1H, t, J 2.2, H-2, Ins), 4.03 (1H, t, J 9.89, H-4 or H-6 , Ins), 4.17 (1H, 
t, J 9.34, H-4 or H-6 , Ins), 4.36 (1H, dq, J 6.78, Ins-0-CH=Ctf-CH3), 4.44 (1H, dq, J
6.78, Ins-0-CH=Ctf-CH3), 4.53-4.83 (8 H, m, Ins-0-C//2Ph and Ins-0-C/f2PhOMe), 6.08 
(1H, dd, J 1.65, 6.23, Ins-0-Ctf=CH-CH3), 6.26 (1H, dd, J 1.65, 6.41, Ins-0-Ctf=CH- 
CH3), 6.83 (2H, d, J 8.61, Ins-0-CH2P/iOMe), 7.23-7.41 (17H, m, Ins-0-CH2P/z and Ins- 
0-CH2P/iOMe).
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5C (CDCI3 6 8 MHz) 9.27, 9.36 (2q, Ins-0-CH=CH-CH3), 55.16 (q, Ins-0-CH2PhOMe), 
72.57, 74.45, 75.25, 75.69 (4t, Ins-0-CH2Ph and Ins-0-CH2Ph0Me), 75.91, 78.75, 80.34, 
82.53, 82.95, 84.36 (6 d, CH, myoinositol ring carbons), 98.10, 100.50 (2d, Ins-O- 
CH=CH-CH3), 113.67 (d, Ins-0-CH2P/iOMe), 127.34, 127.55, 127.78, 128.07, 128.17, 
128.21, 128.26, 129.89 (8 d, Ins-0-CH2P/* and Ins-0-CH2P/iOMe), 130.81 (s, Cq, Ins-O- 
CH2P/iOMe), 138.27, 138.58 (2s, Cq, Ins-0-CH2P/z), 145.70, 147.68 (2d, Ins-0-CH=CH- 
CH3), 159.09 (s, Cq, Ins-0-CH2P/zOMe).
m/z (-ve ion FAB) 803 [M + NBA, (100%)] 696 (35%) 665 (25%) 559 [M - benzyl 
(20%)] 485(30%) 322(35%) 273(30%) 118(24%).
6.5.11 DL-l,2,5-Tri-0-benzyl-myo-inositol (328)
dl-2 ,3 ,5-Tri-0-benzyl-6-0-p-methoxybenzyl-1,4-di-O-cw-prop-1 -enyl-myo-inositol (331) 
(0.95g, 1.46mmol), was suspended in ethanol-lM HC1 (60ml, 2:1). The mixture was 
heated at reflux temperature for 4h after which TLC (ether) showed a product R{ = 0.30. 
The solvents were evaporated and the solid was partitioned between water and 
dichloromethane ( 1 0 0 ml each) and washed with sodium hydrogen carbonate ( 1 0 0 ml) and 
water (100ml). The organic layer was then dried over magnesium sulphate and then 
evaporated. The title compound (328) was purified by flash chromatography 
(dichloromethane-ethyl acetate, 1:1). Yield, (0.55g, 84%).
The mass spectrum and NMR data have been described in (6.5.6).
6.5.12 DL-2,3,5-Tri-0-benzyI-l,4,6-tris[di(benzyloxyphospho)]-iwyo-inositol (333)
A mixture of bis(benzyloxy)diisopropylaminophosphine (96) (0.69g, 2mmol) and 1H- 
tetrazole (0.2lg, 3mmol) in dry dichloromethane was stirred for 15min. DL-l,2,5-Tri-0- 
benzyl-myo-inositol (328) (0.2g, 0.44mmol) was then added and the reaction was stirred 
for a further 15min. The solution was cooled to -78°C and f-butylhydroperoxide (1ml, 
7mmol) was added and the mixture was stirred for 30min. The reaction mixture was 
partitioned between dichloromethane and a 1 0 % solution of sodium metabisulphite 
( 1 0 0 ml), the organic layer was washed with brine and water (1 0 0 ml of each) and dried 
over magnesium sulphate. The remaining syrup was purified by flash chromatography
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(chloroform-acetone, 10:1), then ethyl acetate-pentane (2:1), to give (333) as a syrup. R{ 
= 0.30 (chloroform-acetone, 10:1). Yield, (0.465g, 85%).
5h (CDC13; 400MHz) 3.41 (1H, dd, J 2.00, 9.76, H-3, Ins), 3.56 (1H, t, J 9.16, H-5, Ins), 
4.21 (1H, dt, J 2.00, 9.46, H-l, Ins), 4.42 (1H, br s, H-2, Ins), 4.44-5.09 (18H, m, Ins-O- 
Ctf2Ph, Ins-0-P(0)0-C//2Ph, H-4 and H-6 , Ins), 6.98-7.41 (45H, m, Ins-0-CH2P/i, Ins- 
0-P(0)0-C H 2P/z).
8 C (CDC13; 100MHz) 68.89, 69.21, 69.41, 69.77, 72.10, 73.53, 75.02 (7t, Ins-0-CH2Ph 
and Ins-0-P(0)0-CH 2Ph), 74.57, 76.32, 77.49, 78.04, 78.78, 79.53 (6 d, CH, myo-inositol 
ring carbons), 127.05, 127.47, 127.66, 127.89, 127.96, 128.05, 128.18, 128.47, 128.57 
(9d, Ins-0-CH2P/i and Ins-OP(0)0-CH2P/i), 135.51, 135.77, 135.90, 137.10, 137.85,
137.98 (6 s, Cq, Ins-0-CH2P/i and Ins-0P(0)0-CH2Ph).
5P (CDC13; 162MHz) -1.56, -1.86, -1.99 (31P-JH decoupled).
m/z (+ve ion FAB) 1231 [M + H, (80%)] 1141(80%) 1051 (30%) 91(100%).
6.5.13 DL-myo-Inositol 1,4,6-trisphosphate (334)
Ammonia was condensed into a three neck flask at -78°C. Small slithers of freshly cut 
sodium were added to the liquid ammonia until the colour remained blue. The ammonia 
was then distilled into a second flask and kept at -78°C. Sodium was then added once 
again until the solution remained blue. DL-2,3,5-Tri-0-benzyl-1,4,6-tris[di(benzyloxy 
phospho)]-myo-inositol (333) (O.lg, 81.3|imol) in dry dioxan (1ml), was then added to 
the sodium in liquid ammonia. The solution was stirred vigorously for 2min during 
which time the sodium in liquid ammonia remained blue. The reaction was quenched 
with methanol and the solvents were evaporated under a stream of nitrogen. The residue 
was dissolved in MilliQ water (250ml) and purified by ion exchange chromatography on 
Q-Sepharose Fast Flow, eluting with a gradient of TEAB buffer 0-1000mmol at pH 8 .6 . 
The triethylammonium salt of (334) eluted at ca. 600mmol buffer. Yield, (48.8|imol, 
60%).
5h (D20 ; 270MHz) 3.61 (1H, t, J 9.16, H-5, Ins), 3.72 (1H, dd, J 2.38, 9.71, H-3, Ins), 
4.07 (1H, t, J 9.52, H -l, Ins), 4.20 (1H, br s, H-2, Ins), 4.21 (1H, q, J 9.34, H-4, Ins), 4.33 
(1H, q, J 9.34, H-6 , Ins).
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5P (D20 ; 109MHz) +1.01 (d, J 9.77, -CH-O-PO32), +1.44 (d, J 9.77, -CH-O-PO32), 
+2.02 (d, J 9.77, -CH-O-PO32).
m/z (-ve ion FAB) 419 [M - H, (70%)] 354 (25%) 291 (45%) 266 (30%) 201 (100%) 
188(30%) 113(45%).
Accurate mass spectrum requires: (M - H)_ = 418.9545. Found 418.9534.
6.5.14 DL-2 ,3 ,5 -Tri-O-benzyI-l,4 ,6 -tris[di(benzyloxyphosphorothio)]-my0 -inositol 
(335)
A mixture of bis(benzyloxy)diisopropylaminophosphine (96) (1.035g, 3mmol), and 1H- 
tetrazole (0.35g, 5mmol) in dry dichloromethane (3ml) was stirred for 15min. d l -  1,2,5- 
Tri-O-benzyl-myo-inositol (328) (0.20g, 0.44mmol) was added to the mixture which was 
then stirred for lOmin. The solvent was evaporated, dry pyridine (1ml), dry DMF (2ml) 
and sulphur (0.192g, 6 mmol) were added and the solution was stirred for 5min, after 
which sulphoxidation was completed as judged by 31P NMR. The solvents were 
evaporated in vacuo at room temperature and the remaining syrup was partitioned 
between dichloromethane and 0.1M HC1 (50ml each). The organic layer was then 
washed with 0.1M TEAB (50ml) and water (50ml). The dichloromethane layer was dried 
over magnesium sulphate and purified by flash chromatography (petroleum ether-ether, 
2:1), R{ = 0.52 and isolated as a syrup. Yield, (0.453g, 81%).
(Found: C, 65.0; H, 5.25. C69H690 12P3S3 requires C, 64.78; H, 5.44).
5h (CDC13; 400MHz) 3.44 (1H, dd, J 1.47, 9.77, H-3, Ins), 3.64 (1H, t, J 10.07, H-5, Ins), 
4.39-5.06 (20H, m, Ins-0-C/72Ph, Ins-0-P(S)0-C/f2Ph, H-4 and H-6 , Ins), 5.29 (1H, dt, J 
9.46, 11.90, H-4, Ins), 5.38 (1H, dt, J 9.46, 12.21, H-6 , Ins), 6.90-7.39 (45H, m, Ins-O- 
CU2Ph, Ins-0-P(S)0-CH2P/i).
5C (CDC13; 6 8 MHz) 69.44, 69.67, 69.86, 70.22, 71.89, 73.24, 74.73 (7t, Ins-0-CH2Ph 
and Ins-0-P(S)0-CH2Ph), 74.66, 76.88, 77.70, 78.07, 79.09, 79.51 (6 d, CH, myo-inositol 
ring carbons), 126.69, 127.23, 127.42, 127.53, 127.70, 127.81, 128.05, 128.18, 128.26,
128.46 (lOd, Ins-O-CH2Ph and Ins-OP(S)0-CH2P/i), 135.33, 135.58, 135.77, 135.82, 
136.00, 137.25, 138.27, 138.37 (8 s, Cq, Ins-0-CH2P/i and Ins-0P(0)0-CH 2P/i).
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5P (CDC13; 162MHz) +66.75 (dq, J 9.28, 9.52), +69.22 (dq, J 9.77, 10.50), +69.38 (dq, J
9.76, 10.74).
m/z (-ve ion FAB) 1186 [M - Bn, (10%)] 1096(1%) 802(1%) 293 (100%) 203(10%) 
95 (47%).
6.5.15 DL-myo-Inositol 1,4,6-trisphosphorothioate (336)
Ammonia was condensed into a three neck flask at -78°C. Pieces of freshly cut sodium 
were added to the liquid ammonia until the colour remained blue. The ammonia was then 
distilled into a second flask and kept at -78°C. Sodium was then added once again until, 
the solution remained blue. DL-2,3,5-Tri-0-benzyl-l,4,6-tris[di(benzyloxyphosphoro 
thio)]-my0 -inositol (335) (O.lg, 78.2pmol) in dry dioxan (1ml), was then added to the 
sodium in liquid ammonia. The solution was stirred vigorously for 2min after which time 
the solution remained blue. The reaction was quenched with methanol (20ml) and the 
solvents were evaporated under a stream of nitrogen. The residue was dissolved in 
MilliQ water (250ml) and purified by ion exchange chromatography on Q-Sepharose Fast 
Flow, eluting with a gradient of TEAB buffer 0-1000mmol at pH 8 .6 . The glassy 
triethylammonium salt of (336) eluted at ca. 600mmol buffer. Yield, (31.28jimol, 40%).
5h (D20 ; 400MHz) 3.64 (1H, t, J 9.16, H-5, Ins), 3.74 (1H, d, J 9.46, H-3, Ins), 4.27 (1H, 
t, J 10.27, H-l, Ins), 4.34 (1H, br s, H-2, Ins), 4.44 (1H, q, J 9.76, H-4, Ins), 4.65 (1H, q, J
9.76, H-6 , Ins).
8 C (D20 ; 100MHz) 73.37, 73.76, 76.08, 77.74, 79.57, 80.28 (6 d, CH, myo-inositol ring 
carbons).
5P (D20 ; 162MHz) +47.74 (d, J 10.20, -CH-0-P(S)022), +48.49 (d, J 12.12, -CH-O- 
P(S)0 2 2 ), +50.27 (d, J 11.29, -CH-0-P(S)02 2 ).
m/z (-ve ion FAB) 466.3 [M - H, (100%)] 432(10%) 371 (80%) 330(5%) 113(10%) 
95 (17%).
Accurate mass spectrum requires: (M - H)" = 466.8860. Found 466.8871.
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6.6 Synthesis of d -  and L-myo-Inositol 1,4,6-Trisphosphate and D-myo-Inositol 1,4,6-
Trisphosphorothioate
6.6.1 d - ( 3 3 7 )  And L-l-0-[S-(+)-0-acetylmandelyI]-3,6-di-0-allyI-5-0-benzyl-4-f?-p- 
methoxybenzyl-myo-inositol (338)
A mixture of d l -  1,4 -di-O-allyl-5 -O-benzyl-6 -O-/?-methoxybenzyl-my0 -inositol (330) 
(4.068g, 8.65mmol), £-(+)-O-acetylmandelic acid (1.75g, 9mmol) and DMAP (0.03g, 
0.25mmol) in dry dichloromethane (10ml) was stirred at -20°C. A solution of DCC 
(1.96g, 9.5mmol), in dry dichloromethane (20ml) was added dropwise over 1.5h at -20°C 
and stirring continued overnight. TLC pentane-ethyl acetate (2:1), showed two products 
Rf = 0.40 and R{ = 0.28. The reaction mixture was filtered through celite which was 
washed thoroughly with dichloromethane (2x100ml). The solvent was evaporated to give 
a syrup which was purified by flash chromatography using pentane-ethyl acetate (2 :1), to 
provide pure d -  l-O-[S-(+)-0-acetylmandelyl]-3,6-di-O-allyl-5-0-benzyl-4-0-/?- 
methoxybenzyl-myo-inositol (337) (2.04g, 36.5%) Rf = 0.40 as a syrup, and l-1 -0 -[S -(+ )- 
0 -acetylmandelyl]-3 ,6 -di-O-allyl-5 -O-benzyl-4 -0 -/?-methoxybenzyl-wy0 -inositol (338) 
(1.96g, 35%) as a solid.
(338) m.p. 103-105°C (from ethanol).
(337) [oc]D = -8 ° (c = 4.6 in CH2C12).
(338) [a]D = +59° (c = 1 in CH2C12).
(337) (Found: C, 68.5; H, 6.55. C37H42O10 requires C, 68.7; H, 6.55).
(338) (Found: C, 68.4; H, 6.50. C37H42O10 requires C, 68.7; H, 6.55).
(337) 6 h (CDC13; 270MHz) 2.15 (3H, s, Ins-02C-CH-(OAc)Ph), 2.65 (1H, s, D20  ex, Ins- 
OH), 3.31 (1H, dd, J 2.57, 9.71, H-3, Ins), 3.42 (1H, J 9.34, H-5, Ins), 3.71 (3H, s, Ins-O- 
CH2PhOMe), 3.85 (1H, t, J 9.34, H-4 or H-6 , Ins), 3.94 (1H, t, J 9.53, H-4 or H-6 , Ins), 
4.08-4.29 (5H, m, Ins-0-C//2CH=CH2 and H-2, Ins), 4.77 (1H, dd, J 2.56, 10.26, H-l, 
Ins), 4.68-4.83 (4H, m, Ins-0-C//2PhOMe, Ins-0-Gtf2Ph), 5.07-5.28 (4H, m, Ins-O- 
CH2CH=C//2), 5.79-6.95 (2H, m, Ins-0-CH2C/7=CH2), 5.97 (1H, s, Ins-O2C-CH- 
(OAc)Ph), 6.80 (2H, d, J 8.61, Ins-0-CH2P/iOMe), 7.21 (2H, d, J 8.61, Ins-O- 
CH2P/iOMe), 7.24-7.52 (10H, m, Ins-0-CH277z0Me, Ins-0-CH2P/i and Ins-02C-C//- 
(OAc )Ph).
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5C (CDC13; 68MHz) 20.31 (q, Ins-02C-CH-(0Ac)Ph, -0C(0)CH3), 54.88 (q, Ins-O- 
CH2PhOMe), 71.53, 74.11, 75.22, 75.52 (4t, Ins-0-CH2CH=CH2, Ins-0-CH2Ph and Ins- 
0-CH 2PhOMe), 67.37, 74.58, 77.86, 79.10, 80.34, 82.66, 82.85 (7d, CH, mjo-inositol 
ring carbons and Ins-02C-CH-(OAc)Ph), 113.47 (d, Ins-0-CH2P/zOMe), 116.52, 117.20 
(2t, Ins-0-CH2CH=CH2), 127.16, 127.22, 127.48, 128.02, 128.55, 128.98, 129.33 (7d, 
Ins-0-CH2P/i, Ins-0-CH2P/zOMe and Ins-02C-CH-(OAc)P/i), 130.63, 133.24, 138.48 
(3s, Cq, Ins-0-CH2P/iOMe, Ins-0-CH2P/i and Ins-02C-CH-(OAc)P/i), 134.18, 134.48 
(2d, Ins-0-CH2CH=CH2), 158.91 (s, Cq, Ins-0-CH2P/iOMe), 168.00, 170.40 (2s, Cq, 
Ins-02C-CH-(OAc)Ph, -OC(0)CH3).
m/z (-ve ion FAB) 799 [M + NBA, (28%)] 645 [M - H, (65%)] 469(31%) 193 (50%) 
175(50%) 149(100%).
(338) SH (CDC13; 270MHz) 2.18 (3H, s, Ins-02C-CH-(OAc)Ph), 2.89 (1H, s, D20  ex, Ins- 
OH), 3.36 (1H, t, J 9.34, H-5, Ins), 3.36 (1H, dd, J 2.56, 9.52, H-3, Ins), 3.52 (1H, dd, J
5.5, 11.91, H-4 or H-6 , Ins), 3.76 (3H, s, Ins-0-CH2PhOMe), 3.77-4.23 (5H, m, Ins-O- 
CH2CH=CH2 and H-4 or H-6 , Ins), 4.29 (1H, br s, D20  ex, J 2.57, H-2, Ins), 4.68-4.91 
(7H, m, Ins-0-CZ/2PhOMe, Ins-0-C//2Ph, Ins-0-CH2CH=C/ / 2 and H -l, Ins), 5.18-5.40 
(3H, m, Ins-0-CH2CH=Ctf2 and Ins-0-CH2C//=CH2), 5.86-6.01 (1H, m, Ins-O- 
CH2C//=CH2), 5.97 (1H, s, Ins-02C-Ctf-(OAc)Ph), 6.82 (2H, d, J 8.79, Ins-O- 
CH2P/iOMe), 7.27-7.35 (12H, m, Ins-0-CH2P/zOMe, Ins-0-CH2P/i and Ins-02C-C//- 
(OAc)P/i).
5C (CDC13; 6 8 MHz) 20.54 (q, Ins-02C-CH-(OAc)Ph, -OC(0)CH3) 55.12 (q, Ins-O- 
CH2PhOMe), 71.70, 73.87, 75.49 75.75 (4t, Ins-O-CH2CH=CH2, Ins-0-CH2Ph and Ins- 
0-CH2PhOMe), 67.61, 74.73, 74.92, 77.89, 79.29, 80.53, 82.85 (7d, CH, mjo-inositol 
ring carbons and Ins-02C-CH-(OAc)Ph), 113.67 (d, Ins-0-CH2P/iOMe), 116.26, 117.53 
(2t, Ins-0-CH2CH=CH2), 127.42, 127.66, 127.97, 128.18, 128.81, 129.38, 129.56 (7d, 
Ins-0-CH2P/i, Ins-0-CH2P/iOMe and Ins-02C-CH-(OAc)P/i), 130.84, 133.14, 138.53 
(3s, Cq, Ins-0 -CH2P/iOMe, Ins-O-CH2Ph and Ins-02C-CH-(OAc)P/i), 134.28, 134.64 
(2d, Ins-0-CH2CH=CH2), 159.11 (s, Cq, Ins-0-CH2P/iOMe), 168.37, 170.48 (2s, Cq, 
Ins-02C-CH-(OAc)Ph, -OC(0)CH3).




A mixture of D-l-0-[5,-(+)-0-acetylmandelyl]-3,6-di-0-allyl-5-0-benzyl-4-0-/?-methoxy 
benzyl-myo-inositol (337), (2.04g, 3.15mmol) and sodium hydroxide (0.8g, 20mmol) in 
methanol was heated at reflux temperature for 30min. The mixture was cooled and 
neutralised with carbon dioxide. The solid was diluted with water (50ml) and evaporated 
to dryness in vacuo. The product was extracted with dichloromethane (5x100ml) and the 
solvent was evaporated to give the product (339) R{ = 0.52 (ether). Yield, (1.34g, 90%).
m.p. 111-113°C (from ethyl acetate-hexane).
[a]D = -51° (c = 1 in CH2C12).
(Found: C, 69.0; H, 7.32. C27H340 7 requires C, 68.90; H, 5.29).
The mass spectrum and NMR data were the same as for the racemic mixture.
6.6.3 D-l,4 -Di-0 -allyl-5 -0 -benzyl-6 -0 -/?-methoxybenzyl-/wy0 -inositol (340)
A mixture of L-l-0-[S-(+)-O-acetylmandelyl]-3,6-di-0-allyl-5-0-benzyl-4-0-p-methoxy 
benzyl-myo-inositol (338), (1.96g, 3.03mmol) and sodium hydroxide (0.8g, 20mmol) in 
methanol was heated at reflux temperature for 30min. Work up was carried out in the 
same way as for (339) R{ = 0.52 (ether). Yield, (1.40g, 98%).
m.p. 111-113°C (from ethyl acetate-hexane).
[oc]D = +51° (c = 1 in CH2C12).
(Found: C, 6 8 .8 ; H, 7.31. C27H340 7 requires C, 68.90; H, 5.29).
The mass spectrum and NMR data were the same as for the racemic mixture.
6.6.4 L-l,4 -Di-0 -allyl-2 .3 ,5 -tri-0 -benzyl-6 -0 -/?-methoxybenzyl-my0 -inositoI (341)
A mixture of L-l,4-di-0-allyl-5-0-benzyl-6-0-p-methoxybenzyl-myo-inositol (339) 
(1.70g, 3.6mmol) and sodium hydride (0.48g, 20mmol) in dry DMF (20ml) was stirred at 
room temperature. Benzyl bromide (1.07ml, 9mmol) was added to the mixture which 
was then stirred for 2h. The excess sodium hydride was destroyed with methanol (5ml) 
and the solvents were evaporated in vacuo. The residue was partitioned between ether 
and water ( 1 0 0 ml of each), the organic layer was separated and dried over magnesium
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sulphate. The title compound (341) was purified by flash chromatography R{ = 0.50
(ether-pentane, 1:1). Yield, (1.82g, 78%).
m.p. 72-73°C (from ethyl acetate-hexane).
[a]D = -19° (c = 1 in CH2C12).
(Found: C, 75.3; H, 7.05. C41H460 7 requires C, 75.6; H, 7.13).
The mass spectrum and NMR data were the same as for the racemic mixture.
6.6.5 D-l,4-Di-0-allyl-2.3,5-tri-0-benzyl-6-O-p-methoxybenzyl-f7iy0-inositol (342)
A mixture of d -  1,4 -di-(9 -allyl-5 -(9 -benzyl-6 -0 -/?-methoxybenzyl-my<9-inositol (340) 
(1.60g, 3.4mmol) and sodium hydride (0.48g, 20mmol) in dry DMF (20ml) was stirred at 
room temperature. Benzyl bromide (1.07ml, 9mmol) was added to the mixture which 
was then stirred for a further 2h. Work up and purification as for the L-enantiomer gave 
the pure title compound (342) R{ = 0.50 (ether-pentane, 1:1). Yield, (2.077g, 94%).
m.p. 72-73°C (from ethyl acetate-hexane).
[a]D = +19° (c = 1 in CH2C12).
(Found: C, 75.3; H, 7.96. C41H460 7 requires C, 75.6; H, 7.13).
The mass spectrum and NMR data were the same as for the racemic mixture.
6.6.6 L-2,3,5-Tri-0-benzyI-fttyo-inositol (345)
A solution of L-l,4 -di-0 -allyl-2 .3 ,5 -tri-0 -benzyl-6 -0 -p-methoxybenzyl-my<9-inositol
(341) (1.55g, 2.37mmol) and freshly sublimed potassium f-butoxide (3.66g, 30mmol) in 
anhydrous DMSO (30ml) was kept at 50°C for 5h, after which TLC (ether-hexane, 1:1) 
showed complete conversion of starting material, R{ = 0.50, into a single product, Rf =
0.72. The dark mixture was cooled water (50ml) was added and the product was 
extracted with ether (4x100ml). The organic layer was dried over magnesium sulphate 
and the solvent was evaporated to give an off-white solid (343). This product was not 
isolated but treated with 1M aqueous HCl-ethanol (60ml, 1:2) for 3h, after which no 
starting material was left. The reaction was cooled and the solvents were evaporated in 
vacuo. The remaining solid was partitioned between dichloromethane and water (100ml 
of each) and the organic layer was dried over magnesium sulphate. The title compound
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(345) was purified by flash chromatography (dichloromethane-ethyl acetate, 1:1), Rf =
0.40 (ether). Yield, (0.71 g, 67%).
m.p. 176-177°C (from ethyl acetate-hexane).
[a]D = -34° (c = 1 in CH2C12).
(Found: C, 72.2; H, 6.72. C27H30O6 requires C, 71.96; H, 6.49).
The mass spectrum and NMR data were the same as for the racemic mixture (328).
6.6.7 D-2,3,5-Tri-0-benzyl-myo-inositol (346)
A solution of D-l,4-di-0-allyl-2,3,5-tri-0-benzyl-6-0-p-methoxybenzyl-myo-inositol
(342) (1.2g, 1.84mmol) and freshly sublimed potassium r-butoxide (3.66g, 30mmol) in 
anhydrous DMSO (30ml) was kept at 50°C for 5h, after which TLC (ether-hexane, 1:1) 
showed complete conversion of starting material Rf = 0.50 into a single product R{ = 0.72. 
The product (344) was worked up, hydrolysed and purified in the same way for the l -  
enantiomer to give (346) with the same R{ = 0.40 (ether) value. Yield, (0.589g, 71%).
m.p. 176-177°C (from ethyl acetate-hexane).
[oc]D = +34° (c = 1 in CH2C12).
(Found: C, 71.9; H, 6.75. C27H30O6 requires C, 71.96; H, 6.49).
The mass spectrum and NMR data were the same as for the racemic mixture (328).
6.6.8 D-2,3,5-Tri-O-benzyl-l,4,6-tris[di(benzyIoxyphospho)]-my0-inositol (349)
A mixture of bis(benzyloxy)diisopropylaminophosphine (96) (1.036g, 4mmol) and 1H- 
tetrazole (0.42g, 6 mmol) in dry dichloromethane (5ml) was stirred for 15min. d - 2 ,3 ,5 -  
Tri-O-benzyl-myo-inositol (346) (0.15g, O.33mmol) was then added and the reaction was 
stirred for a further 15min. The solution was cooled to -78°C and f-butylhydroperoxide 
(lml, 7mmol) was added and the mixture was stirred for 30min. The reaction mixture 
was partitioned between dichloromethane (1 0 0 ml) and a 1 0 % solution of sodium 
metabisulphite (1 0 0 ml), the organic layer was washed with brine and water ( 1 0 0 ml of 
each) dried over magnesium sulphate and evaporated. The remaining syrup was purified 
by flash chromatography (chloroform-acetone, 1 0 :1), then ethyl acetate-pentane (2 :1), to 
give (349) as a syrup. R{ = 0.30 (chloroform-acetone, 10:1). Yield, (0.213g, 65%).
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[a]D = 0° ± 1° (c = 3.6 in CH2C12).
(Found: C, 67.4; H, 5.42. C69H690 15P3 requires C, 67.31; H, 5.65).
The mass spectrum and NMR data were the same as for the racemic mixture.
6.6.9 L-2 ,3 ,5 -Tri-O-benzyI-l,4 ,6 -tris[di(benzyloxyphospho)]-my0 -inositol (350)
A mixture of bis(benzyloxy)diisopropylaminophosphine (96) (0.69g, 2mmol) and 1H- 
tetrazole (0.42g, 6 mmol) in dry dichloromethane (5ml) was stirred for 15min. l-2,3,5- 
Tri-O-benzyl-myo-inositol (346) (0.15g, 0.33mmol) was then added and the reaction was 
stirred for a further 15min. The solution was cooled to -78°C and f-butylhydroperoxide 
(lml, 7mmol) was added and the mixture was stirred for 30min. The mixture was 
worked up in the same way as the D-enantiomer in order to obtain the product (350) as a 
syrup. R{ = 0.30 (chloroform-acetone, 10:1). Yield, (0.236g, 72%).
[a]D = 0° ± 1° (c = 4.1 in CH2C12).
(Found: C, 67.2; H, 5.83. C69H690 15P3 requires C, 67.31; H, 5.65).
The mass spectrum and NMR data were the same as for the racemic mixture.
6.6.10 D-myo-Inositol 1,4,6-trisphosphate (199)
Ammonia was condensed into a three neck flask at -78°C. Freshly cut sodium was added 
to the liquid ammonia until the colour remained blue. The ammonia was then distilled 
into a second flask by gentle heating, and kept at -78°C. Freshly cut sodium was then 
added once again until the solution remained blue. D-2,3,5-Tri-0-benzyl-l,4,6- 
tris[di(benzyloxyphospho)]-myo-inositol (349) (0.1 lg, 89|imol) in dry dioxan (lml), was 
then added to the sodium in liquid ammonia. The solution was stirred vigorously for 
2min in which time the solution remained blue. The reaction was quenched with 
methanol (20ml) and the solvents were evaporated under a stream of nitrogen. The 
residue was dissolved in MilliQ water (250ml) and purified by ion exchange 
chromatography on Q-Sepharose Fast How, eluting with a gradient of TEAB buffer 0- 
lOOOmmol at pH 8 .6 . The triethylammonium salt of (199) eluted at ca. 700mmol buffer. 
Yield, (30.1|imol, 34%). (The NMR spectra were slightly different from the racemic 
mixture due to different pH values of the compound in the NMR tube).
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[a ]D = -29.1° (c = 0.26 in TEAB, pH = 8.6).
5h (D20 ; 400MHz) 3.49 (1H, t, J 9.15, H-5, Ins), 3.58 (1H, dd, J 2.5, 9.77, H-3, Ins), 3.93 
(1H, dt, J 2.5, 9.46, H-l, Ins), 4.07 (1H, br s, H-2, Ins), 4.07 (1H, q, J 9.16, H-4, Ins), 4.20 
(1H, q, J 9.16, H-6 , Ins).
5P (D20 ; 162MHz) +0.97 (d, J 8.3, -CH-O-PO32), +0.39 (d, J 8.79, -CH-O-PO32), -0.03 
(d, J 9.52, -CH-O-PO32 ).
m/z (-ve ion FAB) 419 [M-H,(100%)] 339(10%) 159(7%) 97(7%).
Accurate mass spectrum requires: (M - H)' = 418.9545. Found 418.9563.
6.6.11 L-myo-Inositol 1,4,6-trisphosphate (201)
The deprotection of L-2,3,5-tri-O-benzyl-l,4,6-tris[di(benzyloxyphospho)]-my0-inositol 
(350) (0.1 lg, 89pmol) was carried out in the same way as for the D-enantiomer (349). 
Yield, (53.05pmol, 60%).
[a]D = +25.0° (c = 0.88 in TEAB, pH = 8.6).
5h (D20 ; 270MHz) 3.58 (1H, t, J 9.16, H-5, Ins), 3.68 (1H, dd, J 2.5, 9.71, H-3, Ins), 4.04 
(1H, dt, J 2.5, 9.46, H-l, Ins), 4.17 (1H, br s, H-2, Ins), 4.17 (1H, q, J 9.16, H-4, Ins), 4.29 
(1H, q, J 9.16, H-6 , Ins).
5p (D20 ; 162MHz) +2.11 (d, J 6.67, -CH-O-PO32), +1.44 (d, J 6.67, -CH-O-PO32), 
+1.04 (d, J 8.90, -CH-O-PO3 2 ).
m/z (-ve ion FAB) 419 [M-H,(100%)] 339(10%) 159(7%) 97(7%).
Accurate mass spectrum requires: (M - H)- = 418.9545. Found 418.9523.
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6.6.12 D-2,3,5-Tri-0-benzyI-l,4,6-tris[di(benzyloxyphorothio)]-myo-inositol (351)
A mixture of bis(benzyloxy)diisopropylaminophosphine (96) (1.035g, 3mmol), and 1H- 
tetrazole (0.35g, 5mmol) in dry dichloromethane (3ml) was stirred for 15min. d-2,3,5- 
Tri-O-benzyl-rayo-inositol (346) (0.12g, 0.266mmol) was added to the mixture which 
was then stirred for lOmin. The solvent was evaporated, dry pyridine (lml), dry DMF 
(2ml) and sulphur (0.096g 3mmol) were added and the solution was stirred for 5min, after 
which sulphoxidation was completed as judged by 31P NMR. The solvents were 
evaporated in vacuo at room temperature and the remaining syrup was partitioned 
between dichloromethane and 0.1M HC1 (50ml each). The organic layer was then 
separated, washed with 0.1M TEAB (50ml) and water (50ml). The dichloromethane 
layer was dried over magnesium sulphate and purified by flash chromatography, 
(pentane-ethyl acetate, 3:1), R{ = 0.52 (ether-petroleum ether, 1:2) and isolated as a syrup. 
Yield, (0.28g, 82%).
[a]D = 0° ± 1° (c = 3.6 in CH2C12).
(Found: C, 65.1; H, 5.25. C69H690 12P3S3 requires C, 64.78; H, 5.32).
The mass spectrum and NMR data were the same as for the racemic mixture (335).
6.6.13 D-myo-Inositol 1,4,6-trisphosphorothioate (252)
The deprotection of L-2,3,5-tri-0-benzyl-l,4,6-tris[di(benzyloxyphosphorothio)]-myo- 
inositol (351) (O.llg, 8 6 }imol) was carried out in the same way as for the enantiomer 
(349). Yield, (31.44pmol, 36.5%).
[a]D = -26.9° (c = 0.59 in TEAB, pH = 8 .6 ).
5h (D20 ; 400MHz) 3.45 (1H, t, J 9.15, H-5, Ins), 3.56 (1H, dd, J 2.75, 9.77, H-3, Ins),
3.98 (1H, dt, J 2.44, 9.46, H-l, Ins), 4.24 (1H, q, J 9.46, H-4, Ins), 4.36 (1H, q, J 9.77, H- 
6 , Ins), 4.41 (1H, br s, H-2, Ins).
8 P (D20 ; 162MHz) +47.31 (d, J 9.92, -CH-0-P(S)022), +48.24 (d, J 11.44, -CH-O- 
P(S)02 2 ), +50.00 (d, J 11.45, -CH-0-P(S)022 ).
m/z (-ve ion FAB) 467 [M-H,(100%)] 433(15%) 334(20%) 234(20%) 95(42%).
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Accurate mass spectrum requires: (M - H)_ = 466.8860 Found 466.8871.
6.7 Establishing the Absolute Configuration of D-2,3,5-Tri-0-Benzyl-//iyo-Inositol
6.7.1 D-l,4-Di-0-aIlyl-2,3,5-tri-0-benzyl-myo-inositol (353)
d- 1 ,4-Di-0-allyl-2,3,5-tri-O-benzyl-6-O-/?-methoxybenzyl-mye>-inositol (342) was
suspended in 1M HCl-ethanol (60ml, 1:2). The mixture was heated at reflux temperature 
for 4h, after which TLC (ether-petroleum ether, 1:1), showed the appearance of a major 
product, R{ = 0.40. The reaction was cooled and the solvents were evaporated in vacuo. 
The remaining solid was taken up in dichloromethane (100ml) and washed with water 
(100ml). The organic layer was dried over magnesium sulphate filtered and the solvent 
was evaporated. The residue was purified by flash chromatography to give the title 
compound (353) as a syrup. Yield, (0.45g, 91%).
[a]D = -3° (c = 9 in CH2C12).
(Found: C, 74.9; H, 7.41. C33H380 6 requires C, 74.67; H, 7.22).
The mass spectrum and NMR data were the same as for the racemic mixture (327).
6.7.2 D-l,4-Di-O-allyl-2,3,5,6-tetra-0-benzyl-/?iy0-inositol (354)
A mixture of D-l,4 -di-Oallyl-2 ,3 ,5 -tri-O-benzyl-my0 -inositol (353) (0.293, 0.55mmol) 
and sodium hydride (0.12g, 5mmol) was stirred in dry DMF (10ml) at room temperature. 
Benzyl bromide (0.12ml, l.Ommol) was added and the reaction was stirred for a further 
2h after which TLC (ether-pentane, 1:2) showed a product Rf = 0.60. The excess sodium 
hydride was destroyed with methanol and the solvents were evaporated in vacuo. The 
residue was partitioned between ether and water (50ml of each), the organic layer was 
then dried and evaporated to give a syrup. The residue was purified by flash 
chromatography (ether-pentane, 1:2) to give the title compound (354). Yield, (0.3lg, 
90%).
m.p. 63-65°C (from pentane).
[a]D = +18° (c = 1 in CH2C12).
(Found: C, 77.2; H, 7.15. C^H^Og requires C, 77.39; H, 7.14).
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5h (CDC13; 400MHz) 3.23 (1H, dd, J 2.14, 9.77, H-3 or H-l, Ins), 3.30 (1H, dd, J 2.14, 
10.07, H-3 or H-l, Ins), 3.40 (1H, t, J 9.15, H-5, Ins), 3.93 (1H, t, J 9.77, H-4 or H-6 , Ins),
3.98 (1H, t, J 9.46, H-4 or H-6 , Ins), 3.99 (1H, t, J 2.45, H-2, Ins), 4.04-4.12 (2H, m, Ins- 
0-C tf2CH=CH2), 4.29-4.42 (2H, m, Ins-0-C//2CH=CH2), 4.60, 4.67 (2H, AB, J 10.8, 
Ins-O C/f2Ph), 4.77-4.89 (6 H, m, Ins-0-C//2Ph), 5.12-5.31 (4H, m, Ins-0-CH2CH=Ctf2), 
5.85-6.02 (2H, m, Ins-0-CH2Ctf=CH2), 7.23-7.41 (20H, m, Ins-0-CH2P/z).
5C (CDC13 100MHz) 71.63, 72.84, 73.97, 74.32, 75.84, 75.95 (6 t, Ins-0-CH2CH=CH2, 
Ins-0-CH2Ph), 74.59, 80.65, 80.77, 81.43, 81.58, 83.63 (6 d, CH, myo-inositol ring 
carbons), 116.60, 116.66 (2t, Ins-0-CH2CH=CH2), 127.28, 127.48, 127.79, 127.94,
128.09, 128.31 (6 d, Ins-0-CH2P/i), 134.91, 135.42 (2 d, Ins-0 -CH2CH=CH2), 138.53, 
138.86, 138.91, 138.95 (4s, Cq, Ins-0-CH2PA).
m/z (-ve ion FAB) 773 [M + NBA, (100%)] 6 6 6  (50%) 470 (30%) 322 (38%) 291 
(30%) 140(30%).
6.7.3 D-2,3,4,5-Tetra-0-benzyl-myo-inositoI (355)
A mixture of D-l,4-di-C-allyl-2,3,5,6-tri-0-benzyl-myo-inositol (354) (0.26g, 1.78mmol), 
toluene-/?-sulphonic acid (0.15g, 0.75mmol) and 10% palladium on activated charcoal 
(Fluka, 0.25g) was heated under reflux for 2h in ethanol-water (35ml, 6:1). TLC (ether), 
showed a new spot R{ = 0.50 and debenzylated products at the baseline. The palladium 
on activated charcoal was filtered through celite to give a colourless solution, and the 
solvents were evaporated. The title compound (355) was purified by flash 
chromatography (dichloromethane-ethyl acetate, 1:1). Yield, (0.138g, 61%).
m.p. 103-105°C (from ether); (lit. I386l 105-107°C).
[a]D = +4° (c = 1 in CH2C12); [lit. V*6* [a]D = +3.9° (c = 1 in CHC13)].
(Found: C, 75.6; H, 6.94. C34H360 6 requires C, 75.53; H, 7.71).
6 h (CDC13; 270MHz) 2.35 (1H, br s, D20  ex, Ins-OH), 2.61 (1H, br s, D20  ex, Ins-OH), 
3.28 (1H, dd, J 2.20, 9.89, H-3, Ins), 3.38 (1H, t, J 9.15, H-5, Ins), 3.51 (1H, br d, J 9.53, 
D20  ex, dd, J 2.2, 9.53, H-l, Ins), 3.79 (1H, t, J 9.52, H-4, Ins), 4.05 (1H, t, J 2.20, H-2, 
Ins), 4.15 (1H, t, J 9.46, H-6 , Ins), 4.56-4.93 (8 H, m, Ins-0-Ctf2Ph), 7.21-7.33 (20H, m, 
Ins-O-CH 2Ph).
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8C (CDCI3 100MHz) 72.51, 74.63, 75.21, 75.46 (4t, Ins-0-CH2Ph), 74.64, 73.25, 76.19, 
80.39, 81.88, 83.28 (6d, CH, myo-inositol ring carbons), 127.65, 127.75, 127.78, 127.91, 
128.04, 128.35, 128.43, 128.48, 128.56 (9d, Ins-0-CH2/Vz), 137.85, 138.60, 138.71 (3s, 
Cq, Ins-0-CH2P/i).
m/z (-ve ion FAB) 692 [M + NBA, (100%)] 586 (40%) 539 (55%) 472 (15%) 322 
(25%) 287(20%).
6.8 Synthesis of Benzene 1,2,4-Trisphosphate
6.8.1 l,2,4-Tris-0-(diethoxyphospho)-benzene (357)
Benzene 1,2,4-triol (355) (0.252g, 2mmol) was suspended in dry dichloromethane (5ml) 
and stirred under a blanket of nitrogen. Dry AT,Af-diisopropylethylamine (2.1ml, 12mmol), 
was added to the suspension and the solution turned red in colour. The solution was then 
cooled to -78°C and diethoxychlorophosphine (273) (1.57ml, 9.0mmol) was added 
dropwise. The solution then turned pale yellow, which indicated the hydroxyl groups had 
been phosphitylated. The cooling was removed and water (2ml), was added to the 
solution which was stirred for 30min. f-Butylhydroperoxide (lml, 7mmol, 70%), was 
added dropwise and the mixture was stirred for 15min at room temperature. TLC (ethyl 
acetate-ethanol, 9:1) showed a product R{ = 0.34. The solution was diluted with 
dichloromethane (100ml), and washed with water (100ml), 10% sodium metabisulphite 
(100ml), 0.1M HC1 (50ml), saturated sodium hydrogen carbonate solution (100ml) and 
water (100ml). The organic layer was dried over magnesium sulphate and evaporated to 
give the crude compound as an oil. Flash chromatography (ethyl acetate-ethanol, 9:1) 
gave the pure title compound (357) as a syrup. Yield, (0.79g, 76%).
(Found: C, 40.7; H, 6.42. C18H330 12 P3 requires C, 40.45; H, 6.18).
8H (CDC13; 270MHz) 1.34-1.40 (18H, m, Bz-0-P(0)0-CH2C/f3), 4.17-4.32 (12H, m, Bz- 
0 -P (0 )0 -C //2CH3), 7.03-7.39 (3H, m, H-3, H-5, H-6, Bz).
Sc (CDC13; 68MHz) 15.53, 15.63 (2q, Bz-0-P(0)0-CH2CH3), 64.43, 64.53, 64.64 (3t, 
Bz-0-P(0)0-C H 2CH3), 113.29, 116.39, 121.43 (3d, £ z-0-P(0)0-CH 2CH3), 138.22,
141.38, 146.91 (3s, Cq, £z-0-P(0)0-CH2CH3).
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5P (CDC13; 162MHz) -6.86 (dtt, J 7.83), -7.12 (dtt, J 7.83), -7.28 (dtt, J 7.83).
m/z (+ve ion FAB) 535 [M + H,(100%)] 507(5%) 349(12%) 269(10%).
6.8.2 Benzene 1,2,4-trisphosphate (359)
l,2,4-Tris-0-(diethoxyphospho)-benzene, (357) (0.274g, 528|imol) was dissolved in dry 
dichloromethane. Bromotrimethylsilane (0.836ml, 6.33mmol) was added dropwise to the 
solution which was stirred for 16h. The solvents were evaporated and the residue was 
stirred with water lml. Final purification of (359) was by elution from Q-Sepharose Fast 
Flow using TEAB buffer with a linear gradient 0-1M. The title compound eluted 
between 0.2-0.5M buffer and after evaporation was obtained as its glassy 
triethylammonium salt. Yield, (456pmol, 86%).
5h (D20 ; 400MHz) 6.85 (1H, dd, J, 1.5, 8.85, H-5, Bz), 7.06 (1H, d, J 1.5, H-3, Bz) 7.18 
(1H, d, J 8.85, H-6, Bz).
8P (CDC13; 162MHz) -3.61, (s) -3.92, (s) -4.28, (s).
m/z (-ve ion FAB) 364.9 [M - H, (100%)] 305(27%) 267(15%) 159(10%).
Accurate mass spectrum requires: (M - H)_ = 364.9228. Found 364.9238.
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